The O
inhibition O
of O
c O
- O
fos O
and O
c O
- O
jun O
expression O
by O
IL B-protein
- I-protein
4 I-protein
in O
LPS O
- O
treated O
cells O
was O
shown O
to O
be O
due O
to O
a O
lower O
transcription O
rate O
of O
the O
c O
- O
fos O
and O
c O
- O
jun O
genes O
. O

IL B-protein
- I-protein
4 I-protein
did O
not O
affect O
the O
stability O
of O
the O
c B-protein
- I-protein
fos I-protein
and O
c B-protein
- I-protein
jun I-protein
transcripts I-protein
. O

Finally O
, O
using O
electrophoretic O
mobility O
shift O
assays O
, O
evidence O
was O
obtained O
that O
IL B-protein
- I-protein
4 I-protein
inhibits O
LPS O
- O
induced O
expression O
of O
AP B-protein
- I-protein
1 I-protein
protein O
. O

These O
data O
indicate O
that O
IL B-protein
- I-protein
4 I-protein
suppresses O
the O
induction O
of O
transcription B-protein
factors I-protein
in O
human O
activated O
monocytes O
. O

Transient O
pseudohypoaldosteronism O
in O
obstructive O
renal O
disease O
with O
transient O
reduction O
of O
lymphocytic B-protein
aldosterone I-protein
receptors I-protein
. O

Results O
in O
two O
affected O
infants O
. O

We O
report O
two O
patients O
with O
transient O
pseudohypoaldosteronism O
due O
to O
obstructive O
renal O
disease O
. O

Both O
patients O
presented O
with O
a O
salt O
- O
losing O
episode O
simulating O
adrenal O
insufficiency O
. O

In O
one O
patient O
, O
transient O
reduction O
of O
aldosterone B-protein
receptors I-protein
could O
be O
documented O
, O
while O
in O
the O
second O
patient O
the O
clinical O
and O
biochemical O
parameters O
were O
consistent O
with O
transient O
pseudohypoaldosteronism O
. O

Aldosterone B-protein
receptors I-protein
were O
normal O
in O
both O
patients O
. O

Aldosterone B-protein
- I-protein
specific I-protein
membrane I-protein
receptors I-protein
and O
rapid O
non O
- O
genomic O
actions O
of O
mineralocorticoids O
. O

Functional O
studies O
in O
extrarenal O
, O
non O
- O
epithelial O
cells O
such O
as O
smooth O
muscle O
cells O
and O
more O
recently O
circulating O
human O
lymphocytes O
have O
provided O
increasing O
evidence O
that O
aldosterone O
produces O
not O
only O
classical O
genomic O
effects O
, O
but O
also O
rapid O
, O
non O
- O
genomic O
effects O
on O
transmembrane O
electrolyte O
movements O
. O

These O
involve O
activation O
of O
the O
sodium B-protein
/ I-protein
proton I-protein
exchanger I-protein
of O
the O
cell O
membrane O
at O
very O
low O
, O
physiological O
concentrations O
of O
aldosterone O
with O
an O
acute O
onset O
within O
1 O
- O
2 O
min O
. O

A O
second O
messenger O
cascade O
involved O
is O
the O
inositol O
1 O
, O
4 O
, O
5 O
- O
trisphosphate O
/ O
calcium O
pathway O
which O
responds O
over O
the O
same O
rapid O
time O
course O
. O

Such O
changes O
clearly O
cannot O
be O
explained O
by O
genomic O
mechanisms O
, O
which O
are O
responsible O
for O
later O
effects O
than O
the O
membrane O
related O
rapid O
responses O
. O

The O
mechanisms O
underlying O
these O
rapid O
effects O
of O
aldosterone O
on O
electrolytes O
have O
been O
extensively O
studied O
in O
human O
lymphocytes O
, O
which O
thus O
may O
represent O
valuable O
tools O
in O
the O
delineation O
of O
the O
receptor O
- O
effector O
mechanisms O
involved O
. O

The O
unique O
characteristics O
of O
this O
new O
pathway O
for O
steroid O
action O
include O
its O
rapid O
time O
course O
, O
10 O
, O
000 O
- O
fold O
selectivity O
for O
aldosterone O
over O
cortisol O
and O
the O
ineffectiveness O
of O
spironolactones O
, O
classical O
mineralocorticoid O
antagonists O
, O
as O
antagonists O
of O
the O
response O
. O

Human B-protein
immunodeficiency I-protein
virus I-protein
type I-protein
1 I-protein
Nef I-protein
protein I-protein
inhibits O
NF B-protein
- I-protein
kappa I-protein
B I-protein
induction O
in O
human O
T O
cells O
. O

Human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
can O
establish O
a O
persistent O
and O
latent O
infection O
in O
CD4 O
+ O
T O
lymphocytes O
( O
W O
. O
C O
. O
Greene O
, O
N O
. O
Engl O
. O
J O
. O
Med O
. O
324 O
: O
308 O
- O
317 O
, O
1991 O
; O
S O
. O
M O
. O
Schnittman O
, O
M O
. O
C O
. O
Psallidopoulos O
, O
H O
. O
C O
. O
Lane O
, O
L O
. O
Thompson O
, O
M O
. O
Baseler O
, O
F O
. O
Massari O
, O
C O
. O
H O
. O
Fox O
, O
N O
. O
P O
. O
Salzman O
, O
and O
A O
. O
S O
. O
Fauci O
, O
Science O
245 O
: O
305 O
- O
308 O
, O
1989 O
) O
. O

Production O
of O
HIV O
- O
1 O
from O
latently O
infected O
cells O
requires O
host O
cell O
activation O
by O
T B-protein
- I-protein
cell I-protein
mitogens I-protein
( O
T O
. O
Folks O
, O
D O
. O
M O
. O
Powell O
, O
M O
. O
M O
. O
Lightfoote O
, O
S O
. O
Benn O
, O
M O
. O
A O
. O
Martin O
, O
and O
A O
. O
S O
. O
Fauci O
, O
Science O
231 O
: O
600 O
- O
602 O
, O
1986 O
; O
D O
. O
Zagury O
, O
J O
. O
Bernard O
, O
R O
. O
Leonard O
, O
R O
. O
Cheynier O
, O
M O
. O
Feldman O
, O
P O
. O
S O
. O
Sarin O
, O
and O
R O
. O
C O
. O
Gallo O
, O
Science O
231 O
: O
850 O
- O
853 O
, O
1986 O
) O
. O

This O
activation O
is O
mediated O
by O
the O
host B-protein
transcription I-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
[ O
G O
. O
Nabel O
and O
D O
. O
Baltimore O
, O
Nature O
( O
London O
) O
326 O
: O
711 O
- O
717 O
, O
1987 O
] O
. O

We O
report O
here O
that O
the O
HIV B-protein
- I-protein
1 I-protein
- I-protein
encoded I-protein
Nef I-protein
protein I-protein
inhibits O
the O
induction O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA O
- O
binding O
activity O
by O
T B-protein
- I-protein
cell I-protein
mitogens I-protein
. O

However O
, O
Nef B-protein
does O
not O
affect O
the O
DNA O
- O
binding O
activity O
of O
other O
transcription B-protein
factors I-protein
implicated O
in O
HIV O
- O
1 O
regulation O
, O
including O
SP B-protein
- I-protein
1 I-protein
, O
USF B-protein
, O
URS B-protein
, O
and O
NF B-protein
- I-protein
AT I-protein
. O

Additionally O
, O
Nef B-protein
inhibits O
the O
induction O
of O
HIV O
- O
1 O
- O
and O
interleukin O
2 O
- O
directed O
gene O
expression O
, O
and O
the O
effect O
on O
HIV O
- O
1 O
transcription O
depends O
on O
an O
intact O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
binding O
site O
. O

These O
results O
indicate O
that O
defective O
recruitment O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
may O
underlie O
Nef B-protein
' O
s O
negative O
transcriptional O
effects O
on O
the O
HIV O
- O
1 O
and O
interleukin O
2 O
promoters O
. O

Further O
evidence O
suggests O
that O
Nef B-protein
inhibits O
NF B-protein
- I-protein
kappa I-protein
B I-protein
induction O
by O
interfering O
with O
a O
signal O
derived O
from O
the O
T B-protein
- I-protein
cell I-protein
receptor I-protein
complex I-protein
. O

Expression O
of O
c O
- O
fos O
, O
c O
- O
jun O
and O
jun O
B O
in O
peripheral O
blood O
lymphocytes O
from O
young O
and O
elderly O
adults O
. O

The O
expression O
of O
c O
- O
fos O
, O
c O
- O
jun O
and O
jun O
B O
proto O
- O
oncogenes O
was O
studied O
in O
phytohemagglutinin B-protein
( O
PHA B-protein
) O
activated O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
from O
young O
and O
aged O
humans O
. O

Specific O
mRNAs O
for O
c O
- O
fos O
and O
c O
- O
jun O
were O
detectable O
within O
30 O
min O
after O
cell O
activation O
and O
reached O
maximal O
levels O
within O
2 O
h O
. O

Both O
c O
- O
fos O
and O
jun O
B O
mRNAs O
decreased O
to O
pre O
- O
activation O
levels O
within O
6 O
h O
, O
while O
c O
- O
jun O
mRNA O
remained O
elevated O
. O

In O
PHA B-protein
- O
activated O
PBL O
, O
no O
age O
- O
related O
differences O
were O
observed O
in O
c O
- O
fos O
or O
jun O
B O
mRNA O
expression O
. O

However O
, O
c O
- O
jun O
mRNA O
levels O
decreased O
significantly O
( O
1 O
. O
73 O
+ O
/ O
- O
0 O
. O
08 O
vs O
. O
1 O
. O
16 O
+ O
/ O
- O
0 O
. O
09 O
arbitrary O
units O
, O
P O
< O
0 O
. O
01 O
, O
young O
vs O
. O
old O
) O
in O
PBL O
from O
elderly O
individuals O
activated O
with O
PHA B-protein
. O

Because O
previous O
work O
has O
demonstrated O
that O
T O
cells O
from O
elderly O
individuals O
may O
display O
normal O
proliferative O
responses O
when O
activated O
via O
the O
anti B-protein
- I-protein
CD2 I-protein
pathway O
, O
c O
- O
jun O
and O
jun O
B O
mRNA O
expression O
was O
also O
studied O
in O
anti O
- O
CD2 O
- O
activated O
purified O
T O
cells O
. O

No O
age O
- O
related O
differences O
were O
found O
in O
the O
expression O
of O
either O
of O
these O
two O
proto O
- O
oncogenes O
by O
anti O
- O
CD2 O
activated O
T O
cells O
. O

These O
results O
suggest O
that O
the O
decreased O
IL B-protein
- I-protein
2 I-protein
production O
and O
proliferative O
response O
displayed O
by O
PHA B-protein
- O
activated O
PBL O
from O
elderly O
adults O
may O
be O
related O
to O
age O
- O
related O
changes O
in O
c O
- O
jun O
mRNA O
expression O
and O
in O
the O
ratio O
of O
c O
- O
fos O
to O
c O
- O
jun O
mRNA O
. O

Oct2 B-protein
transactivation O
from O
a O
remote O
enhancer O
position O
requires O
a O
B O
- O
cell O
- O
restricted O
activity O
. O

Previous O
cotransfection O
experiments O
had O
demonstrated O
that O
ectopic O
expression O
of O
the O
lymphocyte B-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
Oct2 B-protein
could O
efficiently O
activate O
a O
promoter O
containing O
an O
octamer O
motif O
. O

Oct2 B-protein
expression O
was O
unable O
to O
stimulate O
a O
multimerized O
octamer O
enhancer O
element O
in O
HeLa O
cells O
, O
however O
. O

We O
have O
tested O
a O
variety O
of O
Oct2 B-protein
isoforms I-protein
generated O
by O
alternative O
splicing O
for O
the O
capability O
to O
activate O
an O
octamer O
enhancer O
in O
nonlymphoid O
cells O
and O
a O
B O
- O
cell O
line O
. O

Our O
analyses O
show O
that O
several O
Oct2 B-protein
isoforms I-protein
can O
stimulate O
from O
a O
remote O
position O
but O
that O
this O
stimulation O
is O
restricted O
to O
B O
cells O
. O

This O
result O
indicates O
the O
involvement O
of O
either O
a O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
cofactor I-protein
or O
a O
specific O
modification O
of O
a O
cofactor B-protein
or O
the O
Oct2 B-protein
protein I-protein
in O
Oct2 B-protein
- O
mediated O
enhancer O
activation O
. O

Mutational O
analyses O
indicate O
that O
the O
carboxy B-protein
- I-protein
terminal I-protein
domain I-protein
of O
Oct2 B-protein
is O
critical O
for O
enhancer O
activation O
. O

Moreover O
, O
this O
domain O
conferred O
enhancing O
activity O
when O
fused O
to O
the O
Oct1 B-protein
protein I-protein
, O
which O
by O
itself O
was O
unable O
to O
stimulate O
from O
a O
remote O
position O
. O

The O
glutamine B-protein
- I-protein
rich I-protein
activation I-protein
domain I-protein
present O
in O
the O
amino B-protein
- I-protein
terminal I-protein
portion I-protein
of I-protein
Oct2 I-protein
and O
the O
POU B-protein
domain I-protein
contribute O
only O
marginally O
to O
the O
transactivation O
function O
from O
a O
distal O
position O
. O

The O
promoter O
of O
the O
CD19 O
gene O
is O
a O
target O
for O
the O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
BSAP B-protein
. O

The O
CD19 B-protein
protein I-protein
is O
expressed O
on O
the O
surface O
of O
all O
B O
- O
lymphoid O
cells O
with O
the O
exception O
of O
terminally O
differentiated O
plasma O
cells O
and O
has O
been O
implicated O
as O
a O
signal O
- O
transducing O
receptor O
in O
the O
control O
of O
proliferation O
and O
differentiation O
. O

Here O
we O
demonstrate O
complete O
correlation O
between O
the O
expression O
pattern O
of O
the O
CD19 O
gene O
and O
the O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
BSAP B-protein
in O
a O
large O
panel O
of O
B O
- O
lymphoid O
cell O
lines O
. O

The O
human O
CD19 O
gene O
has O
been O
cloned O
, O
and O
several O
BSAP B-protein
- O
binding O
sites O
have O
been O
mapped O
by O
in O
vitro O
protein O
- O
DNA O
binding O
studies O
. O

In O
particular O
, O
a O
high O
- O
affinity O
BSAP O
- O
binding O
site O
instead O
of O
a O
TATA O
sequence O
is O
located O
in O
the O
- O
30 O
promoter O
region O
upstream O
of O
a O
cluster O
of O
heterogeneous O
transcription O
start O
sites O
. O

Moreover O
, O
this O
site O
is O
occupied O
by O
BSAP B-protein
in O
vivo O
in O
a O
CD19 O
- O
expressing O
B O
- O
cell O
line O
but O
not O
in O
plasma O
or O
HeLa O
cells O
. O

This O
high O
- O
affinity O
site O
has O
been O
conserved O
in O
the O
promoters O
of O
both O
human O
and O
mouse O
CD19 O
genes O
and O
was O
furthermore O
shown O
to O
confer O
B O
- O
cell O
specificity O
to O
a O
beta O
- O
globin O
reporter O
gene O
in O
transient O
transfection O
experiments O
. O

In O
addition O
, O
BSAP B-protein
was O
found O
to O
be O
the O
only O
abundant O
DNA O
- O
binding O
activity O
of O
B O
- O
cell O
nuclear O
extracts O
that O
interacts O
with O
the O
CD19 O
promoter O
. O

Together O
, O
this O
evidence O
strongly O
implicates O
BSAP B-protein
in O
the O
regulation O
of O
the O
CD19 O
gene O
. O

Eicosanoids O
in O
breast O
cancer O
patients O
before O
and O
after O
mastectomy O
. O

In O
19 O
patients O
with O
a O
malignant O
breast O
tumor O
, O
tumor O
tissue O
and O
blood O
were O
taken O
to O
determine O
the O
eicosanoid O
profile O
and O
platelet O
aggregation O
. O

Values O
were O
compared O
with O
those O
of O
patients O
with O
benign O
tumors O
( O
n O
= O
4 O
) O
, O
or O
undergoing O
a O
mammary O
reduction O
( O
n O
= O
7 O
) O
. O

Postoperatively O
, O
blood O
was O
taken O
as O
well O
in O
order O
to O
compare O
pre O
- O
and O
postoperative O
values O
. O

Eicosanoids O
were O
measured O
in O
peripheral O
blood O
monocytes O
and O
mammary O
tissue O
by O
means O
of O
HPLC O
; O
furthermore O
, O
TXA2 O
, O
6 O
- O
keto O
- O
PGF1 O
alpha O
, O
and O
PGE2 O
were O
determined O
by O
RIA O
. O

Differences O
in O
pre O
- O
and O
postoperative O
values O
of O
cancer O
patients O
were O
seen O
in O
plasma O
RIA O
values O
: O
PGE2 O
and O
6 O
- O
k O
- O
PGF1 O
alpha O
were O
significantly O
higher O
preoperatively O
when O
compared O
with O
postoperatively O
, O
however O
, O
such O
differences O
were O
seen O
in O
the O
control O
groups O
as O
well O
. O

Compared O
to O
benign O
tumor O
or O
mammary O
reduction O
test O
material O
the O
eicosanoid O
profile O
of O
tissue O
obtained O
from O
malignant O
mammary O
tumors O
showed O
important O
differences O
. O

Except O
for O
PGF2 O
alpha O
, O
HHT O
and O
15 O
- O
HETE O
no O
detectable O
quantities O
of O
eicosanoids O
were O
found O
in O
the O
non O
- O
tumor O
material O
, O
whereas O
in O
the O
malignant O
tumor O
material O
substantial O
quantities O
of O
a O
number O
of O
eicosanoid O
metabolites O
were O
present O
. O

Statistically O
significant O
correlations O
could O
be O
established O
between O
patient O
/ O
histopathology O
data O
and O
the O
results O
of O
the O
platelet O
aggregation O
assays O
, O
e O
. O
g O
. O
between O
menopausal O
status O
and O
ADP O
aggregation O
; O
oestrogen B-protein
receptor I-protein
( O
+ O
/ O
- O
) O
and O
collagen B-protein
and O
arachidonic O
acid O
aggregation O
, O
inflammatory O
cell O
infiltration O
score O
and O
arachidonic O
acid O
aggregation O
and O
fibrosis O
score O
and O
ADP O
aggregation O
. O

The O
results O
show O
that O
eicosanoid O
synthesis O
in O
material O
from O
mammary O
cancer O
patients O
is O
different O
from O
that O
in O
benign O
mammary O
tissue O
. O

The O
implications O
, O
in O
particular O
, O
in O
relation O
to O
future O
prognosis O
of O
the O
patient O
, O
remain O
obscure O
. O

Mineralocorticoids O
and O
mineralocorticoid B-protein
receptors I-protein
in O
mononuclear O
leukocytes O
in O
patients O
with O
pregnancy O
- O
induced O
hypertension O
. O

To O
examine O
the O
role O
of O
mineralocorticoids O
in O
the O
pathophysiology O
of O
pregnancy O
- O
induced O
hypertension O
( O
PIH O
) O
, O
we O
studied O
plasma O
aldosterone O
and O
18 O
- O
hydroxycorticosterone O
levels O
in O
25 O
women O
with O
PIH O
and O
25 O
normal O
pregnant O
women O
, O
as O
controls O
. O

Furthermore O
, O
we O
evaluated O
the O
mineralocorticoid B-protein
receptor I-protein
( O
MR B-protein
) O
status O
in O
mononuclear O
leukocytes O
in O
the O
2 O
groups O
. O

MR B-protein
count O
was O
significantly O
( O
P O
less O
than O
0 O
. O
0005 O
) O
decreased O
in O
the O
PIH O
group O
( O
148 O
+ O
/ O
- O
9 O
binding O
sites O
/ O
cell O
) O
compared O
with O
the O
control O
group O
( O
300 O
+ O
/ O
- O
17 O
binding O
sites O
/ O
cell O
; O
mean O
+ O
/ O
- O
SEM O
) O
. O

Plasma O
aldosterone O
in O
women O
with O
PIH O
was O
281 O
+ O
/ O
- O
61 O
pmol O
/ O
L O
; O
in O
normal O
pregnant O
women O
it O
was O
697 O
+ O
/ O
- O
172 O
pmol O
/ O
L O
( O
P O
less O
than O
0 O
. O
025 O
) O
. O

Plasma O
18 O
- O
hydroxycorticosterone O
was O
also O
significantly O
( O
P O
less O
than O
0 O
. O
025 O
) O
lower O
( O
PIH O
, O
1071 O
+ O
/ O
- O
149 O
pmol O
/ O
L O
; O
controls O
, O
1907 O
+ O
/ O
- O
318 O
pmol O
/ O
L O
) O
. O

These O
values O
were O
determined O
at O
the O
onset O
of O
clinical O
symptoms O
of O
PIH O
. O

These O
results O
cannot O
be O
explained O
by O
receptor O
down O
- O
regulation O
due O
to O
higher O
levels O
of O
mineralocorticoids O
in O
PIH O
; O
a O
hitherto O
unknown O
mineralocorticoid O
may O
, O
thus O
, O
be O
responsible O
for O
the O
hypertension O
and O
altered O
MR B-protein
status O
. O

Structure O
function O
analysis O
of O
vitamin O
D O
analogs O
with O
C O
- O
ring O
modifications O
. O

Analogs O
of O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
( O
1 O
alpha O
, O
25 O
- O
( O
OH O
) O
2D3 O
) O
with O
substitutions O
on O
C O
- O
11 O
were O
synthesized O
. O

Small O
apolar O
substitutions O
( O
11 O
alpha O
- O
methyl O
, O
11 O
alpha O
- O
fluoromethyl O
) O
did O
not O
markedly O
decrease O
the O
affinity O
for O
the O
vitamin B-protein
D I-protein
receptor I-protein
, O
but O
larger O
( O
11 O
alpha O
- O
chloromethyl O
or O
11 O
alpha O
- O
or O
11 O
beta O
- O
phenyl O
) O
or O
more O
polar O
substitutions O
( O
11 O
alpha O
- O
hydroxymethyl O
, O
11 O
alpha O
- O
( O
2 O
- O
hydroxyethyl O
] O
decreased O
the O
affinity O
to O
less O
than O
5 O
% O
of O
that O
of O
1 O
alpha O
, O
25 O
- O
OH O
) O
2D3 O
. O

Their O
affinity O
for O
the O
vitamin B-protein
D I-protein
- I-protein
binding I-protein
protein I-protein
, O
however O
, O
increased O
up O
to O
4 O
- O
fold O
. O

The O
biological O
activity O
of O
11 O
alpha O
- O
methyl O
- O
1 O
alpha O
, O
25 O
- O
( O
OH O
) O
2D3 O
closely O
resembled O
that O
of O
the O
natural O
hormone O
on O
normal O
and O
leukemic O
cell O
proliferation O
and O
bone O
resorption O
, O
whereas O
its O
in O
vivo O
effect O
on O
calcium O
metabolism O
of O
the O
rachitic O
chick O
was O
about O
50 O
% O
of O
that O
of O
1 O
alpha O
, O
25 O
- O
( O
OH O
) O
2D3 O
. O

The O
11 O
beta O
- O
methyl O
analog O
had O
a O
greater O
than O
10 O
- O
fold O
lower O
activity O
. O

The O
differentiating O
effects O
of O
the O
other O
C O
- O
11 O
analogs O
on O
human O
promyeloid O
leukemia O
cells O
( O
HL O
- O
60 O
) O
agreed O
well O
with O
their O
bone O
- O
resorbing O
activity O
and O
receptor O
affinity O
, O
but O
they O
demonstrated O
lower O
calcemic O
effects O
in O
vivo O
. O

Large O
or O
polar O
substitutions O
on O
C O
- O
11 O
of O
1 O
alpha O
, O
25 O
- O
( O
OH O
) O
2D3 O
thus O
impair O
the O
binding O
of O
the O
vitamin B-protein
D I-protein
receptor I-protein
but O
increase O
the O
affinity O
to O
vitamin B-protein
D I-protein
- I-protein
binding I-protein
protein I-protein
. O

The O
effects O
of O
many O
C O
- O
11 O
- O
substituted O
1 O
alpha O
, O
25 O
- O
( O
OH O
) O
2D3 O
analogs O
on O
HL O
- O
60 O
cell O
differentiation O
exceeded O
their O
activity O
on O
calcium O
metabolism O
. O

Glucocorticoid B-protein
receptor I-protein
binding O
in O
three O
different O
cell O
types O
in O
major O
depressive O
disorder O
: O
lack O
of O
evidence O
of O
receptor O
binding O
defect O
. O

1 O
. O

In O
order O
to O
further O
understand O
the O
apparent O
glucocorticoid O
resistance O
in O
major O
depressive O
disorder O
, O
circadian O
variation O
in O
cortisol O
concentration O
, O
dexamethasone O
suppression O
and O
glucocorticoid O
receptor O
binding O
in O
mononuclear O
leukocytes O
, O
polymorphonuclear O
leukocytes O
and O
cultured O
skin O
fibroblasts O
were O
measured O
in O
rigidly O
defined O
major O
depressive O
disorder O
patients O
and O
non O
- O
depressed O
psychiatric O
controls O
. O

2 O
. O

Mononuclear O
leukocytes O
binding O
to O
glucocorticoid O
correlated O
significantly O
with O
polymorphonuclear O
leukocytes O
binding O
to O
glucocorticoid O
, O
but O
both O
determinations O
failed O
to O
differentiate O
major O
depressive O
disorder O
and O
control O
subjects O
. O

3 O
. O

Initial O
and O
post O
- O
dexamethasone O
in O
vitro O
fibroblast O
binding O
to O
glucocorticoid O
was O
not O
different O
between O
major O
depressive O
disorder O
and O
non O
- O
depressed O
control O
subjects O
. O

4 O
. O

The O
phenomenon O
of O
glucocorticoid O
resistance O
in O
major O
depressive O
disorder O
remains O
unexplained O
. O

High O
affinity O
aldosterone O
binding O
to O
plasma O
membrane O
rich O
fractions O
from O
mononuclear O
leukocytes O
: O
is O
there O
a O
membrane B-protein
receptor I-protein
for O
mineralocorticoids O
? O
. O

In O
vitro O
effects O
of O
aldosterone O
on O
the O
intracellular O
concentrations O
of O
sodium O
, O
potassium O
and O
calcium O
, O
cell O
volume O
and O
the O
sodium B-protein
- I-protein
proton I-protein
- I-protein
antiport I-protein
have O
been O
described O
in O
intact O
human O
mononuclear O
leukocytes O
( O
HML O
) O
. O

In O
the O
present O
paper O
, O
the O
binding O
of O
a O
[ O
125I O
] O
- O
labeled O
aldosterone O
derivative O
to O
plasma O
membrane O
rich O
fractions O
of O
HML O
was O
studied O
. O

High O
affinity O
binding O
of O
the O
radioligand O
with O
an O
apparent O
Kd O
of O
approximately O
0 O
. O
1 O
nM O
was O
found O
. O

Aldosterone O
displaced O
the O
tracer O
at O
a O
similar O
Kd O
. O

Both O
canrenone O
and O
cortisol O
were O
inactive O
as O
ligands O
up O
to O
concentrations O
of O
0 O
. O
1 O
microM O
. O

The O
findings O
are O
the O
first O
to O
demonstrate O
membrane O
binding O
sites O
with O
a O
high O
affinity O
for O
aldosterone O
, O
but O
not O
for O
cortisol O
. O

These O
data O
are O
perfectly O
compatible O
with O
major O
properties O
of O
steroidal O
effects O
on O
the O
sodium B-protein
- I-protein
proton I-protein
- I-protein
antiport I-protein
in O
HML O
and O
thus O
very O
likely O
represent O
membrane B-protein
receptors I-protein
for O
aldosterone O
. O

Natural O
variants O
of O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
: O
analysis O
of O
promoters O
with O
duplicated O
DNA O
regulatory O
motifs O
. O

Sequence O
variation O
in O
the O
long O
terminal O
repeat O
( O
LTR O
) O
region O
of O
HIV O
- O
1 O
was O
analyzed O
in O
viral O
isolates O
of O
17 O
infected O
individuals O
. O

Two O
classes O
of O
LTR O
size O
variants O
were O
found O
. O

One O
HIV O
- O
1 O
variant O
was O
detected O
containing O
an O
additional O
binding O
site O
for O
the O
transcription O
factor O
Sp1 B-protein
. O

Another O
LTR O
size O
variation O
was O
observed O
in O
four O
patients O
in O
a O
region O
just O
upstream O
of O
the O
NF O
- O
kappa O
B O
enhancer O
. O

This O
variation O
was O
the O
result O
of O
a O
duplication O
of O
a O
short O
DNA O
sequence O
( O
CTG O
- O
motif O
) O
. O

Cell O
culture O
experiments O
demonstrated O
that O
the O
natural O
variant O
with O
four O
Sp1 B-protein
sites O
had O
a O
slightly O
higher O
promoter O
activity O
and O
viral O
replication O
rate O
than O
the O
isogenic O
control O
LTR O
with O
three O
Sp1 B-protein
sites O
. O

No O
positive O
effect O
of O
the O
duplicated O
CTG O
- O
motif O
could O
be O
detected O
. O

In O
order O
to O
measure O
small O
differences O
in O
virus O
production O
more O
accurately O
, O
equal O
amounts O
of O
a O
size O
variant O
and O
the O
wild O
- O
type O
plasmid O
were O
cotransfected O
into O
T O
- O
cells O
. O

The O
virus O
with O
four O
Sp1 O
sites O
did O
outgrow O
the O
three O
Sp1 B-protein
virus O
in O
35 O
days O
of O
culture O
and O
CTG O
- O
monomer O
virus O
outcompeted O
the O
CTG O
- O
dimer O
virus O
in O
42 O
days O
. O

Based O
on O
these O
results O
we O
estimate O
a O
5 O
- O
10 O
% O
difference O
in O
virus O
production O
of O
the O
LTR O
variants O
when O
compared O
to O
that O
of O
wild O
- O
type O
. O

A O
novel B-protein
B I-protein
cell I-protein
- I-protein
derived I-protein
coactivator I-protein
potentiates O
the O
activation O
of O
immunoglobulin O
promoters O
by O
octamer B-protein
- I-protein
binding I-protein
transcription I-protein
factors I-protein
. O

A O
novel O
B O
cell O
- O
restricted O
activity O
, O
required O
for O
high O
levels O
of O
octamer O
/ O
Oct O
- O
dependent O
transcription O
from O
an O
immunoglobulin O
heavy O
chain O
( O
IgH O
) O
promoter O
, O
was O
detected O
in O
an O
in O
vitro O
system O
consisting O
of O
HeLa O
cell O
- O
derived O
extracts O
complemented O
with O
fractionated B-protein
B I-protein
cell I-protein
nuclear I-protein
proteins I-protein
. O

The O
factor O
responsible O
for O
this O
activity O
was O
designated O
Oct B-protein
coactivator I-protein
from O
B O
cells O
( O
OCA B-protein
- I-protein
B I-protein
) O
. O

OCA B-protein
- I-protein
B I-protein
stimulates O
the O
transcription O
from O
an O
IgH O
promoter O
in O
conjunction O
with O
either O
Oct B-protein
- I-protein
1 I-protein
or O
Oct B-protein
- I-protein
2 I-protein
but O
shows O
no O
significant O
effect O
on O
the O
octamer O
/ O
Oct O
- O
dependent O
transcription O
of O
the O
ubiquitously O
expressed O
histone B-protein
H2B I-protein
promoter O
and O
the O
transcription O
of O
USF O
- O
and O
Sp1 O
- O
regulated O
promoters O
. O

Taken O
together O
, O
our O
results O
suggest O
that O
OCA B-protein
- I-protein
B I-protein
is O
a O
tissue O
- O
, O
promoter O
- O
, O
and O
factor O
- O
specific O
coactivator O
and O
that O
OCA B-protein
- I-protein
B I-protein
may O
be O
a O
major O
determinant O
for O
B O
cell O
- O
specific O
activation O
of O
immunoglobulin O
promoters O
. O

In O
light O
of O
the O
evidence O
showing O
physical O
and O
functional O
interactions O
between O
Oct B-protein
factors I-protein
and O
OCA B-protein
- I-protein
B I-protein
, O
we O
propose O
a O
mechanism O
of O
action O
for O
OCA B-protein
- I-protein
B I-protein
and O
discuss O
the O
implications O
of O
OCA B-protein
- I-protein
B I-protein
for O
the O
transcriptional O
regulation O
of O
other O
tissue O
- O
specific O
promoters O
. O

SCL B-protein
and O
related O
hemopoietic B-protein
helix I-protein
- I-protein
loop I-protein
- I-protein
helix I-protein
transcription I-protein
factors I-protein
. O

The O
helix B-protein
- I-protein
loop I-protein
- I-protein
helix I-protein
( I-protein
HLH I-protein
) I-protein
proteins I-protein
are O
a O
family O
of O
transcription B-protein
factors I-protein
that O
include O
proteins O
critical O
to O
differentiation O
and O
development O
in O
species O
ranging O
from O
plants O
to O
mammals O
. O

Five O
members O
of O
this O
family O
( O
MYC B-protein
, O
SCL B-protein
, O
TAL B-protein
- I-protein
2 I-protein
, O
LYL B-protein
- I-protein
1 I-protein
and O
E2A B-protein
) O
are O
implicated O
in O
oncogenic O
events O
in O
human O
lymphoid O
tumors O
because O
of O
their O
consistent O
involvement O
in O
chromosomal O
translocations O
. O

Although O
activated O
in O
T O
cell O
leukemias O
, O
expression O
of O
SCL B-protein
and O
LYL B-protein
- I-protein
1 I-protein
is O
low O
or O
undetectable O
in O
normal O
T O
cell O
populations O
. O

SCL B-protein
is O
expressed O
in O
erythroid O
, O
megakaryocyte O
and O
mast O
cell O
populations O
( O
the O
same O
cell O
lineages O
as O
GATA B-protein
- I-protein
1 I-protein
, O
a O
zinc B-protein
- I-protein
finger I-protein
transcription I-protein
factor I-protein
) O
. O

In O
addition O
, O
both O
SCL B-protein
and O
GATA B-protein
- I-protein
1 I-protein
undergo O
coordinate O
modulation O
during O
chemically O
induced O
erythroid O
differentiation O
of O
mouse O
erythroleukemia O
cells O
and O
are O
down O
- O
modulated O
during O
myeloid O
differentiation O
of O
human O
K562 O
cells O
, O
thus O
implying O
a O
role O
for O
SCL B-protein
in O
erythroid O
differentiation O
events O
. O

However O
, O
in O
contrast O
to O
GATA B-protein
- I-protein
1 I-protein
, O
SCL B-protein
is O
expressed O
in O
the O
developing O
brain O
. O

Studies O
of O
the O
function O
of O
SCL B-protein
suggest O
it O
is O
also O
important O
in O
proliferation O
and O
self O
- O
renewal O
events O
in O
erythroid O
cells O
. O

Induction O
of O
the O
POU B-protein
domain I-protein
transcription I-protein
factor I-protein
Oct B-protein
- I-protein
2 I-protein
during O
T O
- O
cell O
activation O
by O
cognate O
antigen O
. O

Oct B-protein
- I-protein
2 I-protein
is O
a O
transcription B-protein
factor I-protein
that O
binds O
specifically O
to O
octamer O
DNA O
motifs O
in O
the O
promoters O
of O
immunoglobulin O
and O
interleukin O
- O
2 O
genes O
. O

All O
tumor O
cell O
lines O
from O
the O
B O
- O
cell O
lineage O
and O
a O
few O
from O
the O
T O
- O
cell O
lineage O
express O
Oct B-protein
- I-protein
2 I-protein
. O

To O
address O
the O
role O
of O
Oct B-protein
- I-protein
2 I-protein
in O
the O
T O
- O
cell O
lineage O
, O
we O
studied O
the O
expression O
of O
Oct B-protein
- I-protein
2 I-protein
mRNA O
and O
protein O
in O
nontransformed O
human O
and O
mouse O
T O
cells O
. O

Oct B-protein
- I-protein
2 I-protein
was O
found O
in O
CD4 O
+ O
and O
CD8 O
+ O
T O
cells O
prepared O
from O
human O
peripheral O
blood O
and O
in O
mouse O
lymph O
node O
T O
cells O
. O

In O
a O
T O
- O
cell O
clone O
specific O
for O
pigeon B-protein
cytochrome I-protein
c I-protein
in O
the O
context O
of O
I B-protein
- I-protein
Ek I-protein
, O
Oct B-protein
- I-protein
2 I-protein
was O
induced O
by O
antigen O
stimulation O
, O
with O
the O
increase O
in O
Oct B-protein
- I-protein
2 I-protein
protein I-protein
seen O
first O
at O
3 O
h O
after O
activation O
and O
continuing O
for O
at O
least O
24 O
h O
. O

Oct B-protein
- I-protein
2 I-protein
mRNA O
induction O
during O
antigen O
- O
driven O
T O
- O
cell O
activation O
was O
blocked O
by O
cyclosporin O
A O
, O
as O
well O
as O
by O
protein O
synthesis O
inhibitors O
. O

These O
results O
suggest O
that O
Oct B-protein
- I-protein
2 I-protein
participates O
in O
transcriptional O
regulation O
during O
T O
- O
cell O
activation O
. O
The O
relatively O
delayed O
kinetics O
of O
Oct B-protein
- I-protein
2 I-protein
induction O
suggests O
that O
Oct B-protein
- I-protein
2 I-protein
mediates O
the O
changes O
in O
gene O
expression O
which O
occur O
many O
hours O
or O
days O
following O
antigen O
stimulation O
of O
T O
lymphocytes O
. O

Glucocorticoid B-protein
receptor I-protein
in O
patients O
with O
lupus O
nephritis O
: O
relationship O
between O
receptor O
levels O
in O
mononuclear O
leukocytes O
and O
effect O
of O
glucocorticoid O
therapy O
. O

We O
investigated O
the O
clinical O
significance O
of O
glucocorticoid B-protein
receptor I-protein
determination O
in O
20 O
patients O
with O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
who O
afterwards O
developed O
nephrotic O
syndrome O
. O

Glucocorticoid B-protein
receptor I-protein
concentrations O
in O
mononuclear O
leukocytes O
( O
MNL O
) O
in O
these O
patients O
were O
comparable O
with O
those O
in O
both O
other O
patients O
with O
SLE O
and O
healthy O
persons O
. O

Improvement O
in O
urinary O
protein O
excretion O
and O
in O
disease O
activity O
, O
which O
was O
scored O
according O
to O
the O
SLE O
Disease O
Activity O
Index O
system O
of O
the O
University O
of O
Toronto O
, O
closely O
related O
to O
the O
glucocorticoid B-protein
receptor I-protein
concentrations O
in O
MNL O
isolated O
from O
the O
corresponding O
patients O
. O

In O
summary O
, O
glucocorticoid B-protein
receptor I-protein
determination O
in O
patients O
with O
lupus O
nephritis O
may O
be O
a O
predictive O
clue O
for O
assessing O
responsiveness O
to O
glucocorticoid O
therapy O
. O

[ O
Changes O
in O
plasma B-protein
interleukin I-protein
- I-protein
1 I-protein
and O
their O
possible O
relationship O
with O
the O
changes O
in O
glucocorticoid B-protein
receptor I-protein
in O
aged O
long O
- O
distance O
runner O
] O
. O

For O
the O
study O
of O
the O
changes O
in O
plasma B-protein
interleukin I-protein
- I-protein
1 I-protein
( O
IL B-protein
- I-protein
1 I-protein
) O
and O
their O
possible O
relationship O
with O
the O
changes O
in O
glucocorticoid B-protein
receptor I-protein
( O
GR B-protein
) O
, O
plasma B-protein
IL I-protein
- I-protein
1 I-protein
and O
GR B-protein
in O
peripheral O
blood O
leukocytes O
in O
aged O
long O
- O
distance O
runner O
were O
measured O
simultaneously O
. O

The O
activity O
of O
IL B-protein
- I-protein
1 I-protein
was O
expressed O
as O
its O
ability O
to O
stimulate O
3H B-protein
- I-protein
TdR I-protein
incorporation O
in O
the O
thymocytes O
of O
C57 O
mice O
. O

GR B-protein
was O
determined O
by O
whole O
cell O
assay O
with O
3H O
- O
Dex O
. O

The O
results O
showed O
that O
the O
activity O
of O
plasma O
IL B-protein
- I-protein
1 I-protein
in O
aged O
long O
- O
distance O
runner O
was O
209 O
% O
, O
223 O
% O
and O
145 O
% O
of O
the O
control O
at O
14 O
. O
7 O
- O
18 O
. O
7 O
, O
3 O
. O
8 O
- O
7 O
. O
0 O
and O
1 O
. O
5 O
- O
2 O
. O
6 O
KD O
fractions O
. O

The O
GR B-protein
in O
peripheral O
blood O
leukocytes O
in O
aged O
runner O
was O
65 O
% O
of O
the O
control O
. O

Possible O
relationship O
between O
the O
changes O
in O
IL B-protein
- I-protein
1 I-protein
and O
GR B-protein
in O
aged O
long O
- O
distance O
runner O
and O
its O
physiological O
significance O
are O
discussed O
. O

Mineralocorticoid O
effector O
mechanism O
in O
preeclampsia O
. O

Mineralocorticoid O
effector O
mechanisms O
were O
evaluated O
in O
29 O
patients O
with O
preeclampsia O
and O
in O
25 O
uncomplicated O
pregnancies O
by O
measurement O
of O
plasma O
aldosterone O
, O
levels O
of O
mineralocorticoid B-protein
receptor I-protein
( O
MR B-protein
) O
in O
mononuclear O
leucocytes O
, O
and O
subtraction O
potential O
difference O
( O
SPD O
; O
rectal O
minus O
oral O
values O
) O
. O

Mean O
values O
for O
plasma O
aldosterone O
were O
not O
different O
between O
the O
two O
groups O
, O
but O
significant O
differences O
were O
observed O
for O
MR B-protein
( O
preeclampsia O
, O
81 O
+ O
/ O
- O
44 O
receptors O
/ O
cell O
; O
controls O
, O
306 O
+ O
/ O
- O
168 O
) O
and O
SPD O
( O
preeclampsia O
, O
65 O
+ O
/ O
- O
7 O
mV O
; O
controls O
, O
12 O
+ O
/ O
- O
5 O
mV O
) O
. O

In O
six O
cases O
we O
determined O
MR B-protein
, O
plasma O
aldosterone O
, O
and O
SPD O
in O
patients O
with O
preeclampsia O
before O
and O
3 O
months O
after O
delivery O
. O

MR B-protein
were O
reduced O
before O
delivery O
( O
96 O
+ O
/ O
- O
27 O
receptors O
/ O
cell O
) O
, O
and O
SPD O
increased O
( O
64 O
+ O
/ O
- O
8 O
mV O
) O
, O
with O
both O
parameters O
normalizing O
after O
delivery O
( O
MR B-protein
, O
242 O
+ O
/ O
- O
79 O
; O
SPD O
, O
14 O
. O
0 O
+ O
/ O
- O
4 O
mV O
) O
. O

Aldosterone O
levels O
returned O
to O
normal O
nonpregnant O
values O
after O
delivery O
. O

These O
data O
suggest O
an O
important O
role O
for O
abnormalities O
in O
mineralocorticoid O
effector O
mechanisms O
in O
the O
etiology O
of O
preeclampsia O
and O
could O
be O
an O
useful O
marker O
for O
diagnosis O
. O

Kinetics O
of O
nuclear O
translocation O
and O
turnover O
of O
the O
vitamin B-protein
D I-protein
receptor I-protein
in O
human O
HL60 O
leukemia O
cells O
and O
peripheral O
blood O
lymphocytes O
- O
- O
coincident O
rise O
of O
DNA O
- O
relaxing O
activity O
in O
nuclear O
extracts O
. O

High B-protein
affinity I-protein
receptors I-protein
( O
VDR B-protein
) O
for O
1 O
, O
25 O
- O
dihydroxycholecalciferol O
( O
calcitriol O
) O
are O
expressed O
in O
HL60 O
human O
leukemia O
cells O
and O
in O
low O
numbers O
in O
peripheral O
blood O
lymphocytes O
( O
PBL O
) O
. O

HL60 O
cells O
, O
expressing O
some O
characteristics O
of O
promyelocytes O
, O
can O
be O
induced O
to O
monocytoid O
differentiation O
by O
calcitriol O
. O

Specific O
nuclear O
translocation O
of O
[ B-protein
3H I-protein
] I-protein
calcitriol I-protein
/ I-protein
VDR I-protein
was O
examined O
after O
exposure O
of O
whole O
cells O
to O
10 O
( O
- O
9 O
) O
M O
/ O
l O
calcitriol O
in O
the O
presence O
and O
absence O
of O
a O
500 O
- O
fold O
excess O
of O
unlabeled O
ligand O
and O
subsequent O
isolation O
of O
nuclei O
. O

Specific O
nuclear O
translocation O
of O
[ B-protein
3H I-protein
] I-protein
calcitriol I-protein
/ I-protein
VDR I-protein
was O
found O
to O
be O
time O
dependent O
reaching O
a O
maximum O
of O
approximately O
2100 O
binding O
sites O
/ O
nucleus O
after O
3 O
h O
of O
incubation O
in O
HL60 O
cells O
, O
whereas O
a O
maximum O
of O
approximately O
310 O
binding O
sites O
/ O
nucleus O
was O
found O
after O
3 O
h O
in O
PBL O
. O

Pulse O
exposure O
of O
HL60 O
to O
radiolabeled O
hormone O
for O
3 O
h O
followed O
by O
culture O
in O
medium O
without O
serum O
and O
calcitriol O
lead O
to O
nuclear O
retention O
of O
approximately O
1600 B-protein
radiolabeled I-protein
VDR I-protein
by O
8 O
h O
and O
approximately O
1000 O
VDR B-protein
by O
24 O
h O
. O

Radiolabeled B-protein
VDR I-protein
disappeared O
from O
the O
nuclear O
compartment O
with O
a O
halflife O
of O
approximately O
30 O
min O
if O
cells O
were O
cultured O
with O
identical O
concentrations O
of O
unlabeled O
hormone O
after O
the O
pulse O
( O
pulse O
/ O
chase O
- O
experiments O
) O
. O

No O
difference O
of O
VDR B-protein
retention O
in O
pulse O
and O
pulse O
/ O
chase O
- O
experiments O
was O
seen O
in O
PBL O
, O
where O
VDR B-protein
halflife O
was O
approximately O
30 O
min O
. O

No O
specific O
translocation O
into O
the O
nuclear O
compartment O
was O
seen O
when O
isolated O
nuclei O
were O
incubated O
in O
[ O
3H O
] O
calcitriol O
. O

Radiolabeled B-protein
hormone I-protein
/ I-protein
receptor I-protein
complexes I-protein
of O
nuclei O
isolated O
from O
cells O
exposed O
for O
3 O
h O
to O
radiolabeled O
hormone O
- O
- O
in O
contrast O
to O
identical O
experiments O
with O
intact O
cells O
- O
- O
did O
not O
disappear O
from O
the O
nuclear O
compartment O
upon O
incubation O
of O
nuclei O
with O
identical O
concentrations O
of O
the O
unlabeled O
compound O
. O

The O
activity O
of O
DNA B-protein
relaxing I-protein
enzymes I-protein
( O
e O
. O
g O
. O
topoisomerases O
I O
and O
II O
) O
in O
nuclear O
extracts O
was O
measured O
using O
a O
PBR O
322 O
- O
relaxation O
- O
assay O
. O

Enhanced O
overall O
enzyme O
activity O
was O
found O
in O
nuclear O
extracts O
by O
1 O
h O
after O
incubation O
with O
calcitriol O
( O
final O
ethanol O
concentration O
0 O
. O
0001 O
% O
v O
/ O
v O
) O
in O
HL60 O
and O
PBL O
. O

The O
enhanced O
activity O
disappeared O
after O
2 O
h O
in O
PBL O
, O
whereas O
it O
was O
still O
enhanced O
by O
4 O
h O
in O
HL60 O
. O

No O
effect O
was O
seen O
in O
ethanol O
treated O
controls O
. O

We O
conclude O
that O
a O
specific O
nuclear O
translocation O
mechanism O
exists O
for O
calcitriol O
in O
both O
cell O
types O
examined O
, O
most O
likely O
due O
to O
translocation O
of O
receptor B-protein
proteins I-protein
after O
hormone O
binding O
. O

Translocated B-protein
hormone I-protein
/ I-protein
receptor I-protein
complexes I-protein
compete O
for O
a O
limited O
number O
of O
specific O
nuclear O
binding O
sites O
. O

Enhanced O
activity O
of O
topoisomerases B-protein
in O
nuclear O
extracts O
upon O
translocation O
of O
VDR B-protein
might O
reflect O
interaction O
of O
both O
within O
the O
nuclear O
compartment O
, O
thus O
initiating O
DNA O
- O
unwinding O
, O
a O
prerequisite O
of O
transcription O
initiation O
. O

Influence O
of O
estradiol O
and O
tamoxifen O
on O
susceptibility O
of O
human O
breast O
cancer O
cell O
lines O
to O
lysis O
by O
lymphokine O
- O
activated O
killer O
cells O
. O

The O
design O
of O
combination O
hormonal O
and O
immunotherapeutic O
protocols O
for O
breast O
cancer O
patients O
may O
be O
facilitated O
by O
analysis O
of O
preclinical O
in O
vitro O
model O
systems O
. O

Estrogen O
receptor O
positive O
( O
ER O
+ O
: O
MCF O
- O
7 O
) O
and O
negative O
( O
ER O
- O
: O
MDA O
- O
MB O
- O
231 O
) O
human O
breast O
cancer O
cell O
lines O
were O
utilized O
to O
evaluate O
the O
effects O
of O
tamoxifen O
( O
TAM O
) O
and O
estradiol O
( O
E2 O
) O
on O
modulation O
of O
breast O
cancer O
target O
susceptibility O
to O
lysis O
by O
lymphokine O
- O
activated O
killer O
( O
LAK O
) O
cells O
. O

E2 O
- O
stimulated O
ER O
+ O
cells O
were O
more O
susceptible O
to O
lysis O
by O
LAK O
cells O
than O
corresponding O
TAM O
- O
treated O
or O
control O
cells O
, O
while O
treatment O
of O
ER O
- O
cells O
with O
either O
E2 O
or O
TAM O
alone O
did O
not O
alter O
from O
control O
their O
susceptibility O
to O
this O
immune O
- O
mediated O
lysis O
. O

All O
ER O
+ O
and O
ER O
- O
cells O
tested O
remained O
sensitive O
after O
treatment O
with O
TAM O
to O
lysis O
by O
LAK O
cells O
. O

In O
addition O
, O
an O
adenocarcinoma B-protein
reactive I-protein
human I-protein
- I-protein
mouse I-protein
chimeric I-protein
monoclonal I-protein
antibody I-protein
( O
ING B-protein
- I-protein
1 I-protein
) O
was O
able O
to O
significantly O
boost O
in O
vivo O
generated O
LAK O
cell O
- O
mediated O
lysis O
of O
control O
, O
E2 O
- O
treated O
, O
and O
TAM O
- O
treated O
ER O
+ O
and O
ER O
- O
cells O
. O

These O
in O
vitro O
results O
provide O
a O
preclinical O
rationale O
for O
in O
vivo O
testing O
of O
TAM O
, O
interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
, O
and O
breast O
cancer O
reactive O
antibody O
- O
dependent O
cellular O
cytotoxicity O
facilitating O
antibody O
in O
patients O
with O
refractory O
or O
high O
risk O
breast O
cancer O
. O

The O
cellular O
oncogene O
c O
- O
myb O
can O
interact O
synergistically O
with O
the O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
BZLF1 I-protein
transactivator I-protein
in O
lymphoid O
cells O
. O

Regulation O
of O
replicative O
functions O
in O
the O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
genome O
is O
mediated O
through O
activation O
of O
a O
virally B-protein
encoded I-protein
transcription I-protein
factor I-protein
, O
Z B-protein
( O
BZLF1 B-protein
) O
. O

We O
have O
shown O
that O
the O
Z B-protein
gene I-protein
product I-protein
, O
which O
binds O
to O
AP O
- O
1 O
sites O
as O
a O
homodimer B-protein
and O
has O
sequence O
similarity O
to O
c O
- O
Fos O
, O
can O
efficiently O
activate O
the O
EBV O
early O
promoter O
, O
BMRF1 O
, O
in O
certain O
cell O
types O
( O
i O
. O
e O
. O
, O
HeLa O
cells O
) O
but O
not O
others O
( O
i O
. O
e O
. O
, O
Jurkat O
cells O
) O
. O

Here O
we O
demonstrate O
that O
the O
c B-protein
- I-protein
myb I-protein
proto I-protein
- I-protein
oncogene I-protein
product I-protein
, O
which O
is O
itself O
a O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
and O
transcriptional B-protein
transactivator I-protein
, O
can O
interact O
synergistically O
with O
Z B-protein
in O
activating O
the O
BMRF1 O
promoter O
in O
Jurkat O
cells O
( O
a O
T O
- O
cell O
line O
) O
or O
Raji O
cells O
( O
an O
EBV O
- O
positive O
B O
- O
cell O
) O
, O
whereas O
the O
c B-protein
- I-protein
myb I-protein
gene I-protein
product I-protein
by O
itself O
has O
little O
effect O
. O

The O
simian O
virus O
40 O
early O
promoter O
is O
also O
synergistically O
activated O
by O
the O
Z B-protein
/ I-protein
c I-protein
- I-protein
myb I-protein
combination I-protein
. O

Synergistic O
transactivation O
of O
the O
BMRF1 O
promoter O
by O
the O
Z B-protein
/ I-protein
c I-protein
- I-protein
myb I-protein
combination I-protein
appears O
to O
involve O
direct O
binding O
by O
the O
Z B-protein
protein I-protein
but O
not O
the O
c B-protein
- I-protein
myb I-protein
protein I-protein
. O

A O
30 O
- O
bp O
sequence O
in O
the O
BMRF1 O
promoter O
which O
contains O
a O
Z O
binding O
site O
( O
a O
consensus O
AP O
- O
1 O
site O
) O
is O
sufficient O
to O
transfer O
high O
- O
level O
lymphoid O
- O
specific O
responsiveness O
to O
the O
Z B-protein
/ I-protein
c I-protein
- I-protein
myb I-protein
combination I-protein
to O
a O
heterologous O
promoter O
. O

That O
the O
c B-protein
- I-protein
myb I-protein
oncogene I-protein
product I-protein
can O
interact O
synergistically O
with O
an O
EBV B-protein
- I-protein
encoded I-protein
member I-protein
of O
the O
leucine B-protein
zipper I-protein
protein I-protein
family I-protein
suggests O
c O
- O
myb O
is O
likely O
to O
engage O
in O
similar O
interactions O
with O
cellularly B-protein
encoded I-protein
transcription I-protein
factors I-protein
. O

Alpha O
- O
lipoic O
acid O
is O
a O
potent O
inhibitor O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
in O
human O
T O
cells O
. O

Acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
results O
from O
infection O
with O
a O
human O
immunodeficiency O
virus O
( O
HIV O
) O
. O

The O
long O
terminal O
repeat O
( O
LTR O
) O
region O
of O
HIV O
proviral O
DNA O
contains O
binding O
sites O
for O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
, O
and O
this O
transcriptional B-protein
activator I-protein
appears O
to O
regulate O
HIV O
activation O
. O

Recent O
findings O
suggest O
an O
involvement O
of O
reactive O
oxygen O
species O
( O
ROS O
) O
in O
signal O
transduction O
pathways O
leading O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
. O

The O
present O
study O
was O
based O
on O
reports O
that O
antioxidants O
which O
eliminate O
ROS O
should O
block O
the O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
subsequently O
HIV O
transcription O
, O
and O
thus O
antioxidants O
can O
be O
used O
as O
therapeutic O
agents O
for O
AIDS O
. O

Incubation O
of O
Jurkat O
T O
cells O
( O
1 O
x O
10 O
( O
6 O
) O
cells O
/ O
ml O
) O
with O
a O
natural O
thiol O
antioxidant O
, O
alpha O
- O
lipoic O
acid O
, O
prior O
to O
the O
stimulation O
of O
cells O
was O
found O
to O
inhibit O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
induced O
by O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
( O
25 O
ng O
/ O
ml O
) O
or O
by O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
50 O
ng O
/ O
ml O
) O
. O

The O
inhibitory O
action O
of O
alpha O
- O
lipoic O
acid O
was O
found O
to O
be O
very O
potent O
as O
only O
4 O
mM O
was O
needed O
for O
a O
complete O
inhibition O
, O
whereas O
20 O
mM O
was O
required O
for O
N O
- O
acetylcysteine O
. O

These O
results O
indicate O
that O
alpha O
- O
lipoic O
acid O
may O
be O
effective O
in O
AIDS O
therapeutics O
. O

Reticuloendotheliosis O
virus O
long O
terminal O
repeat O
elements O
are O
efficient O
promoters O
in O
cells O
of O
various O
species O
and O
tissue O
origin O
, O
including O
human O
lymphoid O
cells O
. O

Promiscuous O
transcriptional O
activity O
of O
the O
reticuloendotheliosis O
virus O
( O
REV O
) O
long O
terminal O
repeat O
( O
LTR O
) O
was O
detected O
in O
transient O
expression O
assays O
using O
LTR O
- O
chloramphenicol B-protein
acetyltransferase I-protein
- O
encoding O
gene O
chimeras O
, O
and O
cells O
of O
diverse O
species O
and O
tissue O
type O
; O
levels O
of O
expression O
from O
two O
different O
REV O
LTRs O
correlate O
with O
reports O
of O
pathogenicity O
of O
the O
respective O
viruses O
in O
vivo O
. O

REVs O
do O
not O
encode O
a O
transactivator O
targeted O
to O
the O
viral O
LTR O
, O
and O
cells O
infected O
with O
Marek O
' O
s O
disease O
virus O
, O
a O
herpesvirus O
with O
an O
overlapping O
host O
range O
, O
do O
not O
express O
factors O
that O
preferentially O
enhance O
expression O
from O
REV O
or O
avian O
sarcoma O
/ O
leukemia O
virus O
LTRs O
. O

REV O
LTRs O
work O
efficiently O
in O
human O
lymphoid O
cells O
, O
and O
are O
viable O
alternatives O
to O
promoters O
commonly O
used O
for O
expression O
of O
cloned O
genes O
. O

They O
may O
also O
prove O
useful O
in O
the O
identification O
of O
new O
, O
ubiquitous B-protein
cellular I-protein
transcription I-protein
factors I-protein
. O

A O
novel O
Ets B-protein
- I-protein
related I-protein
transcription I-protein
factor I-protein
, O
Elf B-protein
- I-protein
1 I-protein
, O
binds O
to O
human O
immunodeficiency O
virus O
type O
2 O
regulatory O
elements O
that O
are O
required O
for O
inducible O
trans O
activation O
in O
T O
cells O
. O

Human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
and O
HIV O
- O
2 O
are O
structurally O
related O
retroviruses O
which O
both O
cause O
AIDS O
in O
humans O
. O

Although O
both O
viruses O
establish O
latency O
in O
quiescent O
human O
- O
peripheral O
- O
blood O
T O
cells O
, O
the O
asymptomatic O
phase O
of O
HIV O
- O
2 O
infection O
may O
be O
more O
prolonged O
than O
that O
of O
HIV O
- O
1 O
. O

The O
latent O
phases O
of O
both O
HIV O
- O
1 O
and O
HIV O
- O
2 O
infection O
have O
been O
shown O
to O
be O
disrupted O
by O
T O
- O
cell O
activation O
, O
a O
process O
that O
requires O
host O
cell O
transcription O
factors O
. O

In O
the O
case O
of O
HIV O
- O
1 O
, O
the O
transcription O
factor O
NF B-protein
- I-protein
kappa I-protein
B I-protein
is O
sufficient O
for O
inducible O
transcriptional O
activation O
. O

In O
contrast O
, O
factors O
in O
addition O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
are O
required O
to O
activate O
HIV O
- O
2 O
transcription O
in O
infected O
T O
cells O
. O

In O
this O
report O
, O
we O
demonstrate O
that O
a O
novel O
Ets B-protein
- I-protein
related I-protein
transcription I-protein
factor I-protein
, O
Elf B-protein
- I-protein
1 I-protein
, O
binds O
specifically O
to O
two O
purine O
- O
rich O
motifs O
in O
the O
HIV O
- O
2 O
enhancer O
. O

Mutagenesis O
experiments O
demonstrated O
that O
these O
Elf B-protein
- I-protein
1 I-protein
binding O
sites O
are O
required O
for O
induction O
of O
HIV O
- O
2 O
transcription O
following O
T O
- O
cell O
- O
receptor O
- O
mediated O
T O
- O
cell O
activation O
. O

Moreover O
, O
Elf B-protein
- I-protein
1 I-protein
is O
the O
only O
factor O
present O
in O
activated O
T O
- O
cell O
nuclear O
extracts O
that O
binds O
to O
these O
sites O
in O
electrophoretic O
mobility O
shift O
assays O
. O

Thus O
, O
Elf B-protein
- I-protein
1 I-protein
is O
a O
novel B-protein
transcription I-protein
factor I-protein
that O
appears O
to O
be O
required O
for O
the O
T O
- O
cell O
- O
receptor O
- O
mediated O
trans O
activation O
of O
HIV O
- O
2 O
gene O
expression O
. O

These O
results O
may O
explain O
differences O
in O
the O
clinical O
spectra O
of O
diseases O
caused O
by O
HIV O
- O
1 O
and O
HIV O
- O
2 O
and O
may O
also O
have O
implications O
for O
the O
design O
of O
therapeutic O
approaches O
to O
HIV O
- O
2 O
infection O
. O

Okadaic O
acid O
is O
a O
potent O
inducer O
of O
AP B-protein
- I-protein
1 I-protein
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
and O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
in O
human O
B O
lymphocytes O
. O

Treatment O
of O
human O
B O
lymphocytes O
with O
an O
optimal O
concentration O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases O
1 O
and O
2A O
, O
resulted O
in O
the O
induction O
of O
the O
transcription B-protein
factor I-protein
, O
AP B-protein
- I-protein
1 I-protein
and O
a O
marked O
increase O
in O
NF B-protein
- I-protein
kappa I-protein
B I-protein
levels O
. O

In O
contrast O
, O
no O
effect O
on O
the O
levels O
of O
the O
octamer B-protein
binding I-protein
proteins I-protein
, O
Oct B-protein
- I-protein
1 I-protein
or O
Oct B-protein
- I-protein
2 I-protein
, O
were O
found O
. O

Since O
both O
AP B-protein
- I-protein
1 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
have O
been O
reported O
to O
be O
important O
in O
the O
induction O
of O
the O
tumor B-protein
necrosis I-protein
factor I-protein
- I-protein
alpha I-protein
( O
TNF O
- O
alpha O
) O
gene O
we O
examined O
the O
effects O
of O
okadaic O
acid O
on O
TNF O
- O
alpha O
mRNA O
levels O
. O

Treatment O
with O
okadaic O
acid O
resulted O
in O
a O
striking O
increase O
in O
TNF O
- O
alpha O
mRNA O
transcripts O
within O
1 O
h O
of O
stimulation O
and O
large O
amounts O
of O
TNF B-protein
- I-protein
alpha I-protein
were O
released O
into O
the O
culture O
media O
. O

Although O
okadaic O
acid O
provides O
a O
potent O
inductive O
signal O
for O
AP B-protein
- I-protein
1 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
it O
did O
not O
induce O
either O
B O
cell O
proliferation O
or O
immunoglobulin B-protein
secretion O
. O

Heterodimerization O
and O
transcriptional O
activation O
in O
vitro O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
proteins I-protein
. O

The O
NF B-protein
- I-protein
kappa I-protein
B I-protein
family I-protein
of O
transcription B-protein
proteins I-protein
represents O
multiple O
DNA O
binding O
, O
rel B-protein
related I-protein
polypeptides I-protein
that O
contribute O
to O
regulation O
of O
genes O
involved O
in O
immune O
responsiveness O
and O
inflammation O
, O
as O
well O
as O
activation O
of O
the O
HIV O
long O
terminal O
repeat O
. O

In O
this O
study O
multiple O
NF B-protein
- I-protein
kappa I-protein
B I-protein
related I-protein
polypeptides I-protein
ranging O
from O
85 O
to O
45 O
kDa O
were O
examined O
for O
their O
capacity O
to O
interact O
with O
the O
PRDII O
regulatory O
element O
of O
interferon O
beta O
and O
were O
shown O
to O
possess O
distinct O
intrinsic O
DNA O
binding O
affinities O
for O
this O
NF B-protein
- I-protein
kappa I-protein
B I-protein
site O
and O
form O
multiple O
DNA O
binding O
homo O
- O
and O
heterodimer O
complexes O
in O
co O
- O
renaturation O
experiments O
. O

Furthermore O
, O
using O
DNA O
templates O
containing O
two O
copies O
of O
the O
PRDII O
domain O
linked O
to O
the O
rabbit O
beta O
globin O
gene O
, O
the O
purified O
polypeptides O
specifically O
stimulated O
NF B-protein
- I-protein
kappa I-protein
B I-protein
dependent O
transcription O
in O
an O
in O
vitro O
reconstitution O
assay O
as O
heterodimers O
but O
not O
as O
p50 B-protein
homodimers I-protein
. O

These O
experiments O
emphasize O
the O
role O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
dimerization O
as O
a O
distinct O
level O
of O
transcriptional O
control O
that O
may O
permit O
functional O
diversification O
of O
a O
limited O
number O
of O
regulatory B-protein
proteins I-protein
. O

c O
- O
myc O
mRNA O
expression O
in O
minor O
salivary O
glands O
of O
patients O
with O
Sjogren O
' O
s O
syndrome O
. O

c O
- O
myc O
protooncogene O
is O
implicated O
in O
the O
pathogenesis O
of O
B O
cell O
lymphoid O
malignancies O
and O
high O
levels O
of O
c O
- O
myc O
mRNA O
expression O
are O
observed O
in O
activated O
blood O
mononuclear O
cells O
. O

Sjogren O
' O
s O
syndrome O
( O
SS O
) O
is O
characterized O
by O
lymphocytic O
infiltrates O
of O
exocrine O
glands O
, O
remarkable O
B O
cell O
hyperreactivity O
and O
a O
strong O
predisposition O
to O
B O
cell O
neoplasia O
. O

In O
this O
study O
, O
c O
- O
myc O
protooncogene O
mRNA O
expression O
in O
29 O
labial O
minor O
salivary O
gland O
biopsies O
from O
patients O
with O
primary O
SS O
and O
15 O
controls O
was O
examined O
using O
in O
situ O
hybridization O
histochemistry O
. O

Two O
40mer O
oligonucleotides O
from O
the O
1st O
and O
the O
2nd O
exon O
of O
the O
c O
- O
myc O
gene O
, O
labeled O
with O
35S O
, O
were O
used O
as O
probes O
. O

To O
detect O
the O
origin O
of O
the O
cell O
hybridized O
with O
a O
c O
- O
myc O
probe O
, O
a O
combined O
immunochemistry O
in O
situ O
hybridization O
histochemistry O
technique O
was O
used O
. O

High O
c O
- O
myc O
mRNA O
expression O
was O
detected O
on O
acinar O
epithelial O
cells O
. O

c B-protein
- I-protein
myc I-protein
did O
not O
correlate O
with O
c B-protein
- I-protein
fos I-protein
and O
c B-protein
- I-protein
jun I-protein
protein O
expression O
. O

Stronger O
c O
- O
myc O
mRNA O
expression O
was O
detected O
in O
labial O
salivary O
glands O
of O
patients O
with O
longer O
disease O
duration O
( O
p O
less O
than O
or O
equal O
to O
0 O
. O
002 O
) O
and O
more O
intense O
T O
lymphocyte O
infiltrates O
( O
p O
less O
than O
0 O
. O
05 O
) O
although O
these O
patients O
revealed O
no O
hypergammaglobulinemia O
. O

No O
correlation O
was O
observed O
between O
c O
- O
myc O
mRNA O
and O
B O
lymphocyte O
monoclonicity O
or O
lymphoma O
. O

In O
conclusion O
, O
strong O
c O
- O
myc O
mRNA O
expression O
was O
observed O
on O
epithelial O
cells O
of O
labial O
salivary O
glands O
from O
patients O
with O
primary O
SS O
. O

Our O
findings O
may O
indicate O
the O
presence O
of O
a O
reactivated O
virus O
hosted O
in O
these O
cells O
. O

Corticosteroid B-protein
receptors I-protein
and O
lymphocyte O
subsets O
in O
mononuclear O
leukocytes O
in O
aging O
. O

Plasma O
cortisol O
and O
aldosterone O
levels O
and O
number O
of O
related O
receptors O
in O
mononuclear O
leukocytes O
were O
measured O
in O
49 O
healthy O
aged O
subjects O
( O
62 O
- O
97 O
yr O
) O
and O
in O
21 O
adult O
controls O
( O
21 O
- O
50 O
yr O
) O
. O

In O
all O
subjects O
, O
in O
addition O
, O
lymphocyte O
subsets O
were O
determined O
as O
an O
index O
of O
corticosteroid O
action O
. O

The O
mean O
number O
of O
type O
I O
and O
type O
II O
receptors O
was O
significantly O
lower O
in O
aged O
subjects O
than O
in O
controls O
( O
respectively O
, O
198 O
+ O
/ O
- O
96 O
and O
272 O
+ O
/ O
- O
97 O
receptors B-protein
/ O
cell O
for O
type B-protein
I I-protein
, O
and O
1 O
, O
794 O
+ O
/ O
- O
803 O
and O
3 O
, O
339 O
+ O
/ O
- O
918 O
for O
type O
II B-protein
receptors I-protein
) O
. O

Plasma O
aldosterone O
and O
cortisol O
and O
lymphocyte O
subsets O
were O
not O
different O
in O
the O
two O
groups O
. O

All O
of O
the O
parameters O
were O
also O
tested O
for O
correlation O
, O
and O
a O
significant O
inverse O
correlation O
was O
found O
between O
age O
and O
type B-protein
I I-protein
and O
type B-protein
II I-protein
receptors I-protein
when O
all O
subjects O
were O
plotted O
and O
between O
aged O
and O
CD4 O
and O
age O
and O
CD4 O
/ O
CD8 O
in O
the O
aged O
group O
. O

These O
data O
show O
that O
aged O
subjects O
have O
reductions O
of O
corticosteroid B-protein
receptors I-protein
that O
are O
not O
associated O
with O
increase O
of O
related O
steroids O
and O
that O
this O
situation O
probably O
represents O
a O
concomitant O
of O
the O
normal O
aging O
process O
. O

T O
cell O
- O
specific O
negative O
regulation O
of O
transcription O
of O
the O
human B-protein
cytokine I-protein
IL I-protein
- I-protein
4 I-protein
. O

IL B-protein
- I-protein
4 I-protein
secreted O
by O
activated O
T O
cells O
is O
a O
pleiotropic B-protein
cytokine I-protein
affecting O
growth O
and O
differentiation O
of O
diverse O
cell O
types O
such O
as O
T O
cells O
, O
B O
cells O
, O
and O
mast O
cells O
. O

We O
investigated O
the O
upstream O
regulatory O
elements O
of O
the O
human O
IL O
- O
4 O
promoter O
. O

A O
novel O
T O
cell O
- O
specific O
negative O
regulatory O
element O
( O
NRE O
) O
composed O
of O
two O
protein O
- O
binding O
sites O
were O
mapped O
in O
the O
5 O
' O
flanking O
region O
of O
the O
IL O
- O
4 O
gene O
: O
- O
311CTCCCTTCT O
- O
303 O
( O
NRE O
- O
I O
) O
and O
- O
288CTTTTTGCTT O
- O
TGC O
- O
300 O
( O
NRE O
- O
II O
) O
. O

A O
T B-protein
cell I-protein
- I-protein
specific I-protein
protein I-protein
Neg B-protein
- I-protein
1 I-protein
and O
a O
ubiquitous B-protein
protein I-protein
Neg B-protein
- I-protein
2 I-protein
binding O
to O
NRE O
- O
I O
and O
NRE O
- O
II O
, O
respectively O
, O
were O
identified O
. O

Furthermore O
, O
a O
positive O
regulatory O
element O
was O
found O
45 O
bp O
downstream O
of O
the O
NRE O
. O

The O
enhancer O
activity O
of O
the O
PRE O
was O
completely O
suppressed O
when O
the O
NRE O
was O
present O
. O

These O
data O
suggest O
that O
IL O
- O
4 O
promoter O
activity O
is O
normally O
down O
- O
regulated O
by O
an O
NRE O
via O
repression O
of O
the O
enhancer O
positive O
regulatory O
element O
. O

These O
data O
may O
have O
implications O
for O
the O
stringent O
control O
of O
IL B-protein
- I-protein
4 I-protein
expression O
in O
T O
cells O
. O

Interleukin O
6 O
- O
induced O
differentiation O
of O
a O
human O
B O
cell O
line O
into O
IgM O
- O
secreting O
plasma O
cells O
is O
mediated O
by O
c O
- O
fos O
. O

The O
role O
of O
the O
protooncogene O
c O
- O
fos O
in O
interleukin B-protein
( I-protein
IL I-protein
) I-protein
6 I-protein
- O
induced O
B O
cell O
differentiation O
was O
assessed O
. O

Treatment O
of O
SKW O
6 O
. O
4 O
cells O
with O
IL B-protein
6 I-protein
induced O
a O
transient O
and O
early O
stimulation O
of O
c O
- O
fos O
sense O
mRNA O
expression O
. O

The O
effect O
appeared O
within O
30 O
min O
and O
returned O
to O
basal O
levels O
after O
2 O
h O
. O

The O
addition O
of O
antisense O
oligonucleotides O
to O
c O
- O
fos O
significantly O
inhibited O
IL B-protein
6 I-protein
- O
induced O
IgM B-protein
production O
by O
SKW O
6 O
. O
4 O
cells O
( O
p O
less O
than O
0 O
. O
001 O
) O
, O
whereas O
control O
oligonucleotides O
had O
no O
inhibitory O
effect O
. O

These O
results O
indicate O
that O
activation O
of O
c O
- O
fos O
is O
involved O
in O
IL B-protein
6 I-protein
- O
induced O
differentiation O
of O
SKW O
6 O
. O
4 O
cells O
into O
IgM O
- O
secreting O
cells O
. O

Transcriptional O
regulation O
during O
T O
- O
cell O
development O
: O
the O
alpha O
TCR O
gene O
as O
a O
molecular O
model O
. O

The O
regulation O
of O
gene O
expression O
during O
lymphocyte O
differentiation O
is O
a O
complex O
process O
involving O
interactions O
between O
multiple O
positive O
and O
negative O
transcriptional O
regulatory O
elements O
. O

In O
this O
article O
, O
transcriptional O
regulation O
of O
the O
archetypal O
T O
- O
cell O
- O
specific O
gene O
, O
alpha O
TCR O
, O
is O
discussed O
. O

Major O
recent O
developments O
, O
including O
the O
identification O
of O
novel O
families O
of O
transcription O
factors O
that O
regulate O
multiple O
T O
- O
cell O
genes O
during O
thymocyte O
ontogeny O
and O
T O
- O
cell O
activation O
, O
are O
described O
. O

Photoaffinity O
labeling O
of O
plasma B-protein
membrane I-protein
receptors I-protein
for O
aldosterone O
from O
human O
mononuclear O
leukocytes O
. O

Non O
- O
genomic O
effects O
of O
aldosterone O
on O
the O
sodium B-protein
- I-protein
proton I-protein
- I-protein
antiport I-protein
have O
been O
shown O
in O
human O
mononuclear O
leukocytes O
which O
could O
be O
related O
to O
a O
new O
aldosterone B-protein
membrane I-protein
receptor I-protein
. O

In O
the O
present O
paper O
plasma O
membranes O
from O
human O
mononuclear O
leukocytes O
were O
covalently O
photolabeled O
with O
a O
[ O
125I O
] O
- O
aldosterone O
derivative O
. O

Sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gel O
electrophoresis O
showed O
significant O
aldosterone O
binding O
at O
a O
molecular O
weight O
of O
approximately O
50000 O
Dalton O
which O
was O
absent O
with O
1 O
microM O
cold O
aldosterone O
, O
but O
not O
cortisol O
in O
the O
binding O
media O
. O

The O
presence O
of O
the O
sulfhydryl O
agent O
dithiothreitol O
did O
not O
affect O
results O
suggesting O
the O
absence O
of O
disulfide B-protein
bridges I-protein
in O
the O
steroid B-protein
binding I-protein
domain I-protein
of O
the O
receptor O
. O

These O
data O
are O
the O
first O
to O
define O
the O
molecular O
weight O
of O
the O
membrane B-protein
receptor I-protein
for O
aldosterone O
. O

Redox O
status O
of O
cells O
influences O
constitutive O
or O
induced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
and O
HIV O
long O
terminal O
repeat O
activity O
in O
human O
T O
and O
monocytic O
cell O
lines O
. O

We O
have O
tested O
the O
hypothesis O
that O
cellular O
activation O
events O
occurring O
in O
T O
lymphocytes O
and O
monocytes O
and O
mediated O
through O
translocation O
of O
the O
transcription B-protein
factor I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
are O
dependent O
upon O
the O
constitutive O
redox O
status O
of O
these O
cells O
. O

We O
used O
phenolic O
, O
lipid O
- O
soluble O
, O
chain O
- O
breaking O
antioxidants O
( O
butylated O
hydroxyanisole O
( O
BHA O
) O
, O
nordihydroquairetic O
acid O
, O
or O
alpha O
- O
tocopherol O
( O
vitamin O
E O
) O
to O
show O
that O
peroxyl O
radical O
scavenging O
in O
unstimulated O
and O
PMA O
- O
or O
TNF O
- O
stimulated O
cells O
blocks O
the O
functions O
depending O
on O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
. O

BHA O
was O
found O
to O
suppress O
not O
only O
PMA O
- O
or O
TNF O
- O
induced O
, O
but O
also O
constitutive O
, O
HIV O
- O
enhancer O
activity O
concomitant O
to O
an O
inhibition O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activity O
in O
both O
lymphoblastoid O
T O
( O
J O
. O
Jhan O
) O
and O
monocytic O
( O
U937 O
) O
cell O
lines O
. O

This O
was O
also O
true O
for O
KBF O
( O
p50 O
homodimer O
) O
binding O
activity O
in O
U937 O
cells O
. O

Secretion O
of O
TNF B-protein
, O
the O
product O
of O
another O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
gene O
, O
was O
abolished O
by O
BHA O
in O
PMA O
- O
stimulated O
U937 O
cells O
. O

The O
anti O
- O
oxidative O
effect O
of O
BHA O
was O
accompanied O
by O
an O
increase O
in O
thiol O
, O
but O
not O
glutathione O
, O
content O
in O
stimulated O
and O
unstimulated O
T O
cell O
, O
whereas O
TNF B-protein
stimulation O
itself O
barely O
modified O
the O
cellular O
thiol O
level O
. O

Oxidative O
stress O
obtained O
by O
the O
addition O
of O
H2O2 O
to O
the O
culture O
medium O
of O
J O
. O
Jhan O
or O
U937 O
cells O
could O
not O
by O
itself O
induce O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
. O

These O
observations O
suggest O
that O
TNF B-protein
and O
PMA B-protein
do O
not O
lead O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
through O
induction O
of O
changes O
in O
the O
cell O
redox O
status O
. O

Rather O
, O
TNF B-protein
and O
PMA B-protein
can O
exert O
their O
effect O
only O
if O
cells O
are O
in O
an O
appropriate O
redox O
status O
, O
because O
prior O
modification O
toward O
reduction O
with O
BHA O
treatment O
prevents O
this O
activation O
. O

It O
appears O
that O
a O
basal O
redox O
equilibrium O
tending O
toward O
oxidation O
is O
a O
prerequisite O
for O
full O
activation O
of O
transduction O
pathways O
regulating O
the O
activity O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
genes O
. O

Selection O
of O
optimal O
kappa O
B O
/ O
Rel O
DNA O
- O
binding O
motifs O
: O
interaction O
of O
both O
subunits O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
with O
DNA O
is O
required O
for O
transcriptional O
activation O
. O

Analysis O
of O
the O
p50 B-protein
and O
p65 B-protein
subunits I-protein
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
complex I-protein
has O
revealed O
that O
both O
proteins O
can O
interact O
with O
related O
DNA O
sequences O
through O
either O
homo O
- O
or O
heterodimer O
formation O
. O

In O
addition O
, O
the O
product O
of O
the O
proto O
- O
oncogene O
c O
- O
rel O
can O
bind O
to O
similar O
DNA O
motifs O
by O
itself O
or O
as O
a O
heterodimer O
with O
p50 B-protein
or O
p65 B-protein
. O

However O
, O
these O
studies O
have O
used O
a O
limited O
number O
of O
known O
kappa O
B O
DNA O
motifs O
, O
and O
the O
question O
of O
the O
optimal O
DNA O
sequences O
preferred O
by O
each O
homodimer O
has O
not O
been O
addressed O
. O

Using O
purified O
recombinant O
p50 B-protein
, O
p65 B-protein
, O
and O
c B-protein
- I-protein
Rel I-protein
proteins I-protein
, O
optimal O
DNA O
- O
binding O
motifs O
were O
selected O
from O
a O
pool O
of O
random O
oligonucleotides O
. O

Alignment O
of O
the O
selected O
sequences O
allowed O
us O
to O
predict O
a O
consensus O
sequence O
for O
binding O
of O
the O
individual O
homodimeric B-protein
Rel I-protein
- I-protein
related I-protein
proteins I-protein
, O
and O
DNA O
- O
protein O
binding O
analysis O
of O
the O
selected O
DNA O
sequences O
revealed O
sequence O
specificity O
of O
the O
proteins O
. O

Contrary O
to O
previous O
assumptions O
, O
we O
observed O
that O
p65 B-protein
homodimers O
can O
interact O
with O
a O
subset O
of O
DNA O
sequences O
not O
recognized O
by O
p50 B-protein
homodimers I-protein
. O

Differential O
binding O
affinities O
were O
also O
obtained O
with O
p50 O
- O
and O
c O
- O
Rel O
- O
selected O
sequences O
. O

Using O
either O
a O
p50 O
- O
or O
p65 O
- O
selected O
kappa O
B O
motif O
, O
which O
displayed O
differential O
binding O
with O
respect O
to O
the O
other O
protein O
, O
little O
to O
no O
binding O
was O
observed O
with O
the O
heterodimeric B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
. O

Similarly O
, O
in O
transfection O
experiments O
in O
which O
the O
selective O
kappa O
B O
binding O
sites O
were O
used O
to O
drive O
the O
expression O
of O
a O
chloramphenicol B-protein
acetyltransferase I-protein
reporter O
construct O
, O
the O
p65 B-protein
- O
and O
p50 B-protein
- O
selected O
motifs O
were O
activated O
only O
in O
the O
presence O
of O
p65 B-protein
and O
p50 B-protein
/ I-protein
65 I-protein
( O
a O
chimeric B-protein
protein I-protein
with O
the O
p50 B-protein
DNA I-protein
binding I-protein
domain I-protein
and O
p65 B-protein
activation I-protein
domain I-protein
) O
expression O
vectors O
, O
respectively O
, O
and O
neither O
demonstrated O
a O
significant O
response O
to O
stimuli O
that O
induce O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
. O

These O
findings O
demonstrate O
that O
interaction O
of O
both O
subunits O
of O
the O
heterodimeric B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
with O
DNA O
is O
required O
for O
DNA O
binding O
and O
transcriptional O
activation O
and O
suggest O
that O
transcriptional O
activation O
mediated O
by O
the O
individual O
rel B-protein
- I-protein
related I-protein
proteins I-protein
will O
differ O
dramatically O
, O
depending O
on O
the O
specific O
kappa O
B O
motifs O
present O
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
induction O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 B-protein
subunit O
gene O
promoter O
underlies O
self O
- O
perpetuation O
of O
human O
immunodeficiency O
virus O
transcription O
in O
monocytic O
cells O
. O

The O
molecular O
mechanisms O
underlying O
the O
sustained O
nuclear O
translocation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
observed O
in O
U937 O
monocytic O
cells O
chronically O
infected O
with O
human O
immunodeficiency O
virus O
( O
HIV O
) O
were O
studied O
. O

The O
activity O
of O
the O
promoter O
regulating O
the O
synthesis O
of O
the O
p105 B-protein
precursor I-protein
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 I-protein
subunit I-protein
was O
enhanced O
in O
these O
cells O
. O

Deletions O
in O
this O
promoter O
indicated O
that O
this O
upregulation O
was O
mediated O
through O
the O
NF O
- O
kappa O
B O
- O
but O
not O
the O
AP O
- O
1 O
- O
binding O
motif O
, O
by O
bona O
fide O
p50 B-protein
/ I-protein
p65 I-protein
heterodimers I-protein
. O

Analysis O
of O
cytosolic O
extracts O
indicated O
that O
NF B-protein
- I-protein
kappa I-protein
B I-protein
levels O
were O
increased O
in O
HIV O
- O
infected O
cells O
. O

In O
contrast O
to O
the O
transient O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activation O
induced O
by O
phorbol O
ester O
, O
the O
permanent O
NF B-protein
- I-protein
kappa I-protein
B I-protein
translocation O
induced O
by O
HIV O
infection O
was O
not O
dependent O
on O
PKC O
isoenzymes O
alpha O
and O
beta O
as O
shown O
by O
the O
use O
of O
a O
specific O
inhibitor O
( O
GF O
109203X O
) O
. O

These O
observations O
indicate O
that O
during O
chronic O
HIV O
infection O
of O
U937 O
cells O
, O
continuous O
NF B-protein
- I-protein
kappa I-protein
B I-protein
( O
p50 B-protein
/ I-protein
p65 I-protein
) O
translocation O
results O
in O
p105 O
promoter O
upregulation O
with O
subsequent O
cytosolic O
NF B-protein
- I-protein
kappa I-protein
B I-protein
accumulation O
, O
ready O
for O
further O
translocation O
. O

This O
HIV O
- O
mediated O
mechanism O
results O
in O
a O
self O
- O
perpetuating O
loop O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
production O
. O

Activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
interleukin B-protein
2 I-protein
in O
human O
blood O
monocytes O
. O

We O
report O
here O
that O
interleukin B-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
acts O
on O
human O
blood O
monocytes O
by O
enhancing O
binding O
activity O
of O
the O
transcription B-protein
factor I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
to O
its O
consensus O
sequence O
in O
the O
5 O
' O
regulatory O
enhancer O
region O
of O
the O
IL B-protein
- I-protein
2 I-protein
receptor O
alpha O
chain O
( O
p55 B-protein
) O
. O

Similarly O
, O
IL B-protein
- I-protein
2 I-protein
activates O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
the O
human O
monocytic O
cell O
line O
U O
937 O
, O
but O
not O
in O
resting O
human O
T O
- O
cells O
. O

This O
effect O
is O
detectable O
within O
15 O
min O
and O
peaks O
1 O
h O
after O
exposure O
to O
IL B-protein
- I-protein
2 I-protein
. O

Enhanced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activity O
is O
followed O
by O
functional O
activation O
in O
that O
inducibility O
of O
the O
IL B-protein
- I-protein
2 I-protein
receptor I-protein
alpha I-protein
chain I-protein
is O
mediated O
by O
enhanced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
and O
that O
a O
heterologous O
promoter O
containing O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
consensus O
sequence O
( O
- O
291 O
to O
- O
245 O
) O
of O
the O
IL O
- O
2 O
receptor O
alpha O
chain O
gene O
is O
activated O
. O

In O
addition O
, O
IL B-protein
- I-protein
2 I-protein
is O
capable O
of O
increasing O
transcript O
levels O
of O
the O
p50 B-protein
gene O
coding O
for O
the O
p50 B-protein
subunit I-protein
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription O
factor O
, O
whereas O
mRNA O
levels O
of O
the O
p65 B-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
gene O
remained O
unchanged O
. O

Studies O
on O
the O
biological O
activity O
of O
triiodothyronine O
sulfate O
. O

Hepatic O
microsomes O
and O
isolated O
hepatocytes O
in O
short O
term O
culture O
desulfate O
T3 O
sulfate O
( O
T3SO4 O
) O
. O

We O
, O
therefore O
, O
wished O
to O
determine O
whether O
T3SO4 O
could O
mimic O
the O
action O
of O
thyroid O
hormone O
in O
vitro O
. O

T3SO4 O
had O
no O
thyromimetic O
effect O
on O
the O
activity O
of O
Ca B-protein
( I-protein
2 I-protein
+ I-protein
) I-protein
- I-protein
ATPase I-protein
in O
human O
erythrocyte O
membranes O
at O
doses O
up O
to O
10 O
, O
000 O
times O
the O
maximally O
effective O
dose O
of O
T3 O
( O
10 O
( O
- O
10 O
) O
mol O
/ O
L O
) O
. O

In O
GH4C1 O
pituitary O
cells O
, O
T3SO4 O
failed O
to O
displace O
[ O
125I O
] O
T3 O
from O
nuclear B-protein
receptors I-protein
in O
intact O
cells O
or O
soluble O
preparations O
. O

Thus O
, O
T3SO4 O
was O
not O
directly O
thyromimetic O
in O
either O
an O
isolated O
human O
membrane O
system O
or O
a O
pituitary O
cell O
system O
in O
which O
nuclear O
receptor O
occupancy O
correlates O
with O
GH O
synthesis O
. O

Thyroid O
hormones O
inhibit O
[ O
3H O
] O
glycosaminoglycan O
synthesis O
by O
cultured O
human O
dermal O
fibroblasts O
, O
and O
T3SO4 O
displayed O
about O
0 O
. O
5 O
% O
the O
activity O
of O
T3 O
at O
72 O
h O
. O

Human O
fibroblasts O
contained O
roughly O
the O
same O
level O
of O
microsomal O
p B-protein
- I-protein
nitrophenyl I-protein
sulfatase I-protein
activity O
as O
that O
previously O
observed O
in O
hepatic O
microsomes O
. O

Propylthiouracil O
( O
50 O
mumol O
/ O
L O
) O
did O
not O
affect O
the O
action O
of O
T3SO4 O
, O
suggesting O
that O
deiodination O
was O
not O
important O
for O
this O
activity O
of O
T3SO4 O
. O

Thus O
, O
it O
appears O
T3SO4 O
has O
no O
intrinsic O
biological O
activity O
, O
but O
, O
under O
certain O
circumstances O
, O
may O
be O
reactivated O
by O
desulfation O
. O

Human O
T O
cell O
activation O
through O
the O
activation B-protein
- I-protein
inducer I-protein
molecule I-protein
/ I-protein
CD69 I-protein
enhances O
the O
activity O
of O
transcription B-protein
factor I-protein
AP I-protein
- I-protein
1 I-protein
. O

The O
induction O
of O
the O
AP B-protein
- I-protein
1 I-protein
transcription I-protein
factor I-protein
has O
been O
ascribed O
to O
the O
early O
events O
leading O
to O
T O
cell O
differentiation O
and O
activation O
. O

We O
have O
studied O
the O
regulation O
of O
AP B-protein
- I-protein
1 I-protein
activity O
in O
human O
peripheral O
blood O
T O
lymphocytes O
stimulated O
through O
the O
activation O
inducer O
molecule O
( O
AIM O
) O
/ O
CD69 B-protein
activation O
pathway O
. O

Phorbol O
esters O
are O
required O
to O
induce O
AIM B-protein
/ I-protein
CD69 I-protein
cell O
- O
surface O
expression O
as O
well O
as O
for O
triggering O
the O
proliferation O
of O
T O
cells O
in O
conjunction O
with O
anti B-protein
- I-protein
AIM I-protein
mAb I-protein
. O

Mobility O
shift O
assays O
showed O
that O
addition O
of O
anti B-protein
- I-protein
AIM I-protein
mAb I-protein
to O
PMA B-protein
- O
treated O
T O
lymphocytes O
markedly O
enhanced O
the O
binding O
activity O
of O
AP B-protein
- I-protein
1 I-protein
to O
its O
cognate O
sequence O
, O
the O
phorbol O
ester O
response O
element O
. O

In O
contrast O
, O
anti B-protein
- I-protein
AIM I-protein
mAb I-protein
did O
not O
induce O
any O
change O
in O
the O
binding O
activity O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
a O
transcription B-protein
factor I-protein
whose O
activity O
is O
also O
regulated O
by O
protein B-protein
kinase I-protein
C I-protein
. O

The O
increase O
in O
AP B-protein
- I-protein
1 I-protein
- O
binding O
activity O
was O
accompanied O
by O
the O
marked O
stimulation O
of O
the O
transcription O
of O
c B-protein
- I-protein
fos I-protein
but O
not O
that O
of O
c B-protein
- I-protein
jun I-protein
. O

Blockade O
of O
the O
DNA B-protein
- I-protein
binding I-protein
complexes I-protein
with O
an O
anti B-protein
- I-protein
Fos I-protein
mAb I-protein
demonstrated O
a O
direct O
participation O
of O
c B-protein
- I-protein
Fos I-protein
in O
the O
AP B-protein
- I-protein
1 I-protein
complexes I-protein
induced O
by O
anti B-protein
- I-protein
AIM I-protein
mAb I-protein
. O

Most O
of O
the O
AP B-protein
- I-protein
1 I-protein
activity O
could O
be O
eliminated O
when O
the O
anti B-protein
- I-protein
AIM I-protein
mAb I-protein
was O
added O
to O
the O
culture O
medium O
in O
the O
presence O
of O
cycloheximide O
, O
suggesting O
that O
de O
novo O
protein O
synthesis O
is O
crucial O
for O
the O
induction O
of O
AP B-protein
- I-protein
1 I-protein
- O
binding O
activity O
. O

These O
data O
provide O
the O
evidence O
that O
activation O
of O
human O
peripheral O
blood O
T O
cells O
through O
the O
AIM O
activation O
pathway O
regulate O
the O
activity O
of O
AP B-protein
- I-protein
1 I-protein
. O

Therefore O
, O
this O
pathway O
appears O
as O
a O
crucial O
step O
in O
the O
initiation O
of O
early O
T O
cell O
activation O
events O
. O

Gangliosides O
suppress O
tumor B-protein
necrosis I-protein
factor I-protein
production O
in O
human O
monocytes O
. O

Both O
normal O
and O
malignant O
cells O
contain O
gangliosides O
as O
important O
cell O
membrane O
constituents O
that O
, O
after O
being O
shed O
, O
may O
influence O
cells O
of O
the O
immune O
system O
. O

We O
have O
studied O
the O
impact O
of O
gangliosides O
on O
the O
expression O
of O
TNF B-protein
in O
blood O
monocytes O
and O
in O
the O
monocytic O
cell O
line O
Mono O
Mac O
6 O
. O

Although O
under O
standard O
culture O
conditions O
, O
bovine O
brain O
gangliosides O
( O
100 O
micrograms O
/ O
ml O
) O
suppressed O
LPS O
- O
stimulated O
TNF B-protein
production O
5 O
- O
fold O
in O
PBMC O
and O
10 O
- O
fold O
in O
Mono O
Mac O
6 O
cells O
, O
suppression O
was O
more O
efficient O
under O
serum O
- O
free O
conditions O
. O

Looking O
at O
highly O
purified O
gangliosides O
, O
GD3 O
, O
GD1a O
, O
GM3 O
, O
GM2 O
, O
and O
GM1 O
were O
all O
effective O
in O
reducing O
TNF B-protein
production O
in O
PBMC O
, O
and O
in O
Mono O
Mac O
6 O
by O
factor O
10 O
to O
50 O
. O

The O
suppressive O
activity O
was O
lost O
in O
molecules O
, O
lacking O
the O
sugar O
moiety O
or O
the O
lipid O
moiety O
. O

Gangliosides O
appear O
to O
act O
at O
an O
early O
step O
of O
activation O
in O
that O
TNF B-protein
transcripts O
were O
reduced O
and O
the O
mobilization O
of O
the O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
was O
blocked O
. O

Furthermore O
, O
in O
time O
kinetics O
, O
gangliosides O
were O
effective O
for O
up O
to O
30 O
min O
after O
addition O
of O
LPS O
, O
but O
not O
thereafter O
. O

However O
, O
the O
expression O
of O
the O
CD14 B-protein
Ag I-protein
, O
a O
receptor B-protein
molecule I-protein
for O
LPS B-protein
- I-protein
LPS I-protein
binding I-protein
protein I-protein
complexes I-protein
, O
was O
unaffected O
by O
gangliosides O
. O

Finally O
, O
when O
using O
Staphylococcus O
aureus O
or O
platelet B-protein
activating I-protein
factor I-protein
as O
a O
stimulus O
, O
gangliosides O
were O
able O
to O
suppress O
TNF B-protein
production O
in O
Mono O
Mac O
6 O
cells O
by O
factor O
5 O
to O
10 O
, O
as O
well O
. O

On O
the O
other O
hand O
, O
phorbol O
ester O
- O
induced O
production O
of O
O2 O
- O
was O
similar O
in O
cells O
treated O
with O
and O
without O
gangliosides O
. O

Taken O
together O
, O
our O
data O
demonstrate O
that O
TNF B-protein
gene O
expression O
in O
monocytes O
induced O
by O
different O
types O
of O
stimuli O
can O
be O
blocked O
by O
gangliosides O
at O
an O
early O
step O
of O
signal O
transduction O
. O

A O
novel O
mitogen B-protein
- I-protein
inducible I-protein
gene I-protein
product I-protein
related O
to O
p50 B-protein
/ I-protein
p105 I-protein
- I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
participates O
in O
transactivation O
through O
a O
kappa O
B O
site O
. O

A O
Rel B-protein
- I-protein
related I-protein
, I-protein
mitogen I-protein
- I-protein
inducible I-protein
, I-protein
kappa I-protein
B I-protein
- I-protein
binding I-protein
protein I-protein
has O
been O
cloned O
as O
an O
immediate O
- O
early O
activation O
gene O
of O
human O
peripheral O
blood O
T O
cells O
. O

The O
cDNA O
has O
an O
open O
reading O
frame O
of O
900 O
amino O
acids O
capable O
of O
encoding O
a O
97 B-protein
- I-protein
kDa I-protein
protein I-protein
. O

This O
protein O
is O
most O
similar O
to O
the O
105 O
- O
kDa O
precursor O
polypeptide O
of O
p50 B-protein
- I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
. O

Like O
the O
105 O
- O
kDa O
precursor O
, O
it O
contains O
an O
amino B-protein
- I-protein
terminal I-protein
Rel I-protein
- I-protein
related I-protein
domain I-protein
of O
about O
300 O
amino O
acids O
and O
a O
carboxy B-protein
- I-protein
terminal I-protein
domain I-protein
containing O
six O
full B-protein
cell I-protein
cycle I-protein
or O
ankyrin B-protein
repeats I-protein
. O

In O
vitro B-protein
- I-protein
translated I-protein
proteins I-protein
, O
truncated O
downstream O
of O
the O
Rel O
domain O
and O
excluding O
the O
repeats O
, O
bind O
kappa O
B O
sites O
. O

We O
refer O
to O
the O
kappa B-protein
B I-protein
- I-protein
binding I-protein
, I-protein
truncated I-protein
protein I-protein
as O
p50B B-protein
by O
analogy O
with O
p50 B-protein
- I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
and O
to O
the O
full O
- O
length O
protein O
as O
p97 B-protein
. O

p50B B-protein
is O
able O
to O
form O
heteromeric B-protein
kappa I-protein
B I-protein
- I-protein
binding I-protein
complexes I-protein
with O
RelB B-protein
, O
as O
well O
as O
with O
p65 B-protein
and O
p50 B-protein
, O
the O
two O
subunits O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Transient O
- O
transfection O
experiments O
in O
embryonal O
carcinoma O
cells O
demonstrate O
a O
functional O
cooperation O
between O
p50B B-protein
and O
RelB B-protein
or O
p65 B-protein
in O
transactivation O
of O
a O
reporter O
plasmid O
dependent O
on O
a O
kappa O
B O
site O
. O

The O
data O
imply O
the O
existence O
of O
a O
complex O
family O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
like I-protein
transcription I-protein
factors I-protein
. O

Surrogate O
thyroglobulin B-protein
receptors I-protein
and O
T O
cell O
proliferation O
in O
Hashimoto O
' O
s O
thyroiditis O
. O

Immunoglobulin B-protein
molecules I-protein
on O
the O
surface O
of O
a O
B O
lymphocyte O
are O
the O
endogenous O
" O
receptors O
" O
to O
which O
specific O
antigens O
bind O
. O

Studies O
in O
mice O
have O
shown O
that O
a O
monoclonal B-protein
antibody I-protein
, O
conjugated O
with O
palmitate O
to O
provide O
a O
lipid O
tail O
, O
can O
be O
inserted O
into O
the O
cell O
membrane O
to O
provide O
a O
" O
surrogate B-protein
" I-protein
antigen I-protein
receptor I-protein
. O

We O
have O
investigated O
whether O
a O
palmitate B-protein
conjugate I-protein
of O
a O
human O
monoclonal B-protein
antibody I-protein
specific O
for O
thyroglobulin B-protein
( O
TG B-protein
) O
could O
function O
as O
a O
surrogate B-protein
TG I-protein
receptor I-protein
on O
blood O
mononuclear O
cells O
separated O
into O
fractions O
enriched O
for O
T O
cells O
or O
depleted O
of O
T O
cells O
( O
non O
- O
T O
cells O
) O
. O

Using O
flow O
cytometry O
, O
we O
detected O
surrogate B-protein
TG I-protein
receptors I-protein
on O
non O
- O
T O
( O
but O
not O
on O
T O
) O
cells O
from O
11 O
of O
11 O
individuals O
studied O
( O
5 O
Hashimoto O
patients O
and O
6 O
control O
donors O
) O
. O

In O
contrast O
, O
endogenous B-protein
TG I-protein
receptors I-protein
could O
only O
be O
detected O
on O
non O
- O
T O
cells O
from O
1 O
of O
3 O
Hashimoto O
patients O
and O
from O
0 O
of O
4 O
control O
donors O
. O

Because O
of O
the O
efficient O
binding O
of O
TG B-protein
by O
surrogate B-protein
receptors I-protein
on O
non O
- O
T O
cells O
, O
we O
assessed O
the O
ability O
of O
such O
cells O
to O
present O
TG B-protein
to O
T O
cells O
. O

Proliferation O
in O
response O
to O
TG B-protein
was O
observed O
in O
T O
cells O
from O
only O
1 O
of O
5 O
Hashimoto O
patients O
. O

This O
low O
frequency O
of O
response O
was O
no O
different O
from O
that O
previously O
detected O
using O
cultures O
of O
T O
cells O
and O
autologous O
dendritic O
cells O
. O

Therefore O
, O
the O
successful O
generation O
of O
surrogate B-protein
receptors I-protein
on O
non O
- O
T O
cells O
is O
not O
associated O
with O
more O
efficient O
TG B-protein
presentation O
of O
T O
cells O
. O

Furthermore O
, O
the O
significance O
of O
the O
present O
study O
is O
that O
the O
T O
cells O
, O
not O
the O
antigen O
- O
presenting O
cells O
, O
are O
likely O
to O
be O
the O
limiting O
element O
in O
the O
T O
cell O
proliferative O
response O
to O
TG B-protein
and O
other O
thyroid B-protein
autoantigens I-protein
. O

Targeted O
degradation O
of O
c B-protein
- I-protein
Fos I-protein
, O
but O
not O
v B-protein
- I-protein
Fos I-protein
, O
by O
a O
phosphorylation B-protein
- I-protein
dependent I-protein
signal I-protein
on O
c B-protein
- I-protein
Jun I-protein
. O

The O
proto B-protein
- I-protein
oncogene I-protein
products I-protein
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
heterodimerize O
through O
their O
leucine B-protein
zippers I-protein
to O
form O
the O
AP B-protein
- I-protein
1 I-protein
transcription I-protein
factor I-protein
. O

The O
transcriptional O
activity O
of O
the O
heterodimer O
is O
regulated O
by O
signal O
- O
dependent O
phosphorylation O
and O
dephosphorylation O
events O
. O

The O
stability O
of O
c B-protein
- I-protein
Fos I-protein
was O
found O
to O
also O
be O
controlled O
by O
intracellular O
signal O
transduction O
. O

In O
transient O
expression O
and O
in O
vitro O
degradation O
experiments O
, O
the O
stability O
of O
c B-protein
- I-protein
Fos I-protein
was O
decreased O
when O
the O
protein O
was O
dimerized O
with O
phosphorylated B-protein
c I-protein
- I-protein
Jun I-protein
. O

c B-protein
- I-protein
Jun I-protein
protein O
isolated O
from O
phorbol O
ester O
- O
induced O
cells O
did O
not O
target O
c B-protein
- I-protein
Fos I-protein
for O
degradation O
, O
which O
suggests O
that O
c B-protein
- I-protein
Fos I-protein
is O
transiently O
stabilized O
after O
stimulation O
of O
cell O
growth O
. O

v B-protein
- I-protein
Fos I-protein
protein I-protein
, O
the O
retroviral O
counterpart O
of O
c B-protein
- I-protein
Fos I-protein
, O
was O
not O
susceptible O
to O
degradation O
targeted O
by O
c B-protein
- I-protein
Jun I-protein
. O

The O
regulation O
of O
the O
human O
tumor O
necrosis O
factor O
alpha O
promoter O
region O
in O
macrophage O
, O
T O
cell O
, O
and O
B O
cell O
lines O
. O

The O
1311 O
- O
base O
pair O
human O
tumor O
necrosis O
factor O
( O
TNF O
) O
alpha O
promoter O
region O
was O
fused O
to O
the O
luciferase O
( O
Luc O
) O
reporter O
gene O
and O
studied O
in O
a O
transient O
transfection O
system O
in O
three O
TNF O
producing O
cell O
lines O
, O
the O
U937 O
macrophage O
cell O
line O
, O
the O
MLA O
144 O
T O
cell O
line O
, O
and O
the O
729 O
- O
6 O
B O
cell O
line O
. O

This O
full O
length O
promoter O
construct O
can O
be O
induced O
by O
phorbol O
13 O
- O
myristate O
acetate O
( O
PMA O
) O
in O
each O
of O
these O
cell O
types O
. O

Analysis O
of O
a O
series O
of O
5 O
' O
- O
truncations O
showed O
several O
peaks O
of O
basal O
and O
PMA O
induced O
activity O
suggesting O
the O
presence O
of O
several O
positive O
and O
negative O
regulatory O
elements O
. O

A O
PMA O
responsive O
element O
was O
localized O
to O
a O
region O
between O
- O
95 O
and O
- O
36 O
bp O
relative O
to O
the O
transcription O
start O
site O
. O

Within O
this O
region O
, O
single O
AP O
- O
2 O
- O
and O
AP O
- O
1 O
- O
like O
consensus O
sequences O
were O
noted O
. O

These O
AP O
- O
2 O
and O
AP O
- O
1 O
sites O
were O
each O
modified O
with O
a O
double O
point O
mutation O
. O

A O
modest O
( O
20 O
- O
50 O
% O
) O
reduction O
in O
TNF O
promoter O
activity O
was O
observed O
with O
the O
AP O
- O
2 O
site O
mutation O
. O

However O
, O
mutation O
of O
the O
AP O
- O
1 O
site O
markedly O
diminished O
both O
the O
basal O
and O
PMA O
- O
activated O
promoter O
activity O
. O

Also O
co O
- O
transfections O
of O
the O
wild O
- O
type O
promoter O
construct O
with O
an O
AP O
- O
1 O
/ O
c O
- O
jun O
expression O
vector O
resulted O
in O
augmented O
basal O
and O
PMA O
- O
induced O
promoter O
activity O
. O

Stable O
expression O
of O
transdominant B-protein
Rev I-protein
protein I-protein
in O
human O
T O
cells O
inhibits O
human O
immunodeficiency O
virus O
replication O
. O

The O
human O
immunodeficiency O
virus O
( O
HIV O
) O
Rev B-protein
protein I-protein
is O
essential O
for O
viral O
structural O
protein O
expression O
( O
Gag B-protein
, O
Pol B-protein
, O
and O
Env B-protein
) O
and O
, O
hence O
, O
for O
viral O
replication O
. O

In O
transient O
transfection O
assays O
, O
mutant O
forms O
of O
Rev B-protein
have O
been O
identified O
that O
inhibit O
wild O
- O
type O
Rev B-protein
activity O
and O
therefore O
suppress O
viral O
replication O
. O

To O
determine O
whether O
such O
transdominant B-protein
Rev I-protein
proteins I-protein
could O
provide O
long O
- O
term O
protection O
against O
HIV O
infection O
without O
affecting O
T O
cell O
function O
, O
T O
leukemia O
cell O
lines O
were O
stably O
transduced O
with O
a O
retroviral O
vector O
encoding O
a O
transdominant O
mutant O
of O
the O
Rev B-protein
protein I-protein
, O
M10 B-protein
. O

While O
all O
the O
M10 B-protein
- O
expressing O
cell O
lines O
remained O
infectable O
by O
HIV O
- O
1 O
, O
these O
same O
cells O
failed O
to O
support O
a O
productive O
replication O
cycle O
when O
infected O
with O
a O
cloned O
isolate O
of O
HIV O
- O
1 O
. O

In O
addition O
, O
two O
out O
of O
three O
M10 B-protein
- O
expressing O
CEM O
clones O
were O
also O
resistant O
to O
highly O
productive O
infection O
by O
a O
heterogeneous O
HIV O
- O
1 O
pool O
. O

Expression O
of O
M10 B-protein
did O
not O
affect O
induction O
of O
HIV O
transcription O
mediated O
by O
the O
kappa O
B O
regulatory O
element O
or O
Tat B-protein
. O

Importantly O
, O
constitutive O
expression O
of O
Rev B-protein
M10 I-protein
did O
not O
alter O
the O
secretion O
of O
interleukin B-protein
2 I-protein
in O
response O
to O
mitogen O
stimulation O
of O
EL O
- O
4 O
and O
Jurkat O
cells O
. O

The O
inhibition O
of O
HIV O
infection O
in O
cells O
stably O
expressing O
a O
transdominant B-protein
Rev I-protein
protein I-protein
, O
in O
the O
absence O
of O
any O
deleterious O
effect O
on O
T O
cell O
function O
, O
suggests O
that O
such O
a O
strategy O
could O
provide O
a O
therapeutic O
effect O
in O
the O
T O
lymphocytes O
of O
acquired O
immunodeficiency O
syndrome O
patients O
. O

Simple O
derivation O
of O
TFIID O
- O
dependent O
RNA B-protein
polymerase I-protein
II I-protein
transcription O
systems O
from O
Schizosaccharomyces O
pombe O
and O
other O
organisms O
, O
and O
factors O
required O
for O
transcriptional O
activation O
. O

Resolution O
of O
whole O
cell O
extract O
through O
two O
chromatographic O
steps O
yields O
a O
single O
protein O
fraction O
requiring O
only O
the O
addition O
of O
TFIID B-protein
for O
the O
initiation O
of O
transcription O
at O
RNA B-protein
polymerase I-protein
II I-protein
promoters O
. O

This O
approach O
allows O
the O
convenient O
generation O
of O
RNA B-protein
polymerase I-protein
II I-protein
transcription O
systems O
from O
Saccharomyces O
cerevisiae O
, O
human O
lymphocytes O
, O
and O
Schizosaccharomyces O
pombe O
. O

TFIIDs B-protein
from O
all O
three O
organisms O
are O
interchangeable O
among O
all O
three O
systems O
. O

The O
S O
. O
cerevisiae O
and O
Sch O
. O
pombe O
systems O
support O
effects O
of O
acidic B-protein
activator I-protein
proteins I-protein
, O
provided O
a O
further O
protein O
fraction O
from O
S O
. O
cerevisiae O
is O
supplied O
. O

This O
further O
fraction O
is O
distinct O
from O
the O
mediator O
of O
transcriptional O
activation O
described O
previously O
and O
represents O
a O
second O
component O
in O
addition O
to O
general B-protein
initiation I-protein
factors I-protein
that O
may O
facilitate O
a O
response O
to O
acidic B-protein
activators I-protein
. O

Regulation O
of O
c O
- O
jun O
expression O
during O
induction O
of O
monocytic O
differentiation O
by O
okadaic O
acid O
. O

The O
present O
work O
has O
examined O
the O
effects O
of O
okadaic O
acid O
, O
an O
inhibitor O
of O
type O
1 O
and O
2A O
protein O
phosphatases O
, O
on O
the O
regulation O
of O
c O
- O
jun O
expression O
during O
monocytic O
differentiation O
of O
U O
- O
937 O
leukemia O
cells O
. O

The O
results O
demonstrate O
that O
okadaic O
acid O
treatment O
is O
associated O
with O
induction O
of O
a O
differentiated O
monocyte O
phenotype O
characterized O
by O
: O
( O
a O
) O
growth O
arrest O
; O
( O
b O
) O
increases O
in O
Mac B-protein
- I-protein
1 I-protein
cell I-protein
surface I-protein
antigen I-protein
expression O
; O
( O
c O
) O
down O
- O
regulation O
of O
c B-protein
- I-protein
myc I-protein
transcripts I-protein
; O
and O
( O
d O
) O
induction O
of O
tumor B-protein
necrosis I-protein
factor I-protein
gene O
expression O
. O

This O
induction O
of O
monocytic O
differentiation O
was O
associated O
with O
transient O
increases O
in O
c O
- O
jun O
mRNA O
levels O
, O
which O
were O
maximal O
at O
6 O
h O
. O

Similar O
effects O
were O
obtained O
for O
the O
c O
- O
fos O
gene O
. O

Run O
- O
on O
analysis O
demonstrated O
detectable O
levels O
of O
c O
- O
jun O
transcription O
in O
U O
- O
937 O
cells O
and O
that O
this O
rate O
is O
increased O
approximately O
40 O
- O
fold O
following O
okadaic O
acid O
exposure O
. O

c O
- O
jun O
mRNA O
levels O
were O
superinduced O
in O
cells O
treated O
with O
both O
okadaic O
acid O
and O
cycloheximide O
, O
whereas O
inhibition O
of O
protein O
synthesis O
had O
little O
, O
if O
any O
, O
effect O
on O
okadaic O
acid O
- O
induced O
c O
- O
jun O
transcription O
. O

The O
half O
- O
life O
of O
c O
- O
jun O
mRNA O
was O
similar O
( O
45 O
- O
50 O
min O
) O
in O
both O
untreated O
and O
okadaic O
acid O
- O
induced O
cells O
. O

In O
contrast O
, O
treatment O
with O
both O
okadaic O
acid O
and O
cycloheximide O
was O
associated O
with O
stabilization O
( O
t O
1 O
/ O
2 O
= O
90 O
min O
) O
of O
c B-protein
- I-protein
jun I-protein
transcripts I-protein
. O

Taken O
together O
, O
these O
findings O
indicate O
that O
the O
induction O
of O
c O
- O
jun O
transcription O
by O
okadaic O
acid O
is O
controlled O
primarily O
by O
a O
transcriptional O
mechanism O
. O

Since O
previous O
studies O
have O
demonstrated O
that O
the O
c O
- O
jun O
gene O
is O
autoinduced O
by O
Jun B-protein
/ I-protein
AP I-protein
- I-protein
1 I-protein
, O
we O
also O
studied O
transcription O
of O
c O
- O
jun O
promoter O
( O
positions O
- O
132 O
/ O
+ O
170 O
) O
- O
reporter O
gene O
constructs O
with O
and O
without O
a O
mutated O
AP O
- O
1 O
element O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Mitogen O
stimulation O
of O
T O
- O
cells O
increases O
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
protein O
levels O
, O
AP O
- O
1 O
binding O
and O
AP O
- O
1 O
transcriptional O
activity O
. O

We O
have O
analysed O
the O
effect O
of O
mitogenic O
lectins O
on O
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
protein O
levels O
as O
well O
as O
on O
activator O
protein O
- O
1 O
( O
AP O
- O
1 O
) O
binding O
and O
enhancer O
activity O
in O
Jurkat O
T O
- O
cells O
. O

Both O
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
protein O
levels O
were O
increased O
after O
Con O
A O
and O
PHA O
stimulation O
. O

Since O
T O
- O
cell O
stimulation O
increases O
both O
intracellular O
Ca2 O
+ O
and O
cAMP O
levels O
and O
activates O
protein O
kinase O
C O
( O
PKC O
) O
, O
the O
possible O
involvement O
of O
these O
intracellular O
messengers O
in O
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
induction O
was O
tested O
. O

PMA O
, O
which O
directly O
activates O
PKC O
, O
mimicked O
the O
effect O
of O
the O
lectins O
on O
c O
- O
Fos O
and O
c B-protein
- I-protein
Jun I-protein
, O
but O
elevation O
of O
either O
intracellular O
Ca2 O
+ O
or O
cAMP O
levels O
had O
little O
or O
no O
effect O
. O

The O
mitogen O
- O
induced O
increase O
of O
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
immunoreactivity O
was O
inhibited O
by O
H O
- O
7 O
, O
a O
kinase O
inhibitor O
with O
relatively O
high O
specificity O
for O
PKC O
, O
and O
less O
efficiently O
by O
H O
- O
8 O
, O
a O
structurally O
related O
kinase O
inhibitor O
less O
active O
on O
PKC O
, O
but O
more O
active O
on O
cyclic O
nucleotide O
- O
dependent O
kinases O
. O

Con O
A O
stimulation O
was O
found O
to O
increase O
both O
binding O
of O
AP O
- O
1 O
to O
the O
AP O
- O
1 O
consensus O
sequence O
, O
TRE O
, O
and O
AP O
- O
1 O
enhancer O
activity O
, O
in O
Jurkat O
cells O
. O

PMA O
was O
also O
found O
to O
increase O
the O
AP O
- O
1 O
enhancer O
activity O
, O
whereas O
elevation O
of O
Ca2 O
+ O
or O
cAMP O
had O
only O
minor O
effects O
. O

We O
conclude O
that O
stimulation O
with O
mitogenic O
lectins O
is O
sufficient O
to O
increase O
both O
c B-protein
- I-protein
Fos I-protein
and O
c B-protein
- I-protein
Jun I-protein
protein O
levels O
, O
AP O
- O
1 O
binding O
and O
AP O
- O
1 O
enhancer O
activity O
in O
Jurkat O
cells O
and O
that O
they O
act O
via O
mechanisms O
that O
could O
involve O
the O
activation O
of O
PKC O
. O

An O
11 O
- O
base O
- O
pair O
DNA O
sequence O
motif O
apparently O
unique O
to O
the O
human O
interleukin O
4 O
gene O
confers O
responsiveness O
to O
T O
- O
cell O
activation O
signals O
. O

We O
have O
identified O
a O
DNA O
segment O
that O
confers O
responsiveness O
to O
antigen O
stimulation O
signals O
on O
the O
human O
interleukin O
( O
IL O
) O
4 O
gene O
in O
Jurkat O
cells O
. O

The O
human O
IL O
- O
4 O
gene O
, O
of O
10 O
kilobases O
, O
is O
composed O
of O
four O
exons O
and O
three O
introns O
. O

A O
cis O
- O
acting O
element O
( O
P O
sequence O
) O
resides O
in O
the O
5 O
' O
upstream O
region O
; O
no O
additional O
DNA O
segments O
with O
enhancer O
activity O
were O
identified O
in O
the O
human O
IL O
- O
4 O
gene O
. O

For O
further O
mapping O
purposes O
, O
a O
fusion O
promoter O
was O
constructed O
with O
the O
granulocyte O
/ O
macrophage O
colony O
- O
stimulating O
factor O
basic O
promoter O
containing O
60 O
base O
pairs O
of O
sequence O
upstream O
from O
the O
cap O
site O
of O
the O
mouse B-protein
granulocyte I-protein
/ I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
gene O
and O
various O
lengths O
of O
the O
5 O
' O
upstream O
sequence O
of O
the O
IL O
- O
4 O
gene O
. O

The O
P O
sequence O
was O
located O
between O
positions O
- O
79 O
and O
- O
69 O
relative O
to O
the O
transcription O
start O
site O
of O
the O
human O
IL O
- O
4 O
gene O
, O
and O
this O
location O
was O
confirmed O
by O
base O
- O
substitution O
mutations O
. O

The O
plasmids O
carrying O
multiple O
copies O
of O
the O
P O
sequence O
showed O
higher O
responsiveness O
to O
the O
stimulation O
. O

The O
binding B-protein
protein I-protein
( O
s O
) O
that O
recognize O
the O
P O
sequence O
of O
the O
IL O
- O
4 O
gene O
were O
identified O
by O
DNA O
- O
mobility O
- O
shift O
assays O
. O

The O
binding O
of O
NF B-protein
( I-protein
P I-protein
) I-protein
( O
a O
DNA B-protein
binding I-protein
protein I-protein
that O
specifically O
recognizes O
the O
P O
sequence O
) O
to O
the O
P O
sequence O
was O
abolished O
when O
oligonucleotides O
carrying O
base O
substitutions O
were O
used O
, O
indicating O
that O
the O
NF B-protein
( I-protein
P I-protein
) I-protein
interaction O
is O
sequence O
- O
specific O
and O
that O
binding O
specificity O
of O
the O
protein O
paralleled O
the O
sequence O
requirements O
for O
IL B-protein
- I-protein
4 I-protein
expression O
in O
vivo O
. O

The O
P O
sequence O
does O
not O
share O
homology O
with O
the O
5 O
' O
upstream O
sequence O
of O
the O
IL O
- O
2 O
gene O
, O
even O
though O
surrounding O
sequences O
of O
the O
IL O
- O
4 O
gene O
share O
high O
homology O
with O
the O
IL O
- O
2 O
gene O
. O

We O
conclude O
that O
a O
different O
set O
of O
proteins B-protein
recognize O
IL O
- O
2 O
and O
IL O
- O
4 O
genes O
. O

Leukotriene O
B4 O
stimulates O
c O
- O
fos O
and O
c O
- O
jun O
gene O
transcription O
and O
AP B-protein
- I-protein
1 I-protein
binding O
activity O
in O
human O
monocytes O
. O

We O
have O
examined O
the O
effect O
of O
leukotriene O
B4 O
( O
LTB4 O
) O
, O
a O
potent O
lipid O
proinflammatory B-protein
mediator I-protein
, O
on O
the O
expression O
of O
the O
proto O
- O
oncogenes O
c O
- O
jun O
and O
c O
- O
fos O
. O

In O
addition O
, O
we O
looked O
at O
the O
modulation O
of O
nuclear B-protein
factors I-protein
binding O
specifically O
to O
the O
AP O
- O
1 O
element O
after O
LTB4 O
stimulation O
. O

LTB4 O
increased O
the O
expression O
of O
the O
c O
- O
fos O
gene O
in O
a O
time O
- O
and O
concentration O
- O
dependent O
manner O
. O

The O
c O
- O
jun O
mRNA O
, O
which O
is O
constitutively O
expressed O
in O
human O
peripheral O
- O
blood O
monocytes O
at O
relatively O
high O
levels O
, O
was O
also O
slightly O
augmented O
by O
LTB4 O
, O
although O
to O
a O
much O
lower O
extent O
than O
c O
- O
fos O
. O

The O
kinetics O
of O
expression O
of O
the O
two O
genes O
were O
also O
slightly O
different O
, O
with O
c O
- O
fos O
mRNA O
reaching O
a O
peak O
at O
15 O
min O
after O
stimulation O
and O
c O
- O
jun O
at O
30 O
min O
. O

Both O
messages O
rapidly O
declined O
thereafter O
. O

Stability O
of O
the O
c O
- O
fos O
and O
c O
- O
jun O
mRNA O
was O
not O
affected O
by O
LTB4 O
, O
as O
assessed O
after O
actinomycin O
D O
treatment O
. O

Nuclear O
transcription O
studies O
in O
vitro O
showed O
that O
LTB4 O
increased O
the O
transcription O
of O
the O
c O
- O
fos O
gene O
7 O
- O
fold O
and O
the O
c O
- O
jun O
gene O
1 O
. O
4 O
- O
fold O
. O

Resting O
monocytes O
contained O
nuclear B-protein
factors I-protein
binding O
to O
the O
AP O
- O
1 O
element O
, O
but O
stimulation O
of O
monocytes O
with O
LTB4 O
induced O
greater O
AP B-protein
- I-protein
1 I-protein
- O
binding O
activity O
of O
nuclear B-protein
proteins I-protein
. O

These O
results O
indicate O
that O
LTB4 O
may O
regulate O
the O
production O
of O
different O
cytokines B-protein
by O
modulating O
the O
yield O
and O
/ O
or O
the O
function O
of O
transcription B-protein
factors I-protein
such O
as O
AP B-protein
- I-protein
1 I-protein
- O
binding O
proto B-protein
- I-protein
oncogene I-protein
products I-protein
. O

Modulation O
of O
normal O
erythroid O
differentiation O
by O
the O
endogenous O
thyroid O
hormone O
and O
retinoic B-protein
acid I-protein
receptors I-protein
: O
a O
possible O
target O
for O
v O
- O
erbA O
oncogene O
action O
. O

The O
v O
- O
erbA O
oncogene O
, O
a O
mutated O
version O
of O
the O
thyroid B-protein
hormone I-protein
receptor I-protein
alpha I-protein
( O
c B-protein
- I-protein
erbA I-protein
/ I-protein
TR I-protein
- I-protein
alpha I-protein
) O
, O
inhibits O
erythroid O
differentiation O
and O
constitutively O
represses O
transcription O
of O
certain O
erythrocyte O
genes O
, O
suggesting O
a O
normal O
function O
of O
the O
proto O
- O
oncogene O
c O
- O
erbA O
in O
erythropoiesis O
. O

Here O
we O
demonstrate O
that O
the O
endogenous O
thyroid B-protein
hormone I-protein
receptor I-protein
alpha I-protein
( O
c B-protein
- I-protein
erbA I-protein
/ I-protein
TR I-protein
- I-protein
alpha I-protein
) O
and O
the O
closely O
related O
retinoic B-protein
acid I-protein
receptor I-protein
alpha I-protein
( O
RAR B-protein
- I-protein
alpha I-protein
) O
play O
a O
role O
in O
the O
regulation O
of O
normal O
erythroid O
differentiation O
. O

Retinoic O
acid O
( O
RA O
) O
distinctly O
modulated O
the O
erythroid O
differentiation O
program O
of O
normal O
erythroid O
progenitors O
and O
erythroblasts O
reversibly O
transformed O
by O
a O
conditional O
tyrosine O
kinase O
oncogene O
. O

When O
added O
pulsewise O
to O
immature O
cells O
, O
differentiation O
was O
accelerated O
while O
more O
mature O
cells O
underwent O
premature O
cell O
death O
. O

Thyroid O
hormone O
( O
T3 O
) O
alone O
caused O
similar O
but O
weaker O
effects O
. O

Interestingly O
, O
T3 O
strongly O
enhanced O
the O
action O
of O
RA O
, O
suggesting O
cooperative O
action O
of O
the O
two O
receptors O
in O
modulating O
erythroid O
differentiation O
. O

Expression O
of O
the O
human B-protein
RAR I-protein
- I-protein
alpha I-protein
in O
receptor O
- O
negative O
erythroblasts O
conferred O
RA O
- O
induced O
regulation O
of O
differentiation O
to O
the O
otherwise O
unresponsive O
cells O
, O
thus O
showing O
that O
the O
RAR B-protein
- I-protein
alpha I-protein
is O
essential O
for O
the O
RA O
effect O
. O

Likewise O
, O
enhanced O
expression O
of O
exogenous B-protein
c I-protein
- I-protein
erbA I-protein
/ I-protein
TR I-protein
- I-protein
alpha I-protein
in O
erythroblasts O
rendered O
them O
susceptible O
to O
modulation O
of O
differentiation O
by O
T3 O
, O
suggesting O
a O
similar O
function O
of O
both O
receptors O
. O

Activation O
of O
lymphokine O
genes O
in O
T O
cells O
: O
role O
of O
cis O
- O
acting O
DNA O
elements O
that O
respond O
to O
T O
cell O
activation O
signals O
. O

Activation O
of O
T O
cells O
is O
initiated O
by O
the O
recognition O
of O
antigen B-protein
on O
antigen O
presenting O
cells O
to O
exert O
the O
effector O
functions O
in O
immune O
and O
inflammatory O
responses O
. O

Two O
types O
of O
helper O
T O
cell O
( O
Th O
) O
clones O
( O
Th1 O
and O
Th2 O
) O
are O
defined O
on O
the O
basis O
of O
different O
patterns O
of O
cytokine B-protein
( O
lymphokine B-protein
) O
secretion O
. O

They O
determine O
the O
outcome O
of O
an O
antigenic O
response O
toward O
humoral O
or O
cell O
- O
mediated O
immunity O
. O

Although O
lymphokine B-protein
genes O
are O
coordinately O
regulated O
upon O
antigen O
stimulation O
, O
they O
are O
regulated O
by O
the O
mechanisms O
common O
to O
all O
as O
well O
as O
those O
which O
are O
unique O
to O
each O
gene O
. O

For O
most O
lymphokine O
genes O
, O
a O
combination O
of O
phorbol O
esters O
( O
phorbol O
12 O
- O
myristate O
13 O
acetate O
, O
PMA O
) O
and O
calcium O
ionophores O
( O
A23187 O
) O
is O
required O
for O
their O
maximal O
induction O
. O

Yet O
phorbol O
ester O
alone O
or O
calcium O
ionophore O
alone O
produce O
several O
lymphokines B-protein
. O

The O
production O
of O
the O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
is O
completely O
dependent O
on O
the O
two O
signals O
. O

We O
have O
previously O
found O
a O
cis O
- O
acting O
region O
spanning O
the O
GM B-protein
- I-protein
CSF I-protein
promoter O
region O
( O
positions O
- O
95 O
to O
+ O
27 O
) O
that O
confers O
inducibility O
to O
reporter O
genes O
in O
transient O
transfection O
assays O
. O

Further O
analysis O
identified O
three O
elements O
required O
for O
efficient O
induction O
, O
referred O
to O
as O
GM2 O
, O
GC O
- O
box O
and O
conserved O
lymphokine B-protein
element O
( O
CLE0 O
) O
. O

GM2 O
defines O
a O
binding O
site O
for O
protein O
( O
s O
) O
whose O
binding O
is O
inducible O
by O
PMA O
. O

One O
protein O
, O
NF B-protein
- I-protein
GM2 I-protein
is O
similar O
to O
the O
transcription B-protein
factor I-protein
NF B-protein
- I-protein
kB I-protein
. O

GC O
- O
box O
is O
a O
binding O
site O
for O
constitutively B-protein
bound I-protein
proteins I-protein
. O

CLEO O
defines O
a O
binding O
site O
for O
protein O
( O
s O
) O
whose O
optimum O
binding O
is O
stimulated O
by O
PMA O
and O
A23187 O
. O

Viral B-protein
trans I-protein
- I-protein
activators I-protein
such O
as O
Tax B-protein
( O
human O
T O
cell O
leukemia O
virus O
- O
1 O
, O
HTLV O
- O
1 O
) O
and O
E2 B-protein
( O
bovine O
papilloma O
virus O
, O
BPV O
) O
proteins O
are O
other O
agents O
which O
activate O
lymphokine O
gene O
expression O
by O
bypassing O
T B-protein
cell I-protein
receptor I-protein
( O
TCR B-protein
) O
mediated O
signaling O
. O

The O
trans O
- O
activation O
domain O
of O
E2 B-protein
and O
Tax B-protein
is O
interchangeable O
although O
they O
have O
no O
obvious O
sequence O
homology O
between O
them O
. O

The O
viral B-protein
trans I-protein
- I-protein
activators I-protein
appear O
to O
target O
specific O
DNA B-protein
binding I-protein
protein I-protein
such O
as O
NF B-protein
- I-protein
kB I-protein
and O
Sp1 B-protein
to O
cis O
- O
acting O
DNA O
site O
and O
promote O
lymphokine O
gene O
expression O
without O
TCR B-protein
- O
mediated O
stimulation O
. O

Mutations O
in O
the O
Pit O
- O
1 O
gene O
in O
children O
with O
combined O
pituitary O
hormone O
deficiency O
. O

Pit B-protein
- I-protein
1 I-protein
is O
a O
pituitary B-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
that O
binds O
to O
and O
transactivates O
promoters O
of O
growth O
hormone O
and O
prolactin O
genes O
. O

In O
three O
unrelated O
Japanese O
children O
with O
combined O
pituitary O
hormone O
deficiency O
, O
we O
identified O
three O
point O
mutations O
in O
the O
Pit B-protein
- I-protein
1 I-protein
gene O
, O
Pro24Leu O
, O
Arg143Gln O
, O
and O
Arg271Trp O
, O
located O
on O
the O
major O
transactivation O
region O
, O
POU O
- O
specific O
domain O
, O
and O
POU O
- O
homeodomain O
, O
respectively O
. O

Activation O
of O
protein B-protein
kinase I-protein
C I-protein
and O
elevation O
of O
cAMP O
interact O
synergistically O
to O
raise O
c B-protein
- I-protein
Fos I-protein
and O
AP B-protein
- I-protein
1 I-protein
activity O
in O
Jurkat O
cells O
. O

We O
have O
earlier O
found O
that O
in O
Jurkat O
cells O
activation O
of O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
enhances O
the O
cyclic O
adenosine O
monophosphate O
( O
cAMP O
) O
accumulation O
induced O
by O
adenosine O
receptor O
stimulation O
or O
activation O
of O
Gs B-protein
. O

Here O
we O
have O
therefore O
examined O
the O
effect O
of O
the O
phorbol O
ester O
PMA O
( O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
) O
which O
stimulates O
PKC B-protein
and O
a O
combination O
of O
the O
adenosine B-protein
receptor I-protein
agonist O
NECA O
( O
5 O
' O
- O
( O
N O
- O
ethyl O
) O
- O
carboxamido O
adenosine O
) O
and O
forskolin O
to O
raise O
cAMP O
, O
on O
the O
levels O
of O
c B-protein
- I-protein
Fos I-protein
and O
Jun B-protein
and O
on O
the O
binding O
and O
transcriptional O
activity O
of O
the O
transcription B-protein
factor I-protein
, O
activator B-protein
protein I-protein
- I-protein
1 I-protein
( O
AP B-protein
- I-protein
1 I-protein
) O
. O

PMA O
treatment O
caused O
a O
concentration O
- O
and O
time O
- O
dependent O
increase O
in O
both O
c O
- O
Fos O
and O
Jun O
immunoreactivity O
in O
contrast O
to O
cAMP O
elevation O
that O
had O
only O
a O
slight O
effect O
. O

Both O
PMA O
and O
the O
combination O
of O
NECA O
and O
forskolin O
acted O
together O
either O
to O
increase O
( O
c B-protein
- I-protein
Fos I-protein
) O
or O
decrease O
( O
Jun B-protein
) O
protein O
levels O
as O
well O
as O
increasing O
AP B-protein
- I-protein
1 I-protein
binding O
, O
as O
judged O
by O
gel O
- O
shift O
assay O
, O
and O
AP B-protein
- I-protein
1 I-protein
transcriptional O
activity O
. O

Furthermore O
there O
was O
a O
clear O
- O
cut O
synergy O
between O
the O
PKC B-protein
stimulator O
and O
the O
cAMP O
elevating O
agents O
. O

The O
results O
demonstrate O
that O
the O
simultaneous O
activation O
of O
PKC B-protein
and O
elevation O
of O
cAMP O
leads O
to O
an O
enhanced O
AP B-protein
- I-protein
1 I-protein
transcriptional O
activity O
in O
a O
T O
- O
leukemia O
cell O
line O
, O
suggesting O
that O
the O
previously O
observed O
interaction O
between O
the O
parallel O
signal O
transduction O
pathways O
may O
have O
functional O
consequences O
at O
the O
level O
of O
gene O
transcription O
. O

Inhibition O
of O
anti B-protein
- I-protein
CD3 I-protein
monoclonal I-protein
antibody I-protein
- O
induced O
T O
- O
cell O
proliferation O
by O
dexamethasone O
, O
isoproterenol O
, O
or O
prostaglandin O
E2 O
either O
alone O
or O
in O
combination O
. O

1 O
. O

The O
purpose O
of O
these O
studies O
was O
to O
investigate O
the O
modulation O
of O
the O
proliferation O
of O
human O
T O
cells O
obtained O
from O
peripheral O
blood O
by O
dexamethasone O
( O
DEX O
) O
, O
isoproterenol O
( O
ISO O
) O
, O
and O
prostaglandin O
E2 O
( O
PGE2 O
) O
. O

The O
former O
two O
substances O
interact O
with O
T O
cells O
via O
the O
glucocorticoid O
and O
beta O
- O
adrenergic O
receptors O
respectively O
. O

When O
occupied O
by O
their O
natural O
ligands O
, O
glucocorticosteroids O
and O
catecholamines O
, O
these O
receptors O
have O
a O
role O
in O
modulating O
T O
- O
cell O
function O
during O
stress O
. O

During O
the O
inflammatory O
response O
increased O
levels O
of O
PGE2 O
bind O
to O
their O
receptors O
on O
T O
cells O
and O
thus O
alter O
responsiveness O
. O

Proliferation O
of O
T O
cells O
was O
induced O
by O
immobilized O
anti B-protein
- I-protein
CD3 I-protein
monoclonal I-protein
antibody I-protein
( O
mAb B-protein
) O
in O
the O
presence O
or O
absence O
of O
an O
additional O
costimulatory O
signal O
delivered O
by O
anti B-protein
- I-protein
CD28 I-protein
mAb I-protein
. O

2 O
. O

Various O
physiologic O
concentrations O
of O
DEX O
, O
ISO O
, O
or O
PGE2 O
were O
added O
at O
the O
time O
of O
initiation O
of O
the O
cultures O
and O
subsequent O
proliferation O
of O
the O
unstimulated O
T O
cells O
was O
determined O
. O

The O
results O
demonstrate O
that O
physiologic O
concentrations O
of O
all O
three O
of O
these O
agents O
inhibit O
the O
anti B-protein
- I-protein
CD3 I-protein
mAb I-protein
- O
induced O
proliferation O
of O
T O
cells O
. O

3 O
. O

Although O
DEX O
and O
PGE2 O
were O
equipotent O
in O
suppressing O
T O
- O
cell O
proliferation O
, O
ISO O
was O
much O
less O
effective O
. O

4 O
. O

Because O
concomitant O
elevations O
in O
the O
peripheral O
levels O
of O
these O
substances O
may O
occur O
, O
experiments O
were O
performed O
to O
determine O
the O
T O
- O
cell O
inhibitory O
effects O
of O
DEX O
together O
with O
either O
PGE2 O
or O
ISO O
. O

Synergistic O
suppression O
of O
T O
- O
cell O
proliferation O
was O
observed O
when O
various O
concentrations O
of O
DEX O
and O
PGE2 O
, O
but O
not O
DEX O
and O
ISO O
, O
were O
added O
to O
cultures O
. O

This O
synergistic O
suppression O
could O
not O
be O
explained O
by O
an O
increase O
in O
cAMP O
accumulation O
in O
T O
cells O
stimulated O
with O
DEX O
and O
PGE2 O
. O

5 O
. O

Finally O
, O
the O
addition O
of O
anti B-protein
- I-protein
CD28 I-protein
mAb I-protein
to O
anti O
- O
CD3 O
mAb O
- O
stimulated O
T O
cells O
overcame O
much O
of O
the O
suppression O
of O
proliferation O
induced O
by O
PGE2 O
or O
ISO O
but O
less O
so O
than O
that O
induced O
by O
DEX O
. O

In O
vivo O
footprint O
analysis O
of O
the O
HLA O
- O
DRA O
gene O
promoter O
: O
cell O
- O
specific O
interaction O
at O
the O
octamer O
site O
and O
up O
- O
regulation O
of O
X O
box O
binding O
by O
interferon B-protein
gamma I-protein
. O

Analysis O
of O
the O
major B-protein
histocompatibility I-protein
complex I-protein
class I-protein
II I-protein
gene O
promoter O
DRA O
has O
previously O
identified O
at O
least O
five O
cis O
- O
acting O
regions O
required O
for O
maximal O
expression O
. O

We O
have O
examined O
the O
DRA O
promoter O
for O
protein O
- O
DNA O
interactions O
in O
the O
intact O
cell O
, O
which O
may O
mediate O
transcriptional O
activation O
. O

Using O
in O
vivo O
genomic O
footprinting O
we O
identified O
interactions O
in O
B O
- O
cell O
lines O
at O
the O
octamer O
site O
and O
the O
Y O
, O
X1 O
, O
and O
X2 O
boxes O
. O

Class O
II O
antigen O
expressing O
T O
- O
cell O
lines O
maintained O
contacts O
identical O
to O
B O
- O
cell O
lines O
, O
while O
class O
II O
- O
negative O
T O
- O
cell O
lines O
exhibited O
no O
interactions O
. O

In O
lymphoid O
cell O
lines O
, O
the O
octamer O
site O
is O
occupied O
and O
required O
for O
maximal O
expression O
. O

This O
is O
most O
likely O
due O
to O
the O
presence O
of O
the O
lymphoid B-protein
- I-protein
specific I-protein
OTF I-protein
- I-protein
2 I-protein
factor I-protein
. O

In O
contrast O
, O
the O
class O
II O
- O
positive O
nonlymphoid O
glioblastoma O
cell O
line O
does O
not O
exhibit O
interactions O
at O
the O
octamer O
site O
despite O
the O
presence O
of O
the O
ubiquitous B-protein
OTF I-protein
- I-protein
1 I-protein
factor I-protein
and O
an O
open O
binding O
site O
. O

Thus O
, O
the O
DRA O
promoter O
discriminates O
against O
OTF B-protein
- I-protein
1 I-protein
activation O
at O
the O
level O
of O
DNA O
binding O
in O
the O
glioblastoma O
line O
. O

Interferon B-protein
gamma I-protein
induces O
class O
II O
expression O
in O
this O
glioblastoma O
cell O
line O
and O
, O
in O
parallel O
, O
up O
- O
regulates O
X1 O
and O
X2 O
box O
protein O
- O
DNA O
interactions O
, O
while O
all O
other O
interactions O
remain O
unchanged O
. O

These O
results O
suggest O
that O
interferon B-protein
gamma I-protein
functions O
on O
a O
poised O
promoter O
by O
altering O
weak O
, O
nonproductive O
interactions O
at O
the O
X O
boxes O
to O
strong O
interactions O
. O

These O
findings O
provide O
direct O
in O
vivo O
evidence O
to O
strongly O
suggest O
that O
the O
modulation O
of O
X1 O
and O
X2 O
interactions O
is O
an O
important O
constituent O
of O
the O
interferon B-protein
gamma I-protein
induction O
pathway O
. O

Estrogen O
binding O
sites O
in O
peripheral O
blood O
monocytes O
and O
effects O
of O
danazol O
on O
their O
sites O
in O
vitro O
. O

1 O
. O

This O
study O
was O
designed O
to O
investigate O
the O
presence O
of O
estrogen O
type O
I O
( O
high O
affinity O
, O
low O
capacity O
) O
and O
type O
II O
( O
low O
affinity O
, O
high O
capacity O
) O
binding O
sites O
in O
human O
peripheral O
blood O
monocytes O
and O
the O
effects O
of O
danazol O
on O
these O
sites O
. O

2 O
. O

These O
two O
types O
of O
estrogen O
binding O
sites O
existed O
in O
human O
peripheral O
blood O
monocytes O
. O

3 O
. O

Danazol O
bound O
to O
these O
sites O
in O
high O
concentration O
( O
10 O
( O
- O
6 O
) O
M O
, O
clinical O
serum O
concentration O
during O
danazol O
therapy O
) O
and O
decreased O
the O
number O
of O
both O
sites O
. O

4 O
. O

It O
is O
suggested O
that O
danazol O
has O
an O
anti O
- O
estrogenic O
action O
to O
the O
monocytes O
through O
the O
competition O
and O
suppression O
of O
estrogen O
binding O
sites O
as O
seen O
in O
the O
estrogen O
target O
organ O
. O

A O
microtitre O
assay O
system O
for O
glucocorticoid B-protein
receptors I-protein
: O
decreased O
receptor O
concentration O
in O
myocardial O
infarction O
. O

A O
major O
difficulty O
in O
determination O
of O
glucocorticoid O
receptor O
sites O
is O
the O
very O
complicated O
assay O
procedure O
. O

Therefore O
, O
we O
describe O
a O
microtitre O
assay O
system O
for O
glucocorticoid B-protein
receptors I-protein
which O
is O
a O
whole O
- O
cell O
competitive O
binding O
radioassay O
using O
[ O
3H O
] O
- O
dexamethasone O
as O
radioligand O
. O

This O
modification O
of O
a O
previously O
described O
protocol O
simplifies O
and O
reduces O
laboratory O
work O
and O
allows O
assay O
reproducibility O
to O
be O
controlled O
more O
reliably O
. O

Thus O
enabled O
to O
perform O
the O
test O
on O
multiple O
blood O
samples O
in O
parallel O
, O
we O
investigated O
cardiac O
infarction O
patients O
over O
a O
12 O
- O
day O
period O
to O
test O
if O
glucocorticoid B-protein
receptor I-protein
binding O
is O
altered O
in O
this O
' O
stressful O
' O
disease O
. O

On O
the O
first O
day O
of O
the O
disease O
, O
glucocorticoid B-protein
receptor I-protein
capacity O
was O
significantly O
decreased O
without O
alteration O
of O
the O
receptor O
- O
ligand O
affinity O
, O
whereas O
on O
days O
4 O
and O
12 O
the O
number O
of O
receptor O
sites O
was O
normal O
again O
. O

This O
result O
fits O
well O
into O
the O
general O
observation O
of O
stress O
- O
induced O
down O
- O
regulation O
of O
immune O
responses O
. O

SRC O
- O
related O
proto O
- O
oncogenes O
and O
transcription B-protein
factors I-protein
in O
primary O
human O
T O
cells O
: O
modulation O
by O
cyclosporin O
A O
and O
FK506 O
. O

Activation O
of O
T O
lymphocytes O
induces O
transcription O
of O
genes O
encoding O
for O
lymphokines B-protein
. O

Interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
gene O
expression O
is O
controlled O
transcriptionally O
by O
the O
cooperative O
activity O
of O
specific O
trans B-protein
- I-protein
activating I-protein
factors I-protein
that O
bind O
to O
the O
IL B-protein
- I-protein
2 I-protein
enhancer O
. O

Cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
inhibit O
the O
production O
of O
IL B-protein
- I-protein
2 I-protein
in O
T O
lymphocytes O
at O
the O
level O
of O
gene O
transcription O
. O

A O
member O
of O
the O
src O
gene O
family O
, O
the O
lymphocyte B-protein
- I-protein
specific I-protein
protein I-protein
tyrosine I-protein
kinase I-protein
, O
p56lck B-protein
, O
has O
been O
implicated O
in O
IL B-protein
- I-protein
2 I-protein
production O
. O

CsA O
was O
found O
not O
to O
inhibit O
lck B-protein
gene O
expression O
, O
nor O
the O
activity O
of O
the O
lck B-protein
gene I-protein
product I-protein
. O

However O
, O
CsA O
and O
FK506 O
inhibit O
the O
appearance O
of O
DNA O
binding O
activity O
of O
factors O
that O
bind O
to O
the O
NF O
- O
AT O
and O
AP O
- O
1 O
sites O
in O
the O
IL B-protein
- I-protein
2 I-protein
enhancer O
. O

Since O
the O
induction O
of O
NF B-protein
- I-protein
AT I-protein
and O
AP B-protein
- I-protein
1 I-protein
is O
induced O
by O
the O
same O
stimuli O
that O
stimulate O
IL B-protein
- I-protein
2 I-protein
production O
, O
these O
results O
indicate O
that O
the O
immunosuppressant O
action O
of O
CsA O
and O
FK506 O
is O
exerted O
at O
the O
level O
of O
these O
trans B-protein
- I-protein
activating I-protein
factors I-protein
. O

The O
AP O
- O
1 O
site O
at O
- O
150 O
bp O
, O
but O
not O
the O
NF O
- O
kappa O
B O
site O
, O
is O
likely O
to O
represent O
the O
major O
target O
of O
protein B-protein
kinase I-protein
C I-protein
in O
the O
interleukin B-protein
2 I-protein
promoter O
. O

Stimulation O
of O
T O
cells O
with O
antigen O
results O
in O
activation O
of O
several O
kinases B-protein
, O
including O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
, O
that O
may O
mediate O
the O
later O
induction O
of O
activation O
- O
related O
genes O
. O

We O
have O
examined O
the O
potential O
role O
of O
PKC B-protein
in O
induction O
of O
the O
interleukin B-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
gene O
in O
T O
cells O
stimulated O
through O
the O
T B-protein
cell I-protein
receptor I-protein
/ I-protein
CD3 I-protein
complex I-protein
. O

We O
have O
previously O
shown O
that O
prolonged O
treatment O
of O
the O
untransformed O
T O
cell O
clone O
Ar O
- O
5 O
with O
phorbol O
esters O
results O
in O
downmodulation O
of O
the O
alpha O
and O
beta O
isozymes O
of O
PKC B-protein
, O
and O
abrogates O
induction O
of O
IL O
- O
2 O
mRNA O
and O
protein B-protein
. O

Here O
we O
show O
that O
phorbol O
ester O
treatment O
also O
abolishes O
induction O
of O
chloramphenicol B-protein
acetyltransferase I-protein
activity O
in O
Ar O
- O
5 O
cells O
transfected O
with O
a O
plasmid O
containing O
the O
IL O
- O
2 O
promoter O
linked O
to O
this O
reporter O
gene O
. O

The O
IL O
- O
2 O
promoter O
contains O
binding O
sites O
for O
nuclear B-protein
factors I-protein
including O
NFAT B-protein
- I-protein
1 I-protein
, O
Oct B-protein
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
and O
AP B-protein
- I-protein
1 I-protein
, O
which O
are O
all O
potentially O
sensitive O
to O
activation O
of O
PKC B-protein
. O

We O
show O
that O
induction O
of O
a O
trimer O
of O
the O
NFAT O
and O
Oct O
sites O
is O
not O
sensitive O
to O
phorbol O
ester O
treatment O
, O
and O
that O
mutations O
in O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
site O
have O
no O
effect O
on O
inducibility O
of O
the O
IL O
- O
2 O
promoter O
. O

In O
contrast O
, O
mutations O
in O
the O
AP O
- O
1 O
site O
located O
at O
- O
150 O
bp O
almost O
completely O
abrogate O
induction O
of O
the O
IL O
- O
2 O
promoter O
, O
and O
appearance O
of O
an O
inducible B-protein
nuclear I-protein
factor I-protein
binding O
to O
this O
site O
is O
sensitive O
to O
PKC B-protein
depletion O
. O

Moreover O
, O
cotransfections O
with O
c O
- O
fos O
and O
c O
- O
jun O
expression O
plasmids O
markedly O
enhance O
induction O
of O
the O
IL O
- O
2 O
promoter O
in O
minimally O
stimulated O
T O
cells O
. O

Our O
results O
indicate O
that O
the O
AP O
- O
1 O
site O
at O
- O
150 O
bp O
represents O
a O
major O
, O
if O
not O
the O
only O
, O
site O
of O
PKC B-protein
responsiveness O
in O
the O
IL O
- O
2 O
promoter O
. O

[ O
Effect O
of O
antihypertensive O
therapy O
with O
captopril O
on O
gluco O
- O
and O
mineralocorticoid O
receptors O
of O
peripheral O
blood O
lymphocytes O
in O
hypertensive O
patients O
of O
various O
age O
] O
. O

Binding O
of O
3H O
- O
dexamethasone O
and O
3H O
- O
aldosterone O
by O
peripheral B-protein
lymphocyte I-protein
receptors I-protein
was O
investigated O
in O
healthy O
persons O
and O
hypertensive O
patients O
before O
and O
after O
2 O
- O
week O
captopril O
treatment O
. O

The O
number O
of O
glucocorticoid O
and O
mineralocorticoid B-protein
binding I-protein
sites I-protein
was O
increased O
in O
hypertensives O
vs O
normotensives O
. O

The O
treatment O
with O
the O
ACE O
inhibitor O
captopril O
led O
to O
activation O
of O
hormone O
- O
receptor O
interactions O
. O

There O
was O
a O
more O
marked O
rise O
of O
the O
number O
of O
receptors B-protein
in O
middle O
- O
aged O
( O
44 O
- O
55 O
years O
) O
hypertensives O
vs O
elderly O
( O
61 O
- O
80 O
years O
) O
subjects O
after O
captopril O
treatment O
. O

The O
use O
of O
interferon O
- O
gamma O
- O
treated O
U937 O
cells O
in O
chemiluminescence O
assays O
to O
detect O
red O
cell O
, O
platelet O
and O
granulocyte O
antibodies O
of O
potential O
clinical O
significance O
. O

The O
chemiluminescent O
( O
CL O
) O
response O
of O
interferon O
- O
gamma O
- O
treated O
U937 O
( O
IFN O
- O
U937 O
) O
cells O
to O
sensitized O
target O
cells O
has O
been O
used O
to O
detect O
red B-protein
cell I-protein
, O
platelet B-protein
and O
granulocyte B-protein
antibodies I-protein
. O

A O
clone O
of O
U937 O
cells O
was O
selected O
which O
expressed O
Fc B-protein
receptor I-protein
I I-protein
( O
Fc B-protein
gamma I-protein
RI I-protein
) O
and O
which O
, O
after O
incubation O
with O
IFN B-protein
- I-protein
gamma I-protein
for O
72 O
h O
, O
was O
capable O
of O
generating O
high O
levels O
of O
lucigenin O
- O
enhanced O
CL O
. O

The O
CL O
responses O
of O
IFN O
- O
U937 O
cells O
and O
peripheral O
blood O
human O
monocytes O
to O
sensitized O
red O
cells O
, O
platelets O
or O
granulocytes O
were O
then O
compared O
. O

Assays O
using O
monocytes O
or O
IFN O
- O
U937 O
cells O
were O
of O
comparable O
sensitivity O
for O
detection O
of O
antibodies B-protein
against O
all O
three O
types O
of O
target O
cell O
. O

In O
addition O
, O
the O
use O
of O
IFN O
- O
U937 O
cells O
reduced O
interassay O
variation O
and O
simplified O
assay O
performance O
. O

The O
potential O
clinical O
usefulness O
of O
these O
CL O
assays O
was O
suggested O
by O
the O
ability O
of O
both O
monocytes O
and O
IFN O
- O
U937 O
cells O
to O
respond O
to O
red O
cells O
, O
platelets O
or O
granulocytes O
sensitized O
with O
sera O
from O
pregnant O
women O
whose O
babies O
had O
either O
haemolytic O
disease O
of O
the O
newborn O
( O
HDN O
) O
, O
alloimmune O
thrombocytopenia O
or O
alloimmune O
neutropenia O
respectively O
. O

In O
addition O
, O
monocytes O
and O
IFN O
- O
U937 O
cells O
both O
responded O
to O
red O
cells O
sensitized O
with O
antibodies B-protein
against O
a O
variety O
of O
specificities O
of O
assumed O
( O
although O
not O
documented O
) O
clinical O
significance O
for O
blood O
transfusion O
recipients O
. O

In O
contrast O
, O
monocytes O
and O
IFN O
- O
U937 O
cells O
responded O
only O
weakly O
to O
red O
cells O
sensitized O
with O
either O
anti B-protein
- I-protein
D I-protein
in O
sera O
from O
mothers O
of O
babies O
unaffected O
by O
HDN O
, O
or O
with O
antisera O
containing O
high B-protein
titre I-protein
antibodies I-protein
with O
specificities O
not O
normally O
associated O
with O
significantly O
reduced O
red O
cell O
survival O
. O

Ablation O
of O
transplanted O
HTLV O
- O
I O
Tax O
- O
transformed O
tumors O
in O
mice O
by O
antisense O
inhibition O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
[ O
published O
erratum O
appears O
in O
Science O
1993 O
Mar O
12 O
; O
259 O
( O
5101 O
) O
: O
1523 O
] O
. O

Mice O
transgenic O
for O
the O
human O
T O
cell O
leukemia O
virus O
( O
HTLV O
- O
I O
) O
Tax B-protein
gene O
develop O
fibroblastic O
tumors O
that O
express O
NF O
- O
kappa O
B O
- O
inducible O
early O
genes O
. O

In O
vitro O
inhibition O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
by O
antisense O
oligodeoxynucleotides O
( O
ODNs O
) O
inhibited O
growth O
of O
these O
culture O
- O
adapted O
Tax O
- O
transformed O
fibroblasts O
as O
well O
as O
an O
HTLV O
- O
I O
- O
transformed O
human O
lymphocyte O
line O
. O

In O
contrast O
, O
antisense O
inhibition O
of O
Tax B-protein
itself O
had O
no O
apparent O
effect O
on O
cell O
growth O
. O

Mice O
treated O
with O
antisense O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
ODNs O
showed O
rapid O
regression O
of O
transplanted O
fibrosarcomas O
. O

This O
suggests O
that O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
may O
be O
necessary O
for O
the O
maintenance O
of O
the O
malignant O
phenotype O
and O
provides O
a O
therapeutic O
approach O
for O
HTLV O
- O
I O
- O
associated O
disease O
. O

Membrane B-protein
receptors I-protein
for O
aldosterone O
: O
a O
novel O
pathway O
for O
mineralocorticoid O
action O
. O

Rapid O
nongenomic O
in O
vitro O
effects O
of O
aldosterone O
on O
intracellular O
electrolytes O
, O
cell O
volume O
, O
and O
Na B-protein
( I-protein
+ I-protein
) I-protein
- I-protein
H I-protein
+ I-protein
antiport I-protein
have O
been O
found O
in O
human O
mononuclear O
leukocytes O
( O
HML O
) O
. O

Binding O
of O
125I O
- O
labeled O
aldosterone O
to O
plasma O
membranes O
of O
HML O
shares O
important O
features O
with O
these O
functional O
data O
. O

This O
includes O
a O
very O
low O
apparent O
dissociation O
constant O
( O
Kd O
) O
of O
0 O
. O
1 O
nM O
for O
both O
aldosterone O
and O
the O
effect O
on O
the O
Na B-protein
( I-protein
+ I-protein
) I-protein
- I-protein
H I-protein
( I-protein
+ I-protein
) I-protein
- I-protein
antiport I-protein
, O
a O
high O
turnover O
rate O
, O
and O
the O
almost O
exclusive O
binding O
selectivity O
for O
aldosterone O
. O

Dexamethasone O
, O
RU O
26988 O
, O
corticosterone O
, O
ouabain O
, O
amiloride O
, O
and O
18 O
- O
hydroxyprogesterone O
were O
inactive O
as O
ligands O
. O

Deoxycorticosterone O
acetate O
had O
an O
intermediate O
activity O
with O
an O
apparent O
Kd O
of O
100 O
nM O
. O

These O
findings O
are O
the O
first O
to O
demonstrate O
membrane O
binding O
of O
aldosterone O
being O
compatible O
with O
major O
aspects O
of O
its O
nongenomic O
effects O
. O

Leukotriene O
B4 O
transcriptionally O
activates O
interleukin B-protein
- I-protein
6 I-protein
expression O
involving O
NK B-protein
- I-protein
chi I-protein
B I-protein
and O
NF B-protein
- I-protein
IL6 I-protein
. O

Leukotriene O
B4 O
( O
LTB4 O
) O
is O
a O
notable O
participant O
in O
inflammation O
and O
chemotaxis O
. O

It O
is O
, O
however O
, O
still O
unclear O
whether O
LTB4 O
acts O
in O
this O
regard O
directly O
or O
indirectly O
by O
stimulating O
the O
release O
of O
chemotactic O
and O
inflammatory B-protein
cytokines I-protein
. O

Here O
we O
report O
that O
LTB4 O
induces O
synthesis O
of O
interleukin B-protein
( I-protein
IL I-protein
) I-protein
- I-protein
6 I-protein
by O
human O
blood O
monocytes O
through O
transcriptional O
activation O
of O
the O
IL B-protein
- I-protein
6 I-protein
gene O
. O

We O
furthermore O
demonstrate O
that O
this O
process O
involves O
activation O
of O
the O
transcription B-protein
factor I-protein
NF B-protein
- I-protein
chi I-protein
B I-protein
and O
, O
to O
a O
lesser O
extent O
, O
of O
NF B-protein
- I-protein
IL6 I-protein
, O
while O
the O
activity O
of O
the O
transcription B-protein
factor I-protein
AP B-protein
- I-protein
1 I-protein
, O
shown O
to O
otherwise O
confer O
IL B-protein
- I-protein
6 I-protein
inducibility O
, O
appeared O
to O
be O
unaffected O
by O
LTB4 O
. O

Involvement O
of O
NF B-protein
- I-protein
chi I-protein
B I-protein
and O
NF B-protein
- I-protein
IL6 I-protein
in O
induction O
of O
IL B-protein
- I-protein
6 I-protein
transcription O
by O
monocytes O
was O
demonstrated O
using O
deleted O
forms O
of O
the O
IL B-protein
- I-protein
6 I-protein
promoter O
. O

Activation O
of O
the O
IL B-protein
- I-protein
6 I-protein
promoter O
by O
LTB4 O
was O
not O
only O
associated O
with O
accumulation O
of O
the O
respective O
transcripts O
but O
resulted O
in O
synthesis O
of O
functional O
IL B-protein
- I-protein
6 I-protein
protein I-protein
as O
well O
. O

In O
addition O
, O
LTB4 O
mediated O
transactivation O
of O
a O
heterologous O
promoter O
construct O
containing O
the O
NF B-protein
- I-protein
chi I-protein
B I-protein
or O
the O
NF B-protein
- I-protein
IL6 I-protein
enhancer O
, O
but O
not O
the O
AP B-protein
- I-protein
1 I-protein
enhancer O
. O

The O
signaling O
events O
mediating O
this O
effect O
appeared O
to O
involve O
the O
release O
of O
H2O2 O
, O
since O
LTB4 O
failed O
to O
induce O
NF B-protein
- I-protein
chi I-protein
B I-protein
or O
NF B-protein
- I-protein
IL6 I-protein
in O
the O
presence O
of O
the O
scavenger O
of O
H2O2 O
, O
N O
- O
acetyl O
- O
L O
- O
cysteine O
. O

Bcl B-protein
- I-protein
2 I-protein
: O
a O
repressor O
of O
lymphocyte O
death O
. O

The O
genes O
and O
mechanisms O
that O
control O
programmed O
cell O
death O
are O
currently O
the O
subject O
of O
intense O
study O
. O

The O
bcl O
- O
2 O
gene O
, O
a O
repressor O
of O
lymphocyte O
death O
, O
is O
perhaps O
the O
best O
understood O
of O
the O
programmed O
cell O
death O
associated O
genes O
. O

Here O
, O
Stanley O
Korsmeyer O
provides O
a O
brief O
overview O
of O
bcl B-protein
- I-protein
2 I-protein
, O
concentrating O
on O
its O
roles O
in O
B O
- O
and O
T O
- O
cell O
development O
and O
in O
oncogenesis O
. O

Cytoplasmic O
domain O
heterogeneity O
and O
functions O
of O
IgG B-protein
Fc I-protein
receptors I-protein
in O
B O
lymphocytes O
. O

B O
lymphocytes O
and O
macrophages O
express O
closely O
related O
immunoglobulin B-protein
G I-protein
( I-protein
IgG I-protein
) I-protein
Fc I-protein
receptors I-protein
( O
Fc B-protein
gamma I-protein
RII I-protein
) O
that O
differ O
only O
in O
the O
structures O
of O
their O
cytoplasmic B-protein
domains I-protein
. O

Because O
of O
cell O
type O
- O
specific O
alternative O
messenger O
RNA O
splicing O
, O
B B-protein
- I-protein
cell I-protein
Fc I-protein
gamma I-protein
RII I-protein
contains O
an O
insertion O
of O
47 O
amino O
acids O
that O
participates O
in O
determining O
receptor O
function O
in O
these O
cells O
. O

Transfection O
of O
an O
Fc B-protein
gamma I-protein
RII I-protein
- O
negative O
B O
- O
cell O
line O
with O
complementary O
DNA O
' O
s O
encoding O
the O
two O
splice O
products O
and O
various O
receptor O
mutants O
indicated O
that O
the O
insertion O
was O
responsible O
for O
preventing O
both O
Fc B-protein
gamma I-protein
RII I-protein
- O
mediated O
endocytosis O
and O
Fc B-protein
gamma I-protein
RII I-protein
- O
mediated O
antigen O
presentation O
. O

The O
insertion O
was O
not O
required O
for O
Fc B-protein
gamma I-protein
RII I-protein
to O
modulate O
surface B-protein
immunoglobulin I-protein
- O
triggered O
B O
- O
cell O
activation O
. O

Instead O
, O
regulation O
of O
activation O
involved O
a O
region O
of O
the O
cytoplasmic B-protein
domain I-protein
common O
to O
both O
the O
lymphocyte O
and O
macrophage O
receptor O
isoforms O
. O

In O
contrast O
, O
the O
insertion O
did O
contribute O
to O
the O
formation O
of O
caps O
in O
response O
to O
receptor O
cross O
- O
linking O
, O
consistent O
with O
suggestions O
that O
the O
lymphocyte O
but O
not O
macrophage O
form O
of O
the O
receptor O
can O
associate O
with O
the O
detergent O
- O
insoluble O
cytoskeleton O
. O

[ O
Age O
- O
related O
changes O
in O
glucocorticoid O
and O
mineralocorticoid O
receptors O
in O
lymphocytes O
of O
healthy O
persons O
and O
patients O
with O
hypertension O
] O
. O

It O
has O
been O
found O
that O
the O
number O
of O
glucocorticoid B-protein
receptors I-protein
in O
lymphocytes O
of O
the O
peripheral O
blood O
of O
healthy O
elderly O
subjects O
increases O
, O
while O
the O
number O
of O
mineralocorticoid O
receptors O
decreases O
. O

The O
mechanisms O
of O
hormone O
- O
receptor O
interactions O
in O
hypertension O
are O
activated O
: O
the O
number O
of O
glucocorticoid O
and O
mineralocorticoid O
binding O
sites O
grows O
in O
hypertensive O
patients O
. O

Still O
a O
more O
essential O
rise O
in O
the O
number O
of O
receptors O
is O
observed O
in O
mid O
- O
age O
hypertensive O
patients O
than O
in O
elderly O
ones O
. O

The O
mechanism O
of O
action O
of O
cyclosporin O
A O
and O
FK506 O
. O

CsA O
and O
FK506 O
are O
powerful O
suppressors O
of O
the O
immune O
system O
, O
most O
notably O
of O
T O
cells O
. O

They O
act O
at O
a O
point O
in O
activation O
that O
lies O
between O
receptor O
ligation O
and O
the O
transcription O
of O
early O
genes O
. O

Here O
, O
Stuart O
Schreiber O
and O
Gerald O
Crabtree O
review O
recent O
findings O
that O
indicate O
CsA O
and O
FK506 O
operate O
as O
prodrugs O
: O
they O
bind O
endogenous B-protein
intracellular I-protein
receptors I-protein
, O
the O
immunophilins B-protein
, O
and O
the O
resulting O
complex O
targets O
the O
protein B-protein
phosphatase I-protein
, I-protein
calcineurin B-protein
, O
to O
exert O
the O
immunosuppressive O
effect O
. O

Induction O
of O
monocytic O
differentiation O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
like O
activities O
by O
human O
immunodeficiency O
virus O
1 O
infection O
of O
myelomonoblastic O
cells O
. O

The O
effects O
of O
human O
immunodeficiency O
virus O
1 O
( O
HIV O
- O
1 O
) O
infection O
on O
cellular O
differentiation O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA O
binding O
activity O
have O
been O
investigated O
in O
a O
new O
model O
of O
myeloid O
differentiation O
. O

PLB O
- O
985 O
cells O
represent O
a O
bipotential O
myelomonoblastic O
cell O
population O
capable O
of O
either O
granulocytic O
or O
monocytic O
differentiation O
after O
induction O
with O
appropriate O
inducers O
. O

By O
virtue O
of O
the O
presence O
of O
CD4 B-protein
on O
the O
cell O
surface O
, O
PLB O
- O
985 O
cells O
were O
chronically O
infected O
with O
HIV O
- O
1 O
strain O
IIIB O
. O

PLB O
- O
IIIB O
cells O
clearly O
possessed O
a O
more O
monocytic O
phenotype O
than O
the O
parental O
myeloblasts O
, O
as O
determined O
by O
differential O
staining O
, O
increased O
expression O
of O
the O
myeloid B-protein
- I-protein
specific I-protein
surface I-protein
markers I-protein
, O
and O
transcription O
of O
the O
c O
- O
fms O
proto O
- O
oncogene O
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activity O
was O
inducible O
by O
tumor B-protein
necrosis I-protein
factor I-protein
and O
phorbol O
myristate O
acetate O
in O
PLB O
- O
985 O
. O

However O
, O
in O
PLB O
- O
IIIB O
cells O
, O
constitutive O
expression O
of O
a O
novel O
NF B-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
was O
detected O
, O
composed O
of O
proteins B-protein
ranging O
between O
70 O
and O
110 O
kD O
. O

These O
proteins B-protein
interacted O
specifically O
with O
the O
symmetric O
NF O
- O
kappa O
B O
site O
from O
the O
interferon O
beta O
( O
IFN B-protein
- I-protein
beta I-protein
) O
promoter O
. O

Mutations O
affecting O
the O
5 O
' O
guanine O
residues O
of O
the O
kappa O
B O
site O
were O
unable O
to O
compete O
for O
these O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
related I-protein
proteins I-protein
. O

Inducibility O
of O
endogenous O
IFN O
- O
beta O
and O
IFN O
- O
alpha O
RNA O
was O
also O
increased O
in O
PLB O
- O
IIIB O
cells O
. O

These O
studies O
indicate O
that O
HIV O
- O
1 O
infection O
of O
myelomonoblastic O
cells O
may O
select O
for O
a O
more O
mature O
monocytic O
phenotype O
and O
that O
unique O
subunit O
associations O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA I-protein
binding I-protein
proteins I-protein
may O
contribute O
to O
differential O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
mediated O
gene O
expression O
. O

Cortisol O
receptor O
resistance O
: O
the O
variability O
of O
its O
clinical O
presentation O
and O
response O
to O
treatment O
. O

Primary O
( O
partial O
) O
cortisol B-protein
receptor I-protein
resistance O
was O
previously O
reported O
in O
a O
total O
of O
7 O
patients O
and O
14 O
asymptomatic O
family O
members O
. O

Its O
occurrence O
is O
considered O
to O
be O
extremely O
rare O
. O

In O
the O
present O
study O
we O
report O
on O
6 O
patients O
( O
2 O
males O
and O
4 O
females O
) O
with O
the O
syndrome O
. O

The O
first O
male O
patient O
presented O
with O
mild O
hypertension O
. O

Hydrochlorothiazide O
therapy O
resulted O
in O
life O
- O
threatening O
hypokalemia O
. O

The O
second O
male O
patient O
had O
slight O
hypertension O
without O
hypokalemia O
. O

All O
four O
female O
patients O
presented O
between O
the O
age O
of O
20 O
- O
30 O
yr O
with O
acne O
, O
hirsutism O
, O
and O
irregular O
menstruations O
. O

Low O
dose O
dexamethasone O
therapy O
( O
1 O
- O
1 O
. O
5 O
mg O
/ O
day O
) O
was O
of O
clinical O
benefit O
in O
these O
patients O
. O

All O
patients O
showed O
insufficient O
suppression O
of O
serum O
cortisol O
concentrations O
in O
the O
overnight O
1 O
- O
mg O
dexamethasone O
test O
. O

The O
diurnal O
rhythm O
of O
ACTH O
and O
cortisol O
was O
intact O
, O
albeit O
at O
an O
elevated O
level O
. O

There O
was O
a O
normal O
increase O
in O
ACTH O
, O
cortisol O
, O
and O
GH O
( O
except O
in O
one O
obese O
patient O
) O
in O
response O
to O
insulin O
- O
induced O
hypoglycemia O
, O
while O
cortisol O
production O
was O
elevated O
in O
three O
patients O
. O

Circulating O
adrenal O
androgen O
levels O
were O
increased O
in O
all O
patients O
. O

Glucocorticoid B-protein
receptors I-protein
were O
investigated O
in O
a O
whole O
cell O
dexamethasone O
binding O
assay O
in O
mononuclear O
leukocytes O
. O

In O
the O
first O
male O
patient O
, O
the O
number O
of O
receptors O
was O
very O
low O
, O
while O
the O
affinity O
was O
lower O
than O
that O
in O
controls O
. O

A O
lowered O
affinity O
to O
dexamethasone O
was O
found O
in O
one O
female O
patient O
, O
while O
a O
lowered O
number O
of O
receptors O
was O
found O
in O
three O
patients O
. O

In O
the O
second O
male O
patient O
, O
no O
abnormalities O
were O
found O
. O

As O
a O
bioassay O
for O
glucocorticoid O
action O
we O
also O
measured O
dexamethasone O
suppressibility O
of O
mitogen O
- O
stimulated O
incorporation O
of O
[ O
3H O
] O
thymidine O
in O
mononuclear O
leukocytes O
. O

In O
the O
male O
patient O
with O
normal O
receptor O
status O
, O
dexamethasone O
suppressibility O
of O
[ O
3H O
] O
thymidine O
incorporation O
was O
significantly O
lower O
than O
that O
in O
healthy O
controls O
with O
respect O
to O
both O
maximal O
suppression O
and O
IC50 O
. O

Partial O
cortisol O
receptor O
resistance O
might O
be O
less O
rare O
than O
previously O
thought O
. O

In O
the O
six O
patients O
presented O
, O
at O
least O
three O
different O
forms O
can O
be O
recognized O
. O

Therapy O
with O
dexamethasone O
was O
successful O
in O
female O
patients O
with O
acne O
and O
hirsutism O
, O
as O
the O
secondary O
increase O
in O
the O
production O
of O
adrenal O
androgens O
was O
effectively O
controlled O
. O

The O
development O
of O
functionally O
responsive O
T O
cells O
. O

The O
work O
reviewed O
in O
this O
article O
separates O
T O
cell O
development O
into O
four O
phases O
. O

First O
is O
an O
expansion O
phase O
prior O
to O
TCR B-protein
rearrangement O
, O
which O
appears O
to O
be O
correlated O
with O
programming O
of O
at O
least O
some O
response O
genes O
for O
inducibility O
. O

This O
phase O
can O
occur O
to O
some O
extent O
outside O
of O
the O
thymus O
. O

However O
, O
the O
profound O
T O
cell O
deficit O
of O
nude O
mice O
indicates O
that O
the O
thymus O
is O
by O
far O
the O
most O
potent O
site O
for O
inducing O
the O
expansion O
per O
se O
, O
even O
if O
other O
sites O
can O
induce O
some O
response O
acquisition O
. O

Second O
is O
a O
controlled O
phase O
of O
TCR O
gene O
rearrangement O
. O

The O
details O
of O
the O
regulatory O
mechanism O
that O
selects O
particular O
loci O
for O
rearrangement O
are O
still O
not O
known O
. O

It O
seems O
that O
the O
rearrangement O
of O
the O
TCR O
gamma O
loci O
in O
the O
gamma O
delta O
lineage O
may O
not O
always O
take O
place O
at O
a O
developmental O
stage O
strictly O
equivalent O
to O
the O
rearrangement O
of O
TCR O
beta O
in O
the O
alpha O
beta O
lineage O
, O
and O
it O
is O
not O
clear O
just O
how O
early O
the O
two O
lineages O
diverge O
. O

In O
the O
TCR O
alpha O
beta O
lineage O
, O
however O
, O
the O
final O
gene O
rearrangement O
events O
are O
accompanied O
by O
rapid O
proliferation O
and O
an O
interruption O
in O
cellular O
response O
gene O
inducibility O
. O

The O
loss O
of O
conventional O
responsiveness O
is O
probably O
caused O
by O
alterations O
at O
the O
level O
of O
signaling O
, O
and O
may O
be O
a O
manifestation O
of O
the O
physiological O
state O
that O
is O
a O
precondition O
for O
selection O
. O

Third O
is O
the O
complex O
process O
of O
selection O
. O

Whereas O
peripheral O
T O
cells O
can O
undergo O
forms O
of O
positive O
selection O
( O
by O
antigen O
- O
driven O
clonal O
expansion O
) O
and O
negative O
selection O
( O
by O
abortive O
stimulation O
leading O
to O
anergy O
or O
death O
) O
, O
neither O
is O
exactly O
the O
same O
phenomenon O
that O
occurs O
in O
the O
thymic O
cortex O
. O

Negative O
selection O
in O
the O
cortex O
appears O
to O
be O
a O
suicidal O
inversion O
of O
antigen O
responsiveness O
: O
instead O
of O
turning O
on O
IL B-protein
- I-protein
2 I-protein
expression O
, O
the O
activated O
cell O
destroys O
its O
own O
chromatin O
. O

The O
genes O
that O
need O
to O
be O
induced O
for O
this O
response O
are O
not O
yet O
identified O
, O
but O
it O
is O
unquestionably O
a O
form O
of O
activation O
. O

It O
is O
interesting O
that O
in O
humans O
and O
rats O
, O
cortical O
thymocytes O
undergoing O
negative O
selection O
can O
still O
induce O
IL B-protein
- I-protein
2R I-protein
alpha I-protein
expression O
and O
even O
be O
rescued O
in O
vitro O
, O
if O
exogenous B-protein
IL I-protein
- I-protein
2 I-protein
is O
provided O
. O

Perhaps O
murine O
thymocytes O
are O
denied O
this O
form O
of O
rescue O
because O
they O
shut O
off O
IL B-protein
- I-protein
2R I-protein
beta I-protein
chain I-protein
expression O
at O
an O
earlier O
stage O
or O
because O
they O
may O
be O
uncommonly O
Bcl B-protein
- I-protein
2 I-protein
deficient O
( O
cf O
. O
Sentman O
et O
al O
. O
, O
1991 O
; O
Strasser O
et O
al O
. O
, O
1991 O
) O
. O

Even O
so O
, O
medullary O
thymocytes O
remain O
at O
least O
partially O
susceptible O
to O
negative O
selection O
even O
as O
they O
continue O
to O
mature O
. O

I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
masks O
the O
nuclear O
localization O
signal O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
and O
requires O
the O
transactivation B-protein
domain I-protein
to O
inhibit O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
DNA O
binding O
. O

The O
active O
nuclear O
form O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
complex I-protein
is O
composed O
of O
two O
DNA B-protein
binding I-protein
subunits I-protein
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 I-protein
, O
both O
of O
which O
share O
extensive O
N O
- O
terminal O
sequence O
homology O
with O
the O
v B-protein
- I-protein
rel I-protein
oncogene I-protein
product I-protein
. O

The O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
subunit I-protein
provides O
the O
transactivation O
activity O
in O
this O
complex O
and O
serves O
as O
an O
intracellular O
receptor O
for O
a O
cytoplasmic O
inhibitor O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
termed O
I O
kappa O
B O
. O

In O
contrast O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 I-protein
alone O
fails O
to O
stimulate O
kappa O
B O
- O
directed O
transcription O
, O
and O
based O
on O
prior O
in O
vitro O
studies O
, O
is O
not O
directly O
regulated O
by O
I B-protein
kappa I-protein
B I-protein
. O

To O
investigate O
the O
molecular O
basis O
for O
the O
critical O
regulatory O
interaction O
between O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
, O
a O
series O
of O
human B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
mutants I-protein
was O
identified O
that O
functionally O
segregated O
DNA O
binding O
, O
I B-protein
kappa I-protein
B I-protein
- O
mediated O
inhibition O
, O
and O
I B-protein
kappa I-protein
B I-protein
- O
induced O
nuclear O
exclusion O
of O
this O
transcription B-protein
factor I-protein
. O

Results O
from O
in O
vivo O
expression O
studies O
performed O
with O
these O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
mutants I-protein
revealed O
the O
following O
: O
1 O
) O
I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
completely O
inhibits O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
- O
dependent O
transcriptional O
activation O
mediated O
through O
the O
human O
immunodeficiency O
virus O
type O
1 O
kappa O
B O
enhancer O
in O
human O
T O
lymphocytes O
, O
2 O
) O
the O
binding O
of O
I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
is O
sufficient O
to O
retarget O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
from O
the O
nucleus O
to O
the O
cytoplasm O
, O
3 O
) O
selective O
deletion O
of O
the O
functional O
nuclear O
localization O
signal O
present O
in O
the O
Rel B-protein
homology I-protein
domain I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
disrupts O
its O
ability O
to O
engage O
I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
, O
and O
4 O
) O
the O
unique O
C B-protein
- I-protein
terminus I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
attenuates O
its O
own O
nuclear O
localization O
and O
contains O
sequences O
that O
are O
required O
for O
I B-protein
kappa I-protein
B I-protein
- O
mediated O
inhibition O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
DNA O
binding O
activity O
. O

Together O
, O
these O
findings O
suggest O
that O
the O
nuclear O
localization O
signal O
and O
transactivation B-protein
domain I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
constitute O
a O
bipartite O
system O
that O
is O
critically O
involved O
in O
the O
inhibitory O
function O
of O
I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
. O

Unexpectedly O
, O
our O
in O
vivo O
studies O
also O
demonstrate O
that O
I B-protein
kappa I-protein
B I-protein
/ I-protein
MAD I-protein
- I-protein
3 I-protein
binds O
directly O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 I-protein
. O

This O
interaction O
is O
functional O
as O
it O
leads O
to O
retargeting O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p50 I-protein
from O
the O
nucleus O
to O
the O
cytoplasm O
. O

However O
, O
no O
loss O
of O
DNA O
binding O
activity O
is O
observed O
, O
presumably O
reflecting O
the O
unique O
C B-protein
- I-protein
terminal I-protein
domain I-protein
that O
is O
distinct O
from O
that O
present O
in O
NF B-protein
- I-protein
kappa I-protein
B I-protein
p65 I-protein
. O

Characterization O
of O
a O
new O
tissue O
- O
specific O
transcription B-protein
factor I-protein
binding O
to O
the O
simian O
virus O
40 O
enhancer O
TC O
- O
II O
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
element O
. O

We O
have O
biochemically O
and O
functionally O
characterized O
a O
new O
transcription B-protein
factor I-protein
, O
NP B-protein
- I-protein
TCII I-protein
, O
which O
is O
present O
in O
nuclei O
from O
unstimulated O
T O
and O
B O
lymphocytes O
but O
is O
not O
found O
in O
nonhematopoietic O
cells O
. O

This O
factor O
has O
a O
DNA O
- O
binding O
specificity O
similar O
to O
that O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
but O
is O
unrelated O
to O
this O
or O
other O
Rel B-protein
proteins I-protein
by O
functional O
and O
biochemical O
criteria O
. O

It O
can O
also O
be O
distinguished O
from O
other O
previously O
described O
lymphocyte B-protein
- I-protein
specific I-protein
DNA I-protein
- I-protein
binding I-protein
proteins I-protein
. O

The O
candidate B-protein
oncoprotein I-protein
Bcl I-protein
- I-protein
3 I-protein
is O
an O
antagonist O
of O
p50 B-protein
/ I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
- O
mediated O
inhibition O
. O

The O
candidate O
oncogene O
bcl O
- O
3 O
was O
discovered O
as O
a O
translocation O
into O
the O
immunoglobulin O
alpha O
- O
locus O
in O
some O
cases O
of O
B O
- O
cell O
chronic O
lymphocytic O
leukaemias O
. O

The O
protein B-protein
Bcl I-protein
- I-protein
3 I-protein
contains O
seven O
so O
- O
called O
ankyrin B-protein
repeats I-protein
. O

Similar O
repeat B-protein
motifs I-protein
are O
found O
in O
a O
number O
of O
diverse B-protein
regulatory I-protein
proteins I-protein
but O
the O
motifs O
of O
Bcl B-protein
- I-protein
3 I-protein
are O
most O
closely O
related O
to O
those O
found O
in O
I B-protein
kappa I-protein
B I-protein
proteins I-protein
in O
which O
the O
ankyrin B-protein
repeat I-protein
domain O
is O
thought O
to O
be O
directly O
involved O
in O
inhibition O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
. O

No O
biological O
function O
has O
yet O
been O
described O
for O
Bcl B-protein
- I-protein
3 I-protein
, O
but O
it O
was O
noted O
recently O
that O
Bcl B-protein
- I-protein
3 I-protein
interferes O
with O
DNA O
- O
binding O
of O
the O
p50 B-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
vitro O
. O

Here O
we O
demonstrate O
that O
Bcl B-protein
- I-protein
3 I-protein
can O
aid O
kappa O
B O
site O
- O
dependent O
transcription O
in O
vivo O
by O
counteracting O
the O
inhibitory O
effects O
of O
p50 B-protein
/ I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
homodimers I-protein
. O

Bcl B-protein
- I-protein
3 I-protein
may O
therefore O
aid O
activation O
of O
select O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
regulated O
genes O
, O
including O
those O
of O
the O
human O
immunodeficiency O
virus O
. O

[ O
Mechanism O
of O
action O
of O
steroid O
hormones O
. O
I O
. O
Estrogens O
] O
. O

The O
steroid O
hormone O
are O
very O
versatile O
molecules O
: O
although O
they O
are O
related O
among O
them O
by O
their O
chemical O
structure O
, O
they O
have O
very O
diverse O
functions O
and O
including O
antagonic O
. O

Their O
action O
mechanism O
is O
not O
completely O
cleared O
. O

The O
estrogens O
participate O
in O
the O
regulation O
of O
practically O
all O
the O
reproductive O
and O
sexual O
events O
of O
the O
female O
, O
although O
the O
intracellular O
actions O
by O
which O
they O
take O
place O
are O
not O
well O
known O
and O
the O
proposed O
models O
do O
not O
adequately O
satisfy O
the O
questions O
. O

Currently O
it O
is O
accepted O
the O
existence O
of O
a O
cytoplasmic O
and O
/ O
or O
nuclear O
receptor O
, O
without O
explaining O
satisfactorily O
how O
the O
hormones O
come O
to O
the O
nucleus O
. O

The O
endocrine O
events O
that O
are O
rapidly O
expressed O
( O
seconds O
) O
are O
due O
to O
a O
possible O
interaction O
with O
cellular O
membrane O
. O

The O
purpose O
of O
this O
review O
is O
to O
analyze O
and O
concilliate O
the O
reported O
data O
on O
the O
mechanism O
of O
action O
of O
estrogens O
. O

Reduced O
susceptibility O
to O
HIV O
- O
1 O
infection O
of O
ethyl O
- O
methanesulfonate O
- O
treated O
CEM O
subclones O
correlates O
with O
a O
blockade O
in O
their O
protein B-protein
kinase I-protein
C I-protein
signaling O
pathway O
. O

We O
have O
described O
the O
isolation O
of O
chemically O
induced O
CEM O
subclones O
that O
express O
CD4 B-protein
receptors I-protein
and O
bind O
soluble O
gp120 B-protein
, O
yet O
show O
a O
markedly O
reduced O
susceptibility O
to O
infection O
with O
HIV O
- O
1 O
. O

Two O
subclones O
were O
found O
to O
have O
an O
abnormal O
response O
to O
the O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
activator O
PMA O
. O

PMA O
treatment O
induced O
CD3 O
and O
CD25 O
( O
IL O
- O
2R O
) O
receptors O
on O
the O
parental O
line O
and O
on O
other O
ethyl O
- O
methanesulfonate O
- O
derived O
subclones O
, O
but O
not O
on O
these O
two O
mutants O
. O

Direct O
assays O
of O
PKC B-protein
activity O
were O
conducted O
. O

Total O
cellular O
PKC B-protein
enzymatic O
activity O
was O
found O
to O
be O
normal O
in O
these O
subclones O
. O

PMA O
- O
induced O
CD4 B-protein
down O
- O
modulation O
occurred O
normally O
. O

In O
addition O
, O
activation O
of O
c B-protein
- I-protein
raf I-protein
kinase I-protein
was O
normal O
. O

Since O
HIV O
- O
1 O
long O
terminal O
repeat O
contains O
two O
functional O
nuclear O
factor O
kB O
( O
NF B-protein
- I-protein
kB I-protein
) O
regulatory O
elements O
, O
we O
studied O
the O
ability O
of O
PMA O
to O
induce O
NF B-protein
- I-protein
kB I-protein
binding O
activity O
by O
different O
assays O
. O

Chloramphenicol B-protein
acetyl I-protein
transferase I-protein
( O
CAT B-protein
) O
assays O
using O
the O
HIV O
- O
1 O
( O
- O
139 O
) O
long O
terminal O
repeat O
- O
CAT O
construct O
showed O
no O
PMA O
induction O
of O
CAT B-protein
activity O
in O
these O
subclones O
( O
unlike O
the O
parental O
line O
and O
other O
subclones O
) O
. O

Okadaic O
acid O
, O
an O
inhibitor O
of O
phosphatases O
1 O
and O
2A O
, O
did O
not O
overcome O
the O
defect O
in O
these O
subclones O
. O

Gel O
retardation O
assays O
, O
using O
a O
32P O
- O
probe O
containing O
the O
HIV O
- O
1 O
NF B-protein
- I-protein
kB I-protein
probe O
and O
nuclear O
extracts O
from O
PMA O
- O
treated O
cells O
, O
showed O
significantly O
reduced O
induction O
of O
nuclear B-protein
NF I-protein
- I-protein
kB I-protein
binding I-protein
proteins I-protein
in O
these O
two O
subclones O
compared O
with O
wild B-protein
type I-protein
CEM I-protein
and O
a O
control O
subclone O
. O

Deoxycholate O
treatment O
of O
cytoplasmic O
extracts O
from O
these O
subclones O
released O
much O
reduced O
NF B-protein
- I-protein
kB I-protein
binding I-protein
proteins I-protein
from O
their O
cytoplasmic O
pools O
. O

Thus O
, O
reduced O
levels O
of O
PKC B-protein
- O
induced O
nuclear O
NF B-protein
- I-protein
kB I-protein
activity O
in O
two O
T O
cell O
subclones O
did O
not O
affect O
their O
normal O
cell O
growth O
, O
but O
correlated O
with O
a O
pronounced O
reduction O
in O
their O
susceptibility O
to O
HIV O
- O
1 O
infection O
. O

Nuclear B-protein
factor I-protein
of O
activated O
T O
cells O
contains O
Fos B-protein
and O
Jun B-protein
. O

The O
nuclear B-protein
factor I-protein
NF I-protein
- I-protein
AT I-protein
( O
ref O
. O
1 O
) O
is O
induced O
in O
T O
cells O
stimulated O
through O
the O
T B-protein
- I-protein
cell I-protein
receptor I-protein
/ I-protein
CD3 I-protein
complex I-protein
, O
and O
is O
required O
for O
interleukin B-protein
- I-protein
2 I-protein
( O
IL B-protein
- I-protein
2 I-protein
) O
gene O
induction O
. O

Although O
NF B-protein
- I-protein
AT I-protein
has O
not O
been O
cloned O
or O
purified O
, O
there O
is O
evidence O
that O
it O
is O
a O
major O
target O
for O
immunosuppression O
by O
cyclosporin O
A O
( O
CsA O
) O
and O
FK506 O
( O
refs O
2 O
- O
7 O
) O
. O

NF B-protein
- I-protein
AT I-protein
induction O
may O
require O
two O
activation O
- O
dependent O
events O
: O
the O
CsA O
- O
sensitive O
translocation O
of O
a O
pre O
- O
existing O
component O
and O
the O
CsA O
- O
resistant O
synthesis O
of O
a O
nuclear B-protein
component I-protein
. O

Here O
we O
report O
that O
the O
newly O
synthesized O
nuclear B-protein
component I-protein
of O
NF B-protein
- I-protein
AT I-protein
is O
the O
transcription B-protein
factor I-protein
AP B-protein
- I-protein
1 I-protein
. O

We O
show O
that O
the O
inducible O
nuclear O
form O
of O
NF B-protein
- I-protein
AT I-protein
contains O
Fos B-protein
and O
Jun B-protein
proteins O
. O

Furthermore O
, O
we O
identify O
a O
pre B-protein
- I-protein
existing I-protein
NF I-protein
- I-protein
AT I-protein
- I-protein
binding I-protein
factor I-protein
that O
is O
present O
in O
hypotonic O
extracts O
of O
unstimulated O
T O
cells O
. O

On O
the O
basis O
of O
binding O
, O
reconstitution O
and O
cotransfection O
experiments O
, O
we O
propose O
that O
activation O
of O
NF B-protein
- I-protein
AT I-protein
occurs O
in O
at O
least O
two O
stages O
: O
a O
CsA O
- O
sensitive O
stage O
involving O
modification O
and O
/ O
or O
translocation O
of O
the O
pre O
- O
existing O
NF B-protein
- I-protein
AT I-protein
complex I-protein
, O
and O
a O
CsA O
- O
insensitive O
stage O
involving O
the O
addition O
of O
newly O
synthesized O
Fos B-protein
or O
Fos B-protein
/ I-protein
Jun I-protein
proteins I-protein
to O
the O
pre B-protein
- I-protein
existing I-protein
complex I-protein
. O

A O
lymphoid B-protein
cell I-protein
- I-protein
specific I-protein
nuclear I-protein
factor I-protein
containing O
c B-protein
- I-protein
Rel I-protein
- I-protein
like I-protein
proteins I-protein
preferentially O
interacts O
with O
interleukin O
- O
6 O
kappa O
B O
- O
related O
motifs O
whose O
activities O
are O
repressed O
in O
lymphoid O
cells O
. O

The O
proto B-protein
- I-protein
oncoprotein I-protein
c I-protein
- I-protein
Rel I-protein
is O
a O
member O
of O
the O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
family I-protein
, O
which O
includes O
the O
p50 B-protein
and O
p65 B-protein
subunits I-protein
of O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
. O

We O
show O
here O
that O
c B-protein
- I-protein
Rel I-protein
binds O
to O
kappa O
B O
sites O
as O
homodimers B-protein
as O
well O
as O
heterodimers B-protein
with O
p50 B-protein
. O

These O
homodimers B-protein
and O
heterodimers B-protein
show O
distinct O
DNA O
- O
binding O
specificities O
and O
affinities O
for O
various O
kappa O
B O
motifs O
. O

In O
particular O
, O
the O
c B-protein
- I-protein
Rel I-protein
homodimer I-protein
has O
a O
high O
affinity O
for O
interleukin O
- O
6 O
( O
IL B-protein
- I-protein
6 I-protein
) O
and O
beta O
interferon O
kappa O
B O
sites O
. O

In O
spite O
of O
its O
association O
with O
p50 B-protein
in O
vitro O
, O
however O
, O
we O
found O
a O
lymphoid B-protein
cell I-protein
- I-protein
specific I-protein
nuclear I-protein
factor I-protein
in O
vivo O
that O
contains O
c B-protein
- I-protein
Rel I-protein
but O
not O
p50 B-protein
epitopes I-protein
; O
this O
factor O
, O
termed O
IL B-protein
- I-protein
6 I-protein
kappa I-protein
B I-protein
binding I-protein
factor I-protein
II I-protein
, O
appears O
to O
contain O
the O
c B-protein
- I-protein
Rel I-protein
homodimer I-protein
and O
preferentially O
recognizes O
several O
IL B-protein
- I-protein
6 I-protein
kappa O
B O
- O
related O
kappa O
B O
motifs O
. O

Although O
it O
has O
been O
previously O
shown O
that O
the O
IL B-protein
- I-protein
6 I-protein
kappa O
B O
motif O
functions O
as O
a O
potent O
IL O
- O
1 O
/ O
tumor O
necrosis O
factor O
- O
responsive O
element O
in O
nonlymphoid O
cells O
, O
its O
activity O
was O
found O
to O
be O
repressed O
in O
lymphoid O
cells O
such O
as O
a O
Jurkat O
T O
- O
cell O
line O
. O

We O
also O
present O
evidence O
that O
IL B-protein
- I-protein
6 I-protein
kappa I-protein
B I-protein
binding I-protein
factor I-protein
II I-protein
functions O
as O
a O
repressor O
specific O
for O
IL O
- O
6 O
kappa O
B O
- O
related O
kappa O
B O
motifs O
in O
lymphoid O
cells O
. O

Cortisol O
resistance O
in O
acquired O
immunodeficiency O
syndrome O
. O

This O
study O
concerns O
9 O
iv O
drug O
abusers O
with O
acquired O
immunodeficiency O
syndrome O
( O
AIDS O
) O
who O
developed O
hypercortisolism O
without O
the O
clinical O
signs O
or O
metabolic O
consequences O
of O
hypercortisolism O
. O

All O
patients O
were O
characterized O
by O
an O
Addisonian O
picture O
( O
weakness O
, O
weight O
loss O
, O
hypotension O
, O
hyponatremia O
, O
and O
intense O
mucocutaneous O
melanosis O
) O
. O

An O
acquired O
form O
of O
peripheral O
resistance O
to O
glucocorticoids O
was O
suspected O
. O

We O
, O
therefore O
, O
examined O
glucocorticoid B-protein
receptor I-protein
characteristics O
on O
mononuclear O
leukocytes O
by O
measuring O
[ O
3H O
] O
dexamethasone O
binding O
and O
the O
effect O
of O
dexamethasone O
on O
[ O
3H O
] O
thymidine O
incorporation O
, O
which O
is O
one O
of O
the O
effects O
of O
glucocorticoid B-protein
receptor I-protein
activation O
. O

Glucocorticoid B-protein
receptor I-protein
density O
was O
increased O
in O
AIDS O
patients O
with O
an O
Addisonian O
picture O
( O
group O
1 O
; O
16 O
. O
2 O
+ O
/ O
- O
9 O
. O
4 O
fmol O
/ O
million O
cells O
) O
compared O
to O
values O
in O
12 O
AIDS O
patients O
without O
an O
Addisonian O
picture O
( O
group O
2 O
; O
6 O
. O
05 O
+ O
/ O
- O
2 O
. O
6 O
fmol O
/ O
million O
cells O
; O
P O
less O
than O
0 O
. O
01 O
) O
and O
sex O
- O
and O
age O
- O
matched O
controls O
( O
3 O
. O
15 O
+ O
/ O
- O
2 O
. O
3 O
fmol O
/ O
million O
cells O
; O
P O
less O
than O
0 O
. O
01 O
) O
. O

The O
affinity O
of O
glucocorticoid B-protein
receptors I-protein
( O
Kd O
) O
was O
strikingly O
decreased O
( O
9 O
. O
36 O
+ O
/ O
- O
3 O
. O
44 O
nM O
in O
group O
1 O
; O
3 O
. O
2 O
+ O
/ O
- O
1 O
. O
5 O
nM O
in O
group O
2 O
; O
2 O
. O
0 O
+ O
/ O
- O
0 O
. O
8 O
nM O
in O
controls O
; O
P O
less O
than O
0 O
. O
01 O
) O
. O

[ O
3H O
] O
Thymidine O
incorporation O
was O
decreased O
dose O
- O
dependently O
by O
dexamethasone O
in O
controls O
and O
patients O
; O
the O
effect O
was O
significantly O
blunted O
( O
P O
less O
than O
0 O
. O
05 O
) O
in O
group O
1 O
patients O
, O
which O
suggests O
that O
activation O
of O
glucocorticoid B-protein
receptor I-protein
is O
impaired O
as O
a O
result O
of O
the O
glucocorticoid B-protein
receptor I-protein
abnormality O
. O

In O
conclusion O
, O
AIDS O
patients O
with O
hypercortisolism O
and O
clinical O
features O
of O
peripheral O
resistance O
to O
glucocorticoids O
are O
characterized O
by O
abnormal B-protein
glucocorticoid I-protein
receptors I-protein
on O
lymphocytes O
. O

Resistance O
to O
glucocorticoids O
implies O
a O
complex O
change O
in O
immune O
- O
endocrine O
function O
, O
which O
may O
be O
important O
in O
the O
course O
of O
immunodeficiency O
syndrome O
. O

A O
novel O
primer O
extension O
method O
to O
detect O
the O
number O
of O
CAG O
repeats O
in O
the O
androgen O
receptor O
gene O
in O
families O
with O
X O
- O
linked O
spinal O
and O
bulbar O
muscular O
atrophy O
. O

X O
- O
linked O
spinal O
and O
bulbar O
muscular O
atrophy O
( O
SBMA O
) O
, O
an O
adult O
- O
onset O
form O
of O
motor O
neuron O
disease O
, O
was O
recently O
reported O
to O
be O
caused O
by O
amplification O
of O
the O
CAG O
repeats O
in O
the O
androgen O
receptor O
gene O
. O

We O
report O
here O
a O
simple O
and O
rapid O
strategy O
to O
detect O
the O
precise O
number O
of O
the O
CAGs O
. O

After O
the O
DNA O
fragment O
containing O
the O
CAG O
repeats O
is O
amplified O
by O
the O
polymerase O
chain O
reaction O
, O
a O
primer O
extension O
is O
carried O
out O
; O
the O
extension O
of O
the O
end O
- O
labelled O
reverse O
primer O
adjacent O
to O
3 O
' O
end O
of O
CAG O
repeats O
stops O
at O
the O
first O
T O
after O
CAG O
repeats O
with O
the O
incorporation O
of O
dideoxy O
ATP O
in O
the O
reaction O
mixture O
. O

The O
resultant O
primer O
products O
are O
analysed O
by O
denaturing O
polyacrylamide O
gel O
electrophoresis O
and O
autoradiography O
. O

This O
method O
could O
be O
quite O
useful O
to O
detect O
not O
only O
CAG O
repeats O
in O
SBMA O
but O
also O
other O
polymorphic O
dinucleotide O
and O
trinucleotide O
repeats O
. O

Cellular O
immune O
and O
cytokine O
pathways O
resulting O
in O
tissue B-protein
factor I-protein
expression O
and O
relevance O
to O
septic O
shock O
. O

Cells O
of O
monocyte O
lineage O
serve O
as O
effector O
cells O
in O
the O
cellular O
immune O
response O
. O

In O
addition O
, O
they O
respond O
to O
LPS O
and O
cytokines O
with O
activation O
and O
expression O
of O
inflammatory B-protein
effector I-protein
gene I-protein
products I-protein
similar O
to O
those O
elicited O
by O
the O
antigen O
driven O
response O
. O

The O
response O
to O
antigen O
proceeds O
at O
the O
T O
helper O
cell O
level O
through O
two O
independent O
forms O
of O
cellular O
collaboration O
, O
contact O
and O
lymphokine B-protein
. O

We O
review O
the O
control O
of O
expression O
of O
the O
Tissue B-protein
Factor I-protein
( O
TF B-protein
) O
gene O
and O
the O
function O
of O
the O
TF B-protein
protein I-protein
. O

The O
enhanced O
initiation O
of O
transcription O
of O
the O
TF O
gene O
appears O
to O
require O
engagement O
of O
a O
56 O
bp O
LPS O
Response O
Element O
, O
an O
enhancer O
that O
is O
engaged O
by O
both O
AP B-protein
- I-protein
1 I-protein
type I-protein
heterodimeric I-protein
complexes I-protein
as O
well O
as O
NF B-protein
kappa I-protein
B I-protein
like I-protein
heterodimeric I-protein
complexes I-protein
. O

Dissociation O
of O
NF B-protein
kappa I-protein
B I-protein
from O
Ig B-protein
kappa I-protein
B I-protein
by O
cytokine O
and O
LPS O
stimulation O
, O
and O
possibly O
activated O
T O
cells O
, O
may O
represent O
a O
common O
pathway O
to O
induction O
of O
the O
TF O
and O
other O
inflammatory O
genes O
. O

Enhancement O
of O
expression O
of O
TF B-protein
is O
observed O
upon O
adhesion O
of O
Mo O
to O
endothelial O
cells O
and O
extracellular O
matrix O
proteins O
, O
as O
well O
as O
upon O
engagement O
of O
leukocyte B-protein
integrins I-protein
. O

The O
biological O
effects O
that O
follow O
from O
expression O
of O
TF B-protein
by O
vascular O
cells O
have O
been O
resolved O
by O
analysis O
of O
function O
aided O
by O
the O
use O
of O
recombinant B-protein
full I-protein
length I-protein
TF I-protein
and O
truncated B-protein
surface I-protein
domain I-protein
of O
TF B-protein
. O

The O
rules O
of O
assembly O
of O
the O
cognate O
ligands O
of O
TF B-protein
, O
namely O
the O
zymogen B-protein
plasma I-protein
factors I-protein
VII I-protein
and O
the O
serine B-protein
protease I-protein
factor I-protein
VIIa I-protein
, O
with O
the O
soluble B-protein
surface I-protein
domain I-protein
of O
TF B-protein
in O
free O
solution O
, O
in O
the O
presence O
of O
phospholipid O
surfaces O
and O
cell O
surface O
and O
of O
the O
anchored B-protein
TF I-protein
molecule I-protein
have O
been O
described O
. O

It O
is O
evident O
that O
assembly O
of O
the O
surface B-protein
domain I-protein
of O
TF B-protein
with O
VIIa B-protein
to O
form O
the O
binary O
TF B-protein
. I-protein
VIIa I-protein
complex I-protein
induces O
a O
significant O
increase O
in O
the O
Kcat O
of O
the O
catalytic B-protein
domain I-protein
of O
VIIa B-protein
for O
small O
peptidyl O
substrates O
and O
more O
profoundly O
for O
protein B-protein
substrate I-protein
. O

This O
provides O
substantial O
evidence O
for O
an O
allosteric O
effect O
on O
the O
catalytic O
cleft O
of O
VIIa B-protein
that O
is O
imparted O
by O
binding O
to O
TF B-protein
, O
its O
cognate O
catalytic O
cofactor B-protein
. O

It O
is O
also O
evident O
that O
the O
TF B-protein
. I-protein
VIIa I-protein
complex I-protein
is O
proteolytically O
active O
and O
can O
activate O
the O
zymogen B-protein
plasma I-protein
factor I-protein
X I-protein
to O
the O
serine B-protein
protease I-protein
Xa I-protein
in O
free O
solution O
, O
inferring O
that O
extended O
substrate O
recognition O
by O
induced O
structural O
loci O
of O
the O
TF B-protein
. I-protein
VIIa I-protein
complex I-protein
are O
created O
from O
either O
or O
both O
proteins O
to O
constitute O
a O
new B-protein
recognition I-protein
structure I-protein
. O

It O
is O
also O
evident O
that O
association O
of O
X B-protein
with O
charged O
phospholipid O
surfaces O
enhances O
the O
proteolytic O
activation O
of O
this O
zymogen B-protein
by O
increasing O
recognition O
and O
susceptibility O
of O
the O
sessile O
peptide O
bond O
deduced O
from O
the O
markedly O
decreased O
Km O
and O
increased O
Kcat O
. O

Phorbol O
ester O
reduces O
constitutive B-protein
nuclear I-protein
NF I-protein
kappa I-protein
B I-protein
and O
inhibits O
HIV O
- O
1 O
production O
in O
mature O
human O
monocytic O
cells O
. O

NF B-protein
kappa I-protein
B I-protein
is O
a O
potent O
mediator O
of O
specific O
gene O
expression O
in O
human O
monocytes O
and O
has O
been O
shown O
to O
play O
a O
role O
in O
transcription O
of O
the O
HIV O
- O
1 O
genome O
in O
promonocytic O
leukemias O
. O

There O
is O
little O
information O
available O
on O
the O
response O
of O
NF B-protein
kappa I-protein
B I-protein
to O
cytokines B-protein
in O
normal O
human O
monocytes O
. O

We O
have O
used O
a O
32P O
- O
labeled O
oligonucleotide O
derived O
from O
human O
immunodeficiency O
virus O
( O
HIV O
- O
1 O
) O
long O
terminal O
repeat O
, O
which O
contains O
a O
tandem O
repeat O
of O
the O
NF B-protein
kappa I-protein
B I-protein
binding O
sequence O
, O
as O
a O
probe O
in O
a O
gel O
retardation O
assay O
to O
study O
this O
transcription B-protein
factor I-protein
. O

Using O
this O
assay O
, O
we O
have O
detected O
NF B-protein
kappa I-protein
B I-protein
in O
extracts O
of O
nuclei O
from O
normal O
human O
monocytes O
. O

Treatment O
of O
normal O
monocytes O
with O
12 O
- O
0 O
- O
tetradecanoyl O
phorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
for O
4 O
- O
24 O
h O
caused O
the O
complete O
disappearance O
of O
NF B-protein
kappa I-protein
B I-protein
from O
nuclear O
extracts O
of O
monocytes O
. O

A O
similar O
result O
was O
obtained O
with O
the O
mature O
monocytic O
leukemia O
cell O
line O
THP O
- O
1 O
. O

The O
constitutive B-protein
transcription I-protein
factor I-protein
SP1 B-protein
was O
unaffected O
by O
addition O
of O
TPA O
. O

The O
disappearance O
of O
NF B-protein
kappa I-protein
B I-protein
from O
the O
nucleus O
was O
concentration O
dependent O
between O
10 O
and O
50 O
ng O
/ O
ml O
of O
phorbol O
ester O
. O

In O
THP O
- O
1 O
cells O
, O
TPA O
also O
induced O
a O
new O
, O
faster B-protein
- I-protein
migrating I-protein
NF I-protein
kappa I-protein
B I-protein
species I-protein
not O
induced O
in O
monocytes O
. O

Protein O
kinase O
C O
inhibitor O
staurosporine O
, O
but O
not O
cyclic O
nucleotide O
- O
dependent O
protein O
kinase O
inhibitor O
HA O
- O
1004 O
, O
also O
dramatically O
reduced O
constitutive O
levels O
of O
nuclear B-protein
NF I-protein
kappa I-protein
B I-protein
. O

Finally O
, O
TPA O
addition O
to O
monocytes O
infected O
with O
HIV O
- O
1 O
inhibited O
HIV O
- O
1 O
replication O
, O
as O
determined O
by O
reverse B-protein
transcriptase I-protein
assays O
, O
in O
a O
concentration O
- O
dependent O
manner O
. O

These O
results O
are O
in O
striking O
contrast O
to O
the O
increase O
in O
nuclear O
NF B-protein
kappa I-protein
B I-protein
and O
HIV O
- O
1 O
replication O
induced O
by O
phorbol O
esters O
in O
promonocytic O
leukemia O
cells O
U937 O
and O
HL O
- O
60 O
, O
and O
emphasize O
the O
importance O
of O
studying O
cytokine B-protein
regulation O
of O
HIV O
- O
1 O
in O
normal O
monocytes O
. O

A O
mechanism O
for O
the O
antiinflammatory O
effects O
of O
corticosteroids O
: O
the O
glucocorticoid B-protein
receptor I-protein
regulates O
leukocyte O
adhesion O
to O
endothelial O
cells O
and O
expression O
of O
endothelial B-protein
- I-protein
leukocyte I-protein
adhesion I-protein
molecule I-protein
1 I-protein
and O
intercellular B-protein
adhesion I-protein
molecule I-protein
1 I-protein
. O

Corticosteroids O
are O
the O
preeminent O
antiinflammatory O
agents O
although O
the O
molecular O
mechanisms O
that O
impart O
their O
efficacy O
have O
not O
been O
defined O
. O

The O
endothelium O
plays O
a O
critical O
role O
in O
inflammation O
by O
directing O
circulating O
leukocytes O
into O
extravascular O
tissues O
by O
expressing O
adhesive B-protein
molecules I-protein
for O
leukocytes O
[ O
e O
. O
g O
. O
, O
endothelial B-protein
- I-protein
leukocyte I-protein
adhesion I-protein
molecule I-protein
1 I-protein
( O
ELAM B-protein
- I-protein
1 I-protein
) O
and O
intercellular B-protein
adhesion I-protein
molecule I-protein
1 I-protein
( O
ICAM B-protein
- I-protein
1 I-protein
) O
] O
. O

We O
therefore O
determined O
whether O
corticosteroids O
suppress O
inflammation O
by O
inhibiting O
endothelial O
expression O
of O
adhesion B-protein
molecules I-protein
for O
neutrophils O
( O
polymorphonuclear O
leukocytes O
) O
. O

Preincubation O
of O
endothelial O
cells O
with O
endotoxin O
[ O
lipopolysaccharide O
( O
LPS O
) O
, O
1 O
microgram O
/ O
ml O
] O
led O
to O
a O
4 O
- O
fold O
increase O
in O
subsequent O
adherence O
of O
polymorphonuclear O
leukocytes O
( O
P O
< O
0 O
. O
0001 O
, O
n O
= O
10 O
) O
to O
endothelial O
cells O
, O
an O
increase O
that O
was O
markedly O
attenuated O
when O
endothelial O
cells O
were O
treated O
with O
dexamethasone O
( O
IC50 O
< O
1 O
nM O
, O
P O
< O
0 O
. O
0001 O
, O
n O
= O
6 O
or O
7 O
) O
during O
preincubation O
with O
LPS O
. O

Moreover O
, O
the O
steroid B-protein
receptor I-protein
agonist O
cortisol O
( O
10 O
microM O
) O
, O
but O
not O
its O
inactive O
metabolite O
tetrahydrocortisol O
( O
10 O
microM O
) O
, O
diminished O
LPS O
- O
induced O
endothelial O
cell O
adhesiveness O
. O

Further O
evidence O
that O
the O
action O
of O
dexamethasone O
was O
mediated O
through O
ligation O
of O
corticosteroid B-protein
receptors I-protein
[ O
human B-protein
glucocorticoid I-protein
receptors I-protein
( O
hGRs B-protein
) O
] O
was O
provided O
by O
experiments O
utilizing O
the O
steroid O
antagonist O
RU O
- O
486 O
. O

RU O
- O
486 O
( O
10 O
microM O
) O
, O
which O
prevents O
translocation O
of O
ligated O
hGR B-protein
to O
the O
nucleus O
by O
inhibiting O
dissociation O
of O
hGR B-protein
from O
heat O
shock O
protein O
90 O
, O
completely O
aborted O
the O
effect O
of O
dexamethasone O
on O
adhesiveness O
of O
endothelial O
cells O
( O
P O
< O
0 O
. O
0005 O
, O
n O
= O
3 O
) O
. O

Treatment O
of O
endothelial O
cells O
with O
LPS O
( O
1 O
microgram O
/ O
ml O
) O
stimulated O
transcription O
of O
ELAM B-protein
- I-protein
1 I-protein
, O
as O
shown O
by O
Northern O
blot O
analysis O
, O
and O
expression O
of O
membrane B-protein
- I-protein
associated I-protein
ELAM I-protein
- I-protein
1 I-protein
and O
ICAM B-protein
- I-protein
1 I-protein
, O
as O
shown O
by O
quantitative O
immunofluorescence O
( O
both O
P O
< O
0 O
. O
001 O
, O
n O
= O
9 O
) O
. O

Dexamethasone O
markedly O
inhibited O
LPS O
- O
stimulated O
accumulation O
of O
mRNA O
for O
ELAM B-protein
- I-protein
1 I-protein
and O
expression O
of O
ELAM B-protein
- I-protein
1 I-protein
and O
ICAM B-protein
- I-protein
1 I-protein
( O
IC50 O
< O
10 O
nM O
, O
both O
P O
< O
0 O
. O
001 O
, O
n O
= O
4 O
- O
9 O
) O
; O
inhibition O
of O
expression O
by O
dexamethasone O
was O
reversed O
by O
RU O
- O
486 O
( O
both O
P O
< O
0 O
. O
005 O
, O
n O
= O
4 O
- O
6 O
) O
. O

As O
in O
the O
adhesion O
studies O
, O
cortisol O
but O
not O
tetrahydrocortisol O
inhibited O
expression O
of O
ELAM B-protein
- I-protein
1 I-protein
and O
ICAM B-protein
- I-protein
1 I-protein
( O
both O
P O
< O
0 O
. O
005 O
, O
n O
= O
3 O
or O
4 O
) O
. O

In O
contrast O
, O
sodium O
salicylate O
( O
1 O
mM O
) O
inhibited O
neither O
adhesion O
nor O
expression O
of O
these O
adhesion B-protein
molecules I-protein
. O

These O
studies O
suggest O
that O
antagonism O
by O
dexamethasone O
of O
endotoxin B-protein
- O
induced O
inflammation O
is O
a O
specific O
instance O
of O
the O
general O
biological O
principle O
that O
the O
glucocorticoid B-protein
receptor I-protein
is O
a O
hormone O
- O
dependent O
regulator O
of O
transcription O
. O

Pax O
- O
5 O
encodes O
the O
transcription B-protein
factor I-protein
BSAP B-protein
and O
is O
expressed O
in O
B O
lymphocytes O
, O
the O
developing O
CNS O
, O
and O
adult O
testis O
. O

BSAP B-protein
has O
been O
identified O
previously O
as O
a O
transcription B-protein
factor I-protein
that O
is O
expressed O
at O
early O
, O
but O
not O
late O
, O
stages O
of O
B O
- O
cell O
differentiation O
. O

Biochemical O
purification O
and O
cDNA O
cloning O
has O
now O
revealed O
that O
BSAP B-protein
belongs O
to O
the O
family O
of O
paired B-protein
domain I-protein
proteins I-protein
. O

BSAP B-protein
is O
encoded O
by O
the O
Pax O
- O
5 O
gene O
and O
has O
been O
highly O
conserved O
between O
human O
and O
mouse O
. O

An O
intact O
paired O
domain O
was O
shown O
to O
be O
both O
necessary O
and O
sufficient O
for O
DNA O
binding O
of O
BSAP B-protein
. O

Binding O
studies O
with O
several O
BSAP B-protein
recognition O
sequences O
demonstrated O
that O
the O
sequence O
specificity O
of O
BSAP B-protein
differs O
from O
that O
of O
the O
distantly O
related O
paired B-protein
domain I-protein
protein I-protein
Pax I-protein
- I-protein
1 I-protein
. O

During O
embryogenesis O
, O
the O
BSAP B-protein
gene O
is O
transiently O
expressed O
in O
the O
mesencephalon O
and O
spinal O
cord O
with O
a O
spatial O
and O
temporal O
expression O
pattern O
that O
is O
distinct O
from O
that O
of O
other O
Pax O
genes O
in O
the O
developing O
central O
nervous O
system O
( O
CNS O
) O
. O

Later O
, O
the O
expression O
of O
the O
BSAP O
gene O
shifts O
to O
the O
fetal O
liver O
where O
it O
correlates O
with O
the O
onset O
of O
B O
lymphopoiesis O
. O

BSAP B-protein
expression O
persists O
in O
B O
lymphocytes O
and O
is O
also O
seen O
in O
the O
testis O
of O
the O
adult O
mouse O
. O

All O
of O
this O
evidence O
indicates O
that O
the O
transcription B-protein
factor I-protein
BSAP B-protein
may O
not O
only O
play O
an O
important O
role O
in O
B O
- O
cell O
differentiation O
but O
also O
in O
neural O
development O
and O
spermatogenesis O
. O

Cell O
cycle O
- O
dependent O
initiation O
and O
lineage O
- O
dependent O
abrogation O
of O
GATA B-protein
- I-protein
1 I-protein
expression O
in O
pure O
differentiating O
hematopoietic O
progenitors O
. O

The O
programmed O
activation O
/ O
repression O
of O
transcription B-protein
factors I-protein
in O
early O
hematopoietic O
differentiation O
has O
not O
yet O
been O
explored O
. O

The O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
GATA B-protein
- I-protein
1 I-protein
is O
required O
for O
normal O
erythroid O
development O
and O
regulates O
erythroid O
- O
expressed O
genes O
in O
maturing O
erythroblasts O
. O

We O
analyzed O
GATA B-protein
- I-protein
1 I-protein
expression O
in O
early O
human O
adult O
hematopoiesis O
by O
using O
an O
in O
vitro O
system O
in O
which O
" O
pure O
" O
early O
hematopoietic O
progenitors O
are O
induced O
to O
gradual O
and O
synchronized O
differentiation O
selectively O
along O
the O
erythroid O
or O
granulocyte O
- O
macrophage O
pathway O
by O
differential O
treatment O
with O
hematopoietic O
growth O
factors O
. O

The O
GATA B-protein
- I-protein
1 I-protein
gene O
, O
though O
virtually O
silent O
in O
quiescent O
progenitors O
, O
is O
activated O
after O
entrance O
into O
the O
cell O
cycle O
upon O
stimulation O
with O
hematopoietic O
growth O
factors O
. O

Subsequently O
, O
increasing O
expression O
along O
the O
erythroid O
pathway O
contrasts O
with O
an O
abrupt O
downregulation O
in O
the O
granulocyte O
- O
macrophage O
lineage O
. O

These O
results O
suggest O
a O
microenvironment O
- O
directed O
, O
two O
- O
step O
model O
for O
GATA B-protein
- I-protein
1 I-protein
expression O
in O
differentiating O
hematopoietic O
progenitors O
that O
involves O
( O
i O
) O
cycle O
- O
dependent O
initiation O
and O
( O
ii O
) O
lineage O
- O
dependent O
maintenance O
or O
suppression O
. O

Hypothetically O
, O
on O
/ O
off O
switches O
of O
lineage B-protein
- I-protein
restricted I-protein
transactivators I-protein
may O
underlie O
the O
binary O
fate O
decisions O
of O
hematopoietic O
progenitors O
. O

Specific O
NF B-protein
- I-protein
kappa I-protein
B I-protein
subunits I-protein
act O
in O
concert O
with O
Tat B-protein
to O
stimulate O
human O
immunodeficiency O
virus O
type O
1 O
transcription O
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
is O
a O
protein B-protein
complex I-protein
which O
functions O
in O
concert O
with O
the O
tat B-protein
- I-protein
I I-protein
gene I-protein
product I-protein
to O
stimulate O
human O
immunodeficiency O
virus O
( O
HIV O
) O
transcription O
. O

To O
determine O
whether O
specific O
members O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
family I-protein
contribute O
to O
this O
effect O
, O
we O
have O
examined O
the O
abilities O
of O
different O
NF B-protein
- I-protein
kappa I-protein
B I-protein
subunits I-protein
to O
act O
with O
Tat B-protein
- I-protein
I I-protein
to O
stimulate O
transcription O
of O
HIV O
in O
Jurkat O
T O
- O
leukemia O
cells O
. O

We O
have O
found O
that O
the O
p49 B-protein
( I-protein
100 I-protein
) I-protein
DNA I-protein
binding I-protein
subunit I-protein
, O
together O
with O
p65 B-protein
, O
can O
act O
in O
concert O
with O
Tat B-protein
- I-protein
I I-protein
to O
stimulate O
the O
expression O
of O
HIV O
- O
CAT O
plasmid O
. O

Little O
effect O
was O
observed O
with O
50 B-protein
- I-protein
kDa I-protein
forms I-protein
of O
p105 B-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
or O
rel B-protein
, O
in O
combination O
with O
p65 B-protein
or O
full B-protein
- I-protein
length I-protein
c I-protein
- I-protein
rel I-protein
, O
which O
do O
not O
stimulate O
the O
HIV O
enhancer O
in O
these O
cells O
. O

These O
findings O
suggest O
that O
the O
combination O
of O
p49 B-protein
( I-protein
100 I-protein
) I-protein
and O
p65 B-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
can O
act O
in O
concert O
with O
the O
tat B-protein
- I-protein
I I-protein
gene I-protein
product I-protein
to O
stimulate O
the O
synthesis O
of O
HIV O
RNA O
. O

Stable O
expression O
of O
HB24 O
, O
a O
diverged O
human O
homeobox O
gene O
, O
in O
T O
lymphocytes O
induces O
genes O
involved O
in O
T O
cell O
activation O
and O
growth O
. O

A O
diverged O
homeobox O
gene O
, O
HB24 O
, O
which O
is O
known O
to O
be O
induced O
following O
lymphocyte O
activation O
, O
was O
introduced O
into O
Jurkat O
T O
cells O
under O
the O
control O
of O
a O
constitutive O
promoter O
. O

Stable O
transfectants O
of O
HB24 O
were O
established O
that O
expressed O
high O
levels O
of O
HB24 O
mRNA O
and O
possessed O
an O
altered O
phenotype O
suggestive O
of O
activated O
T O
cells O
. O

A O
number O
of O
genes O
known O
to O
be O
induced O
following O
T O
cell O
activation O
and O
associated O
with O
cell O
growth O
were O
increased O
in O
the O
transfectants O
, O
including O
c O
- O
fos O
, O
c O
- O
myc O
, O
c O
- O
myb O
, O
HLA O
- O
DR O
, O
lck O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
interleukin O
- O
2 O
and O
interleukin O
- O
2 O
receptor O
alpha O
( O
IL O
- O
2R O
alpha O
) O
. O

Analysis O
of O
IL B-protein
- I-protein
2R I-protein
alpha I-protein
expression O
by O
transient O
transfection O
of O
IL O
- O
2R O
alpha O
promoter O
constructs O
into O
the O
HB24 O
transfectants O
revealed O
constitutive O
expression O
( O
about O
60 O
% O
of O
phytohemagglutinin O
- O
and O
phorbol O
ester O
- O
activated O
Jurkat O
cells O
) O
that O
was O
dependent O
on O
the O
kappa O
B O
site O
in O
the O
IL O
- O
2R O
alpha O
promoter O
. O

Furthermore O
, O
as O
a O
consequence O
of O
the O
increased O
HB24 O
mRNA O
levels O
, O
the O
Jurkat O
HB24 O
transfectants O
proliferated O
more O
rapidly O
than O
control O
cell O
lines O
. O

Thus O
, O
stable O
expression O
of O
HB24 O
confers O
an O
activation O
phenotype O
on O
a O
human O
T O
cell O
line O
, O
implicating O
this O
gene O
as O
an O
important O
transcriptional B-protein
factor I-protein
during O
T O
cell O
activation O
and O
growth O
. O

Functional O
interaction O
between O
the O
two O
zinc B-protein
finger I-protein
domains I-protein
of O
the O
v B-protein
- I-protein
erb I-protein
A I-protein
oncoprotein I-protein
. O

The O
v O
- O
erb O
A O
oncogene O
of O
avian O
erythroblastosis O
virus O
is O
a O
mutated O
and O
virally O
transduced O
copy O
of O
a O
host O
cell O
gene O
encoding O
a O
thyroid B-protein
hormone I-protein
receptor I-protein
. O

The O
protein O
expressed O
by O
the O
v O
- O
erb O
A O
oncogene O
binds O
to O
DNA O
and O
acts O
as O
a O
dominant O
negative O
inhibitor O
of O
both O
the O
thyroid B-protein
hormone I-protein
receptor I-protein
and O
the O
closely O
related O
retinoic B-protein
acid I-protein
receptor I-protein
. O

The O
v B-protein
- I-protein
erb I-protein
A I-protein
protein I-protein
has O
sustained O
two O
amino O
acid O
alterations O
within O
its O
DNA B-protein
- I-protein
binding I-protein
domain I-protein
relative O
to O
that O
of O
c B-protein
- I-protein
erb I-protein
A I-protein
, O
one O
of O
which O
, O
at O
serine O
61 O
, O
is O
known O
to O
be O
important O
for O
v B-protein
- I-protein
erb I-protein
A I-protein
function O
in O
the O
neoplastic O
cell O
. O

We O
report O
here O
that O
the O
second O
alteration O
, O
at O
threonine O
78 O
, O
also O
plays O
an O
important O
, O
although O
more O
indirect O
, O
role O
: O
alteration O
of O
the O
sequence O
at O
threonine O
78 O
such O
that O
it O
resembles O
that O
of O
c B-protein
- I-protein
erb I-protein
A I-protein
can O
act O
as O
an O
intragenic O
suppressor O
and O
can O
partially O
restore O
function O
to O
a O
v B-protein
- I-protein
erb I-protein
A I-protein
protein I-protein
rendered O
defective O
due O
to O
a O
mutation O
at O
position B-protein
61 I-protein
. O

Threonine O
78 O
lies O
within O
the O
D B-protein
- I-protein
box I-protein
of O
the O
v B-protein
- I-protein
erb I-protein
A I-protein
protein I-protein
, O
a O
region O
thought O
to O
mediate O
receptor O
- O
receptor O
dimerizations O
, O
and O
is O
not O
in O
physical O
proximity O
to O
the O
serine O
at O
position B-protein
61 I-protein
. O

It O
therefore O
appears O
that O
an O
indirect O
interaction O
occurs O
between O
these O
two O
sites O
and O
that O
this O
interaction O
is O
crucial O
for O
v B-protein
- I-protein
erb I-protein
A I-protein
function O
. O

cis O
- O
acting O
sequences O
required O
for O
inducible O
interleukin O
- O
2 O
enhancer O
function O
bind O
a O
novel O
Ets B-protein
- I-protein
related I-protein
protein I-protein
, O
Elf B-protein
- I-protein
1 I-protein
. O

The O
recent O
definition O
of O
a O
consensus O
DNA O
binding O
sequence O
for O
the O
Ets B-protein
family I-protein
of O
transcription B-protein
factors I-protein
has O
allowed O
the O
identification O
of O
potential O
Ets O
binding O
sites O
in O
the O
promoters O
and O
enhancers O
of O
many O
inducible O
T O
- O
cell O
genes O
. O

In O
the O
studies O
described O
in O
this O
report O
, O
we O
have O
identified O
two O
potential O
Ets O
binding O
sites O
, O
EBS1 O
and O
EBS2 O
, O
which O
are O
conserved O
in O
both O
the O
human O
and O
murine O
interleukin O
- O
2 O
enhancers O
. O

Within O
the O
human O
enhancer O
, O
these O
two O
sites O
are O
located O
within O
the O
previously O
defined O
DNase B-protein
I I-protein
footprints O
, O
NFAT O
- O
1 O
and O
NFIL O
- O
2B O
, O
respectively O
. O

Electrophoretic O
mobility O
shift O
and O
methylation O
interference O
analyses O
demonstrated O
that O
EBS1 O
and O
EBS2 O
are O
essential O
for O
the O
formation O
of O
the O
NFAT B-protein
- I-protein
1 I-protein
and O
NFIL B-protein
- I-protein
2B I-protein
nuclear I-protein
protein I-protein
complexes I-protein
. O

Furthermore O
, O
in O
vitro O
mutagenesis O
experiments O
demonstrated O
that O
inducible O
interleukin O
- O
2 O
enhancer O
function O
requires O
the O
presence O
of O
either O
EBS1 O
or O
EBS2 O
. O

Two O
well O
- O
characterized O
Ets B-protein
family I-protein
members I-protein
, O
Ets B-protein
- I-protein
1 I-protein
and O
Ets B-protein
- I-protein
2 I-protein
, O
are O
reciprocally O
expressed O
during O
T O
- O
cell O
activation O
. O

Surprisingly O
, O
however O
, O
neither O
of O
these O
proteins O
bound O
in O
vitro O
to O
EBS1 O
or O
EBS2 O
. O

We O
therefore O
screened O
a O
T O
- O
cell O
cDNA O
library O
under O
low O
- O
stringency O
conditions O
with O
a O
probe O
from O
the O
DNA B-protein
binding I-protein
domain I-protein
of O
Ets B-protein
- I-protein
1 I-protein
and O
isolated O
a O
novel B-protein
Ets I-protein
family I-protein
member I-protein
, O
Elf B-protein
- I-protein
1 I-protein
. O

Elf B-protein
- I-protein
1 I-protein
contains O
a O
DNA B-protein
binding I-protein
domain I-protein
that O
is O
nearly O
identical O
to O
that O
of O
E74 B-protein
, O
the O
ecdysone B-protein
- I-protein
inducible I-protein
Drosophila I-protein
transcription I-protein
factor I-protein
required O
for O
metamorphosis O
( O
hence O
the O
name O
Elf B-protein
- I-protein
1 I-protein
, O
for O
E74 B-protein
- I-protein
like I-protein
factor I-protein
1 I-protein
) O
. O

Elf B-protein
- I-protein
1 I-protein
bound O
specifically O
to O
both O
EBS1 O
and O
EBS2 O
in O
electrophoretic O
mobility O
shift O
assays O
. O

It O
also O
bound O
to O
the O
purine O
- O
rich O
CD3R O
element O
from O
the O
human O
immunodeficiency O
virus O
type O
2 O
long O
terminal O
repeat O
, O
which O
is O
required O
for O
inducible O
virus O
expression O
in O
response O
to O
signalling O
through O
the O
T B-protein
- I-protein
cell I-protein
receptor I-protein
. O

Taken O
together O
, O
these O
results O
demonstrate O
that O
multiple B-protein
Ets I-protein
family I-protein
members I-protein
with O
apparently O
distinct O
DNA O
binding O
specificities O
regulate O
differential O
gene O
expression O
in O
resting O
and O
activated O
T O
cells O
. O

Binding O
of O
erythroid O
and O
non O
- O
erythroid O
nuclear O
proteins O
to O
the O
silencer O
of O
the O
human O
epsilon O
- O
globin O
- O
encoding O
gene O
. O

To O
clarify O
the O
molecular O
mechanisms O
involved O
in O
the O
developmental O
control O
of O
hemoglobin O
- O
encoding O
genes O
we O
have O
been O
studying O
the O
expression O
of O
these O
genes O
in O
human O
cells O
in O
continuous O
culture O
. O

We O
have O
previously O
reported O
the O
presence O
of O
a O
transcriptional O
control O
element O
with O
the O
properties O
of O
a O
silencer O
extending O
from O
- O
392 O
to O
- O
177 O
bp O
relative O
to O
the O
cap O
site O
of O
the O
human O
epsilon O
- O
globin O
- O
encoding O
gene O
[ O
Cao O
et O
al O
. O
, O
Proc O
. O
Natl O
. O
Acad O
. O
Sci O
. O
USA O
86 O
( O
1989 O
) O
5306 O
- O
5309 O
] O
. O

We O
also O
showed O
that O
this O
silencer O
has O
stronger O
inhibitory O
activity O
in O
HeLa O
cells O
, O
as O
compared O
to O
K562 O
human O
erythroleukemia O
cells O
. O

Using O
deletion O
mutants O
and O
cis O
- O
cloned O
synthetic O
oligodeoxyribonucleotides O
in O
transient O
expression O
assays O
, O
nucleotide O
sequences O
responsible O
for O
this O
effect O
have O
now O
been O
further O
delimited O
to O
44 O
bp O
located O
from O
- O
294 O
to O
- O
251 O
bp O
. O

Gel O
electrophoresis O
mobility O
shift O
assays O
and O
DNaseI B-protein
footprinting O
assays O
demonstrate O
that O
these O
negative O
regulatory O
sequences O
are O
recognized O
differently O
by O
proteins B-protein
present O
in O
nuclear O
extracts O
obtained O
from O
HeLa O
and O
K562 O
cells O
. O

Two O
binding O
proteins O
are O
detected O
in O
K562 O
nuclear O
extracts O
, O
while O
only O
one O
is O
found O
in O
extracts O
from O
HeLa O
cells O
. O

Possible O
mechanisms O
by O
which O
these O
proteins O
may O
regulate O
transcription O
of O
the O
epsilon O
- O
globin O
- O
encoding O
gene O
in O
erythroid O
and O
non O
- O
erythroid O
cells O
are O
discussed O
. O

Calcitriol O
: O
a O
hematolymphopoietrope O
? O
[ O
editorial O
] O
. O

A O
MEDLINE O
search O
of O
the O
English O
- O
language O
literature O
was O
conducted O
using O
the O
indexing O
terms O
' O
immunology O
, O
calcitriol O
and O
vitamin O
D O
' O
to O
identify O
studies O
indicating O
a O
role O
for O
calcitriol O
as O
a O
primary O
immunomodulator O
. O

Sixty O
- O
six O
papers O
published O
between O
January O
1956 O
and O
June O
1991 O
were O
identified O
. O

Forty O
- O
five O
of O
these O
reports O
are O
cited O
in O
this O
review O
. O

The O
data O
strongly O
suggest O
an O
endocrine O
, O
autocrine O
and O
/ O
or O
paracrine O
role O
for O
calcitriol O
in O
immune O
regulation O
. O

No O
unifying O
hypothesis O
has O
yet O
emerged O
explaining O
this O
collection O
of O
data O
. O

This O
paper O
provides O
a O
brief O
review O
of O
immune O
properties O
currently O
attributed O
to O
calcitriol O
. O

Transcription O
of O
the O
hypersensitive O
site O
HS2 O
enhancer O
in O
erythroid O
cells O
. O

In O
the O
human O
genome O
, O
the O
erythroid O
- O
specific O
hypersensitive O
site O
HS2 O
enhancer O
regulates O
the O
transcription O
of O
the O
downstream O
beta O
- O
like O
globin O
genes O
10 O
- O
50 O
kilobases O
away O
. O

The O
mechanism O
of O
HS2 O
enhancer O
function O
is O
not O
known O
. O

The O
present O
study O
employs O
RNA O
protection O
assays O
to O
analyze O
the O
transcriptional O
status O
of O
the O
HS2 O
enhancer O
in O
transfected O
recombinant O
chloramphenicol B-protein
acetyltransferase I-protein
( O
CAT B-protein
) O
plasmids O
. O

In O
erythroid O
K562 O
cells O
in O
which O
the O
HS2 O
enhancer O
is O
active O
, O
the O
HS2 O
sequence O
directs O
the O
synthesis O
of O
long O
enhancer O
transcripts O
that O
are O
initiated O
apparently O
from O
within O
the O
enhancer O
and O
elongated O
through O
the O
intervening O
DNA O
into O
the O
cis O
- O
linked O
CAT O
gene O
. O

In O
nonerythroid O
HL O
- O
60 O
cells O
in O
which O
the O
HS2 O
enhancer O
is O
inactive O
, O
long O
enhancer O
transcripts O
are O
not O
detectable O
. O

Splitting O
the O
HS2 O
enhancer O
between O
two O
tandem O
Ap1 O
sites O
abolishes O
the O
synthesis O
of O
a O
group O
of O
long O
enhancer O
transcripts O
and O
results O
in O
loss O
of O
enhancer O
function O
and O
transcriptional O
silencing O
of O
the O
cis O
- O
linked O
CAT O
gene O
. O

In O
directing O
the O
synthesis O
of O
RNA O
through O
the O
intervening O
DNA O
and O
the O
gene O
by O
a O
tracking O
and O
transcription O
mechanism O
, O
the O
HS2 O
enhancer O
may O
( O
i O
) O
open O
up O
the O
chromatin O
structure O
of O
a O
gene O
domain O
and O
( O
ii O
) O
deliver O
enhancer B-protein
binding I-protein
proteins I-protein
to O
the O
promoter O
sequence O
where O
they O
may O
stimulate O
the O
transcription O
of O
the O
gene O
at O
the O
cap O
site O
. O

Characterization O
of O
a O
novel B-protein
T I-protein
lymphocyte I-protein
protein I-protein
which O
binds O
to O
a O
site O
related O
to O
steroid O
/ O
thyroid O
hormone O
receptor O
response O
elements O
in O
the O
negative O
regulatory O
sequence O
of O
the O
human O
immunodeficiency O
virus O
long O
terminal O
repeat O
. O

We O
have O
previously O
identified O
a O
T B-protein
lymphocyte I-protein
protein I-protein
which O
binds O
to O
a O
site O
within O
the O
LTR O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
and O
exerts O
an O
inhibitory O
effect O
on O
virus O
gene O
expression O
. O

The O
palindromic O
site O
( O
site O
B O
) O
recognized O
by O
this O
protein O
is O
related O
to O
the O
palindromic O
binding O
sites O
of O
members O
of O
the O
steroid B-protein
/ I-protein
thyroid I-protein
hormone I-protein
receptor I-protein
family I-protein
. O

Here O
we O
characterize O
the O
T B-protein
cell I-protein
protein I-protein
binding O
to O
this O
site O
as O
a O
100 O
kD O
protein O
which O
is O
most O
abundant O
in O
T O
cells O
and O
which O
binds O
to O
site O
B O
as O
a O
200 B-protein
kD I-protein
complex I-protein
. O

This O
protein O
is O
distinct O
from O
other O
members O
of O
the O
steroid B-protein
/ I-protein
thyroid I-protein
hormone I-protein
receptor I-protein
family I-protein
including O
the O
COUP B-protein
protein I-protein
which O
has O
a O
closely O
related O
DNA O
binding O
specificity O
. O

TAR O
- O
independent O
transactivation O
by O
Tat B-protein
in O
cells O
derived O
from O
the O
CNS O
: O
a O
novel O
mechanism O
of O
HIV O
- O
1 O
gene O
regulation O
. O

The O
Tat B-protein
protein I-protein
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
is O
essential O
for O
productive O
infection O
and O
is O
a O
potential O
target O
for O
antiviral O
therapy O
. O

Tat B-protein
, O
a O
potent O
activator O
of O
HIV O
- O
1 O
gene O
expression O
, O
serves O
to O
greatly O
increase O
the O
rate O
of O
transcription O
directed O
by O
the O
viral O
promoter O
. O

This O
induction O
, O
which O
seems O
to O
be O
an O
important O
component O
in O
the O
progression O
of O
acquired O
immune O
deficiency O
syndrome O
( O
AIDS O
) O
, O
may O
be O
due O
to O
increased O
transcriptional O
initiation O
, O
increased O
transcriptional O
elongation O
, O
or O
a O
combination O
of O
these O
processes O
. O

Much O
attention O
has O
been O
focused O
on O
the O
interaction O
of O
Tat B-protein
with O
a O
specific O
RNA O
target O
termed O
TAR O
( O
transactivation O
responsive O
) O
which O
is O
present O
in O
the O
leader O
sequence O
of O
all O
HIV O
- O
1 O
mRNAs O
. O

This O
interaction O
is O
believed O
to O
be O
an O
important O
component O
of O
the O
mechanism O
of O
transactivation O
. O

In O
this O
report O
we O
demonstrate O
that O
in O
certain O
CNS O
- O
derived O
cells O
Tat B-protein
is O
capable O
of O
activating O
HIV O
- O
1 O
through O
a O
TAR O
- O
independent O
pathway O
. O

A O
Tat B-protein
- O
responsive O
element O
is O
found O
upstream O
within O
the O
viral O
promoter O
that O
in O
glial O
- O
derived O
cell O
lines O
allows O
transactivation O
in O
the O
absence O
of O
TAR O
. O

Deletion O
mapping O
and O
hybrid O
promoter O
constructs O
demonstrate O
that O
the O
newly O
identified O
Tat B-protein
- O
responsive O
element O
corresponds O
to O
a O
sequence O
within O
the O
viral O
long O
terminal O
repeat O
( O
LTR O
) O
previously O
identified O
as O
the O
HIV O
- O
1 O
enhancer O
, O
or O
NF O
- O
kappa O
B O
domain O
. O

DNA O
band O
- O
shift O
analysis O
reveals O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activity O
in O
glial O
cells O
that O
differs O
from O
that O
present O
in O
T O
lymphoid O
cells O
. O

Further O
, O
we O
observe O
that O
TAR O
- O
deleted O
mutants O
of O
HIV O
- O
1 O
demonstrate O
normal O
late O
gene O
expression O
in O
glial O
cells O
as O
evidenced O
by O
syncytia O
formation O
and O
production O
of O
viral B-protein
p24 I-protein
antigen I-protein
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Transcription B-protein
factor I-protein
AP I-protein
- I-protein
2 I-protein
activates O
gene O
expression O
of O
HTLV O
- O
I O
. O

The O
HTLV O
- O
I O
LTR O
contains O
three O
conserved O
regulatory O
elements O
known O
as O
21 O
base O
pair O
repeats O
which O
are O
required O
for O
stimulation O
of O
gene O
expression O
by O
the O
transactivator B-protein
protein I-protein
tax B-protein
. O

Mutagenesis O
indicates O
that O
the O
21 O
bp O
repeats O
can O
be O
subdivided O
into O
three O
motifs O
, O
A O
, O
B O
and O
C O
, O
each O
of O
which O
influences O
the O
level O
of O
tax B-protein
activation O
. O

The O
A O
site O
in O
the O
21 O
bp O
repeat O
has O
strong O
homology O
with O
previously O
described O
binding O
sites O
for O
the O
transcription B-protein
factor I-protein
AP I-protein
- I-protein
2 I-protein
. O

We O
demonstrated O
that O
AP O
- O
2 O
mRNA O
was O
present O
in O
T O
- O
lymphocytes O
and O
that O
cellular O
factors O
from O
both O
non O
- O
transformed O
and O
transformed O
T O
- O
lymphocytes O
specifically O
bound O
to O
the O
consensus O
motif O
for O
AP B-protein
- I-protein
2 I-protein
in O
each O
21 O
bp O
. O

To O
determine O
the O
role O
of O
AP B-protein
- I-protein
2 I-protein
in O
the O
regulation O
of O
the O
HTLV O
- O
I O
LTR O
gene O
expression O
, O
we O
used O
an O
AP B-protein
- I-protein
2 I-protein
cDNA O
in O
DNA O
binding O
and O
transient O
expression O
assays O
. O

Gel O
retardation O
and O
methylation O
interference O
studies O
revealed O
that O
bacterially B-protein
produced I-protein
AP I-protein
- I-protein
2 I-protein
bound O
specifically O
and O
with O
high O
affinity O
to O
all O
three O
21 O
bp O
repeats O
, O
and O
that O
it O
required O
the O
core O
sequence O
AGGC O
for O
specific O
binding O
. O

Binding O
of O
AP B-protein
- I-protein
2 I-protein
prevented O
the O
subsequent O
binding O
of O
members O
of O
the O
CREB B-protein
/ I-protein
ATF I-protein
family I-protein
to O
an O
adjacent O
regulatory O
motif O
in O
the O
21 O
bp O
repeat O
. O

Transfection O
of O
an O
AP B-protein
- I-protein
2 I-protein
expression O
construct O
into O
T O
- O
lymphocytes O
activated O
gene O
expression O
from O
the O
HTLV O
- O
I O
LTR O
. O

At O
least O
two O
21 O
bp O
repeats O
were O
required O
for O
high O
levels O
of O
AP B-protein
- I-protein
2 I-protein
activation O
and O
mutagenesis O
of O
the O
AP B-protein
- I-protein
2 I-protein
consensus O
binding O
sequences O
in O
the O
21 O
bp O
repeats O
eliminate O
this O
activation O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Activation O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
enhancer O
is O
not O
dependent O
on O
NFAT B-protein
- I-protein
1 I-protein
. O

The O
function O
of O
a O
putative O
NFAT B-protein
- I-protein
1 I-protein
site O
in O
the O
human O
immunodeficiency O
virus O
type O
1 O
enhancer O
has O
been O
analyzed O
. O

Activation O
by O
the O
T B-protein
- I-protein
cell I-protein
antigen I-protein
receptor I-protein
is O
minimal O
in O
Jurkat O
cells O
and O
is O
mediated O
by O
the O
kappa O
B O
sites O
. O

The O
putative O
NFAT B-protein
- I-protein
1 I-protein
region O
is O
not O
required O
for O
the O
response O
to O
anti B-protein
- I-protein
CD3 I-protein
or O
to O
mitogens B-protein
in O
T O
- O
cell O
, O
B O
- O
cell O
, O
or O
monocyte O
/ O
macrophage O
leukemia O
lines O
, O
nor O
is O
it O
a O
cis O
- O
acting O
negative O
regulatory O
element O
. O

The O
B B-protein
cell I-protein
- I-protein
specific I-protein
nuclear I-protein
factor I-protein
OTF B-protein
- I-protein
2 I-protein
positively O
regulates O
transcription O
of O
the O
human O
class O
II O
transplantation O
gene O
, O
DRA O
. O

The O
promoter O
of O
the O
major O
histocompatibility O
class O
II O
gene O
DRA O
contains O
an O
octamer O
element O
( O
ATTTGCAT O
) O
that O
is O
required O
for O
efficient O
DRA O
expression O
in O
B O
cells O
. O

Several O
DNA B-protein
- I-protein
binding I-protein
proteins I-protein
are O
known O
to O
bind O
this O
sequence O
. O

The O
best O
characterized O
are O
the O
B B-protein
cell I-protein
- I-protein
specific I-protein
OTF I-protein
- I-protein
2 I-protein
and O
the O
ubiquitous O
OTF B-protein
- I-protein
1 I-protein
. O

This O
report O
directly O
demonstrates O
that O
OTF B-protein
- I-protein
2 I-protein
but O
not O
OTF B-protein
- I-protein
1 I-protein
regulates O
the O
DRA O
gene O
. O

In O
vitro O
transcription O
analysis O
using O
protein O
fractions O
enriched O
for O
the O
octamer O
- O
binding O
protein O
OTF B-protein
- I-protein
2 I-protein
demonstrate O
a O
positive O
functional O
role O
for O
OTF B-protein
- I-protein
2 I-protein
in O
DRA O
gene O
transcription O
. O

In O
contrast O
, O
OTF B-protein
- I-protein
1 I-protein
- I-protein
enriched I-protein
protein I-protein
fractions I-protein
did O
not O
affect O
DRA O
gene O
transcription O
although O
it O
functionally O
enhanced O
the O
transcription O
of O
another O
gene O
. O

Recombinant B-protein
OTF I-protein
- I-protein
2 I-protein
protein I-protein
produced O
by O
in O
vitro O
transcription O
/ O
translation O
could O
also O
enhance O
DRA O
gene O
transcription O
in O
vitro O
. O

In O
vivo O
transient O
transfection O
studies O
utilizing O
an O
OTF B-protein
- I-protein
2 I-protein
expression O
vector O
resulted O
in O
similar O
findings O
: O
that O
OTF B-protein
- I-protein
2 I-protein
protein I-protein
enhanced O
DRA O
gene O
transcription O
, O
and O
that O
this O
effect O
requires O
an O
intact O
octamer O
element O
. O

Together O
these O
results O
constitute O
the O
first O
direct O
evidence O
of O
a O
positive O
role O
for O
the O
lymphoid B-protein
- I-protein
specific I-protein
octamer I-protein
- I-protein
binding I-protein
factor I-protein
in O
DRA O
gene O
transcription O
. O

Interferon B-protein
- I-protein
gamma I-protein
potentiates O
the O
antiviral O
activity O
and O
the O
expression O
of O
interferon O
- O
stimulated O
genes O
induced O
by O
interferon O
- O
alpha O
in O
U937 O
cells O
. O

Binding O
of O
type B-protein
I I-protein
interferon I-protein
( I-protein
IFN I-protein
- I-protein
alpha I-protein
/ I-protein
beta I-protein
) I-protein
to I-protein
specific I-protein
receptors I-protein
results O
in O
the O
rapid O
transcriptional O
activation O
, O
independent O
of O
protein O
synthesis O
, O
of O
IFN O
- O
alpha O
- O
stimulated O
genes O
( O
ISGs O
) O
in O
human O
fibroblasts O
and O
HeLa O
and O
Daudi O
cell O
lines O
. O

The O
binding O
of O
ISGF3 B-protein
( O
IFN B-protein
- I-protein
stimulated I-protein
gene I-protein
factor I-protein
3 I-protein
) O
to O
the O
conserved O
IFN O
- O
stimulated O
response O
element O
( O
ISRE O
) O
results O
in O
transcriptional O
activation O
. O

This O
factor O
is O
composed O
of O
a O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
( O
ISGF3 B-protein
gamma I-protein
) O
, O
which O
normally O
is O
present O
in O
the O
cytoplasm O
, O
and O
other O
IFN B-protein
- I-protein
alpha I-protein
- I-protein
activated I-protein
proteins I-protein
which O
preexist O
as O
latent B-protein
cytoplasmic I-protein
precursors I-protein
( O
ISGF3 B-protein
alpha I-protein
) O
. O

We O
have O
found O
that O
ISG O
expression O
in O
the O
monocytic O
U937 O
cell O
line O
differs O
from O
most O
cell O
lines O
previously O
examined O
. O

U937 O
cells O
express O
both O
type B-protein
I I-protein
and O
type B-protein
II I-protein
IFN I-protein
receptors I-protein
, O
but O
only O
IFN B-protein
- I-protein
alpha I-protein
is O
capable O
of O
inducing O
antiviral O
protection O
in O
these O
cells O
. O

Pretreatment O
with O
IFN B-protein
- I-protein
gamma I-protein
potentiates O
the O
IFN B-protein
- I-protein
alpha I-protein
- O
induced O
protection O
, O
but O
IFN B-protein
- I-protein
gamma I-protein
alone O
does O
not O
have O
any O
antiviral O
activity O
. O

ISG15 O
mRNA O
accumulation O
in O
U937 O
cells O
is O
not O
detectable O
before O
6 O
h O
of O
IFN B-protein
- I-protein
alpha I-protein
treatment O
, O
peaks O
at O
24 O
h O
, O
and O
requires O
protein O
synthesis O
. O

Although O
IFN B-protein
- I-protein
gamma I-protein
alone O
does O
not O
induce O
ISG O
expression O
, O
IFN B-protein
- I-protein
gamma I-protein
pretreatment O
markedly O
increases O
and O
hastens O
ISG O
expression O
and O
transcriptional O
induction O
. O

Nuclear O
extracts O
assayed O
for O
the O
presence O
of O
ISRE B-protein
binding I-protein
factors I-protein
by O
electrophoretic O
mobility O
shift O
assays O
show O
that O
ISGF3 B-protein
is O
induced O
by O
IFN B-protein
- I-protein
alpha I-protein
within O
6 O
h O
from O
undetectable O
basal O
levels O
in O
untreated O
U937 O
cells O
. O

Activation O
of O
ISGF3 B-protein
alpha I-protein
, O
the O
latent O
component O
of O
ISGF3 B-protein
, O
occurs O
rapidly O
. O

However O
, O
the O
increase O
in O
ISGF3 B-protein
activity O
ultimately O
correlates O
with O
the O
accumulation O
of O
ISGF3 B-protein
gamma I-protein
induced O
by O
IFN B-protein
- I-protein
alpha I-protein
or O
IFN B-protein
- I-protein
gamma I-protein
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Single O
point O
estimation O
of O
glucocorticoid B-protein
receptors I-protein
in O
lymphocytes O
of O
normal O
subjects O
and O
of O
children O
under O
long O
term O
glucocorticoid O
treatment O
. O

A O
single O
point O
assay O
of O
glucocorticoid B-protein
receptors I-protein
( O
GR B-protein
) O
in O
human O
lymphocytes O
based O
on O
the O
measurement O
of O
specific O
dexamethasone O
binding O
has O
been O
developed O
and O
compared O
with O
a O
common O
multi O
- O
point O
Scatchard O
analysis O
. O

The O
assay O
conditions O
- O
concentration O
of O
the O
ligand O
20 O
nmol O
/ O
l O
, O
incubation O
time O
2 O
h O
and O
the O
cell O
count O
2 O
- O
6 O
mil O
. O

cells O
/ O
tube O
in O
the O
assay O
volume O
0 O
. O
25 O
ml O
were O
found O
to O
be O
optimal O
. O

An O
attempt O
was O
also O
undertaken O
to O
use O
a O
cell O
harvester O
for O
the O
separation O
of O
cells O
from O
unbound O
ligand O
. O

Though O
specifically O
bound O
dexamethasone O
measured O
by O
whole O
- O
cell O
assay O
and O
that O
using O
cell O
harvester O
correlated O
well O
, O
almost O
by O
one O
order O
lower O
values O
obtained O
with O
the O
latter O
method O
render O
it O
non O
- O
applicable O
for O
receptor O
quantitation O
. O

The O
results O
from O
9 O
healthy O
volunteers O
( O
average O
GR B-protein
concentration O
7131 O
+ O
/ O
- O
1256 O
sites O
/ O
cell O
) O
correlated O
excellently O
with O
those O
obtained O
by O
the O
Scatchard O
analysis O
. O

The O
single O
point O
assay O
has O
been O
also O
applied O
for O
determination O
of O
GH O
in O
10 O
children O
treated O
with O
large O
doses O
of O
prednisone O
. O

The O
average O
values O
from O
healthy O
volunteers O
did O
not O
differ O
significantly O
from O
those O
found O
in O
these O
children O
, O
though O
much O
broader O
range O
was O
found O
in O
patients O
. O

Glucocorticoid B-protein
receptor I-protein
and O
inhibition O
of O
3 O
- O
O O
- O
methyl O
- O
D O
- O
glucose O
uptake O
by O
glucocorticoids O
in O
peripheral O
blood O
leukocytes O
from O
normal O
humans O
: O
correlation O
between O
receptor O
level O
and O
hormone O
effect O
in O
vitro O
. O

We O
have O
measured O
the O
glucocorticoid B-protein
receptor I-protein
concentration O
in O
mononuclear O
and O
polymorphonuclear O
leukocytes O
, O
both O
of O
which O
were O
isolated O
from O
peripheral O
blood O
from O
ten O
healthy O
male O
volunteers O
. O

In O
parallel O
, O
the O
inhibitory O
effect O
of O
dexamethasone O
on O
3 O
- O
O O
- O
methyl O
- O
D O
- O
glucose O
uptake O
was O
assayed O
in O
the O
corresponding O
mononuclear O
leukocytes O
. O

The O
glucocorticoid B-protein
receptor I-protein
levels O
in O
mononuclear O
leukocytes O
correlated O
with O
those O
in O
polymorphonuclear O
leukocytes O
, O
and O
there O
was O
a O
linear O
relationship O
between O
the O
cellular O
glucocorticoid B-protein
receptor I-protein
levels O
and O
glucocorticoid O
- O
mediated O
inhibition O
of O
the O
uptake O
of O
3 O
- O
O O
- O
methyl O
- O
D O
- O
glucose O
in O
mononuclear O
leukocytes O
. O

When O
mononuclear O
leukocytes O
were O
incubated O
in O
the O
presence O
of O
8 O
- O
bromo O
- O
cAMP O
, O
cellular O
glucocorticoid B-protein
receptor I-protein
levels O
increased O
and O
a O
more O
pronounced O
inhibitory O
effect O
of O
dexamethasone O
was O
observed O
on O
the O
transport O
of O
3 O
- O
O O
- O
methyl O
- O
D O
- O
glucose O
. O

We O
conclude O
that O
the O
cellular O
glucocorticoid B-protein
receptor I-protein
levels O
in O
peripheral O
blood O
leukocytes O
reflect O
in O
vitro O
responsiveness O
to O
glucocorticoids O
in O
mononuclear O
leukocytes O
from O
healthy O
males O
, O
and O
that O
the O
individual O
responsiveness O
may O
alter O
upon O
changes O
in O
the O
cellular O
levels O
of O
glucocorticoid B-protein
receptor I-protein
. O

Transcription B-protein
factor I-protein
activation O
and O
functional O
stimulation O
of O
human O
monocytes O
. O

Activation O
of O
expression O
of O
genes O
encoding O
transcription B-protein
factors I-protein
: O
c O
- O
fos O
and O
c O
- O
jun O
and O
formation O
of O
AP1 B-protein
transcriptional I-protein
complex I-protein
in O
human O
monocytes O
was O
investigated O
. O

It O
was O
found O
that O
lipopolysaccharide O
induced O
strongly O
both O
c O
- O
fos O
and O
c O
- O
jun O
expression O
as O
well O
as O
AP1 B-protein
formation O
. O

Interferon B-protein
gamma I-protein
activated O
strongly O
c O
- O
fos O
and O
weakly O
c O
- O
jun O
and O
AP1 B-protein
. O

Tumor B-protein
necrosis I-protein
factor I-protein
induced O
slightly O
c O
- O
fos O
and O
had O
almost O
no O
effect O
on O
c O
- O
jun O
and O
AP1 B-protein
. O

The O
data O
suggest O
that O
differences O
in O
functional O
responses O
elicited O
in O
monocytes O
by O
all O
three O
factors B-protein
may O
be O
dependent O
on O
different O
routes O
on O
nuclear O
signalling O
employed O
by O
the O
factors B-protein
. O

Regulation O
of O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
production O
by O
glucocorticoids O
in O
human O
monocytes O
: O
the O
mechanism O
of O
action O
depends O
on O
the O
activation O
signal O
. O

Glucocorticoids O
are O
known O
to O
downregulate O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
production O
in O
monocytic O
cells O
by O
two O
different O
mechanims O
: O
direct O
inhibition O
of O
the O
gene O
transcription O
and O
destabilization O
of O
the O
preformed O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
mRNA O
. O

Now O
we O
have O
examined O
the O
effect O
of O
the O
nature O
of O
the O
monocyte O
activating O
signal O
on O
these O
two O
inhibitory O
mechanims O
. O

When O
human O
monocytes O
were O
preincubated O
with O
dexamethasone O
for O
1 O
hour O
and O
then O
stimulated O
either O
with O
bacterial O
lipopolysaccharide O
or O
phorbol O
myristate O
, O
it O
was O
found O
that O
dexamethasone O
inhibited O
the O
lipopolysaccharide O
- O
induced O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
protein O
production O
, O
but O
the O
phorbol O
myristate O
- O
induced O
production O
was O
increased O
3 O
- O
10 O
fold O
. O

This O
difference O
was O
also O
seen O
at O
the O
mRNA O
level O
. O

When O
dexamethasone O
was O
added O
to O
the O
cultures O
3 O
hours O
after O
the O
stimulators O
, O
it O
clearly O
decreased O
the O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
mRNA O
levels O
regardless O
of O
the O
stimulator O
used O
( O
although O
the O
effect O
was O
clearly O
weaker O
on O
the O
PMA O
- O
induced O
mRNA O
) O
. O

Thus O
these O
data O
suggest O
that O
the O
phorbol O
myristate O
- O
induced O
signal O
( O
prolonged O
protein B-protein
kinase I-protein
C I-protein
activation O
? O
) O
cannot O
be O
inhibited O
by O
prior O
incubation O
with O
dexamethasone O
and O
it O
also O
protects O
the O
induced O
mRNA O
for O
the O
degradative O
action O
of O
dexamethasone O
. O

Nuclear B-protein
transcription I-protein
factors I-protein
that O
bind O
to O
elements O
of O
the O
IL O
- O
2 O
promoter O
. O

Induction O
requirements O
in O
primary O
human O
T O
cells O
. O

Prior O
studies O
have O
identified O
several O
elements O
that O
contribute O
to O
the O
activity O
of O
the O
IL O
- O
2 O
promoter O
in O
the O
stimulated O
T O
cell O
line O
, O
Jurkat O
. O

The O
sites O
and O
their O
corresponding O
nuclear O
binding O
factors O
include O
: O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
AP B-protein
- I-protein
1 I-protein
, O
AP B-protein
- I-protein
3 I-protein
, O
OCT B-protein
- I-protein
1 I-protein
, O
and O
NF B-protein
- I-protein
AT I-protein
. O

The O
latter O
" O
nuclear B-protein
factor I-protein
for I-protein
activated I-protein
T I-protein
cells I-protein
" O
likely O
contributes O
to O
the O
tissue O
specificity O
of O
IL B-protein
- I-protein
2 I-protein
gene O
expression O
. O

Using O
electrophoretic O
mobility O
shift O
assays O
, O
we O
have O
studied O
these O
transcription B-protein
factors I-protein
in O
primary O
T O
cells O
from O
human O
blood O
to O
verify O
their O
presence O
in O
a O
physiologic O
setting O
and O
to O
identify O
the O
signals O
that O
stimulate O
factor O
activity O
. O

All O
factors O
are O
induced O
in O
the O
nuclei O
of O
T O
cells O
upon O
activation O
with O
mitogens B-protein
but O
not O
with O
exogenous B-protein
IL I-protein
- I-protein
2 I-protein
growth I-protein
factor I-protein
. O

However O
, O
the O
signaling O
requirements O
and O
sensitivity O
to O
protein O
synthesis O
inhibitors O
differ O
considerably O
. O

Only O
the O
activities O
for O
NF O
- O
AT O
and O
AP O
- O
1 O
sites O
require O
two O
signals O
for O
optimal O
induction O
, O
i O
. O
e O
. O
, O
PMA O
plus O
either O
lectin B-protein
or O
antibody B-protein
to O
the O
CD3 B-protein
or O
CD28 B-protein
surface I-protein
molecules I-protein
. O

Other O
factors O
are O
induced O
by O
lectin B-protein
, O
antibody B-protein
, O
and O
/ O
or O
PMA O
alone O
. O

After O
appropriate O
stimulation O
, O
both O
NF B-protein
- I-protein
AT I-protein
and O
AP B-protein
- I-protein
1 I-protein
are O
peculiarly O
sensitive O
to O
the O
protein O
synthesis O
inhibitor O
anisomycin O
. O

Our O
data O
correlate O
the O
activity O
of O
NF B-protein
- I-protein
AT I-protein
and O
AP B-protein
- I-protein
1 I-protein
in O
gel O
shift O
assays O
with O
the O
two O
signals O
requirements O
for O
IL B-protein
- I-protein
2 I-protein
gene O
expression O
. O

NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
in O
T O
cells O
stably O
expressing O
the O
Tax B-protein
protein I-protein
of O
human O
T O
cell O
lymphotropic O
virus O
type O
I O
. O

The O
effect O
of O
constitutive O
Tax B-protein
expression O
on O
the O
interaction O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
with O
its O
recognition O
sequence O
and O
on O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
gene O
expression O
was O
examined O
in O
T O
lymphoid O
Jurkat O
cell O
lines O
( O
19D O
and O
9J O
) O
stably O
transformed O
with O
a O
Tax B-protein
expression O
vector O
. O

Tax B-protein
expressing O
T O
cell O
lines O
contained O
a O
constitutive O
level O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activity O
, O
detectable O
by O
mobility O
shift O
assay O
and O
uv O
cross O
- O
linking O
using O
a O
palindromic O
NF B-protein
- I-protein
kappa I-protein
B I-protein
probe O
homologous O
to O
the O
interferon O
beta O
PRDII O
site O
. O

In O
Jurkat O
and O
NC2 O
. O
10 O
induction O
with O
phorbol O
esters O
resulted O
in O
the O
appearance O
of O
new O
DNA B-protein
binding I-protein
proteins I-protein
of O
85 O
, O
75 O
, O
and O
54 O
kDa O
, O
whereas O
in O
Tax B-protein
expressing O
cells O
the O
85 B-protein
- I-protein
kDa I-protein
protein I-protein
and O
a O
92 B-protein
- I-protein
kDa I-protein
DNA I-protein
binding I-protein
protein I-protein
were O
constitutively O
induced O
. O

Expression O
of O
Tax B-protein
protein I-protein
in O
19D O
and O
9J O
resulted O
in O
transcription O
of O
the O
endogenous O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
granulocyte O
- O
macrophage O
colony O
stimulating O
factor O
gene O
and O
increased O
basal O
level O
expression O
of O
transfected O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
regulated O
promoters O
. O

Nonetheless O
transcription O
of O
both O
the O
endogenous O
and O
the O
transfected O
gene O
was O
inducible O
by O
PMA O
treatment O
. O

Tax B-protein
expression O
in O
Jurkat O
T O
cells O
may O
alter O
the O
stoichiometry O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
DNA B-protein
binding I-protein
proteins I-protein
and O
thus O
change O
the O
expression O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
regulated O
promoters O
. O

A O
nuclear B-protein
factor I-protein
NF B-protein
- I-protein
GM2 I-protein
that O
interacts O
with O
a O
regulatory O
region O
of O
the O
GM O
- O
CSF O
gene O
essential O
for O
its O
induction O
in O
responses O
to O
T O
- O
cell O
activation O
: O
purification O
from O
human O
T O
- O
cell O
leukemia O
line O
Jurkat O
cells O
and O
similarity O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Activation O
of O
T O
cells O
by O
antigen O
, O
lectin B-protein
, O
or O
a O
combination O
of O
phorbol O
- O
12 O
- O
myristate O
acetate O
( O
PMA O
) O
and O
calcium O
ionophore O
( O
A23187 O
) O
leads O
to O
the O
induction O
of O
genes O
for O
a O
set O
of O
lymphokines B-protein
, O
including O
granulocyte B-protein
- I-protein
macrophage I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
GM B-protein
- I-protein
CSF I-protein
) O
. O

We O
demonstrated O
in O
earlier O
studies O
that O
the O
upstream O
region O
of O
the O
mouse O
GM B-protein
- I-protein
CSF I-protein
promoter O
at O
positions O
between O
- O
95 O
and O
- O
73 O
is O
essential O
for O
transcriptional O
activation O
in O
response O
to O
PMA O
/ O
A23187 O
. O

This O
region O
contains O
two O
DNA O
- O
binding O
motifs O
, O
GM2 O
and O
GC O
- O
box O
. O

The O
GM2 O
sequence O
( O
GGTAGTTCCC O
) O
is O
recognized O
by O
an O
inducible B-protein
factor I-protein
NF I-protein
- I-protein
GM2 I-protein
; O
the O
other O
( O
CCGCCC O
) O
by O
constitutive B-protein
factors I-protein
A1 B-protein
, O
A2 B-protein
, O
and O
B B-protein
. O

To O
elucidate O
the O
mechanism O
of O
GM B-protein
- I-protein
CSF I-protein
gene O
activation O
, O
we O
have O
purified O
the O
inducible B-protein
factor I-protein
NF I-protein
- I-protein
GM2 I-protein
from O
the O
nuclear O
extract O
of O
stimulated O
Jurkat O
cells O
on O
the O
basis O
of O
specific O
DNA O
- O
binding O
activity O
. O

The O
purified O
NF B-protein
- I-protein
GM2 I-protein
consists O
of O
50 O
( O
p50 B-protein
) O
and O
65 O
kDa O
( O
p65 B-protein
) O
polypeptides O
and O
has O
a O
binding O
activity O
specific O
for O
both O
the O
GM B-protein
- I-protein
CSF I-protein
and O
immunoglobulin O
kappa O
( O
GGAAAGTCCC O
) O
enhancers O
. O

Electrophoretically O
purified O
p50 B-protein
alone O
can O
form O
a O
protein B-protein
- I-protein
DNA I-protein
complex I-protein
, O
but O
in O
the O
mixture O
, O
p50 B-protein
associates O
preferentially O
with O
p65 B-protein
to O
form O
the O
NF B-protein
- I-protein
GM2 I-protein
complex I-protein
. O

In O
addition O
, O
p65 B-protein
gave O
per O
se O
, O
with O
low O
affinity O
, O
a O
protein B-protein
- I-protein
DNA I-protein
complex I-protein
that O
migrated O
more O
slowly O
than O
native O
NF B-protein
- I-protein
GM2 I-protein
complex I-protein
. O

Furthermore O
, O
an O
antiserum O
against O
KBF1 B-protein
( O
identical O
to O
50 B-protein
kDa I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
protein I-protein
) O
reacted O
with O
the O
p50 B-protein
of O
NF B-protein
- I-protein
GM2 I-protein
, O
indicating O
that O
the O
NF B-protein
- I-protein
GM2 I-protein
polypeptide I-protein
cannot O
be O
immunologically O
differentiated O
from O
the O
50 B-protein
kDa I-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

The O
purified O
NF B-protein
- I-protein
GM2 I-protein
activated O
in O
vitro O
transcription O
from O
the O
kappa O
B O
enhancer O
, O
while O
it O
failed O
to O
stimulate O
transcription O
from O
the O
GM O
- O
CSF O
promoter O
harboring O
the O
GM2 O
sequence O
. O

This O
suggests O
that O
the O
activation O
mechanism O
of O
the O
GM B-protein
- I-protein
CSF I-protein
gene O
through O
the O
GM2 O
/ O
GC O
- O
box O
sequence O
is O
different O
from O
that O
of O
genes O
carrying O
the O
kappa O
B O
enhancer O
alone O
. O

Characterization O
of O
an O
immediate O
- O
early O
gene O
induced O
in O
adherent O
monocytes O
that O
encodes O
I B-protein
kappa I-protein
B I-protein
- O
like O
activity O
. O

We O
have O
cloned O
a O
group O
of O
cDNAs O
representing O
mRNAs O
that O
are O
rapidly O
induced O
following O
adherence O
of O
human O
monocytes O
. O

One O
of O
the O
induced O
transcripts O
( O
MAD O
- O
3 O
) O
encodes O
a O
protein O
of O
317 O
amino O
acids O
with O
one O
domain O
containing O
five B-protein
tandem I-protein
repeats I-protein
of O
the O
cdc10 B-protein
/ I-protein
ankyrin I-protein
motif I-protein
, O
which O
is O
60 O
% O
similar O
( O
46 O
% O
identical O
) O
to O
the O
ankyrin B-protein
repeat I-protein
region I-protein
of O
the O
precursor O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
/ I-protein
KBF1 I-protein
p50 I-protein
. O

The O
C B-protein
- I-protein
terminus I-protein
has O
a O
putative O
protein B-protein
kinase I-protein
C I-protein
phosphorylation I-protein
site I-protein
. O

In O
vitro O
translated O
MAD B-protein
- I-protein
3 I-protein
protein I-protein
was O
found O
to O
specifically O
inhibit O
the O
DNA O
- O
binding O
activity O
of O
the O
p50 B-protein
/ I-protein
p65 I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
but O
not O
that O
of O
the O
p50 B-protein
/ I-protein
p50 I-protein
KBF1 I-protein
factor I-protein
or O
of O
other O
DNA B-protein
- I-protein
binding I-protein
proteins I-protein
. O

The O
MAD O
- O
3 O
cDNA O
encodes O
an O
I B-protein
kappa I-protein
B I-protein
- I-protein
like I-protein
protein I-protein
that O
is O
likely O
to O
be O
involved O
in O
regulation O
of O
transcriptional O
responses O
to O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
including O
adhesion O
- O
dependent O
pathways O
of O
monocyte O
activation O
. O

Cortivazol O
mediated O
induction O
of O
glucocorticoid B-protein
receptor I-protein
messenger O
ribonucleic O
acid O
in O
wild O
- O
type O
and O
dexamethasone O
- O
resistant O
human O
leukemic O
( O
CEM O
) O
cells O
. O

Cortivazol O
is O
a O
phenylpyrazolo O
glucocorticoid O
of O
high O
potency O
and O
unusual O
structure O
. O

In O
both O
wild O
- O
type O
and O
highly O
dexamethasone O
( O
dex O
) O
- O
resistant O
clones O
of O
the O
human O
leukemic O
cell O
line O
CEM O
, O
exposure O
to O
cortivazol O
leads O
to O
cell O
death O
. O

It O
has O
been O
shown O
recently O
that O
in O
wild O
- O
type O
CEM O
cells O
but O
not O
in O
a O
dex O
- O
resistant O
, O
glucocorticoid B-protein
receptor I-protein
( O
GR O
) O
- O
defective O
clone O
ICR O
- O
27 O
TK O
- O
3 O
, O
dex O
induces O
GR O
mRNA O
. O

To O
test O
the O
hypothesis O
that O
cortivazol O
acts O
in O
dex O
- O
resistant O
cells O
by O
making O
use O
of O
the O
residual O
GR B-protein
found O
there O
, O
wild O
- O
type O
and O
dex O
- O
resistant O
clones O
were O
treated O
with O
various O
concentrations O
of O
cortivazol O
and O
induction O
of O
GR B-protein
mRNA O
was O
studied O
. O

Cortivazol O
significantly O
induced O
GR B-protein
mRNA O
in O
the O
normal O
CEM O
- O
C7 O
as O
well O
as O
in O
two O
classes O
of O
dex O
- O
resistant O
clones O
, O
although O
the O
dex O
- O
resistant O
clones O
needed O
at O
least O
10 O
times O
more O
cortivazol O
than O
the O
normal O
cells O
for O
significant O
GR B-protein
mRNA O
induction O
. O

Increased O
levels O
of O
GR B-protein
mRNA O
were O
noticed O
as O
early O
as O
3 O
h O
after O
treatment O
. O

A O
general O
correlation O
between O
induction O
of O
GR B-protein
mRNA O
and O
lysis O
of O
the O
normal O
and O
dex O
- O
resistant O
cells O
was O
found O
. O

Positive O
induction O
of O
GR B-protein
mRNA O
might O
be O
one O
of O
the O
earliest O
crucial O
steps O
in O
the O
lysis O
of O
normal O
and O
dex O
- O
resistant O
CEM O
cells O
, O
or O
might O
serve O
as O
a O
marker O
for O
the O
process O
. O

However O
, O
the O
lysis O
pathway O
in O
the O
dex O
- O
resistant O
cells O
is O
defective O
in O
that O
dex O
- O
resistant O
clones O
needed O
significantly O
more O
cortivazol O
than O
the O
normal O
cells O
for O
lysis O
of O
the O
cells O
. O

HIV O
enhancer O
activity O
perpetuated O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
induction O
on O
infection O
of O
monocytes O
[ O
see O
comments O
] O
. O

Permissiveness O
to O
replication O
of O
human O
immunodeficiency O
virus O
( O
HIV O
) O
differs O
in O
T O
lymphocytes O
and O
macrophages O
. O

In O
T O
cells O
, O
HIV O
transcription O
is O
poorly O
detected O
in O
vivo O
. O

Cloned O
, O
normal O
T O
lymphocytes O
show O
very O
little O
, O
if O
any O
, O
basal O
activity O
of O
the O
HIV O
enhancer O
and O
low O
nuclear O
expression O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
a O
potent B-protein
transcriptional I-protein
activator I-protein
of O
the O
HIV O
enhancer O
. O

In O
contrast O
, O
fixed O
tissue O
macrophages O
express O
detectable O
HIV B-protein
proteins I-protein
, O
indicating O
permanent O
virus O
transcription O
. O

One O
explanation O
for O
the O
perpetuation O
of O
virus O
infection O
in O
macrophages O
could O
be O
sustained O
nuclear O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
. O

However O
, O
the O
U937 O
monocytic O
cell O
line O
, O
which O
is O
fully O
permissive O
to O
HIV O
replication O
, O
is O
known O
to O
express O
only O
low O
levels O
of O
nuclear B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
. O

We O
show O
here O
that O
chronic O
HIV O
infection O
results O
in O
both O
induction O
of O
a O
nuclear B-protein
factor I-protein
with O
antigenic O
properties O
indistinguishable O
from O
those O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
permanently O
increased O
HIV O
enhancer O
activity O
. O

This O
phenomenon O
, O
which O
is O
independent O
of O
tumour B-protein
necrosis I-protein
factor I-protein
, O
is O
associated O
with O
HIV O
replication O
, O
and O
is O
thus O
likely O
to O
explain O
at O
least O
in O
part O
the O
perpetuation O
of O
HIV O
infection O
in O
monocytes O
. O

Isolation O
of O
a O
rel O
- O
related O
human O
cDNA O
that O
potentially O
encodes O
the O
65 B-protein
- I-protein
kD I-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
[ O
published O
erratum O
appears O
in O
Science O
1991 O
Oct O
4 O
; O
254 O
( O
5028 O
) O
: O
11 O
] O
. O

A O
DNA O
probe O
that O
spanned O
a O
domain O
conserved O
among O
the O
proto O
- O
oncogene O
c O
- O
rel O
, O
the O
Drosophila B-protein
morphogen I-protein
dorsal I-protein
, O
and O
the O
p50 B-protein
DNA I-protein
binding I-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
was O
generated O
from O
Jurkat O
T O
cell O
complementary O
DNA O
with O
the O
polymerase O
chain O
reaction O
( O
PCR O
) O
and O
degenerate O
oligonucleotides O
. O

This O
probe O
was O
used O
to O
identify O
a O
rel O
- O
related O
complementary O
DNA O
that O
hybridized O
to O
a O
2 O
. O
6 O
- O
kilobase O
messenger O
RNA O
present O
in O
human O
T O
and O
B O
lymphocytes O
. O

In O
vitro O
transcription O
and O
translation O
of O
the O
complementary O
DNA O
resulted O
in O
the O
synthesis O
of O
a O
protein O
with O
an O
apparent O
molecular O
size O
of O
65 B-protein
kilodaltons I-protein
( O
kD O
) O
. O

The O
translated O
protein O
showed O
weak O
DNA O
binding O
with O
a O
specificity O
for O
the O
kappa O
B O
binding O
motif O
. O

This O
protein B-protein
- I-protein
DNA I-protein
complex I-protein
comigrated O
with O
the O
complex O
obtained O
with O
the O
purified B-protein
human I-protein
p65 I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
subunit I-protein
and O
binding O
was O
inhibited O
by O
I B-protein
kappa I-protein
B I-protein
- I-protein
alpha I-protein
and O
- B-protein
beta I-protein
proteins I-protein
. O

In O
addition O
, O
the O
65 B-protein
- I-protein
kD I-protein
protein I-protein
associated O
with O
the O
p50 B-protein
subunit I-protein
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
the O
kappa O
B O
probe O
to O
form O
a O
complex O
with O
the O
same O
electrophoretic O
mobility O
as O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
DNA I-protein
complex I-protein
. O

Therefore O
the O
rel B-protein
- I-protein
related I-protein
65 I-protein
- I-protein
kD I-protein
protein I-protein
may O
represent O
the O
p65 B-protein
subunit I-protein
of O
the O
active B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
complex I-protein
. O

The O
human O
myelomonocytic O
cell O
line O
U O
- O
937 O
as O
a O
model O
for O
studying O
alterations O
in O
steroid O
- O
induced O
monokine O
gene O
expression O
: O
marked O
enhancement O
of O
lipopolysaccharide O
- O
stimulated O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
messenger O
RNA O
levels O
by O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
. O

The O
active O
metabolite O
of O
vitamin O
D O
, O
1 O
, O
25 O
- O
dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
] O
, O
is O
a O
potent O
regulator O
of O
human O
monocyte O
/ O
macrophage O
function O
in O
vitro O
. O

To O
establish O
a O
model O
for O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
regulation O
of O
human O
monocyte O
monokine O
synthesis O
, O
three O
human O
cell O
lines O
( O
U O
- O
937 O
, O
THP O
- O
1 O
, O
and O
HL O
- O
60 O
) O
were O
examined O
for O
: O
1 O
) O
the O
presence O
of O
functional O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
receptors O
; O
2 O
) O
the O
accumulation O
of O
interleukin B-protein
- I-protein
1 I-protein
beta I-protein
( O
IL B-protein
- I-protein
1 I-protein
beta I-protein
) O
mRNA O
and O
IL B-protein
- I-protein
1 I-protein
beta I-protein
protein I-protein
in O
response O
to O
lipopolysaccharide O
( O
LPS O
) O
; O
and O
3 O
) O
the O
regulation O
of O
this O
response O
by O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
. O

All O
three O
cell O
lines O
expressed O
vitamin O
D O
receptor O
and O
had O
increased O
levels O
of O
IL B-protein
- I-protein
1 I-protein
beta I-protein
mRNA O
in O
response O
to O
LPS O
. O

Preincubation O
of O
cells O
with O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
augmented O
IL B-protein
- I-protein
1 I-protein
beta I-protein
mRNA O
levels O
only O
in O
U O
- O
937 O
and O
HL O
- O
60 O
cells O
. O

From O
these O
data O
, O
and O
taking O
into O
consideration O
their O
state O
of O
differentiation O
and O
relative O
ease O
of O
culture O
, O
U O
- O
937 O
was O
chosen O
over O
HL O
- O
60 O
and O
THP O
- O
1 O
as O
the O
cell O
line O
we O
further O
characterized O
. O

In O
U O
- O
937 O
cells O
, O
optimum O
time O
and O
dose O
of O
pretreatment O
with O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
were O
determined O
to O
be O
12 O
- O
24 O
h O
at O
a O
receptor O
saturating O
concentration O
of O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
( O
10 O
nM O
) O
. O

Preincubation O
of O
cells O
with O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
had O
no O
effect O
on O
the O
time O
course O
of O
IL B-protein
- I-protein
1 I-protein
beta I-protein
mRNA O
appearance O
in O
response O
to O
LPS O
. O

However O
, O
exposure O
of O
U O
- O
937 O
cells O
to O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
increased O
by O
200 O
% O
the O
level O
of O
IL B-protein
- I-protein
1 I-protein
beta I-protein
mRNA O
detected O
and O
decreased O
by O
three O
orders O
of O
magnitude O
the O
concentration O
of O
LPS O
required O
to O
achieve O
steady O
state O
mRNA O
levels O
equivalent O
to O
those O
observed O
in O
U O
- O
937 O
cells O
not O
preincubated O
with O
the O
hormone O
. O
2 O
+ O
o O
. O

Regulation O
of O
M B-protein
- I-protein
CSF I-protein
expression O
by O
M B-protein
- I-protein
CSF I-protein
: O
role O
of O
protein B-protein
kinase I-protein
C I-protein
and O
transcription B-protein
factor I-protein
NF I-protein
kappa I-protein
B I-protein
. O

Macrophage B-protein
- I-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
M B-protein
- I-protein
CSF I-protein
) O
, O
also O
referred O
to O
as O
CSF B-protein
- I-protein
1 I-protein
, O
regulates O
the O
survival O
, O
growth O
, O
differentiation O
and O
functional O
activity O
of O
monocytes O
by O
binding O
to O
a O
single O
class O
of O
high B-protein
- I-protein
affinity I-protein
cell I-protein
surface I-protein
receptors I-protein
, O
known O
to O
be O
the O
product O
of O
the O
c O
- O
fms O
protooncogene O
. O

The O
detection O
of O
both O
M O
- O
CSF O
and O
c O
- O
fms O
expression O
by O
cells O
of O
the O
monocyte O
lineage O
has O
suggested O
that O
M B-protein
- I-protein
CSF I-protein
may O
act O
by O
an O
autocrine O
mechanism O
. O

Interestingly O
, O
it O
has O
been O
shown O
that O
M B-protein
- I-protein
CSF I-protein
can O
induce O
the O
expression O
of O
its O
own O
gene O
. O

Although O
sensitivity O
to O
M B-protein
- I-protein
CSF I-protein
can O
be O
modulated O
by O
regulation O
of O
receptor O
expression O
and O
function O
, O
M B-protein
- I-protein
CSF I-protein
responsiveness O
is O
largely O
determined O
at O
a O
postreceptor O
level O
. O

To O
date O
, O
little O
is O
known O
about O
the O
intracellular O
pathway O
of O
M B-protein
- I-protein
CSF I-protein
signal O
transduction O
. O

We O
have O
therefore O
investigated O
the O
changes O
in O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
activity O
upon O
exposure O
of O
monocytes O
to O
M B-protein
- I-protein
CSF I-protein
. O

We O
show O
that O
M B-protein
- I-protein
CSF I-protein
activates O
and O
translocates O
PKC B-protein
. O

Inhibition O
of O
PKC B-protein
by O
the O
isoquinoline O
derivative O
H7 O
abolishes O
induction O
of O
M B-protein
- I-protein
CSF I-protein
by O
M B-protein
- I-protein
CSF I-protein
. O

Furthermore O
, O
activation O
of O
PKC B-protein
was O
pertussis O
- O
toxin O
- O
sensitive O
and O
was O
associated O
with O
the O
detection O
of O
an O
NF B-protein
kappa I-protein
B I-protein
protein I-protein
in O
nuclear O
extracts O
of O
M B-protein
- I-protein
CSF I-protein
- O
induced O
blood O
monocytes O
but O
not O
in O
monocytes O
exposed O
to O
medium O
treatment O
only O
. O

The O
results O
suggest O
that O
M B-protein
- I-protein
CSF I-protein
induction O
of O
M B-protein
- I-protein
CSF I-protein
involves O
G B-protein
proteins I-protein
, O
PKC B-protein
and O
NF B-protein
kappa I-protein
B I-protein
. O

Clone O
pAT O
133 O
identifies O
a O
gene O
that O
encodes O
another O
human O
member O
of O
a O
class O
of O
growth O
factor O
- O
induced O
genes O
with O
almost O
identical O
zinc B-protein
- I-protein
finger I-protein
domains I-protein
. O

We O
report O
the O
structure O
and O
regulation O
of O
a O
gene O
represented O
by O
clone O
pAT O
133 O
, O
which O
is O
induced O
upon O
transition O
from O
a O
resting O
state O
( O
G0 O
) O
through O
the O
early O
phase O
of O
the O
cell O
cycle O
( O
G1 O
) O
. O

The O
pAT O
133 O
gene O
is O
immediately O
induced O
, O
with O
FOS B-protein
- O
like O
kinetics O
, O
in O
human O
T O
cells O
and O
in O
fibroblasts O
. O

Primary O
structure O
analysis O
showed O
that O
the O
encoded O
protein O
contains O
three O
tandem B-protein
zinc I-protein
- I-protein
finger I-protein
sequences I-protein
of O
the O
type O
Cys2 B-protein
- I-protein
Xaa12 I-protein
- I-protein
His2 I-protein
. O

This O
zinc B-protein
- I-protein
finger I-protein
region I-protein
, O
which O
is O
thought O
to O
bind O
DNA O
in O
a O
sequence O
- O
specific O
manner O
, O
is O
similar O
( O
greater O
than O
80 O
% O
on O
the O
amino O
acid O
level O
) O
to O
two O
previously O
described O
transcription B-protein
factors I-protein
pAT B-protein
225 I-protein
/ I-protein
EGR1 I-protein
and O
pAT O
591 B-protein
/ I-protein
EGR2 I-protein
. O

Except O
for O
the O
conserved O
zinc B-protein
- I-protein
finger I-protein
domains I-protein
, O
the O
amino B-protein
acid I-protein
sequences I-protein
of O
the O
three O
proteins O
are O
distinct O
. O

This O
structural O
similarity O
suggests O
that O
the O
pAT O
133 O
gene O
encodes O
a O
transcription B-protein
factor I-protein
with O
a O
specific O
biological O
function O
. O

Comparing O
the O
regulation O
of O
these O
related O
zinc B-protein
- I-protein
finger I-protein
- O
encoding O
genes O
showed O
coordinate O
induction O
upon O
mitogenic O
stimulation O
of O
resting O
T O
lymphocytes O
and O
of O
resting O
fibroblasts O
. O

However O
, O
upon O
transition O
from O
a O
proliferating O
( O
G1 O
) O
to O
a O
resting O
state O
of O
the O
cell O
cycle O
the O
three O
genes O
were O
differently O
regulated O
. O

In O
human O
histiocytic O
U937 O
cells O
mRNA O
of O
clone O
pAT O
133 O
was O
constitutively O
expressed O
, O
whereas O
mRNA O
of O
pAT B-protein
225 I-protein
/ I-protein
EGR1 I-protein
was O
induced O
upon O
induction O
of O
terminal O
differentiation O
. O

In O
contrast O
mRNA O
representing O
pAT O
591 B-protein
/ I-protein
EGR2 I-protein
was O
not O
expressed O
in O
these O
cells O
. O

This O
difference O
in O
gene O
regulation O
suggests O
distinct O
biological O
roles O
in O
the O
control O
of O
cell O
proliferation O
for O
the O
respective O
proteins O
. O

v B-protein
- I-protein
erbA I-protein
overexpression O
is O
required O
to O
extinguish O
c B-protein
- I-protein
erbA I-protein
function O
in O
erythroid O
cell O
differentiation O
and O
regulation O
of O
the O
erbA O
target O
gene O
CAII O
. O

The O
v B-protein
- I-protein
erbA I-protein
oncoprotein I-protein
represents O
a O
retrovirus O
- O
transduced O
oncogenic O
version O
of O
the O
thyroid B-protein
hormone I-protein
( I-protein
T3 I-protein
/ I-protein
T4 I-protein
) I-protein
receptor I-protein
c B-protein
- I-protein
erbA I-protein
( I-protein
type I-protein
alpha I-protein
) I-protein
. O

It O
contributes O
to O
virus O
- O
induced O
erythroleukemia O
by O
efficiently O
arresting O
differentiation O
of O
red O
cell O
progenitors O
and O
by O
suppressing O
transcription O
of O
erythrocyte O
- O
specific O
genes O
. O

Here O
, O
we O
show O
that O
v B-protein
- I-protein
erbA I-protein
and O
c B-protein
- I-protein
erbA I-protein
bind O
directly O
to O
sequences O
within O
the O
promoter O
of O
the O
erythrocyte B-protein
- I-protein
specific I-protein
carbonic I-protein
anhydrase I-protein
II I-protein
( O
CAII O
) O
, O
a O
gene O
whose O
transcription O
is O
efficiently O
suppressed O
by O
v B-protein
- I-protein
erbA I-protein
. O

This O
erbA O
- O
binding O
site O
confers O
thyroid O
hormone O
responsiveness O
to O
a O
heterologous O
promoter O
in O
transient O
expression O
experiments O
and O
is O
a O
target O
for O
efficient O
down O
- O
regulation O
of O
CAII O
transcription O
by O
the O
v B-protein
- I-protein
erbA I-protein
oncoprotein I-protein
. O

In O
stably O
transformed O
erythroblasts O
coexpressing O
the O
v B-protein
- I-protein
erbA I-protein
oncoprotein I-protein
and O
the O
c B-protein
- I-protein
erbA I-protein
/ I-protein
T3 I-protein
receptor I-protein
at O
an O
approximately O
equimolar O
ratio O
, O
c B-protein
- I-protein
erbA I-protein
activity O
is O
dominant O
over O
v B-protein
- I-protein
erbA I-protein
. O

T3 O
efficiently O
induced O
erythroid O
differentiation O
in O
these O
cells O
, O
thus O
overcoming O
the O
v B-protein
- I-protein
erbA I-protein
- O
mediated O
differentiation O
arrest O
. O

Likewise O
, O
T3 O
activated O
CAII O
transcription O
as O
well O
as O
transient O
expression O
of O
a O
T3 O
- O
responsive O
reporter O
gene O
containing O
the O
CAII O
- O
specific O
erbA O
- O
binding O
site O
. O

The O
c B-protein
- I-protein
erbA I-protein
- O
dependent O
activation O
of O
this O
CAII O
reporter O
construct O
could O
only O
be O
suppressed O
by O
very O
high O
amounts O
of O
v B-protein
- I-protein
erbA I-protein
. O

Our O
results O
suggest O
that O
overexpression O
of O
v B-protein
- I-protein
erbA I-protein
is O
required O
for O
its O
function O
as O
an O
oncoprotein B-protein
. O

Anti B-protein
- I-protein
CD2 I-protein
receptor I-protein
antibodies I-protein
activate O
the O
HIV O
long O
terminal O
repeat O
in O
T O
lymphocytes O
. O

The O
CD2 B-protein
T I-protein
lymphocyte I-protein
glycoprotein I-protein
surface I-protein
molecule I-protein
mediates O
both O
cell O
to O
cell O
adhesion O
and O
T O
cell O
activation O
, O
two O
processes O
that O
are O
involved O
in O
the O
spread O
of O
HIV O
infection O
. O

Treatment O
of O
chronically O
HIV O
- O
infected O
PBMC O
with O
anti B-protein
- I-protein
CD2 I-protein
mAb I-protein
has O
been O
shown O
to O
induce O
the O
expression O
of O
infectious O
virus O
from O
these O
cultures O
. O

In O
this O
study O
we O
investigated O
the O
mechanisms O
whereby O
anti B-protein
- I-protein
CD2 I-protein
antibodies I-protein
stimulate O
viral O
production O
. O

We O
demonstrate O
that O
treatment O
of O
transiently O
transfected O
T O
lymphocytes O
with O
anti B-protein
- I-protein
CD2 I-protein
antibodies I-protein
results O
in O
activation O
of O
the O
HIV O
long O
terminal O
repeat O
. O

Furthermore O
, O
CAT B-protein
assays O
using O
mutated O
HIV O
long O
terminal O
repeat O
- O
CAT O
constructs O
and O
gel O
shift O
assays O
demonstrate O
that O
this O
activation O
is O
dependent O
on O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
enhancer O
. O

These O
studies O
suggest O
that O
interaction O
of O
CD2 B-protein
with O
its O
natural O
ligand O
, O
LFA B-protein
- I-protein
3 I-protein
, O
may O
play O
a O
role O
in O
regulation O
of O
HIV O
expression O
. O

Reactive O
oxygen O
intermediates O
as O
apparently O
widely O
used O
messengers O
in O
the O
activation O
of O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription I-protein
factor I-protein
and O
HIV O
- O
1 O
. O

Hydrogen O
peroxide O
and O
oxygen O
radicals O
are O
agents O
commonly O
produced O
during O
inflammatory O
processes O
. O

In O
this O
study O
, O
we O
show O
that O
micromolar O
concentrations O
of O
H2O2 O
can O
induce O
the O
expression O
and O
replication O
of O
HIV O
- O
1 O
in O
a O
human O
T O
cell O
line O
. O

The O
effect O
is O
mediated O
by O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
transcription B-protein
factor I-protein
which O
is O
potently O
and O
rapidly O
activated O
by O
an O
H2O2 O
treatment O
of O
cells O
from O
its O
inactive B-protein
cytoplasmic I-protein
form I-protein
. O

N O
- O
acetyl O
- O
L O
- O
cysteine O
( O
NAC O
) O
, O
a O
well O
characterized O
antioxidant O
which O
counteracts O
the O
effects O
of O
reactive O
oxygen O
intermediates O
( O
ROI O
) O
in O
living O
cells O
, O
prevented O
the O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
H2O2 O
. O

NAC O
and O
other O
thiol O
compounds O
also O
blocked O
the O
activation O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
cycloheximide O
, O
double O
- O
stranded O
RNA O
, O
calcium O
ionophore O
, O
TNF B-protein
- I-protein
alpha I-protein
, O
active O
phorbol O
ester O
, O
interleukin B-protein
- I-protein
1 I-protein
, O
lipopolysaccharide O
and O
lectin B-protein
. O

This O
suggests O
that O
diverse O
agents O
thought O
to O
activate O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
distinct O
intracellular O
pathways O
might O
all O
act O
through O
a O
common O
mechanism O
involving O
the O
synthesis O
of O
ROI O
. O

ROI O
appear O
to O
serve O
as O
messengers O
mediating O
directly O
or O
indirectly O
the O
release O
of O
the O
inhibitory B-protein
subunit I-protein
I B-protein
kappa I-protein
B I-protein
from O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Inhibition O
of O
transcription B-protein
factors I-protein
belonging O
to O
the O
rel B-protein
/ I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
family I-protein
by O
a O
transdominant B-protein
negative I-protein
mutant I-protein
. O

The O
KBF1 B-protein
factor I-protein
, O
which O
binds O
to O
the O
enhancer O
A O
located O
in O
the O
promoter O
of O
the O
mouse O
MHC O
class O
I O
gene O
H O
- O
2Kb O
, O
is O
indistinguishable O
from O
the O
p50 B-protein
DNA I-protein
binding I-protein
subunit I-protein
of O
the O
transcription O
factor O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
which O
regulates O
a O
series O
of O
genes O
involved O
in O
immune O
and O
inflammatory O
responses O
. O

The O
KBF1 B-protein
/ I-protein
p50 I-protein
factor I-protein
binds O
as O
a O
homodimer B-protein
but O
can O
also O
form O
heterodimers B-protein
with O
the O
products O
of O
other O
members O
of O
the O
same O
family O
, O
like O
the O
c O
- O
rel O
and O
v O
- O
rel O
( O
proto O
) O
oncogenes O
. O

The O
dimerization B-protein
domain I-protein
of O
KBF1 B-protein
/ I-protein
p50 I-protein
is O
contained O
between B-protein
amino I-protein
acids I-protein
201 I-protein
and I-protein
367 I-protein
. O

A O
mutant O
of O
KBF1 B-protein
/ I-protein
p50 I-protein
( O
delta B-protein
SP I-protein
) O
, O
unable O
to O
bind O
to O
DNA O
but O
able O
to O
form O
homo O
- O
or O
heterodimers B-protein
, O
has O
been O
constructed O
. O

This O
protein O
reduces O
or O
abolishes O
in O
vitro O
the O
DNA O
binding O
activity O
of O
wild B-protein
- I-protein
type I-protein
proteins I-protein
of O
the O
same O
family O
( O
KBF1 B-protein
/ I-protein
p50 I-protein
, O
c O
- O
and O
v O
- O
rel O
) O
. O

This O
mutant O
also O
functions O
in O
vivo O
as O
a O
trans B-protein
- I-protein
acting I-protein
dominant I-protein
negative I-protein
regulator I-protein
: O
the O
transcriptional O
inducibility O
of O
the O
HIV O
long O
terminal O
repeat O
( O
which O
contains O
two O
potential O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
sites O
) O
by O
phorbol O
ester O
( O
PMA O
) O
is O
inhibited O
when O
it O
is O
co O
- O
transfected O
into O
CD4 O
+ O
T O
cells O
with O
the O
delta B-protein
SP I-protein
mutant O
. O

Similarly O
the O
basal O
as O
well O
as O
TNF B-protein
or O
IL1 O
- O
induced O
activity O
of O
the O
MHC O
class O
I O
H O
- O
2Kb O
promoter O
can O
be O
inhibited O
by O
this O
mutant O
in O
two O
different O
cell O
lines O
. O

These O
results O
constitute O
the O
first O
formal O
demonstration O
that O
these O
genes O
are O
regulated O
by O
members O
of O
the O
rel B-protein
/ I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
family I-protein
. O

Tissue O
- O
specific O
expression O
of O
the O
platelet O
GPIIb O
gene O
. O

One O
of O
the O
major O
objectives O
in O
the O
study O
of O
thrombogenesis O
is O
to O
determine O
the O
mechanisms O
by O
which O
a O
hematopoietic O
progenitor O
is O
activated O
and O
committed O
to O
the O
megakaryocytic O
lineage O
. O

Recent O
development O
of O
primary O
cultures O
of O
human O
megakaryocytes O
and O
the O
molecular O
cloning O
of O
genes O
that O
are O
specific O
to O
this O
lineage O
offer O
the O
possibility O
of O
getting O
some O
insights O
into O
the O
genetic O
mechanisms O
that O
control O
megakaryocytopoiesis O
. O

One O
gene O
of O
interest O
is O
the O
glycoprotein O
IIb O
( O
GPIIb O
) O
gene O
; O
GPIIb O
, O
the O
alpha B-protein
subunit I-protein
of O
the O
platelet B-protein
cytoadhesin I-protein
GPIIb I-protein
- I-protein
IIIa I-protein
, O
is O
produced O
in O
megakaryocytes O
at O
an O
early O
stage O
of O
the O
differentiation O
, O
whereas O
the O
other O
subunit O
of O
this O
complex O
, O
GPIIIa B-protein
, O
is O
expressed O
in O
other O
cells O
. O

For O
these O
reasons O
, O
the O
5 O
' O
- O
flanking O
region O
of O
the O
GPIIb O
gene O
was O
used O
to O
identify O
the O
regions O
that O
interact O
with O
DNA B-protein
- I-protein
binding I-protein
nuclear I-protein
factors I-protein
. O

A O
fragment O
extending O
from O
- O
643 O
to O
+ O
33 O
is O
capable O
of O
controlling O
the O
tissue O
- O
specific O
expression O
of O
the O
CAT O
gene O
in O
transfection O
experiments O
. O

Within O
this O
region O
, O
we O
have O
identified O
several O
sequences O
that O
are O
implicated O
in O
DNA O
protein O
interactions O
as O
shown O
in O
DNAse B-protein
I I-protein
footprints O
and O
gel O
mobility O
shift O
assays O
. O

One O
region O
, O
centered O
at O
- O
54 O
, O
is O
similar O
to O
a O
nuclear O
factor O
E1 O
- O
binding O
site O
, O
and O
a O
region O
located O
at O
position O
- O
233 O
contains O
a O
CCAAT O
motif O
. O

Two O
domains O
centered O
at O
positions O
- O
345 O
and O
- O
540 O
, O
respectively O
, O
bind O
proteins O
that O
are O
present O
in O
megakaryocytic O
cells O
and O
nonrelated O
cells O
as O
well O
. O

Finally O
, O
two O
other O
domains O
, O
located O
at O
positions O
- O
460 O
and O
- O
510 O
, O
interact O
with O
proteins O
that O
are O
only O
present O
in O
megakaryocytic O
cells O
. O

In O
addition O
, O
deletion O
of O
the O
region O
containing O
these O
two O
domains O
results O
in O
a O
significant O
decrease O
of O
the O
promoter O
activity O
. O

It O
is O
very O
likely O
that O
these O
domains O
bind O
megakaryocyte B-protein
- I-protein
specific I-protein
nuclear I-protein
proteins I-protein
acting O
as O
positive B-protein
transcription I-protein
factors I-protein
. O

Lymphocyte O
glucocorticoid B-protein
receptor I-protein
binding O
during O
depression O
and O
after O
clinical O
recovery O
. O

Lymphocyte B-protein
glucocorticoid I-protein
receptor I-protein
binding O
parameters O
were O
studied O
in O
15 O
severely O
depressed O
patients O
during O
depression O
and O
after O
clinical O
recovery O
, O
and O
in O
15 O
healthy O
controls O
. O

There O
was O
no O
difference O
in O
glucocorticoid B-protein
receptor I-protein
number O
or O
affinity O
between O
depressed O
patients O
and O
recovered O
or O
control O
subjects O
. O

Afternoon O
ACTH O
and O
cortisol O
concentrations O
did O
not O
differ O
significantly O
between O
the O
three O
groups O
. O

No O
relationship O
could O
be O
established O
between O
glucocorticoid B-protein
receptor I-protein
binding O
and O
antidepressant O
medication O
. O

These O
data O
support O
the O
view O
of O
an O
impaired O
ligand O
- O
induced O
plasticity O
of O
glucocorticoid B-protein
receptor I-protein
regulation O
rather O
than O
the O
hypothesis O
of O
decreased O
glucocorticoid B-protein
receptor I-protein
numbers O
during O
depression O
. O

Every O
enhancer O
works O
with O
every O
promoter O
for O
all O
the O
combinations O
tested O
: O
could O
new O
regulatory O
pathways O
evolve O
by O
enhancer O
shuffling O
? O
. O

The O
promoters O
and O
enhancers O
of O
cell O
type O
- O
specific O
genes O
are O
often O
conserved O
in O
evolution O
, O
and O
hence O
one O
might O
expect O
that O
a O
given O
enhancer O
has O
evolved O
to O
work O
best O
with O
its O
own O
promoter O
. O

While O
this O
expectation O
may O
be O
realized O
in O
some O
cases O
, O
we O
have O
not O
found O
evidence O
for O
it O
. O

A O
total O
of O
27 O
combinations O
of O
different O
promoters O
and O
enhancers O
were O
tested O
by O
transfection O
into O
cultured O
cells O
. O

We O
found O
that O
the O
relative O
efficiency O
of O
the O
enhancers O
is O
approximately O
the O
same O
, O
irrespective O
of O
the O
type O
of O
promoter O
used O
, O
i O
. O
e O
. O
, O
there O
was O
no O
strong O
preference O
for O
any O
given O
enhancer O
/ O
promoter O
combination O
. O

Notably O
, O
we O
do O
not O
see O
particularly O
strong O
transcription O
when O
the O
immunoglobulin O
kappa O
enhancer O
( O
or O
the O
immunoglobulin B-protein
heavy I-protein
chain I-protein
enhancer O
) O
is O
used O
to O
activate O
a O
kappa O
gene O
promoter O
. O

We O
propose O
that O
a O
generally O
permissive O
enhancer O
/ O
promoter O
interaction O
is O
of O
evolutionary O
benefit O
for O
higher O
eukaryotes O
: O
by O
enhancer O
shuffling O
, O
genes O
could O
be O
easily O
brought O
under O
a O
new O
type O
of O
inducibility O
/ O
cell O
type O
specificity O
. O

Towards O
a O
molecular O
understanding O
of O
T O
- O
cell O
differentiation O
. O

Lymphoid O
differentiation O
is O
one O
of O
the O
best O
studied O
examples O
of O
mammalian O
development O
. O

Here O
Hans O
Clevers O
and O
Michael O
Owen O
describe O
how O
the O
cloning O
of O
the O
genes O
that O
encode O
T B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
membrane I-protein
proteins I-protein
allows O
the O
identification O
of O
transcription B-protein
factors I-protein
that O
control O
the O
expression O
of O
these O
T O
- O
cell O
genes O
. O

Such O
transcription B-protein
factors I-protein
play O
a O
key O
role O
in O
the O
development O
of O
the O
mature O
T O
- O
cell O
phenotype O
by O
functioning O
as O
' O
master O
regulators O
of O
T O
- O
cell O
differentiation O
' O
. O

A O
study O
on O
the O
circadian O
rhythm O
of O
glucocorticoid B-protein
receptor I-protein
. O

Circadian O
rhythm O
in O
glucocorticoid B-protein
receptor I-protein
( O
GR B-protein
) O
was O
studied O
in O
the O
rat O
liver O
and O
human O
peripheral O
leukocytes O
. O

For O
rats O
exposed O
to O
a O
natural O
environmental O
photic O
cycle O
or O
a O
12L O
: O
12D O
artificial O
light O
regime O
, O
peak O
values O
of O
hepatic B-protein
GR I-protein
were O
detected O
between O
23 O
: O
00 O
and O
02 O
: O
00 O
h O
. O

Except O
for O
a O
4 O
- O
hour O
advancement O
of O
the O
peak O
, O
a O
similar O
circadian O
rhythm O
of O
hepatic B-protein
GR I-protein
was O
detected O
in O
rats O
reared O
under O
a O
reversed O
lighting O
regimen O
( O
12D O
: O
12L O
; O
lights O
on O
between O
18 O
: O
30 O
and O
06 O
: O
30 O
h O
) O
. O

In O
human O
leukocytes O
, O
the O
peak O
value O
of O
GR B-protein
was O
found O
to O
parallel O
that O
of O
plasma O
cortisol O
with O
high O
and O
low O
values O
detected O
at O
04 O
: O
00 O
- O
08 O
: O
00 O
h O
and O
23 O
: O
00 O
- O
24 O
: O
00 O
h O
, O
respectively O
. O

In O
patients O
suffering O
from O
Cushing O
' O
s O
syndrome O
, O
the O
circadian O
rhythm O
of O
plasma O
cortisol O
either O
disappeared O
or O
was O
inverted O
while O
that O
of O
GR B-protein
did O
not O
significantly O
deviate O
from O
the O
normal O
subjects O
. O

For O
apoplexic O
patients O
with O
lesions O
localized O
to O
the O
base O
of O
the O
brain O
as O
indicated O
by O
computerized O
tomography O
, O
the O
diurnal O
variation O
of O
GR B-protein
was O
abolished O
. O

Conversely O
, O
diurnal O
rhythmicity O
persisted O
in O
apoplexy O
patients O
whose O
lesions O
were O
in O
the O
cerebral O
cortex O
. O

Thus O
, O
we O
postulated O
that O
the O
circadian O
modification O
of O
GR B-protein
was O
independent O
of O
the O
diurnal O
fluctuations O
in O
plasma O
cortisol O
level O
or O
the O
circadian O
variations O
in O
environmental O
lighting O
and O
that O
the O
rhythmicity O
might O
be O
regulated O
by O
the O
' O
circadian O
pacemaker O
' O
located O
in O
the O
human O
basal O
brain O
. O

These O
diurnal O
variations O
in O
GR B-protein
might O
serve O
to O
coordinate O
the O
reactivity O
of O
the O
target O
cells O
to O
cortisol O
because O
the O
diurnal O
rhythms O
of O
a O
GR B-protein
- O
mediated O
response O
, O
the O
fractional O
inhibition O
of O
chemotactic O
migration O
rate O
of O
polymorphonuclear O
leukocytes O
by O
cortisol O
, O
were O
found O
to O
be O
synchronous O
with O
those O
of O
GR B-protein
. O

Transcription B-protein
factor I-protein
requirements O
for O
U2 O
snRNA O
- O
encoding O
gene O
activation O
in O
B O
lymphoid O
cells O
. O

Transcription O
of O
a O
human O
U2 O
small O
nuclear O
RNA O
( O
snRNA O
) O
- O
encoding O
gene O
in O
HeLa O
cells O
requires O
a O
distal O
enhancer O
element O
, O
which O
is O
composed O
of O
one O
octamer O
motif O
( O
Oct O
) O
and O
three O
Sp O
1 O
- O
binding O
sites O
. O

To O
study O
the O
transcription B-protein
factor I-protein
requirement O
in O
B O
- O
cells O
, O
different O
U2 O
enhancer O
constructions O
were O
transfected O
into O
the O
lymphoid O
cell O
line O
, O
BJA O
- O
B O
. O

The O
results O
showed O
that O
the O
activation O
of O
U2 O
snRNA O
transcription O
in O
B O
- O
cells O
also O
requires O
an O
enhancer O
comprising O
both O
the O
Oct O
and O
at O
least O
one O
Sp O
1 O
- O
binding O
site O
. O

Deletion O
of O
all O
the O
Sp O
1 O
- O
binding O
sites O
from O
the O
enhancer O
reduces O
transcription O
by O
80 O
- O
90 O
% O
in O
HeLa O
, O
as O
well O
as O
in O
BJA O
- O
B O
cells O
, O
whereas O
the O
removal O
of O
the O
octamer O
- O
binding O
site O
reduces O
transcription O
to O
levels O
below O
detection O
in O
both O
cell O
types O
. O

Enhancers O
containing O
a O
single O
Oct O
have O
, O
nevertheless O
, O
the O
capacity O
to O
partially O
activate O
U2 O
snRNA O
transcription O
in O
both O
HeLa O
cells O
, O
in O
which O
only O
OTF O
- O
1 O
is O
expressed O
, O
and O
in O
BJA O
- O
B O
cells O
in O
which O
OTF B-protein
- I-protein
2 I-protein
is O
the O
predominantly O
expressed O
octamer B-protein
- I-protein
binding I-protein
factor I-protein
. O

The O
most O
likely O
interpretation O
of O
our O
results O
is O
that O
both O
the O
ubiquitous O
transcription B-protein
factor I-protein
, O
OTF B-protein
- I-protein
1 I-protein
, O
and O
the O
B B-protein
- I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
OTF B-protein
- I-protein
2 I-protein
, O
can O
activate O
U2 O
snRNA O
transcription O
. O

The O
results O
also O
revealed O
a O
similar O
functional O
cooperation O
between O
the O
transcription O
factors O
which O
bind O
to O
the O
Oct O
and O
the O
adjacent O
Sp O
1 O
- O
binding O
site O
in O
BJA O
- O
B O
cells O
, O
as O
has O
been O
observed O
in O
HeLa O
cells O
, O
since O
a O
template O
which O
contains O
a O
weak O
binding O
site O
for O
OTFs O
expresses O
wild O
- O
type O
levels O
of O
U2 O
snRNA O
in O
both O
cell O
types O
when O
the O
weak O
octamer O
- O
binding O
site O
is O
combined O
with O
a O
Sp O
1 O
- O
binding O
site O
. O

One O
base O
pair O
change O
abolishes O
the O
T O
cell O
- O
restricted O
activity O
of O
a O
kB O
- O
like O
proto O
- O
enhancer O
element O
from O
the O
interleukin O
2 O
promoter O
. O

The O
inducible O
, O
T O
cell O
- O
specific O
enhancers O
of O
murine O
and O
human O
Interleukin O
2 O
( O
Il B-protein
- I-protein
2 I-protein
) O
genes O
contain O
the O
kB O
- O
like O
sequence O
GGGATTTCACC O
as O
an O
essential O
cis O
- O
acting O
enhancer O
motif O
. O

When O
cloned O
in O
multiple O
copies O
this O
so O
- O
called O
TCEd O
( O
distal O
T O
cell O
element O
) O
acts O
as O
an O
inducible O
proto O
- O
enhancer O
element O
in O
E14 O
T O
lymphoma O
cells O
, O
but O
not O
in O
HeLa O
cells O
. O

In O
extracts O
of O
induced O
, O
Il B-protein
- I-protein
2 I-protein
secreting O
El4 O
cells O
three O
individual O
protein B-protein
factors I-protein
bind O
to O
TCEd O
DNA O
. O

The O
binding O
of O
the O
most O
prominent O
factor O
, O
named O
TCF B-protein
- I-protein
1 I-protein
( O
T B-protein
cell I-protein
factor I-protein
1 I-protein
) O
, O
is O
correlated O
with O
the O
proto O
- O
enhancer O
activity O
of O
TCEd O
. O

TCF B-protein
- I-protein
1 I-protein
consists O
of O
two O
polypeptides O
of O
about O
50 O
kD O
and O
105 O
kD O
; O
the O
former O
seems O
to O
be O
related O
to O
the O
50 B-protein
kD I-protein
polypeptide I-protein
of O
NF B-protein
- I-protein
kB I-protein
. O

Purified B-protein
NF I-protein
- I-protein
kB I-protein
is O
also O
able O
to O
bind O
to O
the O
TCEd O
, O
but O
TCF B-protein
- I-protein
1 I-protein
binds O
stronger O
than O
NF B-protein
- I-protein
kB I-protein
to O
TCEd O
DNA O
. O

The O
conversion O
of O
the O
TCEd O
to O
a O
' O
perfect O
' O
NF B-protein
- I-protein
kB I-protein
binding O
site O
leads O
to O
a O
tighter O
binding O
of O
NF B-protein
- I-protein
kB I-protein
to O
TCEd O
DNA O
and O
, O
as O
a O
functional O
consequence O
, O
to O
the O
activity O
of O
the O
' O
converted O
' O
TCEd O
motifs O
in O
HeLa O
cells O
. O

Thus O
, O
the O
substitution O
of O
the O
underlined O
A O
residue O
to O
a O
C O
within O
the O
GGGATTTCACC O
motif O
abolishes O
its O
T O
cell O
- O
restricted O
activity O
and O
leads O
to O
its O
functioning O
in O
both O
El4 O
cells O
and O
HeLa O
cells O
. O

These O
results O
indicate O
that O
lymphocyte O
- O
specific O
factors O
binding O
to O
the O
TCEd O
are O
involved O
in O
the O
control O
of O
T O
cell O
specific O
- O
transcription O
of O
the O
Il B-protein
- I-protein
2 I-protein
gene O
. O

An O
erythroid O
specific O
enhancer O
upstream O
to O
the O
gene O
encoding O
the O
cell B-protein
- I-protein
type I-protein
specific I-protein
transcription I-protein
factor I-protein
GATA B-protein
- I-protein
1 I-protein
. O

The O
transcription B-protein
factor I-protein
GATA B-protein
- I-protein
1 I-protein
is O
expressed O
in O
a O
subset O
of O
hemopoietic O
cells O
, O
where O
it O
mediates O
the O
cell O
- O
type O
specific O
expression O
of O
several O
genes O
. O

We O
have O
cloned O
the O
mouse O
and O
human O
GATA O
- O
1 O
genes O
. O

A O
region O
upstream O
to O
the O
first O
exon O
, O
and O
highly O
conserved O
between O
mouse O
and O
man O
, O
acts O
as O
an O
erythroid O
specific O
enhancer O
in O
transient O
assays O
, O
if O
linked O
to O
the O
GATA B-protein
- I-protein
1 I-protein
or O
to O
the O
SV40 O
promoter O
. O

The O
activity O
of O
the O
enhancer O
is O
almost O
completely O
dependent O
on O
the O
integrity O
of O
a O
dimeric O
GATA O
- O
1 O
binding O
site O
. O

Demonstration O
of O
a O
1 B-protein
, I-protein
25 I-protein
- I-protein
dihydroxyvitamin I-protein
D3 I-protein
- I-protein
responsive I-protein
protein I-protein
in O
human O
lymphocytes O
: O
immunologic O
crossreactivity O
and O
inverse O
regulation O
with O
the O
vitamin B-protein
D I-protein
receptor I-protein
. O

Using O
Western O
blot O
analysis O
with O
a O
monoclonal B-protein
antibody I-protein
recognizing O
a O
17 B-protein
- I-protein
amino I-protein
acid I-protein
epitope I-protein
of O
the O
1 B-protein
, I-protein
25 I-protein
- I-protein
dihydroxyvitamin I-protein
D3 I-protein
[ I-protein
1 I-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
] I-protein
receptor I-protein
, O
we O
have O
detected O
two O
crossreacting B-protein
proteins I-protein
in O
activated O
normal O
human O
lymphocytes O
. O

The O
smaller O
of O
the O
two O
proteins O
( O
50 B-protein
kDa I-protein
) O
was O
indistinguishable O
from O
the O
classical O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
and O
, O
similar O
to O
the O
classical O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
, O
was O
upregulated O
in O
a O
dose O
- O
dependent O
fashion O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
. O

The O
larger O
crossreacting O
protein O
exhibited O
an O
electrophoretic O
mobility O
of O
80 B-protein
kDa I-protein
, O
was O
localized O
in O
the O
cell O
cytosol O
, O
and O
appeared O
to O
be O
specific O
for O
activated O
lymphocytes O
since O
it O
was O
not O
detected O
in O
several O
other O
human O
cells O
including O
monocytes O
. O

More O
strikingly O
, O
the O
80 B-protein
- I-protein
kDa I-protein
protein I-protein
was O
downregulated O
in O
a O
dose O
- O
dependent O
fashion O
by O
1 O
, O
25 O
( O
OH O
) O
2D3 O
; O
this O
effect O
was O
independent O
of O
the O
mode O
of O
lymphocyte O
activation O
and O
specific O
for O
the O
1 O
, O
25 O
( O
OH O
) O
2D3 O
metabolite O
of O
vitamin O
D3 O
. O

However O
, O
two O
potent O
immunosuppressive O
agents O
, O
glucocorticoids O
and O
cyclosporin O
A O
, O
also O
inhibited O
the O
80 B-protein
- I-protein
kDa I-protein
protein I-protein
. O

Regulation O
of O
glucocorticoid B-protein
receptors I-protein
in O
human O
mononuclear O
cells O
: O
effects O
of O
glucocorticoid O
treatment O
, O
Cushing O
' O
s O
disease O
and O
ketoconazole O
. O

Glucocorticoid B-protein
receptors I-protein
( O
GcR B-protein
) O
were O
determined O
by O
a O
whole O
cell O
assay O
in O
human O
mononulear O
leukocytes O
( O
hMNL O
) O
from O
control O
subjects O
, O
patients O
receiving O
glucocorticoid O
therapy O
for O
systemic O
diseases O
and O
Cushing O
' O
s O
disease O
patients O
with O
or O
without O
ketoconazole O
therapy O
. O

Prolonged O
corticosteroid O
treatment O
resulted O
in O
down O
- O
regulation O
of O
GcR B-protein
, O
while O
the O
mean O
level O
of O
GcR B-protein
in O
Cushing O
' O
s O
disease O
was O
normal O
. O

In O
this O
group O
, O
however O
, O
receptor O
levels O
and O
morning O
plasma O
cortisol O
values O
showed O
a O
negative O
correlation O
, O
indicating O
a O
subtle O
down O
- O
regulatory O
effect O
. O

Furthermore O
, O
GcR B-protein
were O
unaltered O
after O
these O
patients O
received O
ketoconazole O
, O
in O
spite O
of O
a O
marked O
reduction O
in O
morning O
plasma O
cortisol O
and O
urinary O
free O
cortisol O
. O

We O
also O
observed O
that O
ketoconazole O
was O
a O
weak O
competitor O
of O
GcR B-protein
in O
intact O
cells O
, O
although O
it O
significantly O
inhibited O
[ O
3H O
] O
dexamethasone O
binding O
in O
cytosolic O
preparations O
from O
rat O
tissues O
. O

The O
results O
suggested O
that O
GcR B-protein
in O
hMNL O
are O
down O
- O
regulated O
by O
synthetic O
steroids O
given O
in O
vivo O
, O
but O
they O
showed O
very O
mild O
down O
- O
regulation O
in O
hypercortisolemic O
patients O
suffering O
from O
Cushing O
' O
s O
disease O
. O

Finally O
, O
we O
did O
not O
observed O
either O
up O
- O
regulation O
or O
antagonism O
of O
GcR B-protein
by O
ketoconazole O
treatment O
, O
at O
the O
time O
that O
cortisol O
levels O
of O
patients O
with O
Cushing O
' O
s O
disease O
were O
reduced O
. O

This O
indicates O
that O
the O
beneficial O
effects O
of O
ketoconazole O
in O
Cushing O
' O
s O
disease O
are O
due O
to O
adrenal O
cortisol O
suppression O
and O
not O
to O
interaction O
with O
GcR B-protein
of O
target O
cells O
, O
and O
that O
the O
process O
of O
GcR B-protein
regulation O
in O
hMNL O
is O
a O
complex O
phenomenon O
awaiting O
further O
elucidation O
. O

HTLV B-protein
- I-protein
1 I-protein
Tax I-protein
induces O
expression O
of O
various O
immediate O
early O
serum O
responsive O
genes O
. O

Human O
T O
- O
cell O
leukemia O
virus O
type O
1 O
( O
HTLV O
- O
1 O
) O
is O
an O
etiological O
agent O
of O
adult O
T O
- O
cell O
leukemia O
( O
ATL O
) O
. O

We O
showed O
here O
by O
mobility O
- O
shift O
assay O
that O
T O
- O
cell O
lines O
transformed O
with O
the O
virus O
contained O
high O
levels O
of O
AP B-protein
- I-protein
1 I-protein
activities O
. O

Consistent O
with O
this O
result O
, O
these O
cell O
lines O
expressed O
increased O
levels O
of O
mRNAs O
encoding O
the O
AP B-protein
- I-protein
1 I-protein
proteins I-protein
, O
c B-protein
- I-protein
Fos I-protein
, O
Fra B-protein
- I-protein
1 I-protein
, O
c B-protein
- I-protein
Jun I-protein
, O
JunB B-protein
, O
and O
JunD B-protein
. O

Previously O
, O
transcription O
of O
the O
c O
- O
fos O
gene O
has O
been O
reported O
to O
be O
transactivated O
by O
the O
viral B-protein
transcription I-protein
factor I-protein
, O
Tax1 B-protein
. O

By O
using O
the O
human O
T O
- O
cell O
line O
( O
JPX O
- O
9 O
) O
, O
in O
which O
expression O
of O
the O
Tax1 B-protein
is O
inducible O
, O
we O
showed O
that O
expression O
of O
mRNAs O
for O
Fra B-protein
- I-protein
1 I-protein
, O
c B-protein
- I-protein
Jun I-protein
, O
and O
JunD B-protein
was O
also O
transactivated O
by O
Tax1 B-protein
. O

Moreover O
, O
Tax1 B-protein
activated O
expression O
of O
two O
other O
transcription B-protein
factors I-protein
having O
zinc B-protein
finger I-protein
motifs I-protein
, O
Egr B-protein
- I-protein
1 I-protein
and O
Egr B-protein
- I-protein
2 I-protein
, O
in O
the O
same O
cells O
. O

The O
Tax1 B-protein
- O
inducible O
transcription B-protein
factors I-protein
identified O
here O
are O
encoded O
by O
the O
members O
of O
immediate O
early O
genes O
under O
the O
control O
of O
growth O
signals O
. O

Thus O
, O
Tax1 B-protein
was O
suggested O
to O
replace O
growth O
signals O
, O
at O
least O
in O
part O
, O
by O
this O
mechanism O
. O

Glucocorticoid B-protein
receptor I-protein
characteristics O
in O
monocytes O
of O
patients O
with O
corticosteroid O
- O
resistant O
bronchial O
asthma O
. O

The O
mechanism O
of O
corticosteroid O
resistance O
in O
bronchial O
asthma O
has O
been O
studied O
by O
determining O
the O
rank O
order O
of O
potency O
for O
different O
corticosteroids O
in O
inhibiting O
the O
generation O
of O
a O
3 O
kD O
molecule O
from O
peripheral O
blood O
monocytes O
isolated O
from O
corticosteroid O
- O
sensitive O
( O
CS O
) O
and O
corticosteroid O
- O
resistant O
( O
CR O
) O
asthmatic O
subjects O
, O
which O
augments O
leukotriene O
B4 O
( O
LTB4 B-protein
) O
generation O
by O
human O
neutrophils O
( O
PMN O
) O
stimulated O
by O
calcium O
ionophore O
. O

In O
addition O
, O
binding O
studies O
with O
( O
3H O
) O
dexamethasone O
have O
been O
performed O
to O
determine O
the O
dissociation O
constant O
( O
Kd O
) O
and O
receptor O
numbers O
( O
Ro O
) O
in O
the O
monocytes O
of O
these O
two O
groups O
of O
subjects O
. O

The O
concentration O
of O
corticosteroid O
producing O
50 O
% O
inhibition O
( O
IC50 O
) O
was O
600 O
nM O
, O
70 O
nM O
, O
and O
0 O
. O
5 O
nM O
for O
hydrocortisone O
, O
methylprednisolone O
, O
and O
dexamethasone O
, O
respectively O
, O
in O
monocytes O
from O
CS O
individuals O
. O

There O
was O
only O
weak O
inhibition O
of O
the O
generation O
of O
enhancing O
activity O
by O
the O
corticosteroids O
in O
the O
CR O
asthmatic O
individuals O
. O

The O
dexamethasone O
Kd O
was O
2 O
. O
45 O
+ O
/ O
- O
0 O
. O
58 O
nM O
( O
mean O
+ O
/ O
- O
SEM O
, O
n O
= O
6 O
) O
in O
the O
CS O
group O
and O
1 O
. O
6 O
+ O
/ O
- O
0 O
. O
35 O
nM O
( O
mean O
+ O
/ O
- O
SEM O
, O
n O
= O
6 O
) O
in O
the O
CR O
group O
of O
patients O
( O
p O
= O
0 O
. O
14 O
) O
. O

The O
Ro O
in O
the O
CS O
group O
was O
3 O
, O
605 O
+ O
/ O
- O
984 O
binding O
sites O
per O
nucleus O
( O
mean O
+ O
/ O
- O
SEM O
, O
n O
= O
6 O
) O
and O
4 O
, O
757 O
+ O
/ O
- O
692 O
binding O
sites O
per O
nucleus O
( O
mean O
+ O
/ O
- O
SEM O
, O
n O
= O
6 O
) O
in O
the O
CR O
group O
( O
p O
= O
0 O
. O
23 O
) O
. O

These O
findings O
indicate O
that O
corticosteroid O
resistance O
in O
bronchial O
asthma O
cannot O
be O
explained O
by O
abnormalities O
in O
corticosteroid O
receptor O
characteristics O
. O

Vitamin B-protein
D I-protein
receptor I-protein
expression O
in O
human O
lymphocytes O
. O

Signal O
requirements O
and O
characterization O
by O
western O
blots O
and O
DNA O
sequencing O
. O

The O
signals O
controlling O
the O
expression O
of O
the O
receptor B-protein
protein I-protein
for O
1 O
alpha O
, O
25 O
- O
dihydroxyvitamin O
D3 O
in O
normal O
human O
lymphocytes O
and O
the O
relationship O
of O
this O
protein O
to O
the O
classical B-protein
vitamin I-protein
D I-protein
receptor I-protein
were O
examined O
. O

Lymphocytes O
activated O
with O
the O
OKT3 B-protein
antibody I-protein
to O
the O
T B-protein
- I-protein
cell I-protein
antigen I-protein
receptor I-protein
expressed O
fewer O
binding O
sites O
as O
compared O
to O
lymphocytes O
that O
were O
activated O
by O
the O
polyclonal O
activator O
phytohemagglutinin B-protein
( O
PHA B-protein
) O
. O

However O
, O
combination O
of O
OKT3 B-protein
and O
phorbol O
myristate O
acetate O
produced O
a O
concentration O
of O
binding O
sites O
similar O
to O
the O
PHA B-protein
- O
activated O
cells O
. O

The O
receptor O
from O
OKT3 B-protein
and O
OKT3 B-protein
+ O
phorbol O
myristate O
acetate O
- O
activated O
lymphocytes O
exhibited O
decreased O
binding O
to O
DNA O
- O
cellulose O
compared O
to O
PHA B-protein
- O
activated O
lymphocytes O
. O

In O
lymphocytes O
activated O
either O
by O
PHA B-protein
or O
OKT3 B-protein
( O
but O
not O
in O
resting O
cells O
) O
, O
a O
50 B-protein
- I-protein
kDa I-protein
species I-protein
cross O
- O
reacting O
with O
a O
monoclonal B-protein
antibody I-protein
against O
the O
intestinal B-protein
vitamin I-protein
D I-protein
receptor I-protein
was O
detected O
. O

Finally O
, O
RNA O
from O
activated O
lymphocytes O
was O
amplified O
by O
polymerase O
chain O
reaction O
using O
oligonucleotide O
primers O
flanking O
the O
196 O
base O
pair O
long O
region O
encoding O
the O
DNA B-protein
- I-protein
binding I-protein
domain I-protein
of O
the O
human B-protein
intestinal I-protein
receptor I-protein
. O

The O
amplified O
product O
showed O
an O
identical O
nucleotide O
sequence O
to O
the O
DNA B-protein
- I-protein
binding I-protein
domain I-protein
of O
the O
human B-protein
intestinal I-protein
receptor I-protein
. O

These O
findings O
suggest O
that O
expression O
of O
the O
1 B-protein
, I-protein
25 I-protein
- I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
in O
lymphocytes O
is O
triggered O
by O
distinct O
and O
contingent O
signals O
, O
and O
that O
the O
protein O
and O
the O
mRNA O
encoding O
it O
are O
identical O
to O
the O
classical B-protein
vitamin I-protein
D I-protein
receptor I-protein
. O

Comparison O
of O
constitutive O
and O
inducible O
transcriptional O
enhancement O
mediated O
by O
kappa O
B O
- O
related O
sequences O
: O
modulation O
of O
activity O
in O
B O
cells O
by O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
tax O
gene O
. O

The O
kappa O
B O
sequence O
( O
GGGACTTTCC O
) O
binds O
a O
factor O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
that O
is O
constitutively O
found O
in O
its O
functional O
, O
DNA O
binding O
form O
only O
in O
B O
lymphocytes O
. O

A O
factor O
with O
apparently O
indistinguishable O
sequence O
specificity O
can O
be O
induced O
in O
many O
other O
cell O
types O
, O
where O
it O
is O
used O
to O
regulate O
inducible O
gene O
expression O
. O

For O
example O
, O
kappa O
B O
- O
related O
sequences O
have O
been O
shown O
to O
be O
important O
for O
the O
transcription O
of O
a O
few O
inducible O
genes O
, O
such O
as O
the O
interleukin B-protein
2 I-protein
receptor I-protein
alpha I-protein
- I-protein
chain I-protein
gene O
and O
the O
beta B-protein
- I-protein
interferon I-protein
gene O
. O

However O
, O
these O
genes O
are O
not O
constitutively O
active O
in O
B O
lymphocytes O
, O
suggesting O
that O
other O
regulatory O
mechanisms O
must O
play O
a O
role O
in O
determining O
the O
patterns O
of O
expression O
. O

We O
have O
investigated O
the O
constitutive O
and O
inducible O
transcriptional O
activity O
mediated O
by O
five O
kappa O
B O
- O
related O
sequence O
elements O
in O
two O
different O
cell O
types O
. O

We O
show O
that O
in O
S194 O
plasma O
cells O
the O
activity O
of O
each O
element O
correlates O
well O
with O
the O
relative O
affinity O
of O
B B-protein
- I-protein
cell I-protein
- I-protein
derived I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
for O
that O
element O
. O

This O
leads O
to O
significantly O
lower O
transcription O
enhancement O
by O
sites O
derived O
from O
the O
interleukin B-protein
2 I-protein
receptor I-protein
or O
T O
- O
cell O
receptor O
genes O
in O
S194 O
cells O
. O

However O
, O
in O
either O
EL O
- O
4 O
( O
T O
) O
cells O
or O
S194 O
cells O
, O
both O
lower O
- O
affinity O
sites O
can O
be O
significantly O
induced O
by O
the O
tax B-protein
gene I-protein
product I-protein
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
, O
showing O
that O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
can O
be O
modulated O
even O
in O
a O
B O
- O
cell O
line O
that O
constitutively O
expresses O
this O
factor O
. O

Specific O
depletion O
of O
the O
B O
- O
cell O
population O
induced O
by O
aberrant O
expression O
of O
human B-protein
interferon I-protein
regulatory I-protein
factor I-protein
1 I-protein
gene O
in O
transgenic O
mice O
. O

Interferons B-protein
( O
IFNs B-protein
) O
are O
well O
known O
both O
as O
antiviral B-protein
proteins I-protein
and O
as O
potent O
regulators O
of O
cell O
growth O
and O
differentiation O
. O

In O
fact O
, O
IFNs B-protein
inhibit O
growth O
of O
various O
normal O
and O
transformed O
cell O
types O
. O

Previously O
, O
a O
nuclear B-protein
factor I-protein
, O
IRF B-protein
- I-protein
1 I-protein
( O
interferon B-protein
regulatory I-protein
factor I-protein
1 I-protein
) O
, O
which O
binds O
to O
type O
I O
IFN O
and O
some O
IFN B-protein
- O
inducible O
gene O
promoters O
, O
was O
identified O
and O
cloned O
. O

Since O
the O
IRF B-protein
- I-protein
1 I-protein
gene O
is O
both O
virus O
and O
IFN B-protein
inducible O
, O
an O
intriguing O
issue O
is O
raised O
as O
to O
whether O
the O
IRF B-protein
- I-protein
1 I-protein
gene O
is O
functioning O
in O
IFN B-protein
- O
mediated O
regulation O
of O
cell O
growth O
and O
differentiation O
. O

In O
this O
study O
, O
we O
generated O
transgenic O
mice O
carrying O
the O
human O
IRF B-protein
- I-protein
1 I-protein
gene O
linked O
to O
the O
human B-protein
immunoglobulin I-protein
heavy I-protein
- I-protein
chain I-protein
enhancer O
. O

In O
the O
transgenic O
mice O
, O
all O
the O
lymphoid O
tissues O
examined O
showed O
a O
dramatic O
reduction O
in O
the O
number O
of O
B O
lymphocytes O
( O
B O
cells O
) O
. O

Preparation O
and O
analysis O
of O
bone O
marrow O
cells O
from O
the O
chimeric O
mice O
indicated O
that O
the O
bone O
marrow O
is O
the O
effective O
site O
for O
specific O
depletion O
of O
the O
B O
- O
cell O
population O
. O

In O
fact O
, O
transgenic O
bone O
marrow O
cells O
cocultured O
with O
a O
bone O
marrow O
- O
derived O
stromal O
cell O
line O
revealed O
an O
altered O
B O
- O
cell O
maturation O
pattern O
. O

Characterization O
of O
a O
cofactor B-protein
that O
regulates O
dimerization O
of O
a O
mammalian B-protein
homeodomain I-protein
protein I-protein
. O

Dimerization O
among O
transcription B-protein
factors I-protein
has O
become O
a O
recurrent O
theme O
in O
the O
regulation O
of O
eukaryotic O
gene O
expression O
. O

Hepatocyte B-protein
nuclear I-protein
factor I-protein
- I-protein
1 I-protein
alpha I-protein
( O
HNF B-protein
- I-protein
1 I-protein
alpha I-protein
) O
is O
a O
homeodomain B-protein
- I-protein
containing I-protein
protein I-protein
that O
functions O
as O
a O
dimer B-protein
. O

A O
dimerization B-protein
cofactor I-protein
of O
HNF B-protein
- I-protein
1 I-protein
alpha I-protein
( O
DCoH B-protein
) O
was O
identified O
that O
displayed O
a O
restricted O
tissue O
distribution O
and O
did O
not O
bind O
to O
DNA O
, O
but O
, O
rather O
, O
selectively O
stabilized O
HNF B-protein
- I-protein
1 I-protein
alpha I-protein
dimers I-protein
. O

The O
formation O
of O
a O
stable O
tetrameric B-protein
DCoH I-protein
- I-protein
HNF I-protein
- I-protein
1 I-protein
alpha I-protein
complex I-protein
, O
which O
required O
the O
dimerization B-protein
domain I-protein
of O
HNF B-protein
- I-protein
1 I-protein
alpha I-protein
, O
did O
not O
change O
the O
DNA O
binding O
characteristics O
of O
HNF B-protein
- I-protein
1 I-protein
alpha I-protein
, O
but O
enhanced O
its O
transcriptional O
activity O
. O

However O
, O
DCoH B-protein
did O
not O
confer O
transcriptional O
activation O
to O
the O
GAL4 B-protein
DNA I-protein
binding I-protein
domain I-protein
. O

These O
results O
indicate O
that O
DCoH B-protein
regulates O
formation O
of O
transcriptionally O
active O
tetrameric B-protein
complexes I-protein
and O
may O
contribute O
to O
the O
developmental B-protein
specificity I-protein
of O
the O
complex B-protein
. O

Glucocorticoid O
resistance O
in O
chronic O
asthma O
. O

Glucocorticoid O
pharmacokinetics O
, O
glucocorticoid B-protein
receptor I-protein
characteristics O
, O
and O
inhibition O
of O
peripheral O
blood O
T O
cell O
proliferation O
by O
glucocorticoids O
in O
vitro O
. O

A O
total O
of O
37 O
chronic O
, O
severe O
, O
nonsmoking O
asthmatic O
patients O
with O
documented O
reversible O
airways O
obstruction O
were O
classified O
as O
glucocorticoid O
- O
sensitive O
or O
- O
resistant O
on O
the O
basis O
of O
changes O
in O
FEV1 O
, O
FVC O
, O
and O
peak O
expiratory O
flow O
( O
PEF O
) O
after O
oral O
prednisolone O
. O

The O
resistant O
patients O
showed O
no O
significant O
improvements O
in O
airflow O
limitation O
. O

Phytohemagglutinin B-protein
( O
PHA B-protein
) O
- O
induced O
proliferation O
of O
peripheral O
blood O
T O
lymphocytes O
from O
the O
sensitive O
but O
not O
the O
resistant O
asthmatic O
patients O
was O
significantly O
( O
p O
less O
than O
0 O
. O
01 O
) O
inhibited O
by O
dexamethasone O
( O
10 O
( O
- O
7 O
) O
mol O
/ O
L O
) O
, O
reflecting O
a O
shift O
of O
the O
dose O
- O
response O
curve O
. O

When O
all O
the O
asthmatic O
patients O
were O
analyzed O
together O
, O
there O
was O
a O
significant O
correlation O
between O
the O
degree O
of O
sensitivity O
of O
T O
cells O
to O
dexamethasone O
and O
the O
clinical O
responsiveness O
to O
prednisolone O
( O
p O
less O
than O
0 O
. O
01 O
) O
. O

No O
differences O
were O
observed O
between O
six O
of O
the O
sensitive O
and O
resistant O
patients O
in O
the O
clearance O
of O
plasma O
prednisolone O
derived O
from O
orally O
administered O
prednisone O
. O

Peripheral O
blood O
mononuclear O
cell O
glucocorticoid B-protein
receptors I-protein
were O
also O
characterized O
in O
five O
sensitive O
and O
seven O
resistant O
patients O
. O

The O
numbers O
and O
binding O
affinities O
of O
these O
receptors B-protein
could O
not O
account O
for O
the O
observed O
difference O
in O
the O
susceptibility O
of O
these O
cells O
to O
functional O
inhibition O
by O
dexamethasone O
in O
vitro O
. O

These O
results O
suggest O
that O
clinical O
glucocorticoid O
resistance O
in O
chronic O
asthma O
does O
not O
reflect O
abnormal O
glucocorticoid O
clearance O
but O
may O
be O
due O
at O
least O
partly O
to O
a O
relative O
insensitivity O
of O
T O
lymphocytes O
to O
glucocorticoids O
. O

This O
lack O
of O
sensitivity O
is O
unexplained O
but O
is O
not O
attributable O
to O
abnormalities O
of O
cellular B-protein
glucocorticoid I-protein
receptors I-protein
. O

Inhibition O
of O
phorbol O
ester O
- O
induced O
monocytic O
differentiation O
by O
dexamethasone O
is O
associated O
with O
down O
- O
regulation O
of O
c O
- O
fos O
and O
c O
- O
jun O
( O
AP O
- O
1 O
) O
. O

Previous O
studies O
have O
shown O
that O
treatment O
of O
human O
myeloid O
leukemia O
cells O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
is O
associated O
with O
induction O
of O
monocytic O
differentiation O
and O
expression O
of O
the O
c O
- O
jun O
and O
c O
- O
fos O
early O
response O
genes O
. O

The O
present O
work O
demonstrates O
that O
the O
glucocorticoid O
dexamethasone O
inhibits O
TPA O
- O
induced O
increases O
in O
c O
- O
jun O
and O
c O
- O
fos O
mRNA O
levels O
in O
U O
- O
937 O
leukemia O
cells O
. O

These O
findings O
were O
associated O
with O
a O
block O
in O
appearance O
of O
the O
monocytic O
phenotype O
, O
including O
inhibition O
of O
TPA O
- O
induced O
increases O
in O
lamin O
A O
, O
lamin O
C O
, O
and O
vimentin O
transcripts O
. O

Other O
studies O
have O
demonstrated O
that O
TPA O
- O
induced O
monocytic O
differentiation O
and O
expression O
of O
the O
c O
- O
jun O
and O
c O
- O
fos O
genes O
in O
myeloid O
leukemia O
cells O
are O
regulated O
by O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
. O

The O
finding O
that O
dexamethasone O
has O
no O
effect O
on O
TPA O
- O
induced O
activation O
of O
PKC B-protein
suggests O
that O
this O
glucocorticoid O
inhibits O
signals O
downstream O
or O
parallel O
to O
this O
enzyme B-protein
. O

Nuclear O
run O
- O
on O
assays O
demonstrate O
that O
: O
( O
1 O
) O
induction O
of O
c O
- O
jun O
and O
c O
- O
fos O
expression O
by O
TPA O
is O
regulated O
by O
transcriptional O
mechanisms O
, O
( O
2 O
) O
TPA O
- O
induced O
expression O
of O
c O
- O
jun O
and O
c B-protein
- I-protein
fos I-protein
does O
not O
require O
protein O
synthesis O
, O
and O
( O
3 O
) O
TPA O
- O
induced O
expression O
of O
both O
genes O
is O
inhibited O
at O
the O
transcriptional O
level O
by O
dexamethasone O
. O

To O
further O
define O
the O
effects O
of O
dexamethasone O
at O
the O
molecular O
level O
, O
we O
prepared O
a O
series O
of O
deleted O
c O
- O
jun O
promoter O
fragments O
linked O
to O
the O
chloramphenicol B-protein
acetyltransferase I-protein
( O
CAT B-protein
) O
gene O
. O

Increases O
in O
CAT B-protein
activity O
during O
transient O
expression O
of O
these O
constructs O
in O
TPA O
- O
treated O
U O
- O
937 O
cells O
could O
be O
assigned O
to O
the O
region O
( O
- O
97 O
to O
- O
20 O
) O
of O
the O
promoter O
that O
contains O
the O
AP O
- O
1 O
binding O
site O
. O

This O
induction O
of O
CAT B-protein
activity O
was O
sensitive O
to O
dexamethasone O
. O

These O
findings O
suggest O
that O
dexamethasone O
down O
- O
regulates O
TPA O
- O
induced O
transcription O
of O
the O
c O
- O
jun O
gene O
during O
monocytic O
differentiation O
by O
inhibiting O
activation O
of O
the O
AP O
- O
1 O
site O
. O

Tumor O
necrosis O
factor O
- O
alpha O
mRNA O
accumulation O
in O
human O
myelomonocytic O
cell O
lines O
. O

Role O
of O
transcriptional O
regulation O
by O
DNA O
sequence O
motifs O
and O
mRNA O
stabilization O
. O

The O
cytokine B-protein
TNF B-protein
mediates O
many O
of O
the O
pathologic O
signs O
of O
cachexia O
, O
inflammation O
, O
and O
sepsis O
. O

The O
current O
work O
describes O
the O
regulation O
of O
TNF B-protein
in O
human O
myelomonocytic O
cell O
lines O
after O
PMA O
stimulation O
. O

The O
cell O
lines O
exhibit O
a O
low O
level O
of O
constitutive O
TNF B-protein
mRNA O
expression O
. O

Within O
2 O
to O
4 O
h O
of O
PMA O
exposure O
, O
steady O
state O
levels O
of O
TNF B-protein
mRNA O
are O
markedly O
elevated O
in O
all O
myelomonocytic O
cell O
lines O
studied O
. O

This O
rise O
is O
due O
to O
increased O
mRNA O
stability O
, O
which O
increased O
by O
almost O
twofold O
, O
and O
to O
an O
overall O
increase O
in O
transcription O
, O
which O
rises O
by O
more O
than O
sixfold O
. O

At O
the O
level O
of O
the O
genomic O
TNF B-protein
gene O
, O
a O
DNase O
I O
hypersensitive O
site O
is O
detected O
within O
the O
TNF B-protein
promoter O
between O
- O
200 O
to O
- O
100 O
bp O
relative O
to O
the O
transcription O
initiation O
site O
. O

Although O
absent O
in O
nonexpressing O
erythroleukemia O
cell O
lines O
, O
the O
DNase O
I O
site O
is O
present O
in O
uninduced O
myelomonocytic O
cell O
lines O
and O
is O
not O
changed O
after O
PMA O
induction O
. O

The O
PMA O
induction O
of O
c O
- O
fos O
mRNA O
correlated O
well O
with O
TNF B-protein
gene O
induction O
; O
expression O
of O
genes O
encoding O
other O
proteins O
in O
the O
AP B-protein
- I-protein
1 I-protein
complex I-protein
( O
junB B-protein
and O
junD B-protein
) O
were O
also O
induced O
by O
PMA O
. O

The O
nuclear O
extracts O
from O
resting O
and O
induced O
ML O
- O
1 O
cells O
contain O
proteins O
binding O
specifically O
to O
the O
AP O
- O
1 O
, O
AP O
- O
2 O
, O
and O
NF O
kappa O
B O
sequence O
located O
within O
the O
TNF B-protein
promoter O
. O

PMA O
induction O
increases O
the O
level O
of O
a O
number O
of O
specific B-protein
binding I-protein
complexes I-protein
relative O
to O
the O
resting O
cells O
. O

The O
regulatory O
mechanisms O
of O
the O
human O
and O
murine O
TNF O
genes O
are O
discussed O
. O

Enhancement O
of O
human O
immunodeficiency O
virus O
1 O
replication O
in O
monocytes O
by O
1 O
, O
25 O
- O
dihydroxycholecalciferol O
. O

Human O
immunodeficiency O
virus O
( O
HIV O
) O
expression O
and O
replication O
are O
under O
tight O
regulatory O
control O
. O

We O
demonstrate O
that O
1 O
, O
25 O
- O
dihydroxycholecalciferol O
[ O
1 O
, O
25 O
- O
( O
OH O
) O
2D3 O
] O
enhances O
the O
replication O
of O
monocyte O
- O
and O
lymphocyte O
- O
tropic O
strains O
of O
HIV O
- O
1 O
up O
to O
10 O
, O
000 O
- O
fold O
in O
monocyte O
cell O
lines O
, O
peripheral O
blood O
monocytes O
, O
and O
unfractionated O
peripheral O
blood O
mononuclear O
cells O
. O

1 O
, O
25 O
( O
OH O
) O
2D3 O
is O
therefore O
one O
of O
the O
most O
potent O
regulators O
of O
HIV O
- O
1 O
replication O
described O
to O
date O
. O

Precursors O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
enhance O
HIV O
- O
1 O
replication O
in O
proportion O
to O
their O
affinity O
for O
the O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
intracellular I-protein
receptor I-protein
, O
suggesting O
that O
1 O
, O
25 O
( O
OH O
) O
2D3 O
influences O
HIV O
- O
1 O
replication O
by O
mechanisms O
involving O
this O
receptor O
. O

These O
studies O
may O
have O
important O
implications O
for O
the O
design O
of O
effective O
therapy O
of O
HIV O
- O
1 O
infection O
. O

Transforming B-protein
growth I-protein
factor I-protein
- I-protein
beta I-protein
suppresses O
human B-protein
B I-protein
lymphocyte I-protein
Ig I-protein
production O
by O
inhibiting O
synthesis O
and O
the O
switch O
from O
the O
membrane O
form O
to O
the O
secreted O
form O
of O
Ig O
mRNA O
. O

Transforming B-protein
growth I-protein
factor I-protein
- I-protein
beta I-protein
( O
TGF B-protein
- I-protein
beta I-protein
) O
inhibits O
B O
cell O
Ig B-protein
secretion O
and O
reduces O
B O
cell O
membrane O
Ig B-protein
expression O
. O

The O
addition O
of O
TGF B-protein
- I-protein
beta I-protein
to O
human O
B O
lymphocyte O
cultures O
stimulated O
with O
Staphylococcus O
aureus O
Cowan O
strain O
I O
and O
IL B-protein
- I-protein
2 I-protein
completely O
inhibited O
B O
cell O
Ig B-protein
secretion O
( O
greater O
than O
90 O
% O
) O
and O
decreased O
B O
cell O
surface O
IgM O
, O
IgD O
, O
kappa O
L O
chain O
, O
and O
lambda O
L O
chain O
expression O
. O

In O
contrast O
, O
TGF B-protein
- I-protein
beta I-protein
had O
only O
minimal O
effects O
on O
two O
other O
B B-protein
cell I-protein
membrane I-protein
proteins I-protein
, O
HLA B-protein
- I-protein
DR I-protein
and O
CD20 B-protein
. O

Internal O
labeling O
with O
[ O
35S O
] O
methionine O
and O
immunoprecipitation O
with O
anti B-protein
- I-protein
IgM I-protein
, O
anti B-protein
- I-protein
kappa I-protein
, O
and O
anti B-protein
- I-protein
lambda I-protein
antibodies I-protein
revealed O
a O
striking O
reduction O
in O
kappa B-protein
L I-protein
chain I-protein
in O
the O
presence O
of O
TGF B-protein
- I-protein
beta I-protein
. O

A O
less O
pronounced O
reduction O
in O
lambda B-protein
L I-protein
chain I-protein
and O
microH B-protein
chain I-protein
was O
also O
noted O
. O

Northern O
blot O
analysis O
of O
RNA O
purified O
from O
B O
cells O
treated O
with O
TGF B-protein
- I-protein
beta I-protein
for O
varying O
time O
intervals O
revealed O
a O
significant O
decrease O
in O
steady O
state O
kappa O
and O
lambda O
L O
chain O
mRNA O
levels O
. O

Furthermore O
, O
a O
significant O
decrease O
in O
the O
switch O
from O
the O
membrane O
forms O
of O
mu O
and O
gamma O
to O
their O
respective O
secreted O
forms O
was O
noted O
in O
the O
presence O
of O
TGF B-protein
- I-protein
beta I-protein
. O

Nuclear O
run O
- O
on O
experiments O
demonstrated O
decreased O
transcription O
of O
kappa B-protein
L I-protein
chain I-protein
. O

The O
effects O
of O
TGF B-protein
- I-protein
beta I-protein
on O
two O
transcriptional B-protein
regulatory I-protein
factors I-protein
, O
Oct B-protein
- I-protein
2 I-protein
and O
nuclear B-protein
factor I-protein
( I-protein
NF I-protein
) I-protein
kappa I-protein
B I-protein
, O
known O
to O
be O
important O
in O
Ig B-protein
gene O
transcription O
were O
examined O
. O

Oct B-protein
- I-protein
2 I-protein
mRNA O
levels O
and O
both O
Oct B-protein
- I-protein
2 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
proteins I-protein
in O
nuclear O
extracts O
were O
not O
altered O
by O
treatment O
with O
TGF B-protein
- I-protein
beta I-protein
. O

In O
contrast O
, O
levels O
of O
the O
transcriptional B-protein
factor I-protein
AP I-protein
- I-protein
1 I-protein
, O
which O
is O
not O
known O
to O
be O
important O
in O
B O
cell O
Ig B-protein
production O
, O
were O
reduced O
by O
TGF B-protein
- I-protein
beta I-protein
. O

These O
findings O
demonstrate O
that O
TGF B-protein
- I-protein
beta I-protein
decreases O
B O
lymphocyte O
Ig B-protein
secretion O
by O
inhibiting O
the O
synthesis O
of O
Ig O
mRNA O
and O
inhibiting O
the O
switch O
from O
the O
membrane O
form O
to O
the O
secreted O
forms O
of O
mu O
and O
gamma O
mRNA O
. O

The O
mechanism O
by O
which O
TGF B-protein
- I-protein
beta I-protein
inhibits O
Ig O
chain O
synthesis O
is O
unclear O
although O
it O
does O
not O
involve O
inhibition O
of O
the O
binding O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
or O
Oct B-protein
- I-protein
2 I-protein
to O
their O
respective O
target O
sequences O
. O

Murine O
and O
human O
T O
- O
lymphocyte O
GATA O
- O
3 O
factors O
mediate O
transcription O
through O
a O
cis O
- O
regulatory O
element O
within O
the O
human O
T O
- O
cell O
receptor O
delta O
gene O
enhancer O
. O

A O
family O
of O
transcriptional B-protein
activators I-protein
has O
recently O
been O
identified O
in O
chickens O
; O
these O
transcriptional B-protein
activators I-protein
recognize O
a O
common O
consensus O
motif O
( O
WGATAR O
) O
through O
a O
conserved O
C4 B-protein
zinc I-protein
finger I-protein
DNA I-protein
- I-protein
binding I-protein
domain I-protein
. O

One O
of O
the O
members O
of O
this O
multigene O
family O
, O
cGATA B-protein
- I-protein
3 I-protein
, O
is O
most O
abundantly O
expressed O
in O
the O
T O
- O
lymphocyte O
cell O
lineage O
. O

Analysis O
of O
human O
and O
murine O
GATA O
- O
3 O
factors O
shows O
a O
striking O
degree O
of O
amino B-protein
acid I-protein
sequence I-protein
identity O
and O
similar O
patterns O
of O
tissue O
specificity O
of O
expression O
in O
these O
three O
organisms O
. O

The O
murine O
and O
human O
factors O
are O
abundantly O
expressed O
in O
a O
variety O
of O
human O
and O
murine O
T O
- O
cell O
lines O
and O
can O
activate O
transcription O
through O
a O
tissue O
- O
specific O
GATA O
- O
binding O
site O
identified O
within O
the O
human O
T O
- O
cell O
receptor O
delta O
gene O
enhancer O
. O

We O
infer O
that O
the O
murine O
and O
human O
GATA O
- O
3 O
proteins O
play O
a O
central O
and O
highly O
conserved O
role O
in O
vertebrate O
T O
- O
cell O
- O
specific O
transcriptional O
regulation O
. O

Processing O
of O
the O
precursor O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
by O
the O
HIV B-protein
- I-protein
1 I-protein
protease I-protein
during O
acute O
infection O
. O

Transcription O
of O
the O
human O
immunodeficiency O
virus O
type O
- O
1 O
( O
HIV O
- O
1 O
) O
genome O
is O
regulated O
in O
part O
by O
cellular B-protein
factors I-protein
and O
is O
stimulated O
by O
activation O
of O
latently O
infected O
T O
cells O
. O

T O
- O
cell O
activation O
also O
correlates O
with O
the O
induction O
of O
the O
factor O
NF B-protein
- I-protein
kappa I-protein
B I-protein
which O
binds O
to O
two O
adjacent O
sites O
in O
the O
HIV O
- O
1 O
long O
terminal O
repeat O
. O

This O
factor O
consists O
of O
two O
DNA B-protein
- I-protein
binding I-protein
subunits I-protein
of O
relative O
molecular O
mass O
50 O
, O
000 O
( O
50K O
) O
associated O
with O
two O
65K B-protein
subunits I-protein
. O

It O
is O
located O
in O
the O
nucleus O
in O
mature O
B O
cells O
, O
but O
is O
present O
in O
other O
cell O
types O
as O
an O
inactive B-protein
cytoplasmic I-protein
complex I-protein
. O

External O
stimuli O
, O
including O
those O
that O
activate O
T O
cells O
, O
result O
in O
nuclear O
translocation O
of O
active O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

The O
cloning O
of O
the O
complementary O
DNA O
for O
the O
50K B-protein
subunit I-protein
helped O
to O
identify O
an O
exclusively O
cytoplasmic B-protein
105K I-protein
precursor I-protein
( O
p105 B-protein
) O
( O
V O
. O
B O
. O
, O
P O
. O
K O
. O
and O
A O
. O
I O
. O
, O
manuscript O
submitted O
) O
. O

The O
expression O
of O
active O
NF B-protein
- I-protein
kappa I-protein
B I-protein
might O
therefore O
also O
be O
regulated O
by O
the O
extent O
of O
processing O
of O
p105 B-protein
. O

Because O
HIV O
- O
1 O
requires O
active O
NF B-protein
- I-protein
kappa I-protein
B I-protein
for O
efficient O
transcription O
, O
we O
tested O
the O
effect O
of O
HIV O
- O
1 O
infection O
on O
the O
processing O
of O
the O
human B-protein
105K I-protein
precursor I-protein
. O

We O
show O
here O
that O
the O
HIV O
- O
1 O
protease O
can O
process O
p105 B-protein
and O
increases O
levels O
of O
active O
nuclear B-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
complex I-protein
. O

1 B-protein
, I-protein
25 I-protein
- I-protein
Dihydroxyvitamin I-protein
D3 I-protein
receptor I-protein
RNA O
: O
expression O
in O
hematopoietic O
cells O
. O

1 O
, O
25 O
- O
Dihydroxyvitamin O
D3 O
[ O
1 O
, O
25 O
( O
OH O
) O
2D3 O
] O
induces O
differentiation O
and O
inhibits O
proliferation O
of O
myeloid O
leukemic O
cells O
from O
various O
lines O
and O
patients O
; O
these O
effects O
are O
probably O
mediated O
through O
the O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
. O

Little O
is O
known O
of O
expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
in O
hematopoietic O
cells O
. O

We O
examined O
the O
expression O
and O
modulation O
of O
expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
in O
various O
proliferating O
and O
nonproliferating O
hematopoietic O
cells O
. O

Constitutive O
expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
was O
detected O
in O
various O
kinds O
of O
hematopoietic O
cells O
, O
including O
macrophages O
and O
activated O
T O
lymphocytes O
, O
as O
well O
as O
in O
cell O
lines O
KG O
- O
1 O
( O
myeloblasts O
) O
, O
HL O
- O
60 O
( O
promyelocytes O
) O
, O
ML O
- O
3 O
( O
myelomonoblasts O
) O
, O
U937 O
, O
THP O
- O
1 O
( O
monoblasts O
) O
, O
K562 O
( O
erythroblasts O
) O
, O
and O
S O
- O
LB1 O
( O
HTLV O
- O
1 O
- O
transfected O
T O
lymphocytes O
) O
. O

Receptor O
transcripts O
were O
4 O
. O
6 O
kilobases O
( O
kb O
) O
, O
and O
no O
variant O
sizes O
were O
observed O
. O

All O
cell O
lines O
examined O
in O
this O
group O
also O
expressed O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
. O

Most O
B O
lymphocyte O
lines O
expressed O
negligible O
levels O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
and O
protein O
; O
however O
; O
analysis O
of O
a O
lymphoid O
/ O
myeloid O
somatic O
hybrid O
suggested O
that O
suppression O
of O
expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
in O
B O
lymphocytes O
may O
be O
a O
dominant O
characteristic O
. O

HL O
- O
60 O
cells O
were O
cultured O
with O
10 O
( O
- O
7 O
) O
mol O
/ O
L O
1 O
, O
25 O
( O
OH O
) O
2D3 O
for O
24 O
to O
72 O
hours O
, O
and O
levels O
of O
expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
and O
its O
RNA O
were O
examined O
. O

Levels O
of O
RNA O
coding O
for O
the O
receptor B-protein
were O
not O
modulated O
by O
exposure O
to O
high O
levels O
of O
ligand O
. O

Levels O
of O
occupied O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
protein I-protein
increased O
in O
these O
HL O
- O
60 O
cells O
; O
but O
the O
total O
number O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
decreased O
about O
50 O
% O
at O
24 O
hours O
and O
returned O
toward O
normal O
at O
72 O
hours O
. O

Steady O
- O
state O
levels O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
were O
not O
affected O
by O
terminal O
differentiation O
of O
HL O
- O
60 O
toward O
either O
granulocytes O
or O
macrophages O
. O

Nondividing O
macrophages O
from O
normal O
individuals O
also O
expressed O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
. O

In O
contrast O
, O
nondividing O
peripheral O
blood O
lymphocytes O
from O
normal O
individuals O
did O
not O
express O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
; O
with O
stimulation O
of O
proliferation O
of O
these O
cells O
, O
accumulation O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
increased O
markedly O
. O

Half O
- O
life O
( O
t1 O
/ O
2 O
) O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
in O
T O
lymphocytes O
was O
short O
( O
1 O
hour O
) O
as O
determined O
by O
measuring O
decay O
of O
the O
message O
after O
addition O
of O
actinomycin O
D O
. O

Consistent O
with O
this O
short O
t1 O
/ O
2 O
, O
accumulation O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptor I-protein
RNA O
increased O
in O
cells O
as O
their O
protein O
synthesis O
was O
inhibited O
. O

Further O
studies O
are O
required O
to O
understand O
the O
physiologic O
role O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
in O
myeloid O
cells O
and O
proliferating O
T O
lymphocytes O
. O

Expression O
of O
c O
- O
jun O
, O
jun O
B O
and O
jun O
D O
proto O
- O
oncogenes O
in O
human O
peripheral O
- O
blood O
granulocytes O
. O

We O
have O
found O
that O
purified O
human O
peripheral O
- O
blood O
granulocytes O
express O
constitutively O
significant O
levels O
of O
proto O
- O
oncogenes O
c O
- O
jun O
, O
jun O
B O
and O
jun O
D O
mRNA O
. O

Upon O
functional O
activation O
of O
granulocytes O
by O
4 O
beta O
- O
phorbol O
12 O
- O
myristate O
13 O
- O
acetate O
( O
PMA O
) O
, O
the O
levels O
of O
c O
- O
jun O
, O
jun O
B O
and O
jun O
D O
transcripts O
were O
increased O
. O

The O
three O
jun O
genes O
showed O
a O
similar O
time O
course O
in O
their O
induction O
by O
PMA O
, O
maximal O
mRNA O
levels O
being O
reached O
after O
60 O
min O
of O
induction O
. O

These O
results O
suggest O
that O
expression O
of O
c O
- O
jun O
, O
jun O
B O
and O
jun O
D O
genes O
might O
be O
involved O
in O
terminal O
granulocyte O
differentiation O
or O
in O
regulating O
granulocyte O
functionality O
. O

The O
29 B-protein
- I-protein
kDa I-protein
proteins I-protein
phosphorylated O
in O
thrombin O
- O
activated O
human O
platelets O
are O
forms O
of O
the O
estrogen B-protein
receptor I-protein
- I-protein
related I-protein
27 I-protein
- I-protein
kDa I-protein
heat I-protein
shock I-protein
protein I-protein
. O

Thrombin B-protein
plays O
a O
critical O
role O
in O
platelet O
activation O
, O
hemostasis O
, O
and O
thrombosis O
. O

Cellular O
activation O
by O
thrombin O
leads O
to O
the O
phosphorylation O
of O
multiple B-protein
proteins I-protein
, O
most O
of O
which O
are O
unidentified O
. O

We O
have O
characterized O
several O
29 B-protein
- I-protein
kDa I-protein
proteins I-protein
that O
are O
rapidly O
phosphorylated O
following O
exposure O
of O
intact O
human O
platelets O
to O
thrombin B-protein
. O

A O
murine B-protein
monoclonal I-protein
antibody I-protein
raised O
to O
an O
unidentified B-protein
estrogen I-protein
receptor I-protein
- I-protein
related I-protein
29 I-protein
- I-protein
kDa I-protein
protein I-protein
selectively O
recognized O
these O
proteins O
as O
well O
as O
a O
more O
basic O
, O
unphosphorylated B-protein
27 I-protein
- I-protein
kDa I-protein
protein I-protein
. O

Cellular O
activation O
by O
thrombin B-protein
led O
to O
a O
marked O
shift O
in O
the O
proportion O
of O
protein O
from O
the O
27 B-protein
- I-protein
kDa I-protein
unphosphorylated I-protein
form I-protein
to O
the O
29 B-protein
- I-protein
kDa I-protein
phosphoprotein I-protein
species I-protein
. O

Using O
this O
antibody O
, O
we O
isolated O
and O
sequenced O
a O
human O
cDNA O
clone O
encoding O
a O
protein O
that O
was O
identical O
to O
the O
mammalian B-protein
27 I-protein
- I-protein
kDa I-protein
heat I-protein
shock I-protein
protein I-protein
( O
HSP27 B-protein
) O
, O
a O
protein O
of O
uncertain O
function O
that O
is O
known O
to O
be O
phosphorylated O
to O
several O
forms O
and O
to O
be O
transcriptionally O
induced O
by O
estrogen O
. O

The O
29 B-protein
- I-protein
kDa I-protein
proteins I-protein
were O
confirmed O
to O
be O
phosphorylated O
forms O
of O
HSP27 B-protein
by O
immunoprecipitation O
studies O
. O

Thus O
, O
the O
" O
estrogen O
receptor O
- O
related O
protein O
" O
is O
HSP27 B-protein
, O
and O
the O
three O
major O
29 B-protein
- I-protein
kDa I-protein
proteins I-protein
phosphorylated O
in O
thrombin B-protein
- O
activated O
platelets O
are O
forms O
of O
HSP27 B-protein
. O

These O
data O
suggest O
a O
role O
for O
HSP27 B-protein
in O
the O
signal O
transduction O
events O
of O
platelet O
activation O
. O

Isolation O
of O
a O
candidate O
repressor O
/ O
activator O
, O
NF B-protein
- I-protein
E1 I-protein
( O
YY B-protein
- I-protein
1 I-protein
, O
delta B-protein
) O
, O
that O
binds O
to O
the O
immunoglobulin O
kappa O
3 O
' O
enhancer O
and O
the O
immunoglobulin O
heavy O
- O
chain O
mu O
E1 O
site O
. O

We O
have O
determined O
that O
the O
developmental O
control O
of O
immunoglobulin O
kappa O
3 O
' O
enhancer O
( O
kappa O
E3 O
' O
) O
activity O
is O
the O
result O
of O
the O
combined O
influence O
of O
positive O
- O
and O
negative O
- O
acting O
elements O
. O

We O
show O
that O
a O
central O
core O
in O
the O
kappa O
E3 O
' O
enhancer O
is O
active O
at O
the O
pre O
- O
B O
- O
cell O
stage O
but O
is O
repressed O
by O
flanking O
negative O
- O
acting O
elements O
. O

The O
negative O
- O
acting O
sequences O
repress O
enhancer O
activity O
in O
a O
position O
- O
and O
orientation O
- O
independent O
manner O
at O
the O
pre O
- O
B O
- O
cell O
stage O
. O

We O
have O
isolated O
a O
human O
cDNA O
clone O
encoding O
a O
zinc B-protein
finger I-protein
protein I-protein
( O
NF B-protein
- I-protein
E1 I-protein
) O
that O
binds O
to O
the O
negative O
- O
acting O
segment O
of O
the O
kappa O
E3 O
' O
enhancer O
. O

This O
protein O
also O
binds O
to O
the O
immunoglobulin O
heavy O
- O
chain O
enhancer O
mu O
E1 O
site O
. O

NF B-protein
- I-protein
E1 I-protein
is O
encoded O
by O
the O
same O
gene O
as O
the O
YY B-protein
- I-protein
1 I-protein
protein I-protein
, O
which O
binds O
to O
the O
adeno O
- O
associated O
virus O
P5 O
promoter O
. O

NF B-protein
- I-protein
E1 I-protein
is O
also O
the O
human B-protein
homologue I-protein
of O
the O
mouse O
delta O
protein O
, O
which O
binds O
to O
ribosomal O
protein O
gene O
promoters O
. O

The O
predicted O
amino B-protein
acid I-protein
sequence I-protein
of O
this O
protein O
contains O
features O
characteristic O
of O
transcriptional B-protein
activators I-protein
as O
well O
as O
transcriptional B-protein
repressors I-protein
. O

Cotransfection O
studies O
with O
this O
cDNA O
indicate O
that O
it O
can O
repress O
basal O
promoter O
activity O
. O

The O
apparent O
dual O
function O
of O
this O
protein O
is O
discussed O
. O

A O
human O
putative O
lymphocyte O
G0 O
/ O
G1 O
switch O
gene O
containing O
a O
CpG O
- O
rich O
island O
encodes O
a O
small B-protein
basic I-protein
protein I-protein
with O
the O
potential O
to O
be O
phosphorylated O
. O

Genes O
actively O
involved O
in O
the O
G0 O
/ O
G1 O
switch O
( O
G0S O
genes O
) O
may O
be O
differentially O
expressed O
during O
the O
lectin B-protein
- O
induced O
switch O
of O
lymphocytes O
from O
the O
G0 O
to O
the O
G1 O
phases O
of O
the O
cell O
cycle O
. O

This O
paper O
presents O
studies O
of O
G0S2 O
, O
a O
member O
of O
a O
set O
of O
putative O
G0S O
genes O
, O
for O
which O
cDNAs O
were O
cloned O
and O
selected O
on O
the O
basis O
of O
differential O
cDNA O
hybridization O
. O

G0S2 O
mRNA O
increases O
transiently O
within O
1 O
- O
2 O
hr O
of O
the O
addition O
of O
lectin B-protein
or O
cycloheximide O
to O
cultured O
blood O
mononuclear O
cells O
. O

Comparison O
of O
a O
nearly O
full O
- O
length O
cDNA O
sequence O
with O
the O
corresponding O
genomic O
sequence O
reveals O
one O
small O
intron O
and O
an O
open O
reading O
frame O
in O
the O
second O
exon O
. O

The O
derived O
103 B-protein
- I-protein
amino I-protein
- I-protein
acid I-protein
basic I-protein
protein I-protein
has O
two O
potential O
alpha B-protein
- I-protein
helical I-protein
domains I-protein
separated O
by O
a O
hydrophobic B-protein
region I-protein
with O
the O
potential O
to O
generate O
turns O
and O
assume O
a O
beta O
- O
sheet O
conformation O
. O

Consistent O
with O
involvement O
in O
the O
G0 O
/ O
G1 O
switch O
, O
the O
protein O
contains O
potential O
sites O
for O
phosphorylation O
by O
protein B-protein
kinase I-protein
C I-protein
and O
casein B-protein
kinase I-protein
II I-protein
. O

The O
gene O
contains O
a O
CpG B-protein
- I-protein
rich I-protein
island I-protein
suggesting O
expression O
in O
the O
germ O
line O
. O

An O
upstream O
segment O
contains O
tandem O
dinucleotide O
repeats O
( O
CT O
) O
19 O
/ O
( O
CA O
) O
16 O
. O

There O
is O
a O
suitably O
located O
TATA O
box O
, O
but O
potential O
sites O
for O
CCAAT B-protein
- I-protein
box I-protein
binding I-protein
factors I-protein
are O
far O
upstream O
, O
embedded O
in O
a O
42 O
- O
nucleotide O
repeat O
element O
. O

Potential O
sites O
for O
transcription B-protein
factors I-protein
AP1 B-protein
, O
AP2 B-protein
, O
and O
AP3 B-protein
are O
consistent O
with O
rapid O
transcriptional O
activation O
in O
response O
to O
inducing O
agents O
. O

USF B-protein
- I-protein
related I-protein
transcription I-protein
factor I-protein
, O
HIV B-protein
- I-protein
TF1 I-protein
, O
stimulates O
transcription O
of O
human O
immunodeficiency O
virus O
- O
1 O
. O

The O
transcription B-protein
factor I-protein
HIV B-protein
- I-protein
TF1 I-protein
, O
which O
binds O
to O
a O
region O
about O
60 O
bp O
upstream O
from O
the O
enhancer O
of O
the O
human O
immunodeficiency O
virus O
- O
1 O
( O
HIV O
- O
1 O
) O
, O
was O
purified O
from O
human O
B O
cells O
. O

HIV B-protein
- I-protein
TF1 I-protein
had O
a O
molecular O
weight O
of O
39 O
, O
000 O
. O

Binding O
of O
HIV B-protein
- I-protein
TF1 I-protein
to O
the O
HIV O
long O
terminal O
repeat O
( O
LTR O
) O
activated O
transcription O
from O
the O
HIV O
promoter O
in O
vitro O
. O

The O
HIV B-protein
- I-protein
TF1 I-protein
- O
binding O
site O
in O
HIV O
LTR O
was O
similar O
to O
the O
site O
recognized O
by O
upstream B-protein
stimulatory I-protein
factor I-protein
( O
USF B-protein
) O
in O
the O
adenovirus O
major O
late O
promoter O
. O

DNA O
- O
binding O
properties O
of O
HIV B-protein
- I-protein
TF1 I-protein
suggested O
that O
HIV B-protein
- I-protein
TF1 I-protein
might O
be O
identical O
or O
related O
to O
USF B-protein
. O

Interestingly O
, O
treatment O
of O
purified O
HIV B-protein
- I-protein
TF1 I-protein
by O
phosphatase B-protein
greatly O
reduced O
its O
DNA O
- O
binding O
activity O
, O
suggesting O
that O
phosphorylation O
of O
HIV B-protein
- I-protein
TF1 I-protein
was O
essential O
for O
DNA O
binding O
. O

The O
disruption O
of O
HIV B-protein
- I-protein
TF1 I-protein
- O
binding O
site O
induced O
a O
60 O
% O
decrease O
in O
the O
level O
of O
transcription O
from O
the O
HIV O
promoter O
in O
vivo O
. O

These O
results O
suggest O
that O
HIV B-protein
- I-protein
TF1 I-protein
is O
involved O
in O
transcriptional O
regulation O
of O
HIV O
- O
1 O
. O

Severe O
5 O
- O
fluorouracil O
toxicity O
secondary O
to O
dihydropyrimidine B-protein
dehydrogenase I-protein
deficiency O
. O

A O
potentially O
more O
common O
pharmacogenetic O
syndrome O
. O

This O
study O
describes O
the O
inheritance O
of O
a O
defect O
in O
pyrimidine O
catabolism O
and O
its O
association O
with O
drug O
- O
induced O
toxicity O
in O
a O
patient O
receiving O
5 O
- O
fluorouracil O
( O
FUra O
) O
as O
adjuvant O
chemotherapy O
for O
breast O
carcinoma O
. O

The O
study O
population O
included O
the O
affected O
patient O
( O
proband O
) O
, O
nine O
of O
her O
blood O
relatives O
, O
and O
seven O
healthy O
volunteers O
. O

The O
activity O
of O
dihydropyrimidine B-protein
dehydrogenase I-protein
( O
DPD B-protein
) O
, O
the O
initial O
enzyme B-protein
of O
pyrimidine O
( O
and O
FUra O
) O
catabolism O
, O
in O
peripheral O
blood O
mononuclear O
cells O
was O
measured O
in O
each O
subject O
by O
a O
specific O
radiometric O
assay O
using O
FUra O
as O
the O
substrate O
. O

The O
proband O
had O
no O
detectable O
DPD B-protein
activity O
. O

When O
enzyme O
levels O
in O
the O
proband O
and O
relatives O
were O
compared O
with O
that O
in O
controls O
, O
an O
autosomal O
recessive O
pattern O
of O
inheritance O
was O
demonstrated O
. O

This O
is O
the O
third O
patient O
with O
severe O
FUra O
toxicity O
secondary O
to O
an O
alteration O
in O
pyrimidine O
catabolism O
and O
the O
second O
from O
our O
clinic O
population O
suggesting O
that O
the O
frequency O
of O
this O
genetic O
defect O
may O
be O
greater O
than O
previously O
thought O
. O

Monitoring O
DPD B-protein
activity O
may O
be O
important O
in O
the O
management O
of O
patients O
experiencing O
severe O
toxicity O
secondary O
to O
FUra O
chemotherapy O
. O

Transactivation O
of O
the O
human O
immunodeficiency O
virus O
promoter O
by O
human O
herpesvirus O
6 O
( O
HHV O
- O
6 O
) O
strains O
GS O
and O
Z O
- O
29 O
in O
primary O
human O
T O
lymphocytes O
and O
identification O
of O
transactivating O
HHV O
- O
6 O
( O
GS O
) O
gene O
fragments O
. O

Human O
herpesvirus O
6 O
( O
HHV O
- O
6 O
) O
can O
activate O
the O
human O
immunodeficiency O
virus O
( O
HIV O
) O
promoter O
and O
accelerate O
cytopathic O
effects O
in O
HIV O
- O
infected O
human O
T O
cells O
. O

This O
study O
examines O
the O
regions O
of O
the O
HIV O
promoter O
required O
for O
HHV O
- O
6 O
transactivation O
in O
a O
heterogeneous O
population O
of O
primary O
human O
T O
lymphocytes O
with O
or O
without O
antigenic O
stimulation O
. O

Two O
different O
strains O
of O
HHV O
- O
6 O
, O
GS O
and O
Z29 O
, O
transactivated O
the O
HIV O
promoter O
. O

The O
GS O
strain O
transactivated O
the O
promoter O
in O
both O
stimulated O
and O
resting O
T O
cells O
, O
while O
the O
Z29 O
strain O
increased O
HIV O
promoter O
activity O
only O
in O
stimulated O
T O
cells O
. O

Three O
DNA O
clones O
containing O
HHV O
- O
6 O
( O
GS O
) O
genomic O
fragments O
transactivated O
the O
HIV O
promoter O
in O
cotransfected O
T O
cells O
. O

A O
21 O
. O
4 O
- O
kb O
DNA O
clone O
, O
pZVB70 O
, O
showed O
the O
highest O
transactivating O
ability O
, O
while O
two O
other O
DNA O
fragments O
, O
pZVB10 O
( O
6 O
. O
2 O
kb O
) O
and O
pZVH14 O
( O
8 O
. O
7 O
kb O
) O
, O
showed O
lower O
activity O
. O

One O
of O
these O
clones O
, O
pZVH14 O
, O
activated O
the O
HIV O
promoter O
construct O
containing O
a O
mutation O
in O
the O
NF O
kappa O
B O
site O
. O

However O
, O
this O
mutated O
NF O
kappa O
B O
promoter O
was O
not O
transactivated O
during O
HHV O
- O
6 O
( O
GS O
) O
infection O
or O
after O
cotransfection O
with O
pZVB70 O
or O
pZVB10 O
. O

These O
data O
indicate O
that O
the O
NF O
kappa O
B O
sites O
of O
the O
HIV O
promoter O
are O
essential O
for O
its O
transactivation O
during O
HHV O
- O
6 O
( O
GS O
) O
infection O
. O

By O
increasing O
HIV O
promoter O
activity O
in O
primary O
T O
lymphocytes O
, O
HHV O
- O
6 O
may O
consequently O
increase O
HIV O
replication O
, O
leading O
to O
an O
increase O
in O
the O
cytopathic O
effect O
on O
coinfected O
human O
T O
cells O
. O

Inhibition O
of O
HIV O
- O
1 O
replication O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
by O
cysteine O
and O
cysteine O
derivatives O
. O

HIV O
- O
1 O
proviral O
DNA O
contains O
two O
binding O
sites O
for O
the O
transcription B-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

HIV O
- O
1 O
- O
infected O
individuals O
have O
, O
on O
average O
, O
abnormally O
high O
levels O
of O
tumour B-protein
necrosis I-protein
factor I-protein
alpha I-protein
( O
TNF B-protein
alpha I-protein
) O
and O
abnormally O
low O
plasma O
cysteine O
levels O
. O

We O
therefore O
investigated O
the O
effects O
of O
cysteine O
and O
related O
thiols O
on O
HIV O
- O
1 O
replication O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
. O

The O
experiments O
in O
this O
report O
show O
that O
cysteine O
or O
N O
- O
acetylcysteine O
( O
NAC O
) O
raise O
the O
intracellular O
glutathione O
( O
GSH O
) O
level O
and O
inhibit O
HIV O
- O
1 O
replication O
in O
persistently O
infected O
Molt O
- O
4 O
and O
U937 O
cells O
. O

However O
, O
inhibition O
of O
HIV O
- O
1 O
replication O
appears O
not O
to O
be O
directly O
correlated O
with O
GSH O
levels O
. O

Cysteine O
and O
NAC O
also O
inhibit O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
as O
determined O
by O
electrophoretic O
mobility O
shift O
assays O
and O
chloramphenicol B-protein
acetyl I-protein
- I-protein
transferase I-protein
( O
CAT B-protein
) O
gene O
expression O
under O
control O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
sites O
in O
uninfected O
cells O
. O

This O
suggests O
that O
the O
cysteine O
deficiency O
in O
HIV O
- O
1 O
- O
infected O
individuals O
may O
cause O
an O
over O
- O
expression O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
dependent O
genes O
and O
enhance O
HIV O
- O
1 O
replication O
. O

NAC O
may O
be O
considered O
for O
the O
treatment O
of O
HIV O
- O
1 O
- O
infected O
individuals O
. O

A O
thymus B-protein
- I-protein
specific I-protein
member I-protein
of O
the O
HMG B-protein
protein I-protein
family I-protein
regulates O
the O
human B-protein
T I-protein
cell I-protein
receptor I-protein
C I-protein
alpha I-protein
enhancer O
. O

The O
human B-protein
T I-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
plays O
a O
key O
role O
in O
the O
tissue O
- O
specific O
activation O
of O
the O
T B-protein
cell I-protein
receptor I-protein
( O
TCR B-protein
) O
C O
alpha O
enhancer O
and O
binds O
to O
pyrimidine O
- O
rich O
elements O
( O
5 O
' O
- O
PyCTTTG O
- O
3 O
' O
) O
present O
in O
a O
variety O
of O
other O
T O
cell O
- O
specific O
control O
regions O
. O

Using O
amino B-protein
acid I-protein
sequence I-protein
information O
derived O
from O
the O
DNA B-protein
affinity I-protein
- I-protein
purified I-protein
protein I-protein
, O
we O
have O
now O
isolated O
cDNA O
clones O
encoding O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
. O

The O
TCF O
- O
1 O
alpha O
cDNA O
contains O
a O
single O
68 B-protein
- I-protein
amino I-protein
- I-protein
acid I-protein
domain I-protein
that O
is O
homologous O
to O
a O
region O
conserved O
among O
high B-protein
- I-protein
mobility I-protein
group I-protein
( O
HMG B-protein
) O
and O
nonhistone B-protein
chromosomal I-protein
proteins I-protein
. O

Expression O
of O
full O
- O
length O
and O
mutant O
cDNA O
clones O
in O
bacteria O
reveal O
that O
the O
single B-protein
HMG I-protein
motif I-protein
, O
which O
is O
predicted O
to O
contain O
two O
extended O
alpha B-protein
- I-protein
helical I-protein
segments I-protein
, O
is O
sufficient O
to O
direct O
the O
sequence O
- O
specific O
binding O
of O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
to O
DNA O
. O

Northern O
blot O
experiments O
demonstrate O
further O
that O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
mRNA O
is O
highly O
tissue O
specific O
, O
found O
primarily O
in O
the O
thymus O
or O
T O
cell O
lines O
. O

The O
immature O
CEM O
T O
cell O
line O
expresses O
relatively O
low O
levels O
of O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
mRNA O
, O
which O
are O
increased O
upon O
activation O
of O
these O
cells O
by O
phorbol O
esters O
. O

Interestingly O
, O
the O
cloned O
TCF B-protein
- I-protein
1 I-protein
alpha I-protein
protein I-protein
is O
a O
potent O
transcriptional B-protein
activator I-protein
of O
the O
human O
TCR O
alpha O
enhancer O
in O
nonlymphoid O
cell O
lines O
, O
whereas O
the O
activity O
of O
the O
endogenous B-protein
protein I-protein
in O
T O
cell O
lines O
is O
strongly O
dependent O
on O
an O
additional O
T O
cell O
- O
specific O
protein O
that O
interacts O
with O
the O
core O
enhancer O
. O

TCF B-protein
- I-protein
1 I-protein
alpha I-protein
is O
currently O
unique O
among O
the O
newly O
emerging O
family O
of O
DNA B-protein
- I-protein
binding I-protein
regulatory I-protein
proteins I-protein
that O
share O
the O
HMG B-protein
motif I-protein
in O
that O
it O
is O
a O
highly B-protein
tissue I-protein
- I-protein
specific I-protein
RNA I-protein
polymerase I-protein
II I-protein
transcription B-protein
factor I-protein
. O

A O
novel O
HIV O
- O
1 O
isolate O
containing O
alterations O
affecting O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
element O
. O

Three O
molecular O
clones O
of O
HIV O
- O
1 O
, O
derived O
from O
a O
single O
isolate O
( O
AL1 O
) O
, O
exhibited O
distinct O
replicative O
and O
cytopathic O
properties O
during O
propagation O
in O
a O
human O
T O
cell O
line O
. O

The O
phenotypic O
differences O
observed O
were O
attributable O
, O
in O
large O
part O
, O
to O
changes O
affecting O
the O
viral O
LTR O
. O

Nucleotide O
sequence O
and O
PCR O
analyses O
demonstrated O
the O
presence O
of O
novel O
duplications O
or O
deletions O
involving O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
motif O
. O

These O
changes O
in O
the O
enhancer O
element O
were O
identified O
in O
the O
original O
AL1 O
virus O
stock O
. O

Subcloning O
of O
the O
variant O
NF B-protein
- I-protein
kappa I-protein
B I-protein
segments O
into O
LTR O
- O
driven O
CAT B-protein
expression O
vectors O
confirmed O
a O
correlation O
between O
promoter O
activity O
and O
replicative O
/ O
cytopathic O
capacity O
. O

Multiple O
Oct2 B-protein
isoforms I-protein
are O
generated O
by O
alternative O
splicing O
. O

The O
interaction O
of O
the O
Oct2 B-protein
transcription I-protein
factor I-protein
with O
the O
cognate O
octamer O
motif O
ATGCAAAT O
is O
a O
critical O
determinant O
of O
the O
lymphoid O
- O
specific O
expression O
of O
immunoglobulin O
genes O
. O

Ectopic O
expression O
of O
cloned O
Oct2 O
cDNA O
was O
shown O
to O
be O
sufficient O
to O
reconstitute O
at O
least O
some O
aspects O
of O
this O
regulation O
in O
non O
- O
lymphoid O
cells O
. O

We O
describe O
the O
isolation O
and O
characterization O
of O
multiple O
cDNAs O
encoding O
mouse B-protein
Oct2 I-protein
from O
a O
mature O
B O
- O
cell O
line O
and O
we O
show O
that O
a O
variety O
of O
isoforms O
of O
this O
transcription B-protein
factor I-protein
is O
generated O
from O
a O
single O
gene O
by O
an O
alternative O
splicing O
mechanism O
. O

All O
the O
isoforms B-protein
retain O
the O
previously O
characterized O
POU O
- O
domain O
and O
are O
therefore O
able O
to O
bind O
to O
the O
octamer O
motif O
. O

Different O
amounts O
of O
the O
various O
isoforms B-protein
are O
present O
within O
the O
same O
B O
- O
cell O
regardless O
of O
the O
developmental O
stage O
of O
B O
- O
cell O
differentiation O
and O
at O
least O
some O
of O
the O
isoforms B-protein
are O
conserved O
between O
mouse O
and O
humans O
. O

In O
cotransfection O
experiments O
we O
show O
that O
all O
the O
isoforms B-protein
are O
able O
to O
activate O
an O
octamer O
containing O
promoter O
element O
in O
fibroblasts O
revealing O
an O
unexpected O
functional O
redundancy O
. O

Finally O
, O
we O
show O
that O
one O
of O
the O
isoforms B-protein
encodes O
the O
previously O
described O
lymphoid B-protein
- I-protein
specific I-protein
Oct2B I-protein
protein I-protein
which O
has O
been O
suggested O
to O
be O
involved O
in O
the O
function O
of O
the O
octamer O
motif O
in O
the O
context O
of O
the O
immunoglobulin B-protein
heavy I-protein
- I-protein
chain I-protein
( O
IgH B-protein
) O
enhancer O
. O

[ O
Regulation O
of O
intracellular O
cholesterol O
synthesis O
in O
hypercholesterolemia O
by O
glucocorticoids O
] O
. O

The O
rate O
of O
endogenous O
cholesterol O
synthesis O
in O
blood O
lymphocytes O
and O
skin O
fibroblasts O
from O
patients O
with O
type O
IIa O
hyperlipidemia O
was O
found O
to O
be O
increased O
in O
comparison O
with O
healthy O
donors O
. O

The O
cells O
of O
hyperlipidemic O
patients O
had O
lowered O
levels O
of O
glucocorticoid B-protein
receptors I-protein
concomitantly O
with O
a O
partial O
loss O
of O
their O
sensitivity O
to O
glucocorticoids O
. O

In O
fibroblasts O
from O
patients O
with O
hereditary O
hypercholesteremia O
of O
homozygous O
type O
the O
number O
of O
glucocorticoid B-protein
receptors I-protein
did O
not O
exceed O
10 O
% O
of O
their O
content O
in O
normal O
cells O
. O

The O
decrease O
of O
the O
number O
of O
glucocorticoid B-protein
receptors I-protein
in O
patients O
with O
type O
IIa O
hyperlipidemia O
seems O
to O
be O
a O
compensatory O
response O
of O
cells O
culminating O
in O
activation O
of O
endogenous O
cholesterol O
synthesis O
. O

Negative O
regulation O
of O
human O
immunodeficiency O
virus O
type O
1 O
expression O
in O
monocytes O
: O
role O
of O
the O
65 B-protein
- I-protein
kDa I-protein
plus O
50 B-protein
- I-protein
kDa I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
dimer I-protein
. O

Although O
monocytic O
cells O
can O
provide O
a O
reservoir O
for O
viral O
production O
in O
vivo O
, O
their O
regulation O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
transcription O
can O
be O
either O
latent O
, O
restricted O
, O
or O
productive O
. O

These O
differences O
in O
gene O
expression O
have O
not O
been O
molecularly O
defined O
. O

In O
THP O
- O
1 O
cells O
with O
restricted O
HIV O
expression O
, O
there O
is O
an O
absence O
of O
DNA B-protein
- I-protein
protein I-protein
binding I-protein
complex I-protein
formation O
with O
the O
HIV O
- O
1 O
promoter O
- O
enhancer O
associated O
with O
markedly O
less O
viral O
RNA O
production O
. O

This O
absence O
of O
binding O
was O
localized O
to O
the O
NF B-protein
- I-protein
kappa I-protein
B I-protein
region O
of O
the O
HIV O
- O
1 O
enhancer O
; O
the O
65 B-protein
- I-protein
kDa I-protein
plus I-protein
50 I-protein
- I-protein
kDa I-protein
NF I-protein
- I-protein
kappa I-protein
B I-protein
heterodimer I-protein
was O
preferentially O
lost O
. O

Adding O
purified O
NF B-protein
- I-protein
kappa I-protein
B I-protein
protein I-protein
to O
nuclear O
extracts O
from O
cells O
with O
restricted O
expression O
overcomes O
this O
lack O
of O
binding O
. O

In O
addition O
, O
treatment O
of O
these O
nuclear O
extracts O
with O
sodium O
deoxycholate O
restored O
their O
ability O
to O
form O
the O
heterodimer B-protein
, O
suggesting O
the O
presence O
of O
an O
inhibitor O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
. O

Furthermore O
, O
treatment O
of O
nuclear O
extracts O
from O
these O
cells O
that O
had O
restricted O
expression O
with O
lipopolysaccharide O
increased O
viral O
production O
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
activity O
. O

Antiserum O
specific O
for O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding I-protein
proteins I-protein
, O
but O
not O
c O
- O
rel O
- O
specific O
antiserum O
, O
disrupted O
heterodimer B-protein
complex I-protein
formation O
. O

Thus O
, O
both O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
binding I-protein
complexes I-protein
are O
needed O
for O
optimal O
viral O
transcription O
. O

Binding O
of O
the O
65 B-protein
- I-protein
kDa I-protein
plus O
50 B-protein
- I-protein
kDa I-protein
heterodimer I-protein
to O
the O
HIV O
- O
1 O
enhancer O
can O
be O
negatively O
regulated O
in O
monocytes O
, O
providing O
one O
mechanism O
restricting O
HIV O
- O
1 O
gene O
expression O
. O

Glucocorticoid B-protein
receptors I-protein
in O
normal O
leukocytes O
: O
effects O
of O
age O
, O
gender O
, O
season O
, O
and O
plasma O
cortisol O
concentrations O
. O

We O
measured O
glucocorticoid B-protein
receptors I-protein
( O
GR B-protein
) O
in O
mononuclear O
leukocytes O
( O
MNL O
) O
isolated O
from O
peripheral O
blood O
of O
145 O
apparently O
healthy O
volunteers O
( O
86 O
men O
and O
59 O
women O
) O
. O

An O
age O
- O
related O
decrease O
in O
the O
number O
of O
GR B-protein
was O
suggested O
between O
subjects O
younger O
than O
20 O
years O
and O
elderly O
subjects O
; O
there O
was O
no O
apparent O
seasonal O
variation O
in O
GR B-protein
. O

Gender O
difference O
in O
the O
number O
of O
GR B-protein
was O
not O
significant O
, O
although O
women O
showed O
slightly O
fewer O
GR B-protein
. O

Eight O
patients O
with O
dermatomyositis O
/ O
polymyositis O
were O
examined O
to O
determine O
whether O
the O
number O
of O
GR B-protein
in O
MNL O
could O
be O
down O
- O
regulated O
by O
their O
cognate O
ligands O
. O

The O
number O
of O
GR B-protein
in O
MNL O
from O
these O
patients O
was O
significantly O
decreased O
one O
month O
after O
the O
initiation O
of O
prednisolone O
therapy O
. O

However O
, O
in O
normal O
subjects O
, O
the O
GR B-protein
in O
MNL O
did O
not O
demonstrate O
circadian O
variation O
, O
in O
contrast O
to O
concentrations O
of O
plasma O
cortisol O
. O

Synergism O
between O
two O
distinct O
elements O
of O
the O
HTLV O
- O
I O
enhancer O
during O
activation O
by O
the O
trans B-protein
- I-protein
activator I-protein
of O
HTLV O
- O
I O
. O

We O
have O
conducted O
functional O
studies O
of O
the O
enhancer O
elements O
of O
human O
T O
- O
cell O
leukemia O
virus O
type O
I O
( O
HTLV O
- O
I O
) O
using O
the O
human O
T O
- O
cell O
lines O
Jurkat O
and O
MOLT O
4 O
, O
which O
are O
negative O
for O
HTLV O
- O
I O
, O
and O
MT O
- O
2 O
and O
TL O
- O
Mor O
, O
which O
carry O
the O
proviral O
genome O
of O
HTLV O
- O
I O
. O

Two O
distinct O
elements O
have O
been O
implicated O
in O
function O
of O
the O
HTLV O
- O
I O
enhancer O
. O

One O
is O
the O
21 O
- O
base O
- O
pair O
( O
bp O
) O
core O
element O
that O
is O
responsible O
for O
trans O
- O
activation O
by O
the O
HTLV O
- O
I O
trans B-protein
- I-protein
activator I-protein
p40tax B-protein
and O
that O
has O
the O
ability O
to O
bind O
to O
cyclic B-protein
- I-protein
AMP I-protein
responsive I-protein
element I-protein
binding I-protein
factor I-protein
( I-protein
CREB I-protein
) I-protein
- I-protein
like I-protein
factor I-protein
( O
s O
) O
. O

The O
other O
is O
a O
region O
interposed O
between O
the O
21 O
- O
bp O
elements O
. O

In O
this O
study O
we O
demonstrate O
that O
a O
subfragment O
( O
C26 O
) O
in O
the O
region O
between O
the O
21 O
- O
bp O
elements O
is O
involved O
in O
trans O
- O
activation O
by O
p40tax B-protein
, O
possibly O
through O
binding O
to O
an O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- I-protein
like I-protein
nuclear I-protein
factor I-protein
or O
factors O
. O

Formation O
of O
the O
protein B-protein
- I-protein
DNA I-protein
complex I-protein
with O
the O
C26 B-protein
subfragment I-protein
was O
positively O
affected O
by O
p40tax B-protein
. O

The O
C26 O
element O
conferred O
partial O
responsiveness O
to O
p40tax B-protein
when O
linked O
to O
one O
copy O
of O
the O
21 O
- O
bp O
element O
that O
, O
by O
itself O
, O
showed O
little O
activation O
in O
response O
to O
p40tax B-protein
. O

However O
, O
the O
C26 O
element O
alone O
, O
even O
when O
repeated O
, O
could O
not O
be O
activated O
by O
p40tax B-protein
, O
unlike O
other O
NF B-protein
- I-protein
kappa I-protein
B I-protein
- O
binding O
elements O
. O

In O
contrast O
, O
the O
C26 O
element O
itself O
was O
profoundly O
activated O
upon O
stimulation O
with O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
. O

These O
findings O
therefore O
suggest O
that O
the O
HTLV O
- O
I O
enhancer O
contains O
multiple O
functional O
elements O
, O
including O
binding O
sites O
for O
at O
least O
CREB O
- O
and O
NF O
- O
kappa O
B O
- O
like O
factors O
, O
which O
synergistically O
cooperate O
in O
activation O
of O
the O
HTLV O
- O
I O
enhancer O
in O
response O
to O
p40tax B-protein
. O

Our O
results O
also O
demonstrate O
that O
TPA O
- O
dependent O
activation O
of O
the O
HTLV O
- O
I O
enhancer O
may O
be O
mediated O
through O
the O
C26 O
element O
. O

Human O
tumor B-protein
necrosis I-protein
factor I-protein
alpha I-protein
gene O
regulation O
in O
phorbol O
ester O
stimulated O
T O
and O
B O
cell O
lines O
. O

The O
minimal O
region O
of O
the O
human B-protein
tumor I-protein
necrosis I-protein
factor I-protein
alpha I-protein
( O
TNF B-protein
- I-protein
alpha I-protein
) O
gene O
promoter O
necessary O
for O
its O
transcriptional O
induction O
by O
phorbol O
esters O
( O
PMA O
) O
in O
human O
T O
and O
B O
lymphocyte O
cell O
lines O
has O
been O
localized O
between O
- O
52 O
and O
+ O
89 O
nucleotides O
( O
nt O
) O
relative O
to O
the O
gene O
' O
s O
transcriptional O
start O
site O
. O

Comparison O
of O
these O
sequences O
to O
those O
required O
to O
mediate O
virus O
or O
lipopolysaccharide O
( O
LPS O
) O
induction O
of O
the O
gene O
reveal O
significant O
differences O
, O
and O
thus O
, O
the O
sequence O
requirements O
for O
PMA O
induction O
are O
distinct O
from O
those O
that O
mediate O
induction O
by O
virus O
or O
LPS O
. O

Although O
three O
sites O
in O
the O
TNF B-protein
- I-protein
alpha I-protein
promoter O
( O
kappa O
1 O
, O
kappa O
2 O
, O
and O
kappa O
3 O
) O
specifically O
bind O
the O
transcription B-protein
factor I-protein
NF B-protein
- I-protein
kappa I-protein
B I-protein
in O
lymphoid O
nuclear O
extracts O
, O
TNF B-protein
- I-protein
alpha I-protein
mRNA O
induction O
by O
PMA O
does O
not O
correlate O
with O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
activities O
displayed O
by O
different O
T O
and O
B O
cell O
lines O
. O

Moreover O
, O
kappa O
1 O
- O
kappa O
3 O
can O
each O
be O
deleted O
from O
the O
TNF B-protein
- I-protein
alpha I-protein
promoter O
with O
little O
effect O
on O
the O
gene O
' O
s O
inducibility O
by O
PMA O
. O

Therefore O
, O
TNF B-protein
- I-protein
alpha I-protein
mRNA O
induction O
by O
PMA O
, O
like O
its O
induction O
by O
virus O
and O
LPS O
, O
is O
not O
primarily O
mediated O
by O
NF B-protein
- I-protein
kappa I-protein
B I-protein
, O
but O
rather O
is O
mediated O
through O
other O
sequences O
and O
protein B-protein
factors I-protein
. O

Surprisingly O
, O
multimers O
of O
kappa O
1 O
- O
kappa O
3 O
can O
confer O
PMA O
inducibility O
on O
a O
heterologous O
promoter O
in O
a O
B O
( O
Raji O
) O
, O
but O
not O
a O
T O
( O
HUT78 O
) O
cell O
line O
. O

However O
they O
are O
not O
functional O
on O
a O
truncated O
TNF B-protein
- I-protein
alpha I-protein
promoter O
, O
indicating O
that O
promoter O
context O
and O
cell O
type O
specificity O
influence O
the O
PMA O
inducible O
function O
of O
these O
NF B-protein
- I-protein
kappa I-protein
B I-protein
binding O
sites O
. O

Differentiation O
- O
associated O
expression O
of O
the O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
BZLF1 I-protein
transactivator I-protein
protein I-protein
in O
oral O
hairy O
leukoplakia O
. O

The O
BZLF1 B-protein
protein I-protein
of O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
is O
a O
key O
immediate B-protein
- I-protein
early I-protein
protein I-protein
which O
has O
been O
shown O
to O
disrupt O
virus O
latency O
in O
EBV O
- O
infected O
B O
cells O
. O

We O
have O
generated O
a O
monoclonal B-protein
antibody I-protein
, O
BZ1 B-protein
, O
to O
BZLF1 B-protein
which O
reacts O
in O
immunohistology O
, O
immunoblotting O
, O
and O
immunoprecipitation O
and O
which O
recognizes O
both O
the O
active B-protein
, I-protein
dimeric I-protein
form I-protein
and O
the O
inactive B-protein
, I-protein
monomeric I-protein
form I-protein
of O
the O
protein O
. O

Biopsies O
of O
oral O
hairy O
leukoplakia O
, O
an O
AIDS O
- O
associated O
lesion O
characterized O
by O
high O
- O
level O
EBV O
replication O
, O
were O
examined O
by O
immunohistochemistry O
using O
the O
BZ1 B-protein
monoclonal B-protein
antibody I-protein
. O

A O
differentiation O
- O
associated O
pattern O
of O
BZLF1 B-protein
expression O
was O
observed O
, O
BZ1 B-protein
reacting O
with O
nuclei O
of O
the O
upper O
spinous O
layer O
of O
the O
lesion O
. O

This O
finding O
suggests O
that O
the O
BZLF1 B-protein
promoter O
may O
be O
regulated O
by O
the O
degree O
of O
squamous O
differentiation O
. O

A O
comparison O
of O
in O
situ O
hybridization O
to O
EBV O
DNA O
and O
viral B-protein
capsid I-protein
antigen I-protein
staining O
with O
BZ1 B-protein
reactivity O
suggested O
that O
BZLF1 B-protein
expression O
precedes O
rampant O
virus O
replication O
. O

The O
inability O
to O
detect O
EBV O
in O
the O
lower O
epithelial O
layers O
of O
oral O
hairy O
leukoplakia O
raises O
questions O
concerning O
the O
nature O
of O
EBV O
latency O
and O
persistence O
in O
stratified O
squamous O
epithelium O
. O

[ O
Changes O
in O
levels O
of O
leucocytic B-protein
estrogen I-protein
receptor I-protein
in O
patients O
with O
menopausal O
type O
II O
diabetes O
and O
its O
significance O
] O
. O

The O
number O
of O
estrogen B-protein
receptors I-protein
( O
ER B-protein
) O
in O
human O
peripheral O
leucocytes O
in O
12 O
women O
with O
menopausal O
type O
II O
diabetes O
was O
measured O
with O
radio O
- O
ligand O
binding O
method O
. O

The O
results O
were O
compared O
with O
those O
of O
12 O
menopausal O
women O
without O
diabetes O
and O
12 O
normal O
women O
of O
childbearing O
age O
. O

It O
was O
found O
that O
the O
number O
of O
ER B-protein
in O
the O
patients O
was O
significantly O
decreased O
. O

Our O
data O
indicate O
that O
decrease O
of O
ER B-protein
level O
in O
leukocytes O
may O
be O
related O
to O
the O
pathogenesis O
of O
type O
II O
diabetes O
in O
menopausal O
period O
. O

Lymphocyte O
glucocorticoid B-protein
receptor I-protein
number O
in O
posttraumatic O
stress O
disorder O
. O

OBJECTIVE O
: O
The O
authors O
' O
objective O
was O
to O
investigate O
the O
possibility O
that O
glucocorticoid B-protein
receptor I-protein
changes O
may O
be O
involved O
in O
the O
dysregulation O
of O
the O
hypothalamic O
- O
pituitary O
- O
adrenal O
( O
HPA O
) O
axis O
in O
posttraumatic O
stress O
disorder O
( O
PTSD O
) O
. O

METHOD O
: O
They O
measured O
the O
number O
of O
lymphocyte B-protein
cytosolic I-protein
glucocorticoid I-protein
receptors I-protein
and O
plasma O
cortisol O
concentrations O
in O
15 O
consecutively O
admitted O
male O
combat O
Vietnam O
veterans O
with O
PTSD O
and O
in O
a O
normal O
comparison O
group O
of O
11 O
subjects O
. O

RESULTS O
: O
Both O
the O
patients O
and O
the O
normal O
comparison O
subjects O
showed O
a O
morning O
- O
to O
- O
afternoon O
decline O
in O
glucocorticoid B-protein
receptor I-protein
concentrations O
, O
paralleling O
the O
normal O
diurnal O
decline O
in O
cortisol O
levels O
. O

The O
number O
of O
glucocorticoid B-protein
receptors I-protein
was O
63 O
% O
greater O
in O
the O
morning O
and O
26 O
% O
greater O
in O
the O
afternoon O
in O
the O
patients O
with O
PTSD O
than O
in O
the O
normal O
subjects O
. O

No O
group O
differences O
in O
cortisol O
levels O
were O
observed O
, O
nor O
were O
glucocorticoid B-protein
receptor I-protein
number O
and O
cortisol O
levels O
correlated O
. O

The O
number O
of O
morning B-protein
glucocorticoid I-protein
receptors I-protein
was O
positively O
correlated O
with O
symptoms O
of O
PTSD O
and O
anxiety O
. O

CONCLUSIONS O
: O
These O
results O
provide O
further O
evidence O
for O
a O
dysregulation O
of O
the O
HPA O
axis O
in O
PTSD O
. O

The O
finding O
that O
patients O
with O
PTSD O
had O
a O
substantially O
greater O
number O
of O
lymphocyte B-protein
glucocorticoid I-protein
receptors I-protein
than O
normal O
comparison O
subjects O
is O
consistent O
with O
the O
authors O
' O
previous O
observations O
of O
low O
24 O
- O
hour O
urinary O
cortisol O
excretion O
in O
subjects O
with O
PTSD O
. O

Furthermore O
, O
the O
receptor O
changes O
observed O
are O
opposite O
of O
those O
reported O
in O
major O
depressive O
disorder O
. O

The O
present O
data O
, O
along O
with O
other O
findings O
of O
HPA O
abnormalities O
in O
PTSD O
, O
support O
the O
possibility O
of O
a O
greater O
negative O
feedback O
sensitivity O
at O
one O
or O
more O
levels O
of O
the O
HPA O
axis O
. O

Induction O
of O
NF B-protein
- I-protein
kappa I-protein
B I-protein
during O
monocyte O
differentiation O
is O
associated O
with O
activation O
of O
HIV O
- O
gene O
expression O
. O

Cells O
of O
the O
monocyte O
- O
macrophage O
lineage O
are O
important O
targets O
of O
HIV O
infection O
. O

We O
report O
here O
that O
the O
phenotypic O
differentiation O
of O
monocyte O
cell O
lines O
induced O
by O
phorbol O
esters O
or O
tumour B-protein
necrosis I-protein
factor I-protein
alpha I-protein
( O
TNF B-protein
alpha I-protein
) O
is O
associated O
with O
expression O
of O
nuclear B-protein
factor I-protein
kappa I-protein
B I-protein
( O
NF B-protein
- I-protein
kappa I-protein
B I-protein
) O
. O

In O
parallel O
with O
such O
differentiation O
, O
HIV O
transcription O
, O
monitored O
using O
an O
HIV O
long O
terminal O
repeat O
reporter O
gene O
construct O
, O
is O
activated O
in O
such O
cells O
under O
the O
influence O
of O
enhanced O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
. O

Also O
, O
in O
a O
promonocyte O
cell O
line O
chronically O
infected O
with O
HIV O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
expression O
and O
HIV O
transcription O
were O
enhanced O
on O
stimulation O
with O
phorbol O
ester O
or O
TNF B-protein
alpha I-protein
. O

Thus O
, O
stimulation O
of O
monocyte O
cell O
lines O
by O
phorbol O
esters O
or O
TNF B-protein
alpha I-protein
induces O
cell O
differentiation O
and O
activates O
HIV O
transcription O
. O

Such O
a O
process O
may O
have O
fundamental O
implications O
in O
AIDS O
pathogenesis O
in O
vivo O
and O
may O
be O
important O
in O
disease O
progression O
induced O
by O
opportunistic O
infections O
directly O
or O
indirectly O
involving O
macrophages O
. O

Demonstration O
of O
estrogen O
and O
progesterone O
receptors O
as O
well O
as O
Ki O
- O
67 O
and O
p O
- O
145 O
antigens O
in O
single O
tumor O
cells O
from O
blood O
and O
pleural O
effusions O
using O
a O
slide O
assay O
. O

We O
describe O
a O
slide O
assay O
that O
allows O
the O
demonstration O
of O
antigens B-protein
localized O
in O
the O
nucleus O
from O
isolated O
white O
blood O
cells O
as O
well O
as O
from O
single O
tumor O
cells O
derived O
from O
malignant O
effusions O
. O

With O
the O
antibodies O
Ki B-protein
- I-protein
67 I-protein
and O
anti B-protein
- I-protein
p I-protein
- I-protein
145 I-protein
an O
increased O
rate O
of O
nuclear O
and O
nucleolar O
staining O
resulted O
in O
cells O
from O
highly O
malignant O
lymphomas O
. O

An O
almost O
identical O
reaction O
was O
obtained O
when O
tumor O
cells O
from O
malignant O
effusions O
were O
tested O
. O

Cells O
isolated O
from O
the O
blood O
of O
patients O
with O
leukemic O
spread O
of O
lymphomas O
of O
low O
malignancy O
yielded O
a O
weak O
staining O
comparable O
to O
that O
of O
normal O
mesothelial O
cells O
from O
non O
- O
tumorous O
cavity O
fluids O
. O

The O
detection O
of O
estrogen B-protein
and O
progesterone B-protein
receptors I-protein
( O
ER B-protein
and O
PR B-protein
) O
localized O
in O
the O
cell O
nucleus O
can O
be O
achieved O
by O
the O
same O
assay O
. O

The O
reaction O
is O
enhanced O
by O
incubation O
of O
the O
tumor O
cells O
for O
30 O
min O
at O
37 O
degrees O
C O
prior O
to O
fixation O
. O

Pleural O
effusions O
from O
20 O
patients O
with O
breast O
cancer O
were O
tested O
. O

ER B-protein
was O
positive O
in O
13 O
and O
PR B-protein
was O
positive O
in O
12 O
of O
the O
20 O
samples O
. O

In O
5 O
cases O
there O
was O
a O
divergent O
reaction O
with O
ER B-protein
and O
PR B-protein
antibody O
. O

The O
hormone B-protein
receptors I-protein
of O
the O
primary O
tumor O
were O
known O
in O
15 O
( O
ER B-protein
) O
and O
14 O
( O
PR B-protein
) O
patients O
, O
respectively O
. O

In O
each O
cohort O
there O
was O
only O
one O
case O
with O
a O
negative O
reaction O
of O
the O
primary O
tumor O
and O
a O
positive O
reaction O
with O
the O
isolated O
tumor O
cells O
from O
the O
pleural O
effusions O
. O

These O
results O
indicate O
that O
the O
demonstration O
of O
hormone B-protein
receptor I-protein
proteins I-protein
in O
cells O
from O
malignant O
effusions O
is O
possible O
and O
that O
there O
is O
a O
correlation O
with O
the O
status O
of O
the O
primary O
site O
of O
cancer O
. O

Constitutive O
activation O
of O
NF B-protein
- I-protein
kB I-protein
in O
human O
thymocytes O
. O

NF B-protein
- I-protein
kB I-protein
is O
a O
eukaryotic B-protein
transcription I-protein
regulatory I-protein
factor I-protein
. O

In O
T O
cells O
and O
T O
cell O
lines O
, O
NF B-protein
- I-protein
kB I-protein
is O
bound O
to O
a O
cytoplasmic B-protein
proteic I-protein
inhibitor I-protein
, O
the O
IkB B-protein
. O

Treatment O
of O
T O
cells O
with O
mitogens O
( O
phorbol O
esters O
) O
or O
cytokines B-protein
( O
TNF B-protein
alpha I-protein
) O
induces O
NF B-protein
- I-protein
kB I-protein
nuclear O
translocation O
and O
the O
subsequent O
expression O
of O
NF B-protein
- I-protein
kB I-protein
dependent O
T O
cell O
genes O
. O

Here O
we O
examined O
the O
activation O
of O
NF B-protein
- I-protein
kB I-protein
in O
human O
T O
cell O
thymic O
progenitors O
. O

We O
report O
differences O
in O
( O
Ca2 O
+ O
) O
i O
requirement O
for O
NF B-protein
- I-protein
kB I-protein
activation O
in O
thymocytes O
as O
compared O
to O
mature O
T O
cells O
. O

Furthermore O
, O
our O
results O
indicated O
that O
thymocytes O
have O
a O
constitutively B-protein
active I-protein
form I-protein
of O
NF B-protein
- I-protein
kB I-protein
, O
suggesting O
that O
they O
are O
activated O
in O
vivo O
. O

TCF B-protein
- I-protein
1 I-protein
, O
a O
T B-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
of O
the O
HMG B-protein
box I-protein
family I-protein
, O
interacts O
with O
sequence O
motifs O
in O
the O
TCR O
beta O
and O
TCR O
delta O
enhancers O
. O

We O
have O
recently O
identified O
and O
cloned O
TCF B-protein
- I-protein
1 I-protein
, O
a O
T B-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
with O
specificity O
for O
the O
AACAAAG O
motif O
in O
the O
CD3 O
epsilon O
enhancer O
and O
for O
the O
TTCAAAG O
motif O
in O
the O
TCR O
alpha O
enhancer O
. O

TCF B-protein
- I-protein
1 I-protein
belongs O
to O
the O
family O
of O
transcription B-protein
- I-protein
regulating I-protein
proteins I-protein
which O
share O
a O
region O
of O
homology O
termed O
the O
HMG B-protein
- I-protein
box I-protein
. O

Here O
, O
we O
show O
by O
gel O
retardation O
analysis O
that O
TCF B-protein
- I-protein
1 I-protein
specifically O
recognizes O
the O
T O
beta O
5 O
element O
of O
the O
TCR O
beta O
enhancer O
and O
the O
T O
delta O
7 O
element O
of O
the O
TCR O
delta O
enhancer O
. O

Comparison O
of O
the O
sequences O
of O
all O
elements O
recognized O
by O
TCF B-protein
- I-protein
1 I-protein
defines O
a O
consensus O
motif O
A O
/ O
T O
A O
/ O
T O
C O
A O
A O
/ O
G O
A O
G O
. O

These O
observations O
imply O
that O
TCF B-protein
- I-protein
1 I-protein
is O
involved O
in O
the O
control O
of O
several O
T O
cell O
- O
specific O
genes O
and O
might O
thus O
play O
an O
important O
role O
in O
the O
establishment O
and O
maintenance O
of O
the O
mature O
T O
cell O
phenotype O
. O

[ O
Regulatory O
effect O
of O
insulin B-protein
on O
glucocorticoid B-protein
receptor I-protein
in O
human O
peripheral O
leukocytes O
] O
. O

The O
regulatory O
effect O
of O
insulin B-protein
on O
the O
specific O
binding O
power O
of O
glucocorticoid B-protein
receptor I-protein
( O
GR B-protein
) O
of O
human O
leukocytes O
was O
assessed O
by O
the O
unoccupied B-protein
receptor I-protein
sites I-protein
capable O
of O
combining O
with O
[ O
3H O
] O
labelled O
dexamethasone O
measured O
at O
3 O
and O
24 O
h O
after O
incubation O
with O
various O
concentrations O
of O
insulin B-protein
added O
to O
the O
medium O
. O

After O
3 O
h O
incubation O
the O
specific O
binding O
power O
with O
[ O
3H O
] O
Dex O
was O
decreased O
by O
23 O
. O
3 O
+ O
/ O
- O
10 O
. O
0 O
, O
32 O
. O
2 O
+ O
/ O
- O
13 O
. O
2 O
and O
54 O
. O
3 O
+ O
/ O
- O
9 O
. O
2 O
% O
( O
P O
greater O
than O
0 O
. O
05 O
, O
P O
greater O
than O
0 O
. O
05 O
and O
P O
less O
than O
0 O
. O
01 O
as O
compared O
with O
the O
control O
value O
of O
100 O
in O
the O
absence O
of O
insulin B-protein
) O
respectively O
in O
the O
presence O
of O
20 O
mU O
/ O
L O
( O
physiological O
testing O
concentration O
) O
, O
200 O
mU O
/ O
L O
( O
physiological O
upper O
limit O
) O
and O
2 O
, O
000 O
mU O
/ O
L O
( O
pharmacological O
concentration O
) O
insulin B-protein
in O
the O
incubation O
medium O
. O

After O
24 O
h O
incubation O
the O
decrease O
of O
these O
values O
increased O
respectively O
to O
43 O
. O
5 O
+ O
/ O
- O
19 O
. O
0 O
, O
56 O
. O
1 O
+ O
/ O
- O
20 O
. O
7 O
and O
80 O
. O
2 O
+ O
/ O
- O
15 O
. O
5 O
( O
P O
less O
than O
0 O
. O
05 O
, O
P O
less O
than O
0 O
. O
01 O
and O
P O
less O
than O
0 O
. O
01 O
compared O
with O
control O
) O
. O

Thus O
the O
inhibitory O
effect O
of O
insulin B-protein
on O
the O
GR B-protein
binding O
power O
is O
both O
dose O
- O
and O
time O
- O
dependent O
, O
which O
strongly O
suggests O
that O
GR B-protein
is O
tonically O
controlled O
by O
insulin B-protein
concentration O
change O
under O
physiological O
conditions O
. O

The O
effect O
of O
toremifene O
therapy O
on O
serum B-protein
immunoglobulin I-protein
levels O
in O
breast O
cancer O
. O

Estrogens O
and O
anti O
- O
estrogens O
enhance O
the O
number O
of O
immunoglobulin O
( O
Ig O
) O
- O
secreting O
cells O
in O
pokeweed B-protein
mitogen I-protein
( O
PWM B-protein
) O
- O
stimulated O
lymphocyte O
cultures O
. O

Lymphocytes O
from O
patients O
who O
have O
received O
anti O
- O
estrogen O
therapy O
show O
similar O
enhancement O
of O
Ig O
- O
secreting O
cells O
after O
PWM B-protein
stimulation O
. O

In O
this O
study O
the O
effect O
of O
anti O
- O
estrogen O
( O
toremifene O
) O
therapy O
on O
serum B-protein
immunoglobulin I-protein
( O
IgA B-protein
, O
IgM B-protein
, O
IgG B-protein
) O
levels O
in O
breast O
cancer O
patients O
was O
investigated O
. O

Serum O
Ig O
levels O
were O
followed O
up O
to O
two O
years O
after O
or O
during O
the O
therapy O
. O

An O
unexpected O
finding O
was O
that O
the O
Ig O
levels O
decreased O
during O
the O
follow O
- O
up O
period O
. O

This O
decrease O
was O
seen O
in O
patients O
who O
responded O
to O
the O
therapy O
as O
well O
as O
in O
those O
who O
did O
not O
. O

Human B-protein
erythroid I-protein
5 I-protein
- I-protein
aminolevulinate I-protein
synthase I-protein
: O
promoter O
analysis O
and O
identification O
of O
an O
iron O
- O
responsive O
element O
in O
the O
mRNA O
. O

5 B-protein
- I-protein
Aminolevulinate I-protein
synthase I-protein
( O
ALAS B-protein
) O
catalyzes O
the O
first O
step O
of O
the O
heme B-protein
biosynthetic O
pathway O
. O

cDNA O
clones O
for O
the O
human B-protein
erythroid I-protein
ALAS I-protein
isozyme I-protein
were O
isolated O
from O
a O
fetal O
liver O
library O
. O

It O
can O
be O
deduced O
that O
the O
erythroid B-protein
ALAS I-protein
precursor I-protein
protein I-protein
has O
a O
molecular O
weight O
of O
64 O
. O
6 O
kd O
, O
and O
is O
similar O
in O
size O
to O
the O
previously O
isolated O
human B-protein
housekeeping I-protein
ALAS I-protein
precursor I-protein
of O
molecular O
weight O
70 O
. O
6 O
kd O
. O

The O
mature O
mitochondrial O
forms O
of O
the O
erythroid O
and O
housekeeping B-protein
ALAS I-protein
isozymes I-protein
are O
predicted O
to O
have O
molecular O
weights O
of O
59 O
. O
5 O
kd O
and O
64 O
. O
6 O
kd O
, O
respectively O
. O

The O
two O
isozymes B-protein
show O
little O
amino O
acid O
identity O
in O
their O
N B-protein
- I-protein
terminal I-protein
signal I-protein
sequences I-protein
but O
have O
considerable O
sequence O
identity O
in O
the O
C B-protein
- I-protein
terminal I-protein
two I-protein
- I-protein
thirds I-protein
of O
their O
proteins O
. O

An O
analysis O
of O
the O
immediate O
promoter O
of O
the O
human O
erythroid O
ALAS O
gene O
revealed O
several O
putative O
erythroid O
- O
specific O
cis O
- O
acting O
elements O
including O
both O
a O
GATA O
- O
1 O
and O
an O
NF O
- O
E2 O
binding O
site O
. O

An O
iron O
- O
responsive O
element O
( O
IRE O
) O
motif O
has O
been O
identified O
in O
the O
5 O
' O
- O
untranslated O
region O
of O
the O
human O
erythroid O
ALAS O
mRNA O
, O
but O
is O
not O
present O
in O
the O
housekeeping O
ALAS O
mRNA O
. O

Gel O
retardation O
experiments O
established O
that O
this O
IRE O
motif O
formed O
a O
protein B-protein
- I-protein
RNA I-protein
complex I-protein
with O
cytosolic O
extracts O
from O
human O
K562 O
cells O
and O
this O
binding O
was O
strongly O
competed O
with O
IRE O
transcripts O
from O
ferritin O
or O
transferrin O
receptor O
mRNAs O
. O

A O
transcript O
of O
the O
ALAS O
IRE O
, O
mutated O
in O
the O
conserved O
loop O
of O
the O
IRE O
, O
did O
not O
readily O
form O
this O
protein B-protein
- I-protein
RNA I-protein
complex I-protein
. O

These O
results O
suggest O
that O
the O
IRE O
motif O
in O
the O
ALAS O
mRNA O
is O
functional O
and O
imply O
that O
translation O
of O
the O
mRNA O
is O
controlled O
by O
cellular O
iron O
availability O
during O
erythropoiesis O
. O

Regulation O
of O
jun O
and O
fos O
gene O
expression O
in O
human O
monocytes O
by O
the O
macrophage B-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
. O

The O
macrophage B-protein
colony I-protein
- I-protein
stimulating I-protein
factor I-protein
( O
M B-protein
- I-protein
CSF I-protein
) O
is O
required O
for O
the O
growth O
and O
differentiation O
of O
mononuclear O
phagocytes O
. O

However O
, O
the O
signaling O
events O
responsible O
for O
these O
effects O
remain O
unclear O
. O

The O
present O
studies O
have O
examined O
the O
effects O
of O
M B-protein
- I-protein
CSF I-protein
on O
potential O
signaling O
pathways O
involving O
expression O
of O
the O
jun O
and O
fos O
early O
response O
genes O
. O

Low O
levels O
of O
c B-protein
- I-protein
jun I-protein
transcripts I-protein
were O
detectable O
in O
resting O
human O
peripheral O
blood O
monocytes O
. O

Treatment O
of O
these O
cells O
with O
10 O
( O
3 O
) O
units O
/ O
ml O
human B-protein
recombinant I-protein
M I-protein
- I-protein
CSF I-protein
was O
associated O
with O
rapid O
and O
transient O
increases O
in O
c O
- O
jun O
mRNA O
levels O
. O

Nuclear O
run O
- O
on O
assays O
and O
mRNA O
stability O
studies O
demonstrated O
that O
M B-protein
- I-protein
CSF I-protein
regulates O
c O
- O
jun O
expression O
by O
both O
an O
increase O
in O
transcription O
rate O
and O
a O
prolongation O
in O
the O
half O
- O
life O
of O
c O
- O
jun O
transcripts O
. O

M B-protein
- I-protein
CSF I-protein
treatment O
was O
also O
associated O
with O
a O
rapid O
induction O
of O
the O
jun O
- O
B O
gene O
, O
although O
expression O
of O
this O
gene O
was O
prolonged O
compared O
to O
that O
of O
c O
- O
jun O
. O

We O
further O
demonstrate O
that O
M B-protein
- I-protein
CSF I-protein
increases O
c O
- O
fos O
mRNA O
levels O
in O
human O
monocytes O
through O
control O
at O
both O
the O
transcriptional O
and O
posttranscriptional O
levels O
. O

Maximal O
induction O
of O
the O
c O
- O
fos O
gene O
was O
followed O
by O
that O
for O
the O
fos O
- O
B O
gene O
. O

Moreover O
, O
M B-protein
- I-protein
CSF I-protein
- O
induced O
expression O
of O
the O
fos O
- O
related O
gene O
, O
fra O
- O
1 O
, O
was O
delayed O
compared O
to O
that O
for O
both O
c O
- O
fos O
and O
fos O
- O
B O
. O

Taken O
together O
, O
the O
results O
indicate O
that O
M B-protein
- I-protein
CSF I-protein
treatment O
is O
associated O
with O
differential O
activation O
of O
multiple O
members O
of O
the O
jun O
/ O
fos O
family O
and O
that O
expression O
of O
these O
genes O
could O
contribute O
to O
nuclear O
signaling O
mechanisms O
that O
regulate O
a O
specific O
program O
of O
monocyte O
differentiation O
. O

Glucocorticoid B-protein
receptors I-protein
in O
systemic O
lupus O
erythematosus O
. O

Glucocorticosteroids O
remain O
the O
major O
treatment O
modality O
for O
systemic O
lupus O
erythematosus O
( O
SLE O
) O
, O
but O
their O
mechanism O
of O
action O
is O
unclear O
. O

Over O
the O
past O
decade O
it O
has O
become O
clear O
that O
glucocorticosteroid B-protein
receptors I-protein
play O
a O
significant O
role O
in O
the O
mechanism O
of O
glucocorticosteroid O
action O
. O

We O
studied O
glucocorticosteroid B-protein
receptor I-protein
density O
and O
affinity O
on O
peripheral O
blood O
mononuclear O
cells O
by O
the O
glucocorticosteroid O
binding O
assay O
in O
33 O
patients O
with O
SLE O
who O
had O
taken O
no O
glucocorticosteroid O
for O
the O
previous O
6 O
months O
and O
in O
32 O
healthy O
controls O
. O

Patients O
' O
disease O
activity O
was O
measured O
by O
the O
SLE O
Disease O
Activity O
Index O
( O
SLEDAI O
) O
. O

Glucocorticosteroid B-protein
receptors I-protein
on O
leukocytes O
of O
patients O
with O
SLE O
were O
significantly O
higher O
than O
in O
healthy O
controls O
( O
4419 O
+ O
/ O
- O
306 O
vs O
3369 O
+ O
/ O
- O
196 O
, O
p O
less O
than O
0 O
. O
005 O
) O
. O

The O
binding O
affinity O
was O
not O
different O
between O
patients O
and O
controls O
. O

There O
was O
no O
correlation O
between O
glucocorticosteroid B-protein
receptor I-protein
number O
and O
SLE O
disease O
activity O
. O

Kappa B-protein
B I-protein
binding I-protein
proteins I-protein
are O
constitutively O
expressed O
in O
an O
IL O
- O
2 O
autocrine O
human O
T O
cell O
line O
. O

The O
IL O
- O
2 O
and O
the O
IL O
- O
2 O
- O
R O
alpha O
genes O
are O
both O
expressed O
transiently O
in O
normal O
T O
lymphocytes O
after O
Ag O
or O
mitogen O
activation O
. O

In O
contrast O
, O
the O
human O
T O
cell O
line O
, O
IARC O
301 O
, O
expresses O
these O
two O
genes O
constitutively O
and O
we O
have O
previously O
demonstrated O
that O
its O
growth O
depends O
on O
the O
autocrine O
production O
of O
this O
T B-protein
cell I-protein
growth I-protein
factor I-protein
and O
high B-protein
affinity I-protein
IL I-protein
- I-protein
2R I-protein
. O

To O
dissect O
the O
molecular O
basis O
for O
the O
unusual O
persistent O
expression O
of O
the O
IL O
- O
2 O
and O
IL O
- O
2 O
- O
R O
alpha O
genes O
in O
these O
IARC O
301 O
T O
cells O
, O
we O
have O
analyzed O
the O
interactions O
of O
constitutively B-protein
expressed I-protein
nuclear I-protein
proteins I-protein
with O
the O
5 O
' O
flanking O
regions O
of O
the O
IL O
- O
2 O
and O
IL O
- O
2 O
- O
R O
alpha O
genes O
using O
both O
DNase B-protein
I I-protein
footprinting O
and O
gel O
retardation O
techniques O
. O

We O
have O
found O
that O
a O
region O
in O
both O
genes O
( O
- O
276 O
to O
- O
250 O
for O
IL O
- O
2 O
- O
R O
alpha O
and O
- O
203 O
to O
- O
183 O
for O
IL O
- O
2 O
) O
, O
which O
corresponds O
to O
a O
kappa O
B O
enhancer O
element O
, O
is O
specifically O
protected O
by O
nuclear B-protein
proteins I-protein
from O
IARC O
301 O
. O

In O
agreement O
with O
this O
finding O
, O
both O
the O
IL O
- O
2 O
and O
IL O
- O
2 O
- O
R O
alpha O
promoters O
are O
active O
in O
transient O
transfection O
assays O
in O
IARC O
301 O
cells O
. O

In O
contrast O
, O
mutation O
of O
the O
kappa B-protein
B I-protein
enhancer I-protein
results O
in O
markedly O
attenuated O
activities O
of O
both O
promoters O
. O

Two O
proteins O
binding O
the O
kappa O
B O
sequence O
, O
NF B-protein
- I-protein
kappa I-protein
B I-protein
and O
KBF1 B-protein
, O
are O
constitutively O
expressed O
in O
IARC O
301 O
nuclei O
and O
induced O
by O
PMA O
and O
PHA B-protein
in O
Jurkat O
. O

They O
bind O
to O
the O
kappa O
B O
motifs O
with O
different O
relative O
affinities O
that O
may O
reflect O
their O
different O
contribution O
in O
the O
expression O
of O
various O
promoters O
. O

HIV1 O
infection O
of O
human O
monocytes O
and O
macrophages O
promotes O
induction O
or O
translocation O
of O
NF B-protein
- I-protein
KB I-protein
- I-protein
related I-protein
factors I-protein
. O

In O
1991 O
, O
we O
demonstrated O
, O
using O
electrophoretic O
mobility O
shift O
assays O
, O
that O
3 O
different O
factors O
( O
termed O
B1 B-protein
, O
B2 B-protein
and O
B3 B-protein
) O
with O
affinity O
for O
the O
KB O
- O
enhancer O
target O
sequence O
were O
specifically O
detected O
in O
nuclear O
extracts O
from O
HIV1 O
- O
infected O
monocytes O
and O
macrophages O
. O

The O
B2 B-protein
factor I-protein
was O
induced O
in O
the O
nuclei O
of O
these O
cells O
only O
upon O
HIV1 O
infection O
. O

The O
B3 B-protein
factor I-protein
was O
only O
slightly O
evident O
in O
nuclei O
of O
uninfected O
cells O
but O
was O
readily O
detectable O
in O
nuclei O
of O
infected O
monocytes O
. O

Its O
expression O
remained O
very O
low O
in O
nuclei O
of O
HIV1 O
- O
infected O
macrophages O
. O

In O
this O
paper O
, O
we O
demonstrate O
that O
the O
B2 B-protein
factor I-protein
is O
expressed O
in O
the O
cytosol O
of O
monocytes O
and O
macrophages O
as O
a O
DNA B-protein
- I-protein
binding I-protein
protein I-protein
, O
indicating O
that O
it O
is O
not O
associated O
with O
an O
inhibitor O
( O
IKB O
) O
. O

This O
factor O
remained O
clustered O
in O
the O
cytosol O
and O
was O
translocated O
to O
the O
nuclei O
only O
after O
HIV1 O
infection O
. O

The O
B3 B-protein
factor I-protein
is O
detected O
in O
the O
cytosol O
only O
when O
cells O
are O
HIV1 O
- O
infected O
. O

The O
role O
of O
HIV1 O
infection O
in O
the O
expression O
and O
the O
translocation O
of O
these O
factors O
is O
discussed O
. O

Identification O
and O
cloning O
of O
TCF B-protein
- I-protein
1 I-protein
, O
a O
T B-protein
lymphocyte I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
containing O
a O
sequence B-protein
- I-protein
specific I-protein
HMG I-protein
box I-protein
. O

CD3 B-protein
- O
epsilon O
expression O
is O
controlled O
by O
a O
downstream O
T O
lymphocyte O
- O
specific O
enhancer O
element O
. O

We O
report O
the O
identification O
of O
a O
T B-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
TCF B-protein
- I-protein
1 I-protein
, O
binding O
to O
this O
element O
. O

The O
multimerized B-protein
recognition I-protein
motif I-protein
of O
TCF B-protein
- I-protein
1 I-protein
constituted O
a O
T O
cell O
- O
specific O
enhancer O
. O

Subsequent O
cloning O
of O
TCF B-protein
- I-protein
1 I-protein
identified O
three O
splice B-protein
alternatives I-protein
. O

TCF B-protein
- I-protein
1 I-protein
contained O
a O
single O
DNA B-protein
- I-protein
binding I-protein
HMG I-protein
box I-protein
most O
closely O
related O
to O
similar O
boxes O
in O
the O
putative O
mammalian O
sex O
- O
determining O
gene O
SRY O
and O
in O
the O
Schizosaccharomyces O
pombe O
Mc O
mating O
type O
gene O
. O

TCF B-protein
- I-protein
1 I-protein
mRNA O
was O
expressed O
uniquely O
in O
T O
lymphocytes O
. O

Upon O
cotransfection O
into O
non O
- O
T O
cells O
, O
TCF B-protein
- I-protein
1 I-protein
could O
transactivate O
through O
its O
cognate O
motif O
. O

These O
results O
identify O
TCF B-protein
- I-protein
1 I-protein
as O
a O
T B-protein
cell I-protein
- I-protein
specific I-protein
transcription I-protein
factor I-protein
, O
which O
might O
play O
a O
role O
in O
the O
establishment O
of O
the O
mature O
T O
cell O
phenotype O
. O

Identification O
of O
transcriptional B-protein
suppressor I-protein
proteins I-protein
that O
bind O
to O
the O
negative O
regulatory O
element O
of O
the O
human O
immunodeficiency O
virus O
type O
1 O
. O

Two O
different O
proteins O
which O
independently O
bound O
to O
neighboring O
sequences O
within O
the O
negative O
regulatory O
element O
( O
NRE O
) O
of O
human O
immunodeficiency O
virus O
type O
1 O
( O
HIV O
- O
1 O
) O
were O
detected O
in O
the O
nuclear O
extract O
of O
a O
virus O
- O
infected O
human O
T O
cell O
line O
. O

One O
of O
the O
factors O
bound O
to O
a O
novel O
dyad O
symmetrical O
sequence O
. O

This O
sequence O
is O
well O
conserved O
in O
various O
HIV O
- O
1 O
isolates O
and O
partial O
homology O
was O
found O
with O
the O
promoter O
region O
of O
the O
human O
retinoblastoma O
gene O
. O

Similar O
DNA O
binding O
activity O
was O
detected O
in O
a O
variety O
of O
virus O
- O
uninfected O
human O
T O
cell O
lines O
and O
HeLa O
cells O
by O
means O
of O
a O
gel O
mobility O
shift O
assay O
. O

The O
other O
factor O
bound O
to O
a O
putative O
AP O
- O
1 O
recognition O
sequence O
predicted O
for O
the O
HIV O
- O
1 O
NRE O
. O

However O
, O
this O
factor O
did O
not O
bind O
to O
a O
typical O
AP O
- O
1 O
site O
. O

The O
insertion O
of O
multiple O
copies O
of O
the O
binding O
site O
for O
the O
former O
or O
latter O
factor O
into O
a O
heterologous O
promoter O
reduced O
the O
promoter O
activity O
to O
one O
- O
tenth O
or O
one O
- O
third O
, O
respectively O
. O

Thus O
, O
each O
factor O
may O
function O
as O
a O
novel B-protein
negative I-protein
regulator I-protein
of O
transcription O
. O

Protein B-protein
kinase I-protein
C I-protein
activation O
and O
protooncogene O
expression O
in O
differentiation O
/ O
retrodifferentiation O
of O
human O
U O
- O
937 O
leukemia O
cells O
. O

Human O
U O
- O
937 O
leukemia O
cells O
differentiate O
along O
the O
monocytic O
lineage O
following O
3 O
- O
day O
exposures O
to O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
( O
TPA O
) O
. O

This O
induction O
of O
differentiation O
is O
accompanied O
by O
adherence O
and O
loss O
of O
proliferation O
, O
as O
well O
as O
expression O
/ O
repression O
of O
differentiation O
- O
associated O
genes O
. O

Long O
term O
culture O
of O
TPA O
- O
differentiated O
U O
- O
937 O
cells O
in O
the O
absence O
of O
phorbol O
ester O
for O
32 O
- O
36 O
days O
resulted O
in O
a O
process O
of O
retrodifferentiation O
. O

The O
retrodifferentiated O
cells O
detached O
from O
the O
substrate O
and O
reinitiated O
proliferation O
. O

Other O
cellular O
parameters O
, O
such O
as O
glycosidase O
activities O
, O
cytokine B-protein
release O
, O
and O
filament O
expression O
, O
returned O
to O
levels O
similar O
to O
that O
observed O
in O
uninduced O
cells O
. O

Treatment O
of O
U O
- O
937 O
cells O
with O
TPA O
resulted O
in O
a O
rapid O
translocation O
of O
protein B-protein
kinase I-protein
C I-protein
( O
PKC B-protein
) O
from O
the O
cytosol O
to O
cell O
membrane O
fractions O
within O
2 O
- O
8 O
min O
. O

Increased O
levels O
of O
membrane O
- O
associated O
PKC B-protein
activity O
persisted O
until O
17 O
- O
29 O
days O
. O

However O
, O
longer O
periods O
of O
incubation O
were O
associated O
with O
a O
return O
to O
the O
distribution O
of O
PKC B-protein
in O
control O
cells O
. O

Activation O
of O
PKC B-protein
has O
been O
implicated O
in O
the O
regulation O
of O
certain O
immediate O
early O
response O
genes O
, O
and O
in O
the O
present O
studies O
, O
TPA O
rapidly O
induced O
c O
- O
fos O
and O
c O
- O
jun O
gene O
expression O
. O

Levels O
of O
c O
- O
fos O
and O
c O
- O
jun O
transcripts O
remained O
elevated O
during O
periods O
of O
PKC B-protein
activation O
and O
also O
returned O
to O
levels O
observed O
in O
control O
cells O
by O
30 O
- O
36 O
days O
, O
when O
the O
cells O
entered O
retrodifferentiation O
. O

Staurosporine O
, O
a O
nonspecific O
inhibitor O
of O
PKC B-protein
, O
partially O
blocked O
TPA O
- O
induced O
adherence O
and O
growth O
inhibition O
and O
concomitantly O
prevented O
TPA O
- O
induced O
c O
- O
fos O
and O
c O
- O
jun O
gene O
expression O
. O

( O
ABSTRACT O
TRUNCATED O
AT O
250 O
WORDS O
) O
. O

Kappa B-protein
B I-protein
- I-protein
specific I-protein
DNA I-protein
binding I-protein
proteins I-protein
are O
differentially O
inhibited O
by O
enhancer O
mutations O
and O
biological O
oxidation O
. O

Kappa B-protein
B I-protein
( I-protein
kappa I-protein
B I-protein
) I-protein
enhancer I-protein
binding I-protein
proteins I-protein
isolated O
from O
the O
nuclei O
of O
activated O
human O
T O
cells O
produce O
two O
distinct O
nucleoprotein B-protein
complexes I-protein
when O
incubated O
with O
the O
kappa O
B O
element O
from O
the O
interleukin O
- O
2 O
receptor O
- O
alpha O
( O
IL B-protein
- I-protein
2R I-protein
alpha I-protein
) O
gene O
. O

These O
two O
DNA B-protein
- I-protein
protein I-protein
complexes I-protein
are O
composed O
of O
at O
least O
four O
host O
proteins O
( O
p50 B-protein
, O
p55 B-protein
, O
p75 B-protein
, O
p85 B-protein
) O
, O
each O
of O
which O
shares O
structural O
similarity O
with O
the O
v B-protein
- I-protein
rel I-protein
oncogene I-protein
product I-protein
. O

Nuclear O
expression O
of O
these O
proteins O
is O
induced O
with O
distinctly O
biphasic O
kinetics O
following O
phorbol O
ester O
activation O
of O
T O
cells O
( O
p55 B-protein
/ I-protein
p75 I-protein
early I-protein
and O
p50 B-protein
/ I-protein
p85 I-protein
late I-protein
) O
. O

DNA O
- O
protein O
crosslinking O
studies O
have O
revealed O
that O
the O
more O
rapidly O
migrating O
B2 B-protein
complex I-protein
contains O
both O
p50 B-protein
and O
p55 B-protein
while O
the O
more O
slowly O
migrating O
B1 B-protein
complex I-protein
is O
composed O
of O
p50 B-protein
, O
p55 B-protein
, O
p75 B-protein
, O
and O
p85 B-protein
. O

Site O
- O
directed O
mutagenesis O
of O
the O
wild O
- O
type O
IL O
- O
2R O
alpha O
kappa O
B O
enhancer O
( O
GGGGAATCTCCC O
) O
has O
revealed O
that O
the O
binding O
of O
p50 B-protein
and O
p55 B-protein
( O
B2 B-protein
complex I-protein
) O
is O
particularly O
sensitive O
to O
alteration O
of O
the O
5 O
' O
triplet O
of O
deoxyguanosine O
residues O
. O

In O
contrast O
, O
formation O
of O
the O
B1 B-protein
complex I-protein
, O
reflecting O
the O
binding O
of O
p75 B-protein
and O
p85 B-protein
, O
critically O
depends O
upon O
the O
more O
3 O
' O
sequences O
of O
this O
enhancer O
element O
. O

DNA O
binding O
by O
all O
four O
of O
these O
Rel B-protein
- I-protein
related I-protein
factors I-protein
is O
blocked O
by O
selective O
chemical O
modification O
of O
lysine O
and O
arginine O
residues O
, O
suggesting O
that O
both O
of O
these O
basic O
amino O
acids O
are O
required O
for O
binding O
to O
the O
kappa O
B O
element O
. O

Similarly O
, O
covalent O
modification O
of O
free O
sulfhydryl O
groups O
with O
diamide O
( O
reversible O
) O
or O
N O
- O
ethylmaleimide O
( O
irreversible O
) O
results O
in O
a O
complete O
loss O
of O
DNA O
binding O
activity O
. O

In O
contrast O
, O
mild O
oxidation O
with O
glucose B-protein
oxidase I-protein
selectively O
inhibits O
p75 B-protein
and O
p85 B-protein
binding O
while O
not O
blocking O
p50 B-protein
and O
p55 B-protein
interactions O
. O

These O
findings O
suggest O
that O
reduced O
cysteine O
thiols O
play O
an O
important O
role O
in O
the O
DNA O
binding O
activity O
of O
this O
family O
of O
Rel B-protein
- I-protein
related I-protein
transcription I-protein
factors I-protein
. O

[ O
Changes O
in O
leucocytic O
estrogen B-protein
receptor I-protein
levels O
in O
patients O
with O
climacteric O
syndrome O
and O
therapeutic O
effect O
of O
liuwei O
dihuang O
pills O
] O
. O

The O
numbers O
of O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
in O
human O
peripheral O
leucocytes O
in O
22 O
women O
with O
climacteric O
syndrome O
were O
measured O
by O
radioligand O
method O
. O

The O
results O
were O
compared O
with O
those O
of O
12 O
normal O
child O
- O
bearing O
- O
age O
women O
. O

It O
wat O
found O
that O
the O
contents O
of O
leucocytic B-protein
ER I-protein
in O
climacteric O
syndrome O
patients O
were O
significantly O
lower O
than O
normal O
child O
- O
bearing O
- O
age O
women O
. O

The O
authors O
used O
a O
Chinese O
prescription O
- O
- O
Liuwei O
Dihuang O
Pills O
( O
LDP O
) O
to O
treat O
the O
patients O
for O
2 O
months O
. O

The O
numbers O
of O
leucocytic B-protein
ER I-protein
were O
significantly O
increased O
after O
treatment O
. O

The O
data O
indicate O
that O
decrease O
of O
ER B-protein
levels O
in O
cell O
may O
involve O
in O
the O
pathogenesis O
of O
climacteric O
syndrome O
. O

LDP O
not O
only O
increases O
plasma O
estradiol O
levels O
, O
but O
also O
increases O
the O
leucocytic O
ER B-protein
levels O
. O

This O
may O
be O
the O
basis O
of O
the O
therapeutic O
effect O
on O
the O
disease O
. O

Evaluation O
of O
the O
role O
of O
ligand O
and O
thermal O
activation O
of O
specific O
DNA O
binding O
by O
in B-protein
vitro I-protein
synthesized I-protein
human I-protein
glucocorticoid I-protein
receptor I-protein
. O

We O
have O
used O
a O
DNA O
- O
binding O
/ O
immunoprecipitation O
assay O
to O
analyze O
the O
capacity O
of O
human B-protein
glucocorticoid I-protein
receptor I-protein
( O
hGR B-protein
) O
, O
generated O
in O
rabbit O
reticulocyte O
lysates O
, O
to O
bind O
DNA O
. O

In B-protein
vitro I-protein
translated I-protein
hGR I-protein
was O
indistinguishable O
from O
native B-protein
hGR I-protein
, O
as O
determined O
by O
migration O
on O
sodium O
dodecyl O
sulfate O
- O
polyacrylamide O
gels O
, O
sedimentation O
on O
sucrose O
density O
gradients O
, O
and O
reactivity O
with O
antipeptide B-protein
antibodies I-protein
generated O
against O
hGR B-protein
. O

In O
addition O
, O
cell B-protein
- I-protein
free I-protein
synthesized I-protein
hGR I-protein
was O
capable O
of O
specific O
binding O
to O
glucocorticoid O
response O
element O
( O
GRE O
) O
- O
containing O
DNA O
fragments O
. O

Using O
this O
assay O
system O
, O
we O
have O
evaluated O
the O
contributions O
of O
ligand O
binding O
and O
heat O
activation O
to O
DNA O
binding O
by O
these O
glucocorticoid B-protein
receptors I-protein
. O

In B-protein
vitro I-protein
translated I-protein
hGR I-protein
was O
capable O
of O
selective O
DNA O
binding O
even O
in O
the O
absence O
of O
glucocorticoid O
. O

Treatment O
with O
dexamethasone O
or O
the O
antiglucocorticoid O
RU486 O
had O
no O
additional O
effect O
on O
the O
DNA O
- O
binding O
capacity O
when O
receptor O
preparations O
were O
maintained O
at O
0 O
C O
( O
no O
activation O
) O
. O

In O
contrast O
, O
addition O
of O
either O
ligand O
or O
antagonist O
in O
combination O
with O
a O
heat O
activation O
step O
promoted O
DNA O
binding O
by O
approximately O
3 O
- O
fold O
over O
that O
of O
heat O
- O
activated O
unliganded B-protein
receptors I-protein
. O

Agonist O
( O
dexamethasone O
) O
was O
slightly O
more O
effective O
in O
supporting O
specific O
DNA O
binding O
than O
antagonist O
( O
RU486 O
) O
. O

DNA O
binding O
by O
in B-protein
vitro I-protein
synthesized I-protein
GR I-protein
was O
blocked O
by O
the O
addition O
of O
sodium O
molybdate O
to O
the O
receptor O
preparations O
before O
steroid O
addition O
and O
thermal O
activation O
. O

Addition O
of O
KCl O
resulted O
in O
less O
DNA O
binding O
either O
due O
to O
blockage O
of O
DNA O
- O
receptor B-protein
complex I-protein
formation O
or O
disruption O
of O
the O
complexes O
. O

The O
specificity O
of O
DNA O
binding O
by O
cell B-protein
- I-protein
free I-protein
synthesized I-protein
hGR I-protein
was O
analyzed O
further O
by O
examining O
the O
abilities O
of O
various O
DNAs O
to O
compete O
for O
binding O
to O
a O
naturally O
occurring O
GRE O
found O
in O
the O
mouse O
mammary O
tumor O
virus O
- O
long O
terminal O
repeat O
. O

Oligonucleotides O
containing O
the O
consensus O
GRE O
were O
the O
most O
efficient O
competitors O
, O
and O
fragments O
containing O
regulatory O
sequences O
from O
glucocorticoid O
- O
repressible O
genes O
were O
somewhat O
competitive O
, O
whereas O
single O
stranded O
oligonucleotides O
were O
unable O
to O
compete O
for O
mouse O
mammary O
tumor O
virus O
- O
long O
terminal O
repeat O
DNA O
binding O
, O
except O
when O
competitor O
was O
present O
at O
extremely O
high O
concentrations O
. O

Together O
these O
studies O
indicate O
that O
hGR B-protein
synthesized O
in O
rabbit O
reticulocyte O
lysates O
displays O
many O
of O
the O
same O
properties O
, O
including O
GRE O
- O
specific O
DNA O
binding O
, O
observed O
for O
glucocorticoid B-protein
receptor I-protein
present O
in O
cytosolic O
extracts O
of O
mammalian O
cells O
and O
tissues O
. O

Similarities O
between O
the O
effects O
of O
dexamethasone O
and O
RU486 O
suggest O
that O
the O
antiglucocorticoid O
properties O
of O
RU486 O
do O
not O
occur O
at O
the O
level O
of O
specific O
DNA O
binding O
. O

Expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
on O
alveolar O
lymphocytes O
from O
patients O
with O
pulmonary O
granulomatous O
diseases O
. O

1 O
, O
25 O
( O
OH O
) O
2D3 O
is O
known O
to O
be O
produced O
at O
sites O
of O
granulomatous O
reactions O
. O

In O
order O
to O
characterize O
the O
cell O
types O
that O
are O
targets O
for O
this O
immunoregulatory O
hormone O
, O
we O
have O
evaluated O
the O
expression O
of O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
on O
peripheral O
blood O
T O
- O
lymphocytes O
and O
those O
recovered O
from O
the O
lung O
by O
bronchoalveolar O
lavage O
from O
patients O
with O
pulmonary O
granulomatous O
diseases O
( O
tuberculosis O
and O
sarcoidosis O
) O
and O
from O
normal O
control O
subjects O
using O
combined O
autoradiographic O
and O
immunohistochemical O
techniques O
. O

Lavage O
T O
- O
lymphocytes O
from O
patients O
with O
tuberculosis O
or O
with O
sarcoidosis O
, O
but O
not O
those O
from O
normal O
control O
subjects O
, O
expressed O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
as O
demonstrated O
by O
binding O
of O
[ O
3H O
] O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
which O
was O
inhibited O
by O
the O
presence O
of O
excess O
unlabeled O
1 O
, O
25 O
( O
OH O
) O
2D3 O
, O
but O
not O
by O
the O
presence O
of O
unlabeled O
25 O
( O
OH O
) O
D3 O
( O
receptor O
- O
positive O
lymphocytes O
: O
sarcoidosis O
, O
20 O
+ O
/ O
- O
12 O
% O
; O
tuberculosis O
, O
31 O
+ O
/ O
- O
17 O
% O
) O
. O

In O
contrast O
, O
blood O
lymphocytes O
from O
patients O
with O
granulomatous O
diseases O
did O
not O
express O
detectable O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
. O

The O
percentage O
of O
lavage O
T O
- O
lymphocytes O
expressing O
1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
was O
significantly O
greater O
for O
patients O
with O
tuberculosis O
presenting O
with O
isolated O
hilar O
adenopathy O
than O
for O
patients O
with O
pulmonary O
infiltrates O
and O
/ O
or O
cavities O
. O

1 B-protein
, I-protein
25 I-protein
( I-protein
OH I-protein
) I-protein
2D3 I-protein
receptors I-protein
were O
expressed O
to O
a O
greater O
extent O
on O
CD8 O
+ O
T O
- O
lymphocytes O
than O
on O
CD4 O
+ O
T O
- O
lymphocytes O
in O
sarcoidosis O
, O
whereas O
a O
greater O
proportion O
of O
CD4 O
+ O
than O
of O
CD8 O
+ O
T O
- O
lymphocytes O
from O
patients O
with O
tuberculosis O
were O
receptor O
- O
positive O
. O

These O
findings O
support O
the O
conclusion O
that O
the O
interaction O
of O
1 O
, O
25 O
( O
OH O
) O
2D3 O
with O
its O
receptor O
on O
T O
- O
lymphocytes O
may O
play O
an O
important O
role O
in O
the O
regulation O
of O
granulomatous O
reactions O
, O
but O
because O
these O
receptors O
are O
expressed O
on O
different O
lymphocyte O
populations O
, O
the O
net O
effect O
of O
this O
potent O
immunoregulatory B-protein
molecule I-protein
is O
likely O
different O
in O
sarcoidosis O
and O
tuberculosis O
. O

Role O
for O
the O
Epstein B-protein
- I-protein
Barr I-protein
virus I-protein
nuclear I-protein
antigen I-protein
2 I-protein
in O
viral O
promoter O
switching O
during O
initial O
stages O
of O
infection O
. O

During O
latent O
Epstein O
- O
Barr O
virus O
( O
EBV O
) O
infection O
of O
human O
B O
lymphocytes O
, O
six B-protein
viral I-protein
nuclear I-protein
antigen I-protein
( O
EBNAs B-protein
) O
are O
expressed O
from O
long O
primary O
transcripts O
by O
means O
of O
alternative O
splicing O
and O
alternative O
polyadenylylation O
sites O
. O

These O
transcripts O
initiate O
from O
one O
of O
two O
promoters O
, O
Cp O
or O
Wp O
, O
that O
function O
in O
a O
mutually O
exclusive O
fashion O
. O

Wp O
is O
exclusively O
utilized O
during O
the O
initial O
stages O
of O
infection O
of O
primary O
B O
lymphocytes O
, O
followed O
by O
a O
switch O
to O
Cp O
usage O
. O

These O
studies O
have O
been O
extended O
to O
show O
that O
( O
i O
) O
a O
mutant O
EBV O
strain O
lacking O
the O
gene O
encoding O
EBNA B-protein
2 I-protein
fails O
to O
switch O
from O
Wp O
to O
Cp O
usage O
in O
primary O
B O
lymphocytes O
, O
although O
the O
virus O
contains O
a O
functional O
Cp O
; O
( O
ii O
) O
a O
region O
from O
- O
429 O
to O
- O
245 O
base O
pairs O
upstream O
of O
Cp O
is O
essential O
for O
Cp O
activity O
in O
B O
lymphocytes O
, O
but O
only O
in O
the O
context O
of O
upstream O
and O
downstream O
sequences O
; O
( O
iii O
) O
this O
region O
contains O
an O
EBNA B-protein
2 I-protein
- O
dependent O
enhancer O
; O
and O
( O
iv O
) O
DNase B-protein
I I-protein
protection O
employing O
nuclear O
extracts O
from O
B O
and O
T O
lymphocytes O
revealed O
a O
B O
- O
cell O
- O
specific O
footprint O
in O
the O
region O
of O
the O
EBNA B-protein
2 I-protein
- O
dependent O
enhancer O
. O

These O
results O
support O
a O
model O
for O
viral O
promoter O
switching O
during O
the O
initial O
stages O
of O
infection O
in O
which O
Wp O
activity O
leads O
to O
the O
expression O
of O
EBNA B-protein
2 I-protein
, O
followed O
by O
activation O
of O
Cp O
through O
the O
EBNA B-protein
2 I-protein
- O
dependent O
enhancer O
. O

Immune O
response O
of O
peripheral O
blood O
mononuclear O
cells O
to O
HBx B-protein
- I-protein
antigen I-protein
of O
hepatitis O
B O
virus O
. O

The O
hepatitis O
B O
virus O
genome O
encodes O
a O
transcriptional B-protein
transactivator I-protein
protein I-protein
designated O
HBxAg B-protein
. O

We O
have O
investigated O
whether O
this O
antigen O
is O
a O
target O
structure O
for O
human O
T O
- O
lymphocytes O
. O

Using O
recombinant B-protein
HBxAg I-protein
protein I-protein
, O
we O
found O
HBxAg B-protein
- O
specific O
stimulation O
of O
peripheral O
blood O
mononuclear O
cells O
in O
patients O
with O
acute O
hepatitis O
B O
virus O
infection O
( O
6 O
of O
6 O
) O
and O
chronic O
hepatitis O
B O
virus O
infection O
( O
6 O
of O
17 O
) O
but O
not O
in O
healthy O
individuals O
. O

With O
HBxAg B-protein
- O
specific O
synthetic O
polypeptides O
, O
several O
T B-protein
- I-protein
cell I-protein
epitopes I-protein
were O
identified O
. O

Most O
were O
located O
in O
the O
carboxyterminal B-protein
half I-protein
of O
the O
HBxAg B-protein
protein I-protein
. O

Five O
T O
- O
cell O
clones O
specific O
for O
a O
T B-protein
- I-protein
cell I-protein
epitope I-protein
located O
at O
the O
carboxyterminal B-protein
region I-protein
of O
HBxAg B-protein
were O
established O
and O
found O
to O
belong O
to O
the O
CD2 O
/ O
CD4 O
- O
positive O
, O
CD8 O
- O
negative O
subtype O
. O

These O
data O
establish O
for O
the O
first O
time O
HBxAg B-protein
as O
an O
antigen O
in O
the O
cellular O
immune O
response O
. O

[ O
Changes O
in O
leucocytic B-protein
estrogen I-protein
receptor I-protein
levels O
in O
patients O
with O
gynecomastia O
] O
. O

The O
number O
of O
estrogen B-protein
receptor I-protein
( O
ER B-protein
) O
in O
human O
peripheral O
leucocytes O
in O
13 O
men O
with O
gynecomastia O
were O
measured O
by O
radioligand O
binding O
method O
. O
The O
results O
were O
compared O
with O
those O
of O
13 O
sex O
- O
and O
age O
- O
matched O
healthy O
subjects O
. O

It O
was O
found O
that O
the O
number O
of O
ER B-protein
in O
leucocytes O
was O
significantly O
increased O
in O
gynecomastia O
( O
Rs O
of O
leucocytes O
were O
1054 O
+ O
/ O
- O
254 O
sites O
/ O
cell O
) O
. O

It O
suggested O
that O
increase O
of O
ER O
levels O
play O
an O
important O
role O
in O
the O
pathogenesis O
of O
gynecomastia O
. O

The O
NF O
kappa O
B O
independent O
cis O
- O
acting O
sequences O
in O
HIV O
- O
1 O
LTR O
responsive O
to O
T O
- O
cell O
activation O
. O

The O
rate O
of O
transcription O
initiation O
directed O
by O
the O
long O
terminal O
repeat O
( O
LTR O
) O
of O
HIV O
- O
1 O
increases O
in O
response O
to O
mitogenic O
stimuli O
of O
T O
cells O
. O

Here O
we O
show O
that O
the O
response O
of O
the O
HIV O
- O
1 O
LTR O
may O
be O
governed O
by O
two O
independent O
sequences O
located O
5 O
' O
to O
the O
site O
of O
transcription O
initiation O
sequences O
that O
bind O
either O
NFAT B-protein
- I-protein
1 I-protein
or O
NF B-protein
kappa I-protein
B I-protein
. O

The O
rate O
of O
LTR O
- O
directed O
gene O
expression O
increased O
in O
response O
to O
treatment O
with O
either O
a O
phorbol O
ester O
or O
tumor B-protein
necrosis I-protein
factor I-protein
alpha I-protein
if O
either O
the O
NFAT O
- O
1 O
or O
NF B-protein
kappa I-protein
B I-protein
binding O
sites O
were O
deleted O
, O
but O
failed O
to O
respond O
to O
these O
mitogenic O
stimuli O
if O
both O
sequences O
were O
absent O
. O

The O
HIV O
- O
1 O
mutant O
virus O
containing O
both O
NF O
kappa O
B O
and O
NFAT B-protein
- I-protein
1 I-protein
deletion O
was O
able O
to O
replicate O
although O
at O
a O
much O
decreased O
growth O
rate O
, O
while O
the O
deletion O
of O
NFAT B-protein
- I-protein
1 I-protein
alone O
increased O
the O
viral O
growth O
rate O
in O
Jurkat O
cells O
. O

Neither O
deletion O
of O
NF B-protein
kappa I-protein
B I-protein
nor O
deletion O
of O
NFAT B-protein
- I-protein
1 I-protein
decreased O
activation O
of O
viral O
replication O
by O
phorbol O
ester O
. O

cAMP O
- O
dependent O
regulation O
of O
proenkephalin O
by O
JunD B-protein
and O
JunB B-protein
: O
positive O
and O
negative O
effects O
of O
AP B-protein
- I-protein
1 I-protein
proteins I-protein
. O

We O
demonstrate O
that O
JunD B-protein
, O
a O
component O
of O
the O
AP B-protein
- I-protein
1 I-protein
transcription I-protein
factor I-protein
complex I-protein
, O
activates O
transcription O
of O
the O
human O
proenkephalin O
gene O
in O
a O
fashion O
that O
is O
completely O
dependent O
upon O
the O
cAMP B-protein
- I-protein
dependent I-protein
protein I-protein
kinase I-protein
, O
protein B-protein
kinase I-protein
A I-protein
. O

Activation O
of O
proenkephalin O
transcription O
by O
JunD B-protein
is O
dependent O
upon O
a O
previously O
characterized O
cAMP O
- O
, O
phorbol O
ester O
- O
, O
and O
Ca O
( O
2 O
+ O
) O
- O
inducible O
enhancer O
, O
and O
JunD B-protein
is O
shown O
to O
bind O
the O
enhancer O
as O
a O
homodimer B-protein
. O

Another O
component O
of O
the O
AP B-protein
- I-protein
1 I-protein
transcription I-protein
complex I-protein
, O
JunB B-protein
, O
is O
shown O
to O
inhibit O
activation O
mediated O
by O
JunD B-protein
. O

As O
a O
homodimer O
JunB B-protein
is O
unable O
to O
bind O
the O
enhancer O
; O
however O
in O
the O
presence O
of O
c B-protein
- I-protein
Fos I-protein
, O
high O
- O
affinity O
binding O
is O
observed O
. O

Furthermore O
, O
JunD B-protein
is O
shown O
to O
activate O
transcription O
of O
genes O
linked O
to O
both O
cAMP O
and O
phorbol O
ester O
response O
elements O
in O
a O
protein B-protein
kinase I-protein
A I-protein
- O
dependent O
fashion O
, O
further O
blurring O
the O
distinction O
between O
these O
response O
elements O
. O

These O
results O
demonstrate O
that O
the O
transcriptional O
activity O
of O
an O
AP B-protein
- I-protein
1 I-protein
- I-protein
related I-protein
protein I-protein
is O
regulated O
by O
the O
cAMP O
- O
dependent O
second O
- O
messenger O
pathway O
and O
suggest O
that O
JunD B-protein
and O
other O
AP B-protein
- I-protein
1 I-protein
- I-protein
related I-protein
proteins I-protein
may O
play O
an O
important O
role O
in O
the O
regulation O
of O
gene O
expression O
by O
cAMP O
- O
dependent O
intracellular O
signaling O
pathways O
. O

[ O
Plasma O
cortisol O
concentration O
and O
blood O
leukocyte O
content O
of O
glucocorticoid B-protein
receptors I-protein
in O
patients O
with O
deficiency O
- O
cold O
vs O
deficiency O
- O
heat O
syndromes O
] O
. O

Plasma O
cortisol O
concentration O
and O
blood O
leukocyte O
content O
of O
glucocorticoid B-protein
receptors I-protein
( O
GCR B-protein
) O
were O
assayed O
in O
20 O
patients O
with O
deficiency O
syndromes O
, O
10 O
cold O
in O
property O
( O
deficiency O
- O
cold O
) O
, O
the O
other O
10 O
hot O
in O
property O
( O
deficiency O
- O
heat O
) O
, O
and O
also O
in O
10 O
healthy O
individuals O
as O
normal O
control O
for O
the O
purpose O
of O
investigating O
the O
nature O
of O
cold O
and O
heat O
syndromes O
. O

As O
a O
result O
, O
the O
cases O
of O
deficiency O
- O
cold O
syndrome O
( O
DCS O
) O
had O
a O
normal O
concentration O
of O
plasma O
cortisol O
but O
a O
lowered O
content O
of O
GCR B-protein
in O
leukocytes O
when O
compared O
with O
the O
normal O
control O
( O
P O
less O
than O
0 O
. O
05 O
) O
; O
the O
cases O
of O
deficiency O
- O
heat O
syndrome O
( O
DHS O
) O
had O
a O
higher O
concentration O
of O
plasma O
cortisol O
than O
the O
normal O
control O
( O
P O
less O
than O
0 O
. O
05 O
) O
and O
a O
slightly O
higher O
content O
of O
GCR B-protein
in O
leukocytes O
. O

It O
was O
concluded O
that O
the O
DCS O
is O
characterized O
by O
diminished O
biological O
effects O
of O
adrenocortical O
activity O
, O
while O
the O
DHS O
, O
by O
augmented O
biological O
effects O
of O
adrenocortical O
activity O
. O

The O
role O
of O
jun O
and O
fos O
gene O
family O
members O
in O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
induced O
hemopoietic O
differentiation O
. O

Terminal O
differentiation O
of O
the O
leukemic O
cell O
lines O
U O
- O
937 O
and O
HL O
- O
60 O
by O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
is O
accompanied O
by O
marked O
changes O
in O
gene O
expression O
. O

In O
this O
study O
, O
we O
demonstrate O
that O
the O
expression O
of O
jun O
and O
fos O
gene O
family O
members O
is O
induced O
with O
variable O
kinetics O
during O
12 O
- O
O O
- O
tetradecanoylphorbol O
- O
13 O
- O
acetate O
induced O
differentiation O
, O
with O
c O
- O
jun O
expression O
best O
paralleling O
differentiation O
. O

The O
generation O
of O
AP B-protein
- I-protein
1 I-protein
complexes I-protein
, O
as O
measured O
by O
DNA O
binding O
activity O
, O
closely O
parallels O
morphological O
differentiation O
. O

Furthermore O
, O
the O
ability O
of O
these O
complexes O
to O
regulate O
gene O
expression O
is O
demonstrated O
by O
increased O
transcription O
from O
an O
AP B-protein
- I-protein
1 I-protein
driven O
reporter O
construct O
and O
marked O
increases O
in O
the O
expression O
of O
endogenous O
AP O
- O
1 O
regulated O
genes O
. O

Differentiation O
assays O
using O
water O
soluble O
phorbol O
esters O
reveal O
that O
differentiation O
becomes O
irreversible O
soon O
after O
AP B-protein
- I-protein
1 I-protein
appears O
. O

This O
tight O
correlation O
between O
c O
- O
jun O
expression O
, O
the O
generation O
of O
AP B-protein
- I-protein
1 I-protein
activity O
, O
and O
differentiation O
suggests O
a O
critical O
role O
for O
this O
gene O
and O
transcriptional B-protein
complex I-protein
during O
this O
process O
. O

Nuclear O
association O
of O
a O
T B-protein
- I-protein
cell I-protein
transcription I-protein
factor I-protein
blocked O
by O
FK O
- O
506 O
and O
cyclosporin O
A O
[ O
see O
comments O
] O
. O

Cyclosporin O
A O
and O
FK506 O
inhibit O
T O
- O
and O
B O
- O
cell O
activation O
and O
other O
processes O
essential O
to O
an O
effective O
immune O
response O
. O

In O
T O
lymphocytes O
these O
drugs O
disrupt O
an O
unknown O
step O
in O
the O
transmission O
of O
signals O
from O
the O
T B-protein
- I-protein
cell I-protein
antigen I-protein
receptor I-protein
to O
cytokine O
genes O
that O
coordinate O
the O
immune O
response O
. O

The O
putative B-protein
intracellular I-protein
receptors I-protein
for O
FK506 O
and O
cyclosporin O
are O
cis O
- O
trans O
prolyl O
isomerases O
. O

Binding O
of O
the O
drug O
inhibits O
isomerase B-protein
activity O
, O
but O
studies O
with O
other O
prolyl O
isomerase B-protein
inhibitors O
and O
analysis O
of O
cyclosporin O
- O
resistant O
mutants O
in O
yeast O
suggest O
that O
the O
effects O
of O
the O
drug O
result O
from O
the O
formation O
of O
an O
inhibitory B-protein
complex I-protein
between O
the O
drug O
and O
isomerase B-protein
, O
and O
not O
from O
inhibition O
of O
isomerase B-protein
activity O
. O

A O
transcription B-protein
factor I-protein
, O
NF B-protein
- I-protein
AT I-protein
, O
which O
is O
essential O
for O
early O
T O
- O
cell O
gene O
activation O
, O
seems O
to O
be O
a O
specific O
target O
of O
cyclosporin O
A O
and O
FK506 O
action O
because O
transcription O
directed O
by O
this O
protein O
is O
blocked O
in O
T O
cells O
treated O
with O
these O
drugs O
, O
with O
little O
or O
no O
effect O
on O
other O
transcription B-protein
factors I-protein
such O
as O
AP B-protein
- I-protein
1 I-protein
and O
NF B-protein
- I-protein
kappa I-protein
B I-protein
. O

Here O
we O
demonstrate O
that O
NF B-protein
- I-protein
AT I-protein
is O
formed O
when O
a O
signal O
from O
the O
antigen B-protein
receptor I-protein
induces O
a O
pre O
- O
existing O
cytoplasmic O
subunit O
to O
translocate O
to O
the O
nucleus O
and O
combine O
with O
a O
newly O
synthesized O
nuclear O
subunit O
of O
NF B-protein
- I-protein
AT I-protein
. O

FK506 O
and O
cyclosporin O
A O
block O
translocation O
of O
the O
cytoplasmic B-protein
component I-protein
without O
affecting O
synthesis O
of O
the O
nuclear B-protein
subunit I-protein
. O

Glucocorticoid B-protein
receptors I-protein
in O
lymphocytes O
in O
anorexia O
nervosa O
. O

OBJECTIVE O
: O
The O
aim O
was O
to O
explore O
the O
down O
- O
regulation O
of O
the O
glucocorticoid B-protein
receptors I-protein
during O
hypercortisolaemia O
in O
anorexia O
nervosa O
. O

DESIGN O
: O
Urine O
and O
plasma O
samples O
were O
obtained O
for O
cortisol O
determination O
and O
blood O
lymphocytes O
were O
isolated O
for O
receptor O
binding O
studies O
. O

PATIENTS O
: O
Sixteen O
anorexic O
patients O
, O
aged O
16 O
- O
27 O
years O
, O
with O
a O
mean O
+ O
/ O
- O
SEM O
body O
mass O
index O
of O
14 O
. O
2 O
+ O
/ O
- O
2 O
. O
0 O
( O
ranging O
from O
11 O
. O
1 O
to O
17 O
. O
4 O
) O
, O
and O
15 O
normal O
women O
were O
studied O
. O

Six O
patients O
were O
reinvestigated O
after O
a O
significant O
weight O
gain O
. O

MEASUREMENTS O
: O
The O
binding O
capacity O
and O
affinity O
of O
the O
glucocorticoid B-protein
receptors I-protein
were O
measured O
with O
dexamethasone O
as O
ligand O
on O
lymphocytes O
. O

RESULTS O
: O
In O
patients O
, O
both O
total O
and O
free O
plasma O
cortisol O
concentrations O
were O
higher O
than O
in O
the O
normal O
women O
, O
as O
was O
their O
urinary O
free O
cortisol O
; O
the O
number O
of O
glucocorticoid B-protein
receptors I-protein
per O
cell O
( O
Ro O
) O
and O
the O
binding O
affinity O
( O
Kd O
) O
for O
dexamethasone O
were O
, O
however O
, O
not O
significantly O
different O
( O
Ro O
: O
7687 O
+ O
/ O
- O
1750 O
vs O
7347 O
+ O
/ O
- O
1285 O
sites O
/ O
cell O
; O
Kd O
: O
7 O
. O
7 O
+ O
/ O
- O
2 O
. O
4 O
vs O
7 O
. O
4 O
+ O
/ O
- O
1 O
. O
7 O
nM O
at O
24 O
degrees O
C O
) O
. O

After O
weight O
gain O
( O
14 O
+ O
/ O
- O
2 O
to O
16 O
+ O
/ O
- O
2 O
kg O
/ O
m2 O
) O
, O
receptor O
numbers O
were O
8421 O
+ O
/ O
- O
2126 O
( O
pre O
) O
and O
9011 O
+ O
/ O
- O
500 O
( O
post O
) O
sites O
/ O
cell O
, O
which O
are O
not O
significantly O
different O
( O
P O
greater O
than O
0 O
. O
2 O
) O
; O
the O
Kd O
was O
unchanged O
( O
9 O
. O
3 O
+ O
/ O
- O
2 O
. O
6 O
vs O
9 O
. O
2 O
+ O
/ O
- O
2 O
. O
4 O
nM O
) O
. O

CONCLUSIONS O
Hypercortisolaemia O
does O
not O
down O
- O
regulate O
the O
lymphocyte O
glucocorticoid B-protein
receptors I-protein
in O
anorexia O
nervosa O
and O
a O
post O
- O
receptor O
defect O
might O
be O
involved O
in O
peripheral O
tissue O
resistance O
to O
the O
effects O
of O
glucocorticoid O
hormones O
in O
undernutrition O
. O

Inhibition O
of O
protein B-protein
phosphatases I-protein
by O
okadaic O
acid O
induces O
AP1 B-protein
in O
human O
T O
cells O
. O

To O
examine O
the O
role O
of O
protein B-protein
phosphatases I-protein
in O
T O
cell O
activation O
, O
Jurkat O
cells O
were O
treated O
with O
okadaic O
acid O
, O
an O
inhibitor O
of O
type O
1 O
and O
2A O
phosphatases O
, O
and O
nuclear O
extracts O
were O
examined O
for O
the O
presence O
of O
AP1 B-protein
as O
a O
measure O
of O
early O
T O
cell O
activation O
. O

Okadaic O
acid O
was O
found O
to O
be O
a O
potent O
inducer O
of O
AP1 B-protein
. O

In O
contrast O
to O
phorbol O
esters O
such O
as O
phorbol O
myristate O
acetate O
( O
PMA O
) O
, O
the O
induction O
of O
AP1 B-protein
by O
okadaic O
acid O
occurs O
predominantly O
by O
transcriptional O
activation O
of O
the O
jun O
and O
fos O
family O
of O
proto O
- O
oncogenes O
. O

Surprisingly O
, O
while O
the O
addition O
of O
phytohemagglutinin B-protein
further O
enhanced O
the O
induction O
of O
AP1 B-protein
, O
the O
addition O
of O
PMA O
inhibited O
it O
. O

Okadaic O
acid O
treatment O
was O
found O
to O
dramatically O
increase O
mRNA O
transcripts O
of O
the O
jun O
family O
of O
proto O
- O
oncogenes O
including O
c O
- O
jun O
, O
junD O
, O
and O
junB O
and O
to O
a O
lesser O
extent O
the O
fos O
family O
including O
c O
- O
fos O
and O
fra O
- O
1 O
. O

By O
comparison O
, O
PMA O
is O
a O
very O
inefficient O
inducer O
of O
the O
jun O
gene O
family O
in O
Jurkat O
cells O
. O

Similar O
to O
its O
effect O
on O
the O
induction O
of O
AP1 B-protein
by O
okadaic O
acid O
, O
PMA O
inhibits O
the O
induction O
of O
c O
- O
jun O
mRNA O
by O
okadaic O
acid O
. O

Transfection O
of O
c O
- O
jun O
promoter O
constructs O
confirmed O
the O
marked O
difference O
between O
PMA O
and O
okadaic O
acid O
in O
inducing O
c O
- O
jun O
transcription O
. O

The O
induction O
of O
AP1 B-protein
by O
okadaic O
acid O
suggests O
that O
protein O
phosphatases O
1 O
and O
2A O
( O
PP1 B-protein
and O
PP2A B-protein
) O
may O
be O
involved O
in O
T O
cell O
activation O
as O
important O
negative O
regulators O
of O
the O
transcription B-protein
factor I-protein
AP1 B-protein
. O

Cloning O
of O
murine B-protein
TCF I-protein
- I-protein
1 I-protein
, O
a O
T O
cell O
- O
specific O
transcription B-protein
factor I-protein
interacting O
with O
functional O
motifs O
in O
the O
CD3 O
- O
epsilon O
and O
T O
cell O
receptor O
alpha O
enhancers O
. O

CD3 B-protein
- O
epsilon O
gene O
expression O
is O
confined O
to O
the O
T O
cell O
lineage O
. O

We O
have O
recently O
identified O
and O
cloned O
a O
human B-protein
transcription I-protein
factor I-protein
, O
TCF B-protein
- I-protein
1 I-protein
, O
that O
binds O
to O
a O
functional O
element O
in O
the O
T O
lymphocyte O
- O
specific O
enhancer O
of O
CD3 O
- O
epsilon O
. O

In O
a O
panel O
of O
human O
cell O
lines O
, O
TCF B-protein
- I-protein
1 I-protein
expression O
was O
restricted O
to O
T O
lineage O
cells O
. O

TCF B-protein
- I-protein
1 I-protein
belonged O
to O
a O
novel O
family O
of O
genes O
that O
contain O
the O
so O
- O
called O
high O
mobility O
group O
1 O
( O
HMG O
) O
box O
. O

Here O
we O
report O
the O
cloning O
of O
murine B-protein
TCF I-protein
- I-protein
1 I-protein
. O

Two O
splice O
alternatives O
were O
identified O
that O
were O
not O
previously O
observed O
in O
human B-protein
TCF I-protein
- I-protein
1 I-protein
. O

Murine O
and O
human O
TCF O
- O
1 O
displayed O
a O
95 O
. O
5 O
% O
overall O
amino O
acid O
homology O
. O

Recombinant O
murine O
and O
human O
TCF O
- O
1 O
recognized O
the O
same O
sequence O
motif O
in O
the O
CD3 O
- O
epsilon O
enhancer O
as O
judged O
by O
gel O
retardation O
and O
methylation O
interference O
assays O
. O

With O
the O
murine O
cDNA O
clones O
several O
aspects O
of O
TCF B-protein
- I-protein
1 I-protein
were O
analyzed O
. O

First O
, O
deletion O
analysis O
revealed O
that O
a O
region O
of O
TCF B-protein
- I-protein
1 I-protein
containing O
the O
HMG O
box O
was O
sufficient O
for O
sequence O
- O
specific O
binding O
. O

Second O
, O
by O
high O
stringency O
Northern O
blotting O
and O
in O
situ O
hybridization O
, O
TCF B-protein
- I-protein
1 I-protein
expression O
was O
shown O
to O
be O
confined O
to O
the O
thymus O
and O
to O
the O
T O
cell O
areas O
of O
the O
spleen O
. O

Third O
, O
TCF B-protein
- I-protein
1 I-protein
bound O
specifically O
to O
a O
functional O
T O
cell O
- O
specific O
element O
in O
the O
T O
cell O
receptor O
alpha O
( O
TCR O
- O
alpha O
) O
enhancer O
. O

The O
T O
lineage O
- O
specific O
expression O
and O
the O
affinity O
for O
functional O
motifs O
in O
the O
TCR O
- O
alpha O
and O
CD3 O
- O
epsilon O
enhancers O
imply O
an O
important O
role O
for O
TCF B-protein
- I-protein
1 I-protein
in O
the O
establishment O
of O
the O
mature O
T O
cell O
phenotype O
. O

Cloning O
of O
a O
human O
homeobox O
gene O
that O
resembles O
a O
diverged O
Drosophila O
homeobox O
gene O
and O
is O
expressed O
in O
activated O
lymphocytes O
. O

A O
new O
homeobox O
gene O
, O
HB24 O
, O
has O
been O
isolated O
from O
a O
human O
B O
- O
lymphocyte O
cDNA O
library O
. O

Northern O
blot O
analysis O
of O
polyadenylated O
RNA O
purified O
from O
activated O
human O
B O
cells O
revealed O
a O
single O
mRNA O
transcript O
of O
approximately O
2 O
. O
3 O
kb O
. O

Two O
cDNA O
clones O
were O
sequenced O
and O
provided O
2 O
, O
250 O
nucleotides O
( O
nt O
) O
of O
DNA O
sequence O
information O
. O
